0001711279-22-000047.txt : 20220808 0001711279-22-000047.hdr.sgml : 20220808 20220808075049 ACCESSION NUMBER: 0001711279-22-000047 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220808 DATE AS OF CHANGE: 20220808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Krystal Biotech, Inc. CENTRAL INDEX KEY: 0001711279 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 821080209 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38210 FILM NUMBER: 221142594 BUSINESS ADDRESS: STREET 1: 2100 WHARTON STREET STREET 2: SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 BUSINESS PHONE: (412) 586-5830 MAIL ADDRESS: STREET 1: 2100 WHARTON STREET STREET 2: SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 10-Q 1 krys-20220630.htm 10-Q krys-20220630
false2022Q20001711279--12-31P1Y00017112792022-01-012022-06-3000017112792022-07-29xbrli:shares00017112792022-06-30iso4217:USD00017112792021-12-31iso4217:USDxbrli:shares00017112792022-04-012022-06-3000017112792021-04-012021-06-3000017112792021-01-012021-06-300001711279us-gaap:CommonStockMember2021-12-310001711279us-gaap:AdditionalPaidInCapitalMember2021-12-310001711279us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001711279us-gaap:RetainedEarningsMember2021-12-310001711279us-gaap:CommonStockMember2022-01-012022-03-310001711279us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100017112792022-01-012022-03-310001711279us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001711279us-gaap:RetainedEarningsMember2022-01-012022-03-310001711279us-gaap:CommonStockMember2022-03-310001711279us-gaap:AdditionalPaidInCapitalMember2022-03-310001711279us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001711279us-gaap:RetainedEarningsMember2022-03-3100017112792022-03-310001711279us-gaap:CommonStockMember2022-04-012022-06-300001711279us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001711279us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001711279us-gaap:RetainedEarningsMember2022-04-012022-06-300001711279us-gaap:CommonStockMember2022-06-300001711279us-gaap:AdditionalPaidInCapitalMember2022-06-300001711279us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001711279us-gaap:RetainedEarningsMember2022-06-300001711279us-gaap:CommonStockMember2020-12-310001711279us-gaap:AdditionalPaidInCapitalMember2020-12-310001711279us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001711279us-gaap:RetainedEarningsMember2020-12-3100017112792020-12-310001711279us-gaap:CommonStockMember2021-01-012021-03-310001711279us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100017112792021-01-012021-03-310001711279us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001711279us-gaap:RetainedEarningsMember2021-01-012021-03-310001711279us-gaap:CommonStockMember2021-03-310001711279us-gaap:AdditionalPaidInCapitalMember2021-03-310001711279us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001711279us-gaap:RetainedEarningsMember2021-03-3100017112792021-03-310001711279us-gaap:CommonStockMember2021-04-012021-06-300001711279us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001711279us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001711279us-gaap:RetainedEarningsMember2021-04-012021-06-300001711279us-gaap:CommonStockMember2021-06-300001711279us-gaap:AdditionalPaidInCapitalMember2021-06-300001711279us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001711279us-gaap:RetainedEarningsMember2021-06-3000017112792021-06-30krys:segment0001711279srt:MinimumMemberus-gaap:ComputerEquipmentMember2022-01-012022-06-300001711279us-gaap:ComputerEquipmentMembersrt:MaximumMember2022-01-012022-06-300001711279srt:MinimumMemberkrys:LabEquipmentMember2022-01-012022-06-300001711279krys:LabEquipmentMembersrt:MaximumMember2022-01-012022-06-300001711279srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2022-01-012022-06-300001711279srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2022-01-012022-06-300001711279us-gaap:EquipmentMember2021-01-012021-06-300001711279us-gaap:EquipmentMember2022-01-012022-06-300001711279us-gaap:EquipmentMember2022-04-012022-06-300001711279us-gaap:EquipmentMember2021-04-012021-06-300001711279us-gaap:CashMemberus-gaap:FairValueInputsLevel1Member2022-06-300001711279us-gaap:CashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2022-06-300001711279us-gaap:FairValueInputsLevel1Member2022-06-300001711279us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2022-06-300001711279us-gaap:CommercialPaperMember2022-06-300001711279us-gaap:CommercialPaperMemberus-gaap:ShortTermInvestmentsMember2022-06-300001711279us-gaap:CommercialPaperMemberkrys:LongTermMarketableSecuritiesMember2022-06-300001711279us-gaap:CorporateBondSecuritiesMember2022-06-300001711279us-gaap:CorporateBondSecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-06-300001711279us-gaap:CorporateBondSecuritiesMemberkrys:LongTermMarketableSecuritiesMember2022-06-300001711279us-gaap:USTreasurySecuritiesMember2022-06-300001711279us-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-06-300001711279us-gaap:USTreasurySecuritiesMemberkrys:LongTermMarketableSecuritiesMember2022-06-300001711279us-gaap:FairValueInputsLevel2Member2022-06-300001711279us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember2022-06-300001711279krys:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-06-300001711279us-gaap:CashAndCashEquivalentsMember2022-06-300001711279us-gaap:ShortTermInvestmentsMember2022-06-300001711279krys:LongTermMarketableSecuritiesMember2022-06-300001711279us-gaap:CashMemberus-gaap:FairValueInputsLevel1Member2021-12-310001711279us-gaap:CashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2021-12-310001711279us-gaap:FairValueInputsLevel1Member2021-12-310001711279us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2021-12-310001711279us-gaap:CommercialPaperMember2021-12-310001711279us-gaap:CommercialPaperMemberus-gaap:ShortTermInvestmentsMember2021-12-310001711279us-gaap:CommercialPaperMemberkrys:LongTermMarketableSecuritiesMember2021-12-310001711279us-gaap:CorporateBondSecuritiesMember2021-12-310001711279us-gaap:CorporateBondSecuritiesMemberus-gaap:ShortTermInvestmentsMember2021-12-310001711279us-gaap:CorporateBondSecuritiesMemberkrys:LongTermMarketableSecuritiesMember2021-12-310001711279us-gaap:USTreasurySecuritiesMember2021-12-310001711279us-gaap:USTreasurySecuritiesMemberus-gaap:ShortTermInvestmentsMember2021-12-310001711279us-gaap:USTreasurySecuritiesMemberkrys:LongTermMarketableSecuritiesMember2021-12-310001711279us-gaap:FairValueInputsLevel2Member2021-12-310001711279us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember2021-12-310001711279krys:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310001711279us-gaap:CashAndCashEquivalentsMember2021-12-310001711279us-gaap:ShortTermInvestmentsMember2021-12-310001711279krys:LongTermMarketableSecuritiesMember2021-12-310001711279srt:MinimumMemberkrys:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-06-300001711279srt:MaximumMemberkrys:LongTermMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-06-300001711279us-gaap:ConstructionInProgressMember2022-06-300001711279us-gaap:ConstructionInProgressMember2021-12-310001711279us-gaap:LeaseholdImprovementsMember2022-06-300001711279us-gaap:LeaseholdImprovementsMember2021-12-310001711279us-gaap:FurnitureAndFixturesMember2022-06-300001711279us-gaap:FurnitureAndFixturesMember2021-12-310001711279us-gaap:ComputerEquipmentMember2022-06-300001711279us-gaap:ComputerEquipmentMember2021-12-310001711279krys:LabEquipmentMember2022-06-300001711279krys:LabEquipmentMember2021-12-310001711279krys:TwoThousandSixteenLeaseAgreementMember2022-06-30utr:sqft00017112792020-01-2100017112792020-10-152020-10-1500017112792020-10-0500017112792020-10-15xbrli:pure0001711279krys:BostonMassachusettsLeaseMember2021-12-150001711279krys:SwitzerlandLeaseMember2022-05-160001711279krys:SwitzerlandLeaseMember2022-06-300001711279krys:ClinicalSupplyAgreementMember2022-06-300001711279krys:ClinicalSupplyAgreementMember2022-04-012022-06-300001711279krys:ClinicalSupplyAgreementMember2022-01-012022-06-300001711279krys:ClinicalSupplyAgreementMember2021-04-012021-06-300001711279krys:ClinicalSupplyAgreementMember2021-01-012021-06-300001711279krys:OtherContractualObligationsMember2022-06-300001711279krys:OtherContractualObligationsMember2022-04-012022-06-300001711279krys:OtherContractualObligationsMember2022-01-012022-06-300001711279krys:OtherContractualObligationsMember2021-04-012021-06-300001711279krys:OtherContractualObligationsMember2021-01-012021-06-300001711279krys:ASTRAFacilityMember2022-06-3000017112792021-09-130001711279krys:PeriphaGenMember2022-04-282022-04-280001711279krys:PeriphaGenMember2022-01-012022-06-30krys:milestone0001711279krys:MilestoneTwoMemberkrys:PeriphaGenMember2022-01-012022-06-300001711279krys:MilestoneThreeMemberkrys:PeriphaGenMember2022-01-012022-06-300001711279krys:MilestoneOneMemberkrys:PeriphaGenMember2022-01-012022-06-300001711279krys:MilestoneOneMemberkrys:PeriphaGenMember2022-03-122022-03-120001711279krys:MilestoneTwoMemberkrys:PeriphaGenMember2022-03-122022-03-120001711279krys:MilestoneThreeMemberkrys:PeriphaGenMember2022-03-122022-03-120001711279krys:PeriphaGenMember2022-03-122022-03-120001711279krys:PlacementSharesMember2020-12-310001711279krys:PublicOfferingMember2021-01-012021-12-310001711279krys:PublicOfferingMember2021-12-310001711279krys:ATMProgramMember2021-01-012021-12-310001711279krys:PublicOfferingMember2022-04-052022-04-050001711279krys:PublicOfferingMember2022-06-300001711279krys:ATMProgramMember2022-01-012022-06-300001711279krys:PublicOfferingMember2021-12-032021-12-030001711279us-gaap:OverAllotmentOptionMember2021-12-032021-12-030001711279krys:PublicOfferingMember2021-12-0300017112792021-12-032021-12-030001711279krys:PublicOfferingMember2021-02-012021-02-010001711279us-gaap:OverAllotmentOptionMember2021-02-012021-02-010001711279krys:PublicOfferingMember2021-02-0100017112792021-02-012021-02-010001711279us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001711279srt:MinimumMemberkrys:NonEmployeeStockOptionMember2022-01-012022-06-300001711279srt:MaximumMemberkrys:NonEmployeeStockOptionMember2022-01-012022-06-300001711279srt:DirectorMember2022-04-012022-06-300001711279srt:DirectorMember2022-01-012022-06-300001711279srt:DirectorMember2021-04-012021-06-300001711279srt:DirectorMember2021-01-012021-06-300001711279krys:NonEmployeeStockOptionMember2022-01-012022-06-300001711279krys:NonEmployeeStockOptionMember2022-04-012022-06-300001711279krys:NonEmployeeStockOptionMember2021-04-012021-06-300001711279krys:NonEmployeeStockOptionMember2021-01-012021-06-3000017112792021-01-012021-12-310001711279us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001711279us-gaap:EmployeeStockOptionMember2021-04-012021-06-300001711279us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001711279srt:DirectorMemberus-gaap:EmployeeStockOptionMember2022-06-300001711279srt:DirectorMemberus-gaap:EmployeeStockOptionMember2022-01-012022-06-300001711279us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001711279us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300001711279us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001711279us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001711279us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:EmployeeStockOptionMember2022-04-012022-06-300001711279us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:EmployeeStockOptionMember2021-04-012021-06-300001711279us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:EmployeeStockOptionMember2022-01-012022-06-300001711279us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:EmployeeStockOptionMember2021-01-012021-06-300001711279srt:MaximumMemberus-gaap:RestrictedStockMember2022-01-012022-06-300001711279us-gaap:RestrictedStockMember2022-04-012022-06-300001711279us-gaap:RestrictedStockMember2022-01-012022-06-300001711279us-gaap:RestrictedStockMember2021-04-012021-06-300001711279us-gaap:RestrictedStockMember2021-01-012021-06-300001711279us-gaap:RestrictedStockMember2021-12-310001711279us-gaap:RestrictedStockMember2022-06-300001711279us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:RestrictedStockMember2022-04-012022-06-300001711279us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:RestrictedStockMember2021-04-012021-06-300001711279us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:RestrictedStockMember2022-01-012022-06-300001711279us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:RestrictedStockMember2021-01-012021-06-300001711279krys:StockIncentivePlanMember2022-06-300001711279krys:IncentiveStockOptionsMember2022-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________
FORM 10-Q
_____________________________________________________
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2022
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from               to                    
Commission file number: 001-38210
_____________________________________________________
Krystal Biotech, Inc.
(Exact name of registrant as specified in its charter)
_____________________________________________________

Delaware82-1080209
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
2100 Wharton Street, Suite 701
Pittsburgh, Pennsylvania 15203
(Address of principal executive offices and zip code)
(412) 586-5830
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
_____________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange on which registered
Common StockKRYS
NASDAQ Capital Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company    
If emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
As of July 29, 2022, there were 25,664,287 shares of the registrant’s common stock issued and outstanding.



Krystal Biotech, Inc.
TABLE OF CONTENTS
  Page No.
  
  
  
  
  
  
  
  
 
 
 
  
 
   
 
 
 
 
 
 
 
   
 

2


PART I. FINANCIAL INFORMATION
ITEM 1.    FINANCIAL STATEMENTS (UNAUDITED)

Krystal Biotech, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(In thousands, except share and per share data)June 30,
2022
December 31,
2021
Assets
Current assets
Cash and cash equivalents$218,720 $341,246 
Short-term investments206,845 96,850 
Prepaid expenses and other current assets3,205 4,171 
Total current assets428,770 442,267 
Property and equipment, net151,214 112,355 
Long-term investments12,902 64,371 
Right-of-use assets8,279 7,228 
Other non-current assets159 74 
Total assets$601,324 $626,295 
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable$9,229 $8,398 
Current portion of lease liability1,417 1,041 
Accrued expenses and other current liabilities23,781 16,297 
Total current liabilities34,427 25,736 
Lease liability7,716 6,983 
Total liabilities42,143 32,719 
Commitments and contingencies (Note 6)
Stockholders' equity
Preferred stock; $0.00001 par value; 20,000,000 shares authorized at
   June 30, 2022 (unaudited) and December 31, 2021; 2,061,773
   shares issued, and no shares outstanding at June 30, 2022
   (unaudited) and December 31, 2021
  
Common stock; $0.00001 par value; 80,000,000 shares authorized at
   June 30, 2022 (unaudited) and December 31, 2021; 25,664,287
   shares issued and outstanding at June 30, 2022
   (unaudited); and 25,207,985 shares issued and outstanding at December 31, 2021
  
Additional paid-in capital779,583 734,523 
Accumulated other comprehensive loss(1,545)(163)
Accumulated deficit(218,857)(140,784)
Total stockholders' equity559,181 593,576 
Total liabilities and stockholders' equity$601,324 $626,295 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3


Krystal Biotech, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)

 Three Months Ended
June 30,
Six Months Ended
June 30,
(In thousands, except share and per share data)2022202120222021
Expenses
Research and development$10,890 $6,594 $20,204 $12,795 
General and administrative17,863 9,799 33,771 17,951 
Litigation settlement  25,000  
Total operating expenses28,753 16,393 78,975 30,746 
Loss from operations(28,753)(16,393)(78,975)(30,746)
Other Income (Expense)
Interest and other income, net645 30 902 64 
Interest expense   (1,492)
Net loss$(28,108)(16,363)(78,073)(32,174)
Unrealized loss on available-for-sale securities and currency translation adjustment(348)(24)(1,382)(27)
Comprehensive loss$(28,456)$(16,387)$(79,455)$(32,201)
Net loss per common share:
   Basic and diluted
$(1.10)$(0.74)$(3.08)$(1.48)
Weighted-average common shares outstanding:
   Basic and diluted
25,545,167 22,204,659 25,331,000 21,731,711 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4


Krystal Biotech, Inc.
Condensed Consolidated Statements of Stockholders' Equity
(unaudited)
 Common StockAdditional Paid-inAccumulated Other ComprehensiveAccumulatedTotal
Stockholders'
(In thousands, except shares)SharesAmountCapitalLossDeficitEquity
Balances at January 1, 202225,207,985 $ $734,523 $(163)$(140,784)$593,576 
Issuance of common stock, net1,475 — 55 — — 55 
Shares surrendered for taxes and forfeitures(10,379)— (649)— — (649)
Stock-based compensation expense— — 6,571 — — 6,571 
Unrealized loss on investments and other— — — (1,034)— (1,034)
Net loss— — — — (49,965)(49,965)
Balances at March 31, 202225,199,081 $ $740,500 $(1,197)$(190,749)$548,554 
Issuance of common stock, net472,706 — 30,748 — — 30,748 
Shares surrendered for taxes and forfeitures(7,500)— — — — — 
Stock-based compensation expense— — 8,335 — — 8,335 
Unrealized loss on investments and other— — — (348)— (348)
Net loss— — — — (28,108)(28,108)
Balances at June 30, 202225,664,287 $ $779,583 $(1,545)$(218,857)$559,181 
 Common StockAdditional Paid-inAccumulated Other Comprehensive AccumulatedTotal
Stockholders'
(In thousands, except shares)SharesAmountCapitalLossDeficitEquity
Balances at January 1, 202119,714,220 $ $363,292 $6 $(71,214)$292,084 
Issuance of common stock, net2,489,837 — 152,033 — — 152,033 
Stock-based compensation expense— — 2,350 — — 2,350 
Unrealized loss on investments and other— — — (3)— (3)
Net loss— — — — (15,812)(15,812)
Balances at March 31, 202122,204,057 $ $517,675 $3 $(87,026)$430,652 
Issuance of common stock, net975 — 14 — — 14 
Stock-based compensation expense— — 4,261 — — 4,261 
Unrealized loss on investments and other— — — (24)— (24)
Net loss— — — — (16,363)(16,363)
Balances at June 30, 202122,205,032 $ $521,950 $(21)$(103,389)$418,540 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5


Krystal Biotech, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)

 Six Months Ended
June 30,
(In thousands)20222021
Operating Activities
Net loss$(78,073)$(32,174)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization1,991 1,202 
Stock-based compensation expense14,619 6,508 
Non-cash interest expense 1,492 
Other, net(166)(117)
Changes in operating assets and liabilities
Prepaid expenses and other current assets848 1,366 
Other non-current assets15  
Lease liability(286)(175)
Accounts payable24 (680)
Accrued expenses and other current liabilities2,476 2,795 
Net cash used in operating activities(58,552)(19,783)
Investing Activities
Purchases of property and equipment(33,706)(6,462)
Purchases of investments(147,255)(59,561)
Proceeds from maturities of investments86,829 2,959 
Net cash used in investing activities(94,132)(63,064)
Financing Activities
Issuance of common stock, net30,807 152,065 
Taxes paid related to settlement of restricted stock awards(649) 
Repayment of ASTRA build to suit liability (7,960)
Net cash provided by financing activities30,158 144,105 
Net increase (decrease) in cash and cash equivalents(122,526)61,258 
Cash and cash equivalents at beginning of period341,246 268,269 
Cash and cash equivalents at end of period$218,720 $329,527 
Supplemental Disclosures of Non-Cash Investing and Financing Activities
Unpaid purchases of property and equipment included in accounts payable and accrued expenses$22,234 $10,143 
Initial recognition of right-of-use assets1,394 4,060 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6


Krystal Biotech, Inc.  
Notes to Condensed Consolidated Financial Statements
(unaudited)
1.    Organization
Krystal Biotech, Inc. (the “Company,” or “we” or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 24, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. On January 7, 2022, the Company incorporated Krystal Biotech Switzerland GmbH, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's pipeline.
We are a clinical stage biotechnology company leading the field of redosable gene delivery. Using our patented platform that is based on engineered herpes simplex virus type 1 ("HSV-1"), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a doctor’s office or potentially in the patient’s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions. Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities.
Liquidity
As of June 30, 2022, the Company had an accumulated deficit of $218.9 million. With the net proceeds raised from its public and private securities offerings, the Company believes that its cash, cash equivalents and short-term investments of approximately $425.6 million as of June 30, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.
The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to commercialize product candidates.
2.    Summary of Significant Accounting Policies
Basis of Presentation
The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), as found in the Accounting Standards Codification (“ASC”), the Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”), and the rules and regulations of the US Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company’s previously reported financial position or results of operation.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on February 28, 2022.
7


Risks and Uncertainties
The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.
Segment and Geographical Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products.  
Concentrations of Credit Risk and Off-Balance Sheet Risk
Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company’s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.
Cash, Cash Equivalents and Investments
Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90 days or less at the date of purchase.
Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.
As our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders’ equity in the condensed consolidated balance sheets.
8


Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:
Level 1— Valuations based on quoted prices in active markets for identical assets or liabilities.
Level 2— Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.
Level 3— Valuations based on inputs that are both significant to the fair value measurement and unobservable.
To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.
The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company’s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the holding period is longer than one year. The Company classifies all of its investments as available-for-sale.
Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.
Property and Equipment, net
Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:

Computer equipment and software
3 - 7 years
Lab equipment
3 - 7 years
Furniture and fixtures
3 - 7 years
Leasehold improvementlesser of remaining useful life or remaining lease term
Construction in progress ("CIP") is not depreciated until the asset is placed in service.
Impairment of Long-Lived Assets
The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and six months ended June 30, 2022 and 2021.
9


Leases
The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, Leases. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease. Right-of-use lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company’s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.  Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.
For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria. If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.
Research and Development Expenses
Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.
The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company’s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.
In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company’s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.
Stock-Based Compensation Expense
The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, Compensation—Stock Compensation ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant.
ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.
The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i) the expected stock price volatility; (ii) the expected term of the award; (iii) the risk-free interest rate; and (iv) expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.
The Company estimates the expected term of its stock options using the “simplified” method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates
10


are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.
Comprehensive Loss
Comprehensive loss is defined as the change in equity during a period from transactions from non-owner sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.
3.    Net Loss Per Share Attributable to Common Stockholders
Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 3,686,862 and 1,688,965 common share equivalents outstanding as of June 30, 2022 and 2021, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.

Three Months Ended
June 30,
Six Months Ended
June 30,
2022202120222021
(In thousands, except share and per share data)(Unaudited)(Unaudited)
Numerator: 
Net loss per common share$(28,108)$(16,363)$(78,073)$(32,174)
Denominator:
Weighted-average basic and
   diluted common shares
25,545,167 22,204,659 25,331,000 21,731,711 
Basic and diluted net loss per
   common share
$(1.10)$(0.74)$(3.08)$(1.48)

11


4.    Fair Value Instruments
The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of June 30, 2022 and December 31, 2021, respectively (in thousands):

 June 30, 2022
(unaudited)
 Amortized CostGross
Unrealized
Gains
Gross
Unrealized
Losses
Aggregate Fair
Value
Cash and Cash
Equivalents
Short-term
Marketable
Securities (1)
Long-term
Marketable
Securities (2)
Level 1:       
Cash and cash equivalents$218,720 $— $— $218,720 $218,720 $— $— 
Subtotal218,720 — — 218,720 218,720 — — 
Level 2:
Commercial paper46,157 1 (53)46,105 — 46,105  
Corporate bonds97,808  (890)96,918 — 88,853 8,065 
U.S. government agency securities77,317  (593)76,724 — 71,887 4,837 
Subtotal221,282 1 (1,536)219,747 — 206,845 12,902 
Total$440,002 $1 $(1,536)$438,467 $218,720 $206,845 $12,902 
 December 31, 2021
 Amortized CostGross
Unrealized
Gains
Gross
Unrealized
Losses
Aggregate Fair
Value
Cash and Cash
Equivalents
Short-term
Marketable
Securities (1)
Long-term
Marketable
Securities (2)
Level 1:       
Cash and cash equivalents$341,246 $— $— $341,246 $341,246 $— $— 
Subtotal341,246 — — 341,246 341,246 — — 
Level 2:
Commercial paper40,469 1 (4)40,466 — 40,466  
Corporate bonds83,300 10 (114)83,196 — 35,768 47,428 
U.S. government agency securities37,621  (62)37,559 — 20,616 16,943 
Subtotal161,390 11 (180)161,221 — 96,850 64,371 
Total$502,636 $11 $(180)$502,467 $341,246 $96,850 $64,371 
(1)The Company’s short-term marketable securities mature in one year or less.
(2)The Company's long-term marketable securities mature between one year and two years.
See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company’s fair value measurements.
12


5.    Balance Sheet Components
Property and Equipment, Net
Property and equipment, net consist of the following (in thousands):
 June 30,
2022
December 31,
2021
 (Unaudited) 
Construction in progress$142,893 $104,340 
Leasehold improvements5,736 5,723 
Furniture and fixtures900 891 
Computer equipment and software96 85 
Laboratory and manufacturing equipment6,740 5,530 
Total property and equipment156,365 116,569 
Accumulated depreciation and amortization(5,151)(4,214)
Property and equipment, net$151,214 $112,355 
Depreciation expense was $494 thousand and $956 thousand for the three and six months ended June 30, 2022 and $475 thousand and $914 thousand for the three and six months ended June 30, 2021, respectively.
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
 June 30,
2022
December 31,
2021
 (Unaudited) 
Accrued construction in progress$14,631 $9,606 
Accrued professional fees3,812 2,011 
Accrued payroll and benefits2,896 2,882 
Accrued preclinical and clinical expenses2,094 1,602 
Accrued financing costs29 26 
Accrued taxes22 83 
Other current liabilities297 87 
Total$23,781 $16,297 

6.    Commitments and Contingencies
Significant Contracts and Agreements
Lease Agreements
On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and was scheduled to expire on October 31, 2017 (the “2016 Lease”). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately 47,000 square feet and includes the commercial scale cGMP-compliant manufacturing facility, ANCORIS. As a result of the lease amendments, the 2016 Lease expiration date was extended to October 31, 2031.
On December 26, 2019, the Company entered into a lease agreement for a second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord", "Northfield", or "Lessor") with an initial lease term that expired on October 31, 2035. The ASTRA lease contained an option ("Purchase
13


Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the "Ground Lease"). A cash contribution in the amount of $2.4 million was paid to escrow on January 21, 2020. The contribution was intended to reduce the amount of the building construction costs and had the effect of reducing the base rental rate of the lease and as such, was recorded as prepaid rent in the consolidated balance sheet at the time of payment.
On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $9.4 million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020. The Company recorded a $10.0 million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contribution of $2.4 million.
On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $9.4 million. The Company held approximately $1.5 million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement. As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale. As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of June 30, 2022. The interior of the building is currently under construction and is expected to be completed and validated in 2022. From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.
As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $82 thousand, and are subject to a cumulative 10% escalation clause every 5 years through 2071.
On December 15, 2021, the Company entered into a 3 year lease agreement for the Boston, Massachusetts office that commenced in January 2022 and expires in January 2025.
As of June 30, 2022, future minimum commitments under the Company’s operating leases were as follows (in thousands):
 Operating
Leases
2022 (remaining six months)$743 
20231,510 
20241,539 
20251,277 
20261,277 
Thereafter12,063 
Future minimum operating lease payments$18,409 
Less: Interest9,276 
Present value of lease liability$9,133 
On May 16, 2022, the Company entered into a 16 month lease agreement for the Zug, Switzerland office ("Switzerland Lease") that commences on September 1, 2022 and expires December 31, 2023. As of June 30, 2022, the Company has not recorded a right-of-use asset or corresponding lease liability, as the Company has not yet gained control over the Switzerland Lease. Future minimum operating lease payments under the Switzerland Lease are $22 thousand and $89 thousand for the years ending 2022 and 2023, respectively.
14


Supplemental condensed consolidated balance sheet information related to leases is as follows:
(unaudited)
 June 30, 2022December 31, 2021
Operating leases:  
Right-of-use assets$8,279 $7,228 
Current portion of lease liability1,417 1,041 
Lease liability7,716 6,983 
Total lease liability$9,133 $8,024 
Weighted average remaining lease term, in years12.914.4
Weighted average discount rate9.4 %9.5 %

The Company recorded operating lease costs of $391 thousand and $800 thousand for the three and six months ended June 30, 2022 and $278 thousand and $497 thousand for the three and six months ended June 30, 2021, respectively. The Company recorded variable lease costs of $71 thousand and $120 thousand for the three and six months ended June 30, 2022 and $81 thousand and $118 thousand for the three and six months ended June 30, 2021, respectively.
Agreements with Contract Manufacturing Organizations and Contract Research Organizations
The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of June 30, 2022 under these agreements is approximately $2.1 million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $1.2 million and $3.0 million for each of the three and six months ended June 30, 2022 and $718 thousand and $2.5 million for the three and six months ended June 30, 2021.
Commercial Preparedness Activities
The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate. These contracts typically call for the payment of fees for services upon the achievement of certain milestones. The estimated remaining commitment as of June 30, 2022 is $5.1 million. The Company has incurred expenses under these activities of $3.1 million and $6.2 million for the three and six months ended June 30, 2022 and $974 thousand and $2.3 million for the three and six months ended June 30, 2021.
ASTRA Contractual Obligations
The Company has contracted with various third parties to construct our second cGMP facility, ASTRA. Additionally, the Company has entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of June 30, 2022 is $17.9 million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of June 30, 2022.
On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the “Agreement”) with The Whiting-Turner Contracting Company (“Whiting-Turner”), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to 1.75% of the cost of work.
Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be
15


paid by the Company is $83.0 million, subject to certain additions and deductions by change orders as provided by the Agreement. Whiting-Turner’s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner’s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement constitutes only a portion of the total estimated cost of building and equipping ASTRA.
Legal Proceedings
On May 1, 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. The Company answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that the Company did not misappropriate PeriphaGen’s trade secrets or confidential information, and to further declare that the Company is the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages.
On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022. During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions. On March 12, 2022, the Company entered into a binding term sheet to settle the dispute. On April 27, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $25.0 million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications. Upon approval of Krystal’s first product by the U.S. Food and Drug Administration, Krystal will pay PeriphaGen an additional $12.5 million, followed by three additional $12.5 million contingent milestone payments upon reaching $100.0 million in total cumulative sales, $200.0 million in total cumulative sales and $300.0 million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of Krystal products by Krystal and its affiliates and licensees, as reported by Krystal in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $75.0 million.
The Company recorded the $25.0 million under litigation settlement expense on the condensed consolidated statements of operations for the six months ended June 30, 2022. The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of June 30, 2022, and therefore no additional accrual has been recorded.
The Company has received $768 thousand of insurance proceeds during the three and six months ended June 30, 2022 and Company recorded an additional $369 thousand as a receivable within prepaid expenses and other current assets on the condensed consolidated balance sheet as management determined that the amount was probable of collection relating to legal defense costs and expenses associated with the PeriphaGen litigation. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.
7.    Capitalization
Sale of Common Stock
The Company sells shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program") finalized on December 31, 2020, under which Cowen acts as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $150.0 million ("Placement Shares"). The issuance and sale of the Placement Shares by the Company under the Sales Agreement are made pursuant to the Company's effective "shelf" registration statement on Form S-3. During 2021, the Company issued and sold 262,500 shares of common stock at a weighted average price of $66.50 per share for net proceeds of $16.9 million after deducting selling commissions of approximately $524 thousand. During the six months ended June 30, 2022, the Company issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share for net proceeds of $29.1 million after deducting selling commissions of approximately $900 thousand, resulting in a remaining $102.5 million available for issuance under the ATM Program.
16


On December 3, 2021, the Company completed an underwritten public offering of 2,866,667 shares of its common stock, including 200,000 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $75.00 per share. Net proceeds to the Company from the offering were $201.9 million after deducting underwriting discounts and commissions of approximately $12.9 million, and other offering expenses payable by the Company of $227 thousand.
On February 1, 2021, the Company completed an underwritten public offering of 2,211,538 shares of its common stock, including 288,461 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $65.00 per share. Net proceeds to the Company from the offering were $134.9 million after deducting underwriting discounts and commissions of approximately $8.6 million, and other offering expenses payable by the Company of $198 thousand.
8.    Stock-Based Compensation
Stock Options
Options granted to employees and non-employees vest ratably over four-year periods and stock options granted to directors of the company vest ratably over one-year to four-year periods. Stock options have a life of ten years.
The Company granted 544,500 and 1,724,000 stock options to employees and directors of the Company during the three and six months ended June 30, 2022, respectively, and 297,500 and 799,950 stock options to employees and directors of the Company during the three and six months ended June 30, 2021, respectively.
The Company granted 45,000 stock options to non-employees during the three and six months ended June 30, 2022, respectively, and zero stock options to non-employees during the three and six months ended June 30, 2021, respectively.
The following table summarizes the Company’s stock option activity:
 Stock
Options
Outstanding
Weighted-
average
Exercise
Price
Weighted-
average
Remaining
Contractual
Life (Years)
Aggregate
Intrinsic
Value
(In thousands) (1)
Outstanding at December 31, 20212,043,179 $57.00 9.0$31,331 
Granted1,769,000 $62.19 
Exercised(39,399)$44.13 
Cancelled or forfeited(151,642)$55.24 
Expired(876)$74.92 
Outstanding at June 30, 20223,620,262 $59.75 9.1$28,341 
Exercisable at June 30, 2022536,979 $47.48 7.5$11,184 
(1)Aggregate intrinsic value represents the difference between the closing stock price of our common stock on June 30, 2022 and the exercise price of outstanding in-the-money options.
The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three and six months ended June 30, 2022 was $704 thousand and $739 thousand, respectively, and during the three and six months ended June 30, 2021 was $64 thousand and $872 thousand, respectively.
The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the three and six months ended June 30, 2022 was $42.90 and $43.03, respectively, and during the three and six months ended June 30, 2021 was $42.53 and $47.25, respectively.
There was $115.7 million of unrecognized stock-based compensation expense related to employees', non-employees', and directors’ option awards that is expected to be recognized over a weighted-average period of 3.3 years as of June 30, 2022.
The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and six months ended June 30, 2022 and 2021 as follows (in thousands):
17


 Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
(unaudited)(unaudited)
Research and development$1,995 $1,084 $3,363 $1,600 
General and administrative5,776 2,625 10,357 4,240 
Total stock-based compensation$7,771 $3,709 $13,720 $5,840 
We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $146 thousand and $287 thousand of stock-based compensation that was capitalized in the three and six months ended June 30, 2022, respectively, and $66 thousand and $103 thousand of stock-based compensation that was capitalized in the three and six months ended June 30, 2021, respectively.
The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and six months ended June 30, 2022 and 2021:

 Three Months Ended June 30,Six Months Ended March 31,
 2022202120222021
Expected stock price volatility78 %72 %78 %72 %
Expected term of the award (years)6.176.106.216.18
Risk-free interest rate2.92 %1.05 %2.17 %1.02 %
Weighted average exercise price$61.51$66.58$62.19$73.42
Forfeiture rate % % % %
Restricted Stock Awards
Restricted stock awards ("RSAs") granted to employees vest ratably over a four-year period. The Company granted zero RSAs to employees of the Company during the three and six months ended June 30, 2022, respectively, and zero and 98,800 RSAs to employees of the Company during the three and six months ended June 30, 2021, respectively.
Number of SharesWeighted Average
Grant Date
Fair Value
Non-vested RSAs as of December 31, 202198,800 $78.89 
Granted $ 
Vested(14,321)$78.89 
Surrendered or forfeited(17,879)$78.89 
Non-vested RSAs as of June 30, 202266,600 $78.89 
There was $4.7 million of unrecognized stock-based compensation expense related to employees’ awards that is expected to be recognized over a weighted-average period of 2.7 years as of June 30, 2022.
The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and six months ended June 30, 2022 and 2021 as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
(unaudited)(unaudited)
General and administrative$418 $486 $899 $668 
Total stock-based compensation$418 $486 $899 $668 
18


Shares remaining available for grant under the Company’s stock incentive plan were 530,991, with a sublimit for incentive stock options of 1,296, at June 30, 2022.
9.    Subsequent Events
The Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.

19


ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included in Item 1 of Part I of this Quarterly Report on Form 10-Q and with the audited financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on February 28, 2022.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Some of such factors include, but are not limited to:
the initiation, timing, cost, progress and results, of our research and development activities, preclinical studies and clinical trials for B-VEC (previously “KB103” and now known as VyjuvekTM), KB105, KB104, KB407, KB408, KB301, KB303, and any other product candidates;
the continuing impact that the COVID-19 pandemic and measures implemented to prevent its spread may have on our business operations, access to capital, research and development activities, and preclinical and clinical trials for our product candidates;
the timing, scope or results of regulatory filings and approvals, including timing of final US Food and Drug Administration (“FDA”), marketing and other regulatory approval of our product candidates;
our ability to achieve certain accelerated or orphan drug designations from the FDA;
changes in our estimates regarding the potential market opportunity for B-VEC, KB105, KB104, KB407, KB408, KB301, KB303 and any other product candidates;
our ability to raise capital to fund our operations;
increased costs associated with our research and development programs for our product candidates;
our general and administrative expenses;
risks related to our ability to successfully develop and commercialize our product candidates, including B-VEC, KB105, KB104, KB407, KB408, KB301, KB303 and our other product candidates;
our ability to identify and develop new product candidates;
our ability to identify, recruit and retain key personnel;
risks related to our marketing and manufacturing capabilities and strategy;
our business model and strategic plans for our business, product candidates and technology;
the cost of building a medical affairs and commercial organization, including a sales force in anticipation of commercialization of B-VEC and any additional product candidates;
the rate and degree of market acceptance and clinical utility of our product candidates and gene therapy, in general;
our competitive position and the success of competing therapies;
our intellectual property position and our ability to protect and enforce our intellectual property;
our financial performance;
our ability to establish and maintain collaborations or obtain additional funding;
our estimates regarding expenses, future revenue, capital requirements and needs for or ability to obtain additional financing;
20


our ability to successfully avoid or resolve any litigation, intellectual property or other claims, that may be brought against us;
global economic conditions, including the recent rise in inflation; and
the impact of changes in laws and regulations.
Forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in other filings we make with the SEC from time to time. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this Quarterly Report. You should read this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect.
Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Throughout this Form 10-Q, unless the context requires otherwise, all references to “Krystal,” “the Company,” we,” “our,” “us” or similar terms refer to Krystal Biotech, Inc., together with its consolidated subsidiaries.
Overview
We are a clinical stage biotechnology company leading the field of redosable gene delivery. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional’s office or potentially in the patient’s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions. Our innovative technology platform is supported by in-house, commercial scale cGMP manufacturing capabilities.

21



Our Product Candidates
The following table summarizes information regarding our product candidates in various stages of clinical and preclinical development:
krys-20220630_g1.jpg
There can be no assurance that the upcoming milestones will be met on the expected timeline or at all.
22




Pipeline Highlights and Recent Developments
B-VEC is a topical gel containing our novel vector designed to deliver two copies of the COL7A1 transgene for the treatment of dystrophic epidermolysis bullosa ("dystrophic EB"), a serious rare skin disease caused by missing or mutated type VII collagen protein. Our randomized, double-blind, placebo-controlled GEM-3 pivotal study was designed to evaluate topical B-VEC as compared to placebo in dystrophic EB patients. Following public announcement of topline data from the GEM-3 study trial on November 29, 2021, we presented more detailed results at the 2022 American Academy of Dermatology Annual Meeting on March 26, 2022 and at the Society of Investigative Dermatology Annual Meeting on May 19, 2022. On March 28, 2022, we announced that results from the Phase 1 and 2 study of B-VEC were published in Nature Medicine. In 2Q 2021, we began enrolling patients into an open label extension ("OLE") study, including patients who participated in the Phase 3 study, as well as new participants who meet all enrollment criteria. Based on the feedback from the FDA following their review of our human factors validation study report, we announced on April 11, 2022 our plan to offer dystrophic EB patients enrolled in the GEM-3 OLE, the opportunity to be dosed in their homes by a healthcare professional.
On June 22, 2022, we filed a Biologics License Application with the FDA seeking approval of B-VEC for the treatment of patients with dystrophic EB, and we expect to file a Marketing Authorization Application with the European Medicines Agency in 2H 2022. We can provide no assurances as to whether B-VEC will be approved or the ultimate timing of any approval from either agency.
KB407 is an inhaled (nebulized) formulation of our novel vector designed to deliver two copies of the full-length cystic fibrosis transmembrane conductance regulator ("CFTR") transgene for the treatment of cystic fibrosis, a serious rare lung disease caused by missing or mutated CFTR gene. On August 1, 2022, we announced that the FDA had accepted our KB407 Investigational New Drug ("IND") application, and we plan to initiate a Phase 1 clinical study ("CORAL-1/US study") of inhaled KB407 in patients with cystic fibrosis ("CF") in the U.S. in 2H 2022. Previously, on September 29, 2021, we announced that the Bellberry Human Research Ethics Committee in Australia granted approval to conduct a Phase 1 clinical study ("CORAL-1/AU study") of inhaled KB407 in patients with CF. We have begun screening patients for enrollment in the CORAL-1/AU study and plan to initiate dosing in 2H22.
KB105 is a topical gel containing our novel vector designed to deliver two copies of the TGM1 transgene for the treatment of TGM1-deficient autosomal recessive congenital ichthyosis ("TGM1-ARCI"), a serious rare skin disorder caused by missing or mutated TGM1 protein. A randomized, placebo-controlled Phase 1/2 study is ongoing. On July 1, 2021, we announced data from the fourth patient dosed in the trial, showing repeat topical KB105 dosing continued to be well tolerated with no adverse events or evidence of immune response. We plan to resume dosing in the KB105 Phase 1/2 study later this year.
KB104 is a topical gel formulation of our novel vector designed to deliver two copies of the SPINK5 transgene for the treatment of Netherton Syndrome, a debilitating autosomal recessive skin disorder caused by missing or mutated SPINK5 protein. We expect to initiate a Phase 1 clinical study in 2022.
We have several other product candidates in various stages of preclinical development as reflected in the chart above.
We are also leveraging the ability of our platform to deliver proteins of interest to cells in the skin in the context of aesthetic medicine via our wholly-owned subsidiary Jeune Aesthetics, Inc. ("Jeune"). A summary description of Jeune’s lead product candidate and its status is as follows:
KB301 is a solution formulation of our novel vector for intradermal injection designed to deliver two copies of the COL3A1 transgene to address signs of aging or damaged skin caused by declining levels of, or damaged proteins within the extracellular matrix, including type III collagen. On March 22, 2022, we announced positive proof-of-concept efficacy data from Cohort 2 of the PEARL-1 study of KB301. In Q2 2022, subjects from the PEARL-1 Cohort 2 trial were enrolled in a durability trial to evaluate duration of treatment effect, reduction of the unevenness in placebo treated sites, and long term safety monitoring. We anticipate announcing data from the durability trial in 2H 2022 and initiating a Phase 2 trial in 4Q 2022 or early 2023.
Jeune has several other aesthetic medicine product candidates in various stages of preclinical development as reflected in the chart above.

23




COVID-19 Update
To date the impact of the COVID-19 pandemic on our business and clinical trials in the U.S. has been minimal. We will continue to assess the potential impact of the pandemic on our business and operations, including our supply chain and preclinical and clinical trial activities. Outside of the U.S., we have experienced pandemic-related delays in clinical trial initiation in Australia, and we will continue to closely monitor the impact that future pandemic developments have on this and our other clinical trials, going forward. For additional information regarding the impact of the coronavirus pandemic, please see "Risk Factor - Business interruptions resulting from the COVID-19 outbreak or similar public health crises could cause a disruption of the development efforts of our product candidates and adversely impact our business." in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Financial Overview
Revenue
We currently have no approved products for commercial marketing or sale and have not generated any revenue from the sale of products or other sources to date. In the future, we may generate revenue from product sales, royalties on product sales, or license fees, milestones, or other upfront payments if we enter into any collaborations or license agreements. We expect that our future revenue will fluctuate from quarter to quarter for many reasons, including the uncertain timing and amount of any such sales.
Research and Development Expenses
Research and development expenses consist primarily of costs incurred to advance our preclinical and clinical candidates, which include:
expenses incurred under agreements with contract manufacturing organizations, consultants and other vendors that conduct our preclinical activities;
costs of acquiring, developing and manufacturing clinical trial materials and lab supplies;
facility costs, depreciation and other expenses, which include direct expenses for rent and maintenance of facilities and other supplies; and
payroll related expenses, including stock-based compensation expense.
We expense internal research and development costs to operations as incurred. We expense third party costs for research and development activities, such as the manufacturing of preclinical and clinical materials, based on an evaluation of the progress to completion of specific tasks such as manufacturing of drug substance, fill/finish and stability testing, which is provided to us by our vendors.
We expect our research and development expenses will increase as we continue the manufacturing of preclinical and clinical materials and manage the clinical trials of, and seek regulatory approval for, our product candidates and expand our product portfolio. In the near term, we expect that our research and development expenses will increase as we continue our open label extension study for B-VEC, resume dosing with KB105 Phase 1/2 clinical trial, initiate a Phase 2 trial for KB301, initiate a Phase 1 trial for KB407, initiate a Phase 1 trial for KB104, and incur preclinical expenses for our other product candidates. Due to the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration, costs and timing of clinical trials, and, as a result, the actual costs to complete clinical trials may exceed the expected costs. 
General and Administrative Expenses
General and administrative expenses consist principally of salaries and other related costs, including stock-based compensation for personnel in our executive, commercial, business development and other administrative functions. General and administrative expenses also include professional fees associated with corporate and intellectual property-related legal expenses, consulting and accounting services, facility-related costs and expenses associated with obtaining and maintaining patents. Other general and administrative costs include travel expenses.
We anticipate that our general and administrative expenses will increase in the future to support the continued research and development of our product candidates and to operate as a public company. These increases will likely include increased
24


costs for insurance, costs related to the hiring of additional personnel and payments to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate that we will increase our salary and personnel costs and other expenses as a result of our preparation for commercial operations.
ASTRA Capital Expenditures
On March 5, 2021, we closed on the purchase of the building that was constructed to house our second cGMP facility, ASTRA. We are currently in the process of constructing the interior build-out of this facility and we have entered into a contract with Whiting-Turner who manages the construction of ASTRA. Further, we have entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. We expect to continue to incur significant capital expenditures related to ASTRA as we construct and validate this facility, which is expected to be completed in 2022.
Interest Income  
Interest income consists primarily of income earned from our cash, cash equivalents and investments.
Interest Expense
Interest expense consists primarily of non-cash interest expense recognized to accrete the build to suit financial obligation to a balance that equaled the cash consideration that was paid upon the close of the purchase of ASTRA.
Critical Accounting Policies, Significant Judgments and Estimates
There have been no significant changes during the three and six months ended June 30, 2022 to our critical accounting policies, significant judgments and estimates as disclosed in our management’s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December 31, 2021.
25


Results of Operations
Three Months Ended June 30, 2022 and 2021
 
Three Months Ended June 30,
 
 20222021Change
(In thousands)(unaudited) 
Expenses   
Research and development$10,890 $6,594 $4,296 
General and administrative17,863 9,799 8,064 
Total operating expenses28,753 16,393 12,360 
Loss from operations(28,753)(16,393)(12,360)
Other Income (Expense) 
Interest and other income, net645 30 615 
Net loss$(28,108)$(16,363)$(11,745)
Research and Development Expenses 
Research and development expenses increased $4.3 million in the three months ended June 30, 2022 compared to the three months ended June 30, 2021. Higher research and development expenses were due to an increase in preclinical, clinical and pre-commercial manufacturing activities of $1.3 million, payroll related expenses of $1.9 million, which were primarily driven by an increase in headcount to support overall growth, and includes a $911 thousand increase in stock-based compensation, outsourced research and development activities of $803 thousand and other research and development expenses of $316 thousand, primarily due to software related costs and rent.
General and Administrative Expenses
General and administrative expenses increased $8.1 million in the three months ended June 30, 2022 as compared to the three months ended June 30, 2021. Higher general and administrative spending was due largely to increases in payroll related expenses of approximately $6.5 million, which was primarily driven by an increase in headcount in our executive, commercial, business development and other administrative functions to support overall growth, and includes a $3.1 million increase in stock-based compensation, commercial preparedness expenses of approximately $1.7 million, medical affairs costs of $268 thousand, software related costs of $165 thousand, business development costs of $215 thousand, travel related activities of $136 thousand and other administrative expenses of $460 thousand, primarily due to charitable contributions and conference expenses. These increases were offset by a net decrease in legal and professional fees of approximately $1.3 million, which includes $68 thousand of insurance proceeds.
Other Income (Expense)
Interest and other income for the three months ended June 30, 2022 and 2021 was $645 thousand and $30 thousand, respectively, and consisted of interest and dividend income earned from our cash, cash equivalents and investments.
26


Six Months Ended June 30, 2022 and 2021
 Six Months Ended June 30, 
 20222021Change
(In thousands)(unaudited) 
Expenses   
Research and development$20,204 $12,795 $7,409 
General and administrative33,771 17,951 15,820 
Litigation settlement25,000 — 25,000 
Total operating expenses78,975 30,746 48,229 
Loss from operations(78,975)(30,746)(48,229)
Other Income (Expense) 
Interest and other income, net902 64 838 
Interest expense— (1,492)1,492 
Net loss$(78,073)$(32,174)$(45,899)
Research and Development Expenses 
Research and development expenses increased $7.4 million in the six months ended June 30, 2022 compared to the six months ended June 30, 2021. Higher research and development expenses were due to an increase in preclinical, clinical and pre-commercial manufacturing activities of $2.5 million, payroll related expenses of $3.5 million, which were primarily driven by an increase in headcount to support overall growth, and includes a $1.8 million increase in stock-based compensation, outsourced research and development activities of $909 thousand and other research and development expenses of $586 thousand, primarily due to software related costs and rent. These increases were partially offset by a decrease in travel related activities of approximately $61 thousand.
General and Administrative Expenses
General and administrative expenses increased $15.8 million in the six months ended June 30, 2022 as compared to the six months ended June 30, 2021. Higher general and administrative spending was due largely to increases in payroll related expenses of approximately $12.2 million, which was primarily driven by an increase in headcount in our executive, commercial, business development and other administrative functions to support overall growth, and includes a $6.4 million increase in stock-based compensation, commercial preparedness expenses of approximately $3.2 million, medical affairs costs of $336 thousand, software related costs of $295 thousand, business development costs of $378 thousand, travel related activities of $189 thousand, and other administrative expenses of $948 thousand, primarily due to rent, taxes, charitable contributions and conference expenses. These increases were offset by a net decrease in legal and professional fees of approximately $1.7 million, which includes $577 thousand of insurance proceeds.
Litigation settlement
Litigation settlement for the six months ended June 30, 2022 and 2021 was $25.0 million and zero, respectively, and consisted of the settlement of litigation with PeriphaGen. See "Legal Proceedings" in Note 6 of the notes to condensed consolidated financial statements included in this Form 10-Q for more information.
Other Income (Expense)
Interest and other income for the six months ended June 30, 2022 and 2021 was $902 thousand and $64 thousand, respectively, and consisted of interest and dividend income earned from our cash, cash equivalents and investments.
Interest expense for the six months ended June 30, 2022 and 2021 was zero and $1.5 million, respectively, and related to accretion of the financial obligation for the build to suit lease liability during the six months ended June 30, 2021 to a balance that equaled the purchase consideration for ASTRA.
27


Liquidity and Capital Resources
Overview
At June 30, 2022, our cash, cash equivalents and short-term investments balance was approximately $425.6 million. Since operations began, we have incurred operating losses. Our net losses were $28.1 million and $78.1 million for the three and six months ended June 30, 2022, respectively, and $16.4 million and $32.2 million for the three and six months ended June 30, 2021, respectively. At June 30, 2022, we had an accumulated deficit of $218.9 million. With the net proceeds raised from our previous public and private securities offerings and our ability to issue additional shares under our current ATM program, the Company believes that our cash, cash equivalents and short-term investments as of June 30, 2022 will be sufficient to allow the Company to fund operations for at least 12 months from the filing date of this Form 10-Q.
As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of our product candidates and the achievement of a level of revenues adequate to support the Company’s cost structure. Furthermore, we expect to incur increasing costs associated with satisfying regulatory and quality standards, maintaining product and clinical trials, and furthering our efforts around our current and future product candidates. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources.
Costs related to clinical trials can be unpredictable and therefore there can be no guarantee that we will have sufficient capital to fund our continued clinical studies of B-VEC, KB105, KB301 or our planned preclinical studies for our other product candidates, or our operations. Further, we do not expect to generate any product revenues until 4Q 2022, at the earliest, assuming we receive marketing approval for B-VEC on the schedule we currently contemplate. While we are in the process of building out our internal vector manufacturing capacity, some of our manufacturing activities will be contracted out to third parties. Additionally, we currently utilize third-party contract research organizations to carry out some of our clinical development activities. As we seek to obtain regulatory approval for any of our product candidates, we expect to continue to incur significant commercialization expenses as we prepare for product sales, marketing, manufacturing, and distribution. Furthermore, pursuant to our settlement agreement with PeriphaGen, we will be required to pay $12.5 million upon the approval of our first product by the FDA, followed by three additional $12.5 million contingent milestone payments upon reaching $100.0 million in total cumulative sales, $200.0 million in total cumulative sales and $300.0 million in total cumulative sales. Our funds may not be sufficient to enable us to conduct pivotal clinical trials for, seek marketing approval for or commercially launch B-VEC, KB105, KB301 or any other product candidate. Accordingly, to obtain marketing approval for and to commercialize these or any other product candidates, we may be required to obtain further funding through public or private equity offerings, debt financings, collaboration and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, if at all. Our failure to raise capital when needed could have a negative effect on our financial condition and our ability to pursue our business strategy.
Operating Capital Requirements
Our primary uses of capital are, and we expect will continue to be for the near future, compensation and related expenses, manufacturing costs for preclinical and clinical materials, third party clinical trial research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses, payments of settlement amounts to PeriphaGen and general overhead costs. In order to complete the process of obtaining regulatory approval for any of our product candidates and to build the sales, manufacturing, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we may require substantial additional funding.
We have based our projections of operating capital requirements on assumptions that may prove to be incorrect, and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:
the timeline and cost of our OLE study for B-VEC;
the progress, timing and costs of our ongoing Phase 1/2 clinical trials for KB105;
the progress, results and costs of our Phase 2 clinical trials for KB301;
the progress, timing and costs of manufacturing of B-VEC;
the continued development and the filing of an IND application for future product candidates;
the initiation, scope, progress, timing, costs and results of drug discovery, laboratory testing, manufacturing, preclinical studies and clinical trials for any other product candidates that we may pursue in the future, if any;
28


the costs of maintaining our own commercial-scale cGMP manufacturing facilities;
the outcome, timing and costs of seeking regulatory approvals;
the costs associated with the manufacturing process development and evaluation of third-party manufacturers;
the extent to which the costs of our product candidates, if approved, will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors;
the costs of commercialization activities for our current and future product candidates if we receive marketing approval for such product candidates we may develop, including the costs and timing of establishing product sales, medical affairs, marketing, distribution and manufacturing capabilities;
subject to receipt of marketing approval, if any, revenue received from commercial sale of our current and future product candidates;
the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish;
the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or other intellectual property rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreements;
our current license agreements remaining in effect and our achievement of milestones under those agreements;
our ability to establish and maintain collaborations and licenses on favorable terms, if at all; and
the extent to which we acquire or in-license other product candidates and technologies.
We may need to obtain substantial additional funding in order to receive regulatory approval and to commercialize our product candidates. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our existing stockholders may be materially diluted and the terms of these securities could include liquidation or other preferences that could adversely affect the rights of our existing stockholders. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely affect our ability to conduct our business. If we are unable to raise capital when needed or on attractive terms, we could be forced to significantly delay, scale back or discontinue the development or commercialization of our product candidates, seek collaborators at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, and relinquish or license, potentially on unfavorable terms, our rights to our product candidates that we otherwise would seek to develop or commercialize ourselves. 
Sources and Uses of Cash
The following table summarizes our sources and uses of cash for the six months ended June 30, 2022 (in thousands):
 Six Months Ended June 30,
20222021
(unaudited)
Net cash used in operating activities$(58,552)$(19,783)
Net cash used in investing activities(94,132)(63,064)
Net cash provided by financing activities30,158 144,105 
Net increase (decrease) in cash$(122,526)$61,258 
Operating Activities
Net cash used in operating activities for the six months ended June 30, 2022 was $58.6 million and consisted primarily of a net loss of $78.1 million adjusted for non-cash items primarily comprised of depreciation and amortization and stock-based compensation expense of $16.4 million, and including net changes in operating assets and liabilities of approximately $3.1 million.
29


Net cash used in operating activities for the six months ended June 30, 2021 was $19.8 million and consisted primarily of a net loss of $32.2 million adjusted for non-cash items primarily comprised of depreciation and amortization and stock-based compensation expense of approximately $7.7 million and build to suit interest expense of $1.5 million, including net changes in operating assets and liabilities of approximately $3.2 million.
Investing Activities
Net cash used in investing activities for the six months ended June 30, 2022 was $94.1 million and consisted primarily of expenditures of $33.7 million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchases of computer and laboratory equipment, $147.3 million on the purchase of short-term and long-term investments, partially offset by proceeds of $86.8 million received from the maturities of short-term investments.
Net cash used in investing activities for the six months ended June 30, 2021 was $63.1 million and consisted primarily of expenditures of $6.5 million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchases of computer and laboratory equipment, $59.6 million on the purchase of short-term and long-term investments, partially offset by proceeds of $3.0 million received from the maturities of short-term investments.
Financing Activities
Net cash provided by financing activities for the six months ended June 30, 2022 was $30.2 million and consisted primarily of proceeds of $30.8 million received from our ATM Program and exercises of stock options and offset by $649 thousand used for the employee tax withholding payment for settlement of vested restricted stock awards.
During the six months ended June 30, 2022, the Company issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share for net proceeds of $29.1 million after deducting underwriting discounts and commissions of approximately $900 thousand.
For the six months ended June 30, 2022, the Company received proceeds of $1.7 million from the exercise of stock options.
Net cash provided by financing activities for the three months ended June 30, 2021 was $144.1 million and consisted primarily of proceeds of $152.1 million received from our ATM Program, a public offering, and exercises of stock options, partially offset by $8.0 million used for the purchase of the ASTRA building.
On February 1, 2021, the Company completed a public offering of 2,211,538 shares of its common stock at $65.00 per share. Net proceeds to the Company from the offering were $134.9 million after deducting underwriting discounts and commissions of approximately $8.6 million and other offering expenses of approximately $198 thousand.
During the six months ended June 30, 2021, pursuant to the ATM Program the Company issued 262,500 shares of common stock at a weighted average price of $66.50 per share for net proceeds of $16.9 million after deducting underwriting discounts and commissions of approximately $524 thousand. The Company also incurred $172 thousand of other offering expenses related to the ATM Program.
For the six months ended June 30, 2021, the Company received proceeds of $360 thousand from the exercise of stock options.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements as defined in the rules and regulations of the SEC.
Contractual Obligations
There have been no material changes to our contractual obligations as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 other than as described in Note 6 “Commitments and Contingencies” of our condensed consolidated financial statements on this Form 10-Q.

ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Qualitative and Quantitative Disclosures About Market Risk
30


We had cash, cash equivalents and short-term investments of $425.6 million at June 30, 2022, which consist primarily of money market, bank deposits, commercial paper, corporate bonds, and government agency securities. The investments in these financial instruments are made in accordance with an investment policy which specifies the categories, allocations and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments in which we invest could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. To minimize this risk, we intend to maintain a portfolio which may include cash, cash equivalents and short and long-term investment securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt securities and commercial paper, all with various maturity dates. Based on our current investment portfolio, we do not believe that our results of operations or our financial position would be materially affected by an immediate change of 10% in interest rates.
We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our cash, cash equivalents and short-term investments have a significant risk of default or illiquidity. While we believe our cash, cash equivalents and short-term investments do not contain excessive risk, we cannot provide absolute assurance that the investments we make in the future will not be subject to adverse changes in market value. Our cash, cash equivalents and short and long-term investments are recorded at fair value.

ITEM 4.    CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our Chief Executive Officer and our Chief Accounting Officer, with the participation of other members of the Company’s management, have evaluated the effectiveness of the Company’s “disclosure controls and procedures” (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”)) as of the end of the period covered by this quarterly report, and our Chief Executive Officer and our Chief Accounting Officer have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.
Changes in Internal Control over Financial Reporting
In 2021, we implemented a new enterprise resource planning software, Microsoft Dynamics D365 (“Dynamics”), as part of a plan to integrate and upgrade our systems and processes. The implementation of this software is scheduled to continue in phases over a number of years. As the phased implementation of this system occurs, we expect certain changes to our processes and procedures which, in turn, will result in changes to our internal control over financial reporting. We expect Dynamics to strengthen our internal financial controls by automating a number of accounting and reporting processes and activities, thereby decreasing the number of manual processes previously required. Management will continue to evaluate and monitor our internal controls as processes and procedures in each of the affected areas evolve.
Other than as discussed above, no change in our internal control over financial reporting occurred during the quarter ended June 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.


31


PART II. OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS
The information set forth under the heading “Legal Proceedings” in Note 6 of the notes to condensed consolidated financial statements included in Item 1 of Part I of this Form 10-Q is incorporated by reference in response to this item.
Item 1A. Risk Factors.
As disclosed in "Summary Risk Factors" and "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on February 28, 2022, there are a number of risks and uncertainties that may have a material effect on the operating results of our business and our financial condition. There have been no material changes from the risk factors previously disclosed in such filing.
ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3.    DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4.    MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5.    OTHER INFORMATION
None.
32


ITEM 6.    EXHIBITS
Exhibit
Number
  
   
31.1 
   
31.2 
   
32.1 
   
101 
Inline XBRL (Extensible Business Reporting Language). The following materials from this Quarterly Report on Form 10-Q for the period ended June 30, 2022, are formatted in Inline XBRL: (i) consolidated balance sheets of Krystal Biotech, Inc., (ii) consolidated statements of operations of Krystal Biotech, Inc., (iii) consolidated statements of comprehensive income/(loss) of Krystal Biotech, Inc., (iv) consolidated statements of changes in equity of Krystal Biotech, Inc., (v) consolidated statements of cash flows of Krystal Biotech, Inc. and (vi) notes to consolidated financial statements of Krystal Biotech, Inc. The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
   
104 
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL.

33


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
    KRYSTAL BIOTECH, INC.
    (Registrant)
   
Date: August 8, 2022
 By: /s/ Krish S. Krishnan
    Krish S. Krishnan
    President and Chief Executive Officer
(Principal executive officer)
     
   
 By: /s/ Kathryn A. Romano
    Kathryn A. Romano
    Chief Accounting Officer
    (Principal financial and accounting officer)

34
EX-31.1 2 krys-20220630ex311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Krish S. Krishnan, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Krystal Biotech, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the Condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
c.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 8, 2022
By:/s/ Krish S. Krishnan
  Krish S. Krishnan
  President and Chief Executive Officer
   


EX-31.2 3 krys-20220630ex312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF CHIEF ACCOUNTING OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Kathryn A. Romano, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Krystal Biotech, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the Condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
c.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 8, 2022
By:/s/ Kathryn A. Romano
  Kathryn A. Romano
  Chief Accounting Officer
   


EX-32.1 4 krys-20220630ex321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF ACCOUNTING OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Krish S. Krishnan, Chief Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.the Quarterly Report on Form 10-Q for the three months ended June 30, 2022, (the “Periodic Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Krystal Biotech, Inc.
Date: August 8, 2022
By: /s/ Krish S. Krishnan
   Krish S. Krishnan
   President and Chief Executive Officer
 
I, Kathryn A. Romano, Chief Accounting Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.the Quarterly Report on Form 10-Q for the three months ended June 30, 2022, (the “Periodic Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Krystal Biotech, Inc.
Date: August 8, 2022
By: /s/ Kathryn A. Romano
   Kathryn A. Romano
   Chief Accounting Officer


EX-101.SCH 5 krys-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Organization - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2108103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail) link:presentationLink link:calculationLink link:definitionLink 2112104 - Disclosure - Fair Value Instruments link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - Fair Value Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail) link:presentationLink link:calculationLink link:definitionLink 2115105 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 2316304 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 2417407 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) link:presentationLink link:calculationLink link:definitionLink 2418408 - Disclosure - Balance Sheet Components - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2120106 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2321305 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2422410 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail) link:presentationLink link:calculationLink link:definitionLink 2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail) link:presentationLink link:calculationLink link:definitionLink 2424412 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 2125107 - Disclosure - Capitalization link:presentationLink link:calculationLink link:definitionLink 2426413 - Disclosure - Capitalization - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2127108 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2328306 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2429414 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2430415 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 2431416 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail) link:presentationLink link:calculationLink link:definitionLink 2432417 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail) link:presentationLink link:calculationLink link:definitionLink 2433418 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2134109 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 krys-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 krys-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 krys-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Property, Plant and Equipment, Type Long-Lived Tangible Asset [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] ATM Program ATM Program [Member] ATM Program Future minimum operating lease payments Lessee, Operating Lease, Liability, to be Paid Property and Equipment, net Property, Plant and Equipment, Policy [Policy Text Block] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Stock options granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Recognized impairment losses for long lived assets Impairment, Long-Lived Asset, Held-for-Use Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location Balance Sheet Location [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Denominator: Earnings Per Share, Basic [Abstract] Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Weighted-average common shares outstanding: diluted Weighted Average Number of Shares Outstanding, Diluted Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Capitalization, Equity [Table] Schedule of Capitalization, Equity [Table] Expected term of the award (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Finance lease, liability Finance Lease, Liability Total property and equipment Property, Plant and Equipment, Gross Lessor, operating lease, liability, annual lease payments Lessor, Operating Lease, Liability, Annual Lease Payments Lessor, Operating Lease, Liability, Annual Lease Payments Clinical Supply Agreements Clinical Supply Agreement [Member] Clinical supply agreement. Weighted average exercise price (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price. Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant accounting policies. Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Common stock; $0.00001 par value; 80,000,000 shares authorized at    June 30, 2022 (unaudited) and December 31, 2021; 25,664,287    shares issued and outstanding at June 30, 2022    (unaudited); and 25,207,985 shares issued and outstanding at December 31, 2021 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases [Table Text Block] Schedule of supplemental condensed consolidated balance sheet information related to leases. Switzerland Lease Switzerland Lease [Member] Switzerland Lease Financial Instruments [Domain] Financial Instruments [Domain] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Statistical Measurement Statistical Measurement [Domain] Depreciation expense Depreciation Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Milestones [Domain] Milestones [Domain] Milestones [Domain] Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Exercisable at June 30, 2022 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Accrued payroll and benefits Accrued Payroll And Benefits Accrued payroll and benefits. Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Preferred stock, shares authorized Preferred Stock, Shares Authorized Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Lease liability Increase Decrease In Lease Liability Increase (decrease) in lease liability. Current liabilities Liabilities, Current [Abstract] Common stock, shares issued Common Stock, Shares, Issued Net loss Net loss Net loss per common share Net Income (Loss) Attributable to Parent Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Unpaid purchases of property and equipment included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Boston, Massachusetts Lease Boston, Massachusetts Lease [Member] Boston, Massachusetts Lease Income Statement Location Income Statement Location [Domain] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, to be Paid [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity Component Equity Component [Domain] Amendment Flag Amendment Flag Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Project management service fee Professional Fees Operating lease costs Operating Lease, Cost Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Milestone Three Milestone Three [Member] Milestone Three Plan Name Plan Name [Axis] Construction in progress Construction in Progress [Member] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Other current liabilities Other Liabilities, Current Other non-current assets Other Assets, Noncurrent Aggregate Fair Value Debt Securities, Available-for-Sale Number of milestones Number of Milestones Number of Milestones Research and Development Expenses Research, Development, and Computer Software, Policy [Policy Text Block] Weighted- average Remaining Contractual Life (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Exercisable end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Number of operating segment Number of Operating Segments Plan Name Plan Name [Domain] 2022 (remaining six months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Operating lease, term of contract Lessee, Operating Lease, Term of Contract Cash contribution Payment To Escrow For Reducing Lease Rentals Payment to escrow for reducing lease rentals. Weighted-average remaining contractual life (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number ASTRA Facility A S T R A Facility [Member] ASTRA facility. Cash and Cash Equivalents Cash and Cash Equivalents [Axis] Award Type Award Type [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Sale of stock, aggregate offering price Sale Of Stock, Aggregate Offering Price Sale Of Stock, Aggregate Offering Price Non-cash interest expense Other Noncash Expense Current portion of lease liability Operating Lease, Liability, Current Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Adjustments to reconcile net loss to net cash used in operating activities Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Stock Incentive Plan Stock Incentive Plan [Member] Stock incentive plan. Share-based Payment Arrangement, Option Share-Based Payment Arrangement, Option [Member] Other non-current assets Increase (Decrease) in Other Noncurrent Assets Title of Individual Title of Individual [Domain] Expected stock price volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Sale of stock, remaining available issuance amount Sale Of Stock, Remaining Available Issuance Amount Sale Of Stock, Remaining Available Issuance Amount Surrendered or forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Balance Sheet Location Balance Sheet Location [Axis] Sale of stock, price per share (in dollars per share) Sale of Stock, Price Per Share Common stock, shares authorized Common Stock, Shares Authorized Total liabilities Liabilities Weighted average remaining lease term, in years Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Total operating expenses Operating Expenses Maximum Maximum [Member] Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Issuance of common stock, net Stock Issued During Period, Value, New Issues Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Cash, Cash Equivalents and Investments Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Short-term investments Debt Securities, Available-for-Sale, Current Preferred stock, shares issued Preferred Stock, Shares Issued Document Type Document Type Accrued financing costs Accrued Financing Fees, Current Accrued Financing Fees, Current Weighted- average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Entity Small Business Entity Small Business Estimated useful lives of assets Property, Plant and Equipment, Useful Life Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Capitalization Stockholders' Equity Note Disclosure [Text Block] Cancelled or forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Debt securities, available-for-sale, term Debt Securities, Available-for-Sale, Term Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Purchases of investments Payments to Acquire Debt Securities, Available-for-Sale Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] PeriphaGen PeriphaGen [Member] PeriphaGen Entity Shell Company Entity Shell Company Supply Commitment Supply Commitment [Axis] Stock Options Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Litigation settlement, total consideration Litigation Settlement, Total Consideration Litigation Settlement, Total Consideration Public Offering Public Offering [Member] Public Offering 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Aggregate intrinsic value, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Property, Plant and Equipment, Type Long-Lived Tangible Asset [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Title of 12(b) Security Title of 12(b) Security Cumulative escalation clause Cumulative Escalation Clause, Percent Cumulative Escalation Clause, Percent Document Period End Date Document Period End Date Offering expenses Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Purchase price of potential purchase Purchase Price Of Potential Building Purchase Purchase Price Of Potential Building Purchase Present value of lease liability Total lease liability Operating Lease, Liability Total assets Assets Loss contingency, guaranteed maximum price to be paid Loss Contingency, Guaranteed Maximum Price to be Paid Loss Contingency, Guaranteed Maximum Price to be Paid Repayment of ASTRA build to suit liability Payments For Suit Liability Payments For Suit Liability Aggregate fair value, total Cash Cash Equivalents And Debt Securities Available For Sale Cash cash equivalents and debt securities available for sale. Stock-Based Compensation Expense Share-Based Payment Arrangement [Policy Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location Income Statement Location [Axis] 2016 Lease Agreement Two Thousand Sixteen Lease Agreement [Member] Two thousand sixteen lease agreement. Summary of Cash, Cash Equivalents and Available-for-Sale Securities Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Cumulative escalation clause, term Cumulative Escalation Clause, Term Cumulative Escalation Clause, Term Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Schedule of Accrued Expenses And Other Current Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] U.S. government agency securities US Treasury Securities [Member] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Cancelled or forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Litigation settlement, amount awarded to other party Litigation Settlement, Amount Awarded to Other Party Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Non-Employee Stock Option Non Employee Stock Option [Member] Non employee stock option. Accounting Policies [Abstract] Accounting Policies [Abstract] Long-term investments Long-Term Investments Variable lease costs Variable Lease, Cost Accounts payable Accounts Payable, Current Stockholders' equity Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Net Loss Per Share Attributable to Common Stockholders Earnings Per Share [Text Block] Proceeds from insurance settlement, operating activities Proceeds from Insurance Settlement, Operating Activities Fair Value of Stock Options, Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Entity Filer Category Entity Filer Category Short-term Marketable Securities Short-Term Investments [Member] Issuance of common stock, net Proceeds from Issuance of Common Stock Weighted-average common shares outstanding: basic Weighted Average Number of Shares Outstanding, Basic Award Type Award Type [Domain] Estimated weighted average period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted-average remaining contractual life (Years), exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Computer equipment and software Computer Equipment [Member] Stock-based compensation expense Total stock-based compensation Share-Based Payment Arrangement, Expense Supplemental Disclosures of Non-Cash Investing and Financing Activities Noncash Investing and Financing Items [Abstract] Commitments and contingencies (Note 6) Commitments and Contingencies Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Issuance of common stock, net, (in shares) Stock Issued During Period, Shares, New Issues Lessee, operating lease, lease not yet commenced, liability, to be paid, year one Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Year One Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Year One Subsequent Events Subsequent Events [Text Block] Preferred stock; $0.00001 par value; 20,000,000 shares authorized at    June 30, 2022 (unaudited) and December 31, 2021; 2,061,773    shares issued, and no shares outstanding at June 30, 2022    (unaudited) and December 31, 2021 Preferred Stock, Value, Issued Restricted Stock Restricted Stock [Member] Estimated remaining commitment Remaining Commitment Amount Remaining commitment amount. Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] General and administrative General and Administrative Expense [Member] Underwriting discounts and commissions Expense Related to Distribution or Servicing and Underwriting Fees Corporate bonds Corporate Bond Securities [Member] Entity Address, City or Town Entity Address, City or Town Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Cash and Cash Equivalents Cash and Cash Equivalents [Member] Expenses Operating Expenses [Abstract] Cover [Abstract] Cover [Abstract] Leases Lessee, Leases [Policy Text Block] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Minimum Minimum [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Supply Commitment Arrangement Supply Commitment Arrangement [Domain] Contractual obligation Contractual Obligation Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Fair Value Instruments Fair Value Disclosures [Text Block] Taxes paid related to settlement of restricted stock awards Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders' equity Liabilities and Equity Trading Symbol Trading Symbol Entity File Number Entity File Number Total Accrued Expenses And Other Current Liabilities Accrued expenses and other current Liabilities. Research and development Research and Development Expense Milestones [Axis] Milestones [Axis] Milestones Equipment Equipment [Member] Forfeiture rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate. Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Title of Individual Title of Individual [Axis] Level 2 Fair Value, Inputs, Level 2 [Member] Restricted stock award granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Current Fiscal Year End Date Current Fiscal Year End Date Long-term Marketable Securities Long Term Marketable Securities [Member] Long-term marketable securities. Less: Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Cost of work, percentage Cost Of Work, Percentage Cost Of Work, Percentage Net loss per common share: diluted (in dollars per share) Earnings Per Share, Diluted Sale of Stock Sale of Stock [Domain] Use of Estimates Use of Estimates, Policy [Policy Text Block] Aggregate Fair Value Cash and Cash Equivalents, Fair Value Disclosure Stock option vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Accounts payable Increase (Decrease) in Accounts Payable Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Subsequent Events [Abstract] Total current liabilities Liabilities, Current 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Litigation settlement, milestone payments, sales threshold Litigation Settlement, Milestone Payments, Sales Threshold Litigation Settlement, Milestone Payments, Sales Threshold Milestone One Milestone One [Member] Milestone One Net loss per common share: basic (in dollars per share) Earnings Per Share, Basic Interest and other income, net Interest Income Expense And Other Nonoperating Net Interest income (expense) and other nonoperating, net. Stock option expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Schedule of Capitalization, Equity [Line Items] Schedule of Capitalization, Equity [Line Items] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Risks and Uncertainties Risks And Uncertainties [Policy Text Block] Risks and uncertainties. Construction in progress, gross Construction in Progress, Gross Other Income (Expense) Nonoperating Income (Expense) [Abstract] Schedule of Future Minimum Operating Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Proceeds from maturities of investments Proceeds from Sale, Maturity and Collection of Short-Term Investments Entity Address, Address Line One Entity Address, Address Line One Share-based payment arrangement, amount capitalized Share-Based Payment Arrangement, Amount Capitalized Total stockholders' equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Director Director [Member] Over-Allotment Option Over-Allotment Option [Member] Surrendered or forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Accrued preclinical and clinical expenses Accrued Preclinical And Clinical Expenses Accrued preclinical and clinical expenses. Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Interest expense Interest Expense Entity Interactive Data Current Entity Interactive Data Current Sale of stock, number of shares issued in transaction Sale of Stock, Number of Shares Issued in Transaction Unrealized loss on available-for-sale securities and currency translation adjustment Unrealized loss on investments and other OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Cash and Cash Equivalents Cash and Cash Equivalents [Domain] Equity [Abstract] Equity [Abstract] Placement Shares Placement Shares [Member] Placement Shares Accumulated Deficit Retained Earnings [Member] Unrecognized stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Amortized Cost Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost Cash cash equivalents and debt securities available for sale amortized cost. Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Gain related to litigation settlement Gain (Loss) Related to Litigation Settlement Entity Tax Identification Number Entity Tax Identification Number Investment Company, Capital Share Transactions [Abstract] Investment Company, Capital Share Transactions [Abstract] Common Stock Common Stock [Member] Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Additional area of real estate property leased Additional Area Of Real Estate Property Leased Additional area of real estate property leased. Shares remaining available for grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Statement [Table] Statement [Table] Cash, cash equivalents and short-term investments Cash, Cash Equivalents, and Short-Term Investments Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Incentive Stock Options Incentive Stock Options [Member] Incentive stock options. Document Quarterly Report Document Quarterly Report Cash and cash equivalents Cash [Member] Shares surrendered for taxes and forfeitures (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Furniture and fixtures Furniture and Fixtures [Member] Current assets Assets, Current [Abstract] Lease liability Operating Lease, Liability, Noncurrent Statistical Measurement Statistical Measurement [Axis] Litigation settlement Litigation Settlement, Expense Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Leasehold improvements Leasehold Improvements [Member] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Accrued construction in progress Accrued Construction In Progress Current Accrued construction in progress current. Other, net Other Operating Activities, Cash Flow Statement Commercial paper Commercial Paper [Member] Entity Central Index Key Entity Central Index Key Equity Components Equity Components [Axis] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value Litigation Case [Domain] Litigation Case [Domain] Shares surrendered for taxes and forfeitures Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Exercisable end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Other Contractual Obligations Other Contractual Obligations [Member] Other contractual obligations. Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Segment and Geographical Information Segment Reporting, Policy [Policy Text Block] Concentrations of Credit Risk and Off-Balance Sheet Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Document Fiscal Year Focus Document Fiscal Year Focus Milestone Two Milestone Two [Member] Milestone Two Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] City Area Code City Area Code Accrued professional fees Accrued Professional Fees, Current Statement [Line Items] Statement [Line Items] General and administrative General and Administrative Expense Assets Assets [Abstract] Accrued expenses and other current liabilities Accounts Payable and Other Accrued Liabilities, Current Restricted stock award outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Summary of Estimated Useful Lives of Assets Estimated Useful Lives Of Assets [Table Text Block] Tabular disclosure of the estimated useful lives of assets. Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock Sale of Stock [Axis] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Right-of-use assets Operating Lease, Right-of-Use Asset Proceeds from initial offering of shares Proceeds from Issuance Initial Public Offering Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Laboratory and manufacturing equipment Lab Equipment [Member] Lab equipment. Weighted-average grant-date fair value per share of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Lessee, operating lease, lease not yet commenced, liability, to be paid, remainder of fiscal year Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Remainder of Fiscal Year Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Remainder of Fiscal Year Document Transition Report Document Transition Report Local Phone Number Local Phone Number Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Schedule of Company's Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Research and development Research and Development Expense [Member] Escrow deposit Escrow Deposit Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Accrued taxes Accrued Income Taxes Schedule of Net Loss Per Share Attributable to Common Stockholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Initial recognition of right-of-use assets Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding Common Stock, Shares, Outstanding Organization Business Description and Basis of Presentation [Text Block] Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] EX-101.PRE 9 krys-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 krys-20220630_g1.jpg GRAPHIC begin 644 krys-20220630_g1.jpg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Ġ[B*Z@4',;!FRRX)) &, CG-9^J?#K1+W2O#V MJ:#J%W'8ZG>BQD_M()OB8DC=\N!C@\9].:I8RBW9/YVTU5_R)^KS2O\ UV/- MZ*] ^)G@?1O!JB"S.KI>)*$+7\2^1<+M)+Q.H[' (//->?UT4JL:T%..QE.# MIRY6;O@/_D>?#O\ V$;?_P!&K7V77QIX#_Y'GP[_ -A&W_\ 1JU]EU\QG7\2 M'H>QE_PR"BBBOG#U0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\ MH_:2_P"1&L?^PC'_ .BI:]7K@/C1X2U/QEX6M;+2H5GN([U9F5G"#:$D!.2? M5A7;@I1AB(2D[*YSXA.5*21\K45Z#_PH?QE_T#X?_ F/_&C_ (4/XR_Z!\/_ M ($Q_P"-?':[J,@@MD@=O7L.O6L?_A0_C+_ *!\/_@3'_C1_P *'\9? M] ^'_P "8_\ &G+ZE)N\UK?KWWL)?6%:T?P[%3X:_$"+P6VI6UY%Z]N]6_^%#^,O^@?#_X$Q_XT?\*'\9?] ^'_ ,"8_P#&M.?!^T]K[17]2.6O MRA=_9Z('CBY)&1]@ER/^!)5?5/'GA_3O!NH:'X;L;ZW?4IA)=/>NK", M#!V(0-BW\+'@Y'>NGU3XN:%J5Q)J(E\50WCISIT.I&.SW8QP5;#]-O+'6;6XO8&N$NK?R55MD@ZD[F&.B]/>H_!OQ0M=+N/$AU9+Z,ZR MWF&\TQE6XB;+'"EB./FZ]L?E#_PH?QE_T#X?_ F/_&C_ (4/XR_Z!\/_ ($Q M_P"-.7U&3DW->]:^O82^L122B]/(W;[XNZ-<>(?"5['#JCP:.)EF:Z*R32AE M"JV[=\S'&3G'7BJ>A_%BQM?^$AL;Q=4@T[4;V2\@N=-F$5U"6.QT [XZ] M:SO^%#^,O^@?#_X$Q_XT?\*'\9?] ^'_ ,"8_P#&HY<#;EYU]_G?\RKXB]^5 M_=\BW'\2-)M?&.@ZA&VN7MCIQD:274KKSYY"ZXX4MM7'L1GOTJEI/Q TZQN? M'$DD-T5UR.5+;:BY0L7(W_-Q]X=,T[_A0_C+_H'P_P#@3'_C1_PH?QE_T#X? M_ F/_&M+X*UO:+[_ #O^9/\ M&_*_N\K$5UXRT+6/AUI^BZC;Z@FJ::)/LLM MKL\EBQR-^XYQZ@#MUYKGO!?BB3P;XFLM6CB$_D,=T1.-RD$$9['!KIO^%#^, MO^@?#_X$Q_XT?\*'\9?] ^'_ ,"8_P#&M(U<)&,H>T5G?KWW(<*[:ERNZ\AN ML>+/"MKJBZQX>L-275S>K>%KYT$46&+,J*I.03QST%;O_"T/"ECKMWXGL-*U M+_A(KB(KY,[I]ECD( + @[C^7.3P*Q/^%#^,O^@?#_X$Q_XT?\*'\9?] ^'_ M ,"8_P#&L7]3DK.IY?%T[>AHO;K:'X%+5_'%KJ?PVT[03'<'48+U[J65E7RV M#%SP\9&+D,I.[!^7 4 8!SWK0O/BYIS?$C2/$,%I M=-9VMF+6:.1560\,"5PQ'\0ZD=.U97_"A_&7_0/A_P# F/\ QH_X4/XR_P"@ M?#_X$Q_XTO\ 8M;U$[WZ][)_D/\ VCI'MT[%BQ\<>&="C\60:;!JAM]7M/*B M^TK&624[\YPW"_,,=3P:EA^('A?7=-T+_A)=/U)]1T=%CC:Q9/+G5<8#[B". MG;WY[52_X4/XR_Z!\/\ X$Q_XT?\*'\9?] ^'_P)C_QIOZFW?VFO?FUVM^0? MO]N33T^9>7XN6]]<>,KF_MITDUFU%M:QPA66(!64;B2/4<@'OQ61#XTTEO > MBZ#=V=SRM^0O\ :'O%_=\R7QC\0M)U'P9%X>TH:K=1 MBX$_VC671WB4# 1"I/'\AD=Z\YKT'_A0_C+_ *!\/_@3'_C1_P *'\9?] ^' M_P "8_\ &MJ5;"T8\L:B^\SG3K5'=Q?W'-^ _P#D>?#O_81M_P#T:M?9=?-O MA/X+>*]*\4Z/>W-C$EO;7L,TC"X0D*K@DX!YX%?25?/9M5IU9P=.2>G0]3 P ME",N96"BBBO!/2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHKR+X^?M->%_P!G6]\$VOB2PU>]D\6ZJNCV M)TJ&*01S,5 :7?(F$^<OT5Q/P7^+V M@_'CX8Z#X[\,FX_L7686EA2[55FC*NR.DBJS ,K*P(!(XZUVU !1161XN\6: M5X$\+:OXCURZ^PZ-I-K)>WMSY;R>5#&I9VVH"S8 )PH)/84 :]%>/^*OVF/# M5G^S3K7QH\)_\5?X=L],FU*T53)9_;!&Q4KF2/='\RD9*9&.AKH?@'\5E^.7 MP;\)^/5TPZ,->L5O/[/,_G^022"OF;5W#_C1\.]5\8_#J_D\7Z=8M/ $@MIK>26XB0,80LR*VXY M4 XQ\PZU5_9O^+GB3XU_#6/Q+XJ^'>K?##56NY;O6@#U*BBB@ HKSK]H#XZ>'_V;_A;JGCWQ1;ZA=Z/I[PQR0:7$DEP[2R+ M&H57=%ZL,Y8< UX?X=_X*6?#:^U?P[:^)_"GQ ^&MAXAV?V5K7C+0/LFGWF_ M;M*3)(^5.Y3OQL 8$L!S0!]:T5X_)\;/%*_M+0?#5?A?K3^$I-+^WGQ^&?[ MLNTGR,>3LW9 7_6[LG[N.:]@H **** "BOGCP+^UM+XZ^/'Q@^&EKX-E$_@" MS6YCO(K_ ,R35'* B-8?*'EDDX!WMGCBNU_9O^+GB3XU_#6/Q+XJ^'>K?##5 M6NY;O6@#U*BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^"/^"I7_(Q?LW_ /8\0_\ MH<-?>]?*OCK]BOQ'\7_CCX?\8?$/XN7GB;P;X;UB36-$\&PZ#;V:VK%U>.-[ MJ-]TRKL09=-Q /(W$D ^??VJ/VB/%WC#]L#6OA5:W/Q8MO!'A?3(KBXM?@O: M!]:N;J1(G$DLF04@42A?3('!W9!\._BM\:K']DS]I&T\5+\1-&MO#=DUSX/\ M3>-+*?3-<>WD$@V/-QODC\M"75V(,IYQM ^D/C1^Q?<^-/C1#\7?AQ\1=0^% M/Q%:T%C>ZC;Z=%J-M>PA0H$EO(RJ6VJ@Y)'R(=N1FNN\,_LXZG>_"WQGX1^) M_P 1M;^)T_BV!K;4+ZX@AL(H(S&8\6EO$"D'7=_%E@": /F+XU?$_P 9:5_P M29\,^+[+Q;KEGXMFTS1Y)->M]2F2_=GN(P[&<-O)8$@DGD$YJO\ M&>.OB-- M\=OV5/#/A;XBZYX1/BK1##J%S;2M.DK/%&&ED@=O+ED 9MK2!MK$-U%;6J?\ M$P/$OB+X-GX8ZU^T%KFH^$=-<2>'M,_L.&."P;S2Q-QB7?= *S*BET5"<@8^ M6O:?&W['?_"8_%KX(^-_^$N^R?\ "M+5;;[#_9N_^TL*J[O,\X>5]WIM?K0! MXC\)=>\9_L\?\% '^#E[\2?%GQ!\$:WX9;6(AXOOOM]U;3*KMD2E05 \F0;4 M 4B094D CYNTS]HCXG_M'6?C?QI]L_:$36$OKB#PO:_"G32_ARS5%#0QW@5@ MTS[B-XZ[2#DYVC]%-5_9735?VQ-'^.[>)BAT[0FT9?#XL,AR1*/-,_F<<2GY M?+[=:\UT?]@OQ9\)O$_B*X^"GQRU/X8>%]>NS?7GAV3P_:ZM%'(?O>0\S#RA MCY0=I; 7);:* /9?V1_&7CGQ[^SQX.UGXDZ1>:)XVDMY(=2M=0LGLYV>*5XU ME>%E4HTBHLA 'S\ #%?)WQY^)7@SXD?\%'/"?A?QOXIT'0? OPSTF34;E=> MU""T@N-3G12L8:5E#,%DMVVC)'EO[U]X?#_PI-X'\&:3H-QKFI^);BQ@$4FK MZS,);NZ;))>1@!DDGTX&!VKY]^$_[ O@SPOXT^(WBSXB0Z'\6M>\8:NVI"?7 M?#L+)IZ%G80Q+*\V!\^"P*Y"(,?+0!XG_P $LOB+I_AG6OC'\&X-V%TMS;SV+N49HG4L"F5B?@GF8]\U\_P"F?M$?$_\ :.L_&_C3[9^T M(FL)?7$'A>U^%.FE_#EFJ*&ACO K!IGW$;QUVD')SM'W?I?["N@>"_VK=#^, M7@/4-/\ VEVFFOIU_X0TG1(XK6^W)(I'[75HHY#][R'F8>4,?*#M+8"Y+;10!Y M3\7/B7^T=XB_9-^#6OZAI/C?P_))=S0?$)?"=BUIXC6WBE,<$.*CM;CPM\8/V)OC3%X3^/7Q"\9:?I>GR:FUCXAO!'K>F21V\Q:TN MYBFZ:WF*X*8VX1@K?>KZD\:_L\^/KSPIX-LO!/QU\3^$_$'A^WEMI]:U*TAU M==5$A4L]U;R[4>0%?D;^ ,P'6L7X-_L1Z/\ #WP[\3HO%7BG4/'GB;XDQ20> M)- M*O!?P#\:_!^]^,MQKO@S5],FT[1K6;PY#$='\V5I'D+K+ON"=WW2R@)M=3X96@F\0SK+&[)#:DG*!3&2 MQ!X4DG.W!L?LQW7Q7\<>*OBC\-=;E^-^D?"K4="-YHOBGQ]:R6'B#3[E'B#Q M)>E65B^]R!D_+&,*OS9]W^+G[#-E\0(?AKK7AWQMJ/@;XC^ M.@TS3/%=C:I M/YD,:!=LUNS ,,[SC_P""6/PUFM?@#XQ^(MOXU\76UQ8W M.JV%?VNOB1\.?\ @F3I_BN#Q5J. MJ>.M<\5S:';Z]K5RU[/;1GH^*](T+ MXK7ES\,-;-Y+'X/N-%@+V\T\8C$AO-Y=MBJ/E"H&P,\Y)S_"W_!.;PU:?LCR M_ SQ/XDG\06ZZC+JMIKUK9"SFM;ECE'6,R2 [064@M\RLPX." #?\ _LV_$; MX.:%JFMZ'\:/&7C_ ,1S^'[I/['\97BWMA-J;1!K>6'=@VZ+(""NY@5;!(QS M\M?LK_$V]7XM>%]-^*OQC^+G@7XQR:CMOO#'C3!\/:RK2%?L]I"4"Q%UVJKY M'S']WG(%?5OP[_9?^*&AZ;>Z=XR_:*\2>*[#^Q9M'TU--TJ#2)++?&$6Y:6- MG>:9 ,J[MD')Y-+?&7Q \':]\7OC?J?Q-TKP?>KJ.C:0N@6VE%)U* ME&FFB8M+@HF<@$XZC)% #/\ @J]_R9'XQ_Z_-._]+(J^9/B(OCW]MOX _!3X M/>#?A+XR\/V6EKIMSJGC#Q9I@L=/2**U\GS;9RY\]&$COQAB%7"G=Q]]_M7? ML_C]I[X(ZS\/3KI\-_VC+;R_VB+3[5Y?E3+)CR]Z9SMQ]X8S7=?#7P?_ ,*\ M^'?A?PM]K_M#^Q-,MM-^U^5Y?G>3$L>_9D[<[)]/_ ."I M.D>!T\3:N?",/@@2?V)]MD%DTJHW[TP!MA?C[V,^]>2?LO>%?BE^U5-\;=,U M3XZ>.?#.C>'?$][#I:Z+J;I="X=F""2X?<_V:-8UQ!&R EV.17U]/^RR)OVQ M+?X[CQ,5,6A'13H!L,[N&'F^?YG'WON^7VZU\-_L:_ ;QU\4-8_:"O/ _P 7 M-:^%=\WBZ[TR]%OIT5_:W4)>5C^Z=TVO*%#(&.L,KHAN+=EW_ &<)N=^<8V+EBNX' MZBMO^"=7PUC_ &6?^%)S3ZA/9-=_VJ^O@HMZ=1Z?:>!MX7]V%(/[OYUT2VT.VTUI]BE42ZN49Y+A,$95C\Q M&2: / O@3=36/[=_[8%S;R-#<0Z2LDK)Y?V?[1[8W>9WZ4 >,?'S4/BE^S-9_!3XP)\:O&'BG4/%& MKV5MKVAZA-&ND2131"1DM[)5\N(;%9,\MD[@P;)JW^U1^T1XN\8?M@:U\*K6 MY^+%MX(\+Z9%<7%K\%[0/K5S=2)$XDEDR"D"B4+Z9 X.[(^G/VCOV.E_:#^& M?PX\(/XM.A)X/U"SOFNUT[[0;P00F(H%\U?+W9SG+8]#5/XT?L7W/C3XT0_% MWX6A+!F.9#SC M:!]BUYK\$?AAXI^&^EZFWC+XDZM\2]?U*9)9K^_MHK.WA"KM"6]K%\D*GJ0" MHH P?^$3_ .HSJW_@5_\ 6H_X M1/\ ZC.K?^!7_P!:MZB@#!_X1/\ ZC.K?^!7_P!:C_A$_P#J,ZM_X%?_ %JW MJ* ,'_A$_P#J,ZM_X%?_ %J/^$3_ .HSJW_@5_\ 6K>HH P?^$3_ .HSJW_@ M5_\ 6H_X1/\ ZC.K?^!7_P!:MZB@#!_X1/\ ZC.K?^!7_P!:C_A$_P#J,ZM_ MX%?_ %JWJ* ,'_A$_P#J,ZM_X%?_ %J/^$3_ .HSJW_@5_\ 6K>HH P?^$3_ M .HSJW_@5_\ 6H_X1/\ ZC.K?^!7_P!:MZB@#!_X1/\ ZC.K?^!7_P!:C_A$ M_P#J,ZM_X%?_ %JWJ* ,'_A$_P#J,ZM_X%?_ %J/^$3_ .HSJW_@5_\ 6K>H MH P?^$3_ .HSJW_@5_\ 6H_X1/\ ZC.K?^!7_P!:MZB@#!_X1/\ ZC.K?^!7 M_P!:C_A$_P#J,ZM_X%?_ %JWJ* ,'_A$_P#J,ZM_X%?_ %J/^$3_ .HSJW_@ M5_\ 6K>HH P?^$3_ .HSJW_@5_\ 6H_X1/\ ZC.K?^!7_P!:MZB@#!_X1/\ MZC.K?^!7_P!:C_A$_P#J,ZM_X%?_ %JWJ* ,'_A$_P#J,ZM_X%?_ %J/^$3_ M .HSJW_@5_\ 6K>HH P?^$3_ .HSJW_@5_\ 6H_X1/\ ZC.K?^!7_P!:MZB@ M#!_X1/\ ZC.K?^!7_P!:C_A$_P#J,ZM_X%?_ %JWJ* ,'_A$_P#J,ZM_X%?_ M %J/^$3_ .HSJW_@5_\ 6K>HH P?^$3_ .HSJW_@5_\ 6H_X1/\ ZC.K?^!7 M_P!:MZB@#!_X1/\ ZC.K?^!7_P!:C_A$_P#J,ZM_X%?_ %JWJ* ,'_A$_P#J M,ZM_X%?_ %J/^$3_ .HSJW_@5_\ 6K>HH P?^$3_ .HSJW_@5_\ 6H_X1/\ MZC.K?^!7_P!:MZB@#!_X1/\ ZC.K?^!7_P!:C_A$_P#J,ZM_X%?_ %JWJ* , M'_A$_P#J,ZM_X%?_ %J/^$3_ .HSJW_@5_\ 6K>HH P?^$3_ .HSJW_@5_\ M6H_X1/\ ZC.K?^!7_P!:MZB@#!_X1/\ ZC.K?^!7_P!:C_A$_P#J,ZM_X%?_ M %JWJ* ,'_A$_P#J,ZM_X%?_ %J/^$3_ .HSJW_@5_\ 6K>HH P?^$3_ .HS MJW_@5_\ 6H_X1/\ ZC.K?^!7_P!:MZB@#!_X1/\ ZC.K?^!7_P!:N@UR_A_Q)=ZGXV\5Z3,(Q:Z9] MD\@JI#?O(BS;CGGD<5M33<9V73]49R>L?7]&6O\ A$_^HSJW_@5_]:C_ (1/ M_J,ZM_X%?_6K>HK$T,'_ (1/_J,ZM_X%?_6H_P"$3_ZC.K?^!7_UJWJ* ,'_ M (1/_J,ZM_X%?_6H_P"$3_ZC.K?^!7_UJWJ* ,'_ (1/_J,ZM_X%?_6H_P"$ M3_ZC.K?^!7_UJWJ* ,'_ (1/_J,ZM_X%?_6H_P"$3_ZC.K?^!7_UJWJ* ,'_ M (1/_J,ZM_X%?_6H_P"$3_ZC.K?^!7_UJWJ* /.O''AW5[5_#O\ 9.I:U,)= M7@CO/+N&.RV(?>QP. "%Y/'-=/\ \(G_ -1G5O\ P*_^M5'Q_P")[SPS)X8% MF(R-1UJWT^;S%)_=NKEL<\'Y1S765O-/V<&UW,XMHH P?\ A$_^HSJW_@5_]:C_ (1/_J,ZM_X%?_6K>HH P?\ A$_^HSJW_@5_ M]:C_ (1/_J,ZM_X%?_6K>HH P?\ A$_^HSJW_@5_]:C_ (1/_J,ZM_X%?_6K M>HH P?\ A$_^HSJW_@5_]:C_ (1/_J,ZM_X%?_6K>HH \Z^&?AW6+[P'HT^O MZEK5MK$D.;F*6X965MQX(()Z8ZUT_P#PB?\ U&=6_P# K_ZU4?A3XHO/&GP[ MT/6]0$2WE[!YDHA4JF=Q' )/IZUUE;UTXU9IJSN]O4SIM.$6NQ@_\(G_ -1G M5O\ P*_^M1_PB?\ U&=6_P# K_ZU;U%8&A@_\(G_ -1G5O\ P*_^M1_PB?\ MU&=6_P# K_ZU;U% &#_PB?\ U&=6_P# K_ZU'_")_P#49U;_ ,"O_K5O44 8 M/_")_P#49U;_ ,"O_K4?\(G_ -1G5O\ P*_^M6]10!@_\(G_ -1G5O\ P*_^ MM1_PB?\ U&=6_P# K_ZU;U% &#_PB?\ U&=6_P# K_ZU@UR\/B2[D^)UYH!$?V&'1X+Y3M._S' MGF0\YZ8C7C'K6U--J5ET_P C.;V]2U_PB?\ U&=6_P# K_ZU'_")_P#49U;_ M ,"O_K5O45B:&#_PB?\ U&=6_P# K_ZU'_")_P#49U;_ ,"O_K5O44 8/_") M_P#49U;_ ,"O_K4?\(G_ -1G5O\ P*_^M6]10!@_\(G_ -1G5O\ P*_^M1_P MB?\ U&=6_P# K_ZU;U% &#_PB?\ U&=6_P# K_ZU'_")_P#49U;_ ,"O_K5O M44 8/_")_P#49U;_ ,"O_K4?\(G_ -1G5O\ P*_^M6]10!@_\(G_ -1G5O\ MP*_^M6;XD\+W$-#U.Y"BYO+&"YE\L87 M<\:L<#TR:P-?^-7@SPO\4/#?P[U/6?LWC'Q'!+<:7IOV69_M$<2LTC>8J&-, M!&.&8$XXSQ3J74VGW"/PHV?^$3_ZC.K?^!7_ -:C_A$_^HSJW_@5_P#6K!\% M_'3P/\1/'GBOP;X;UU=7\0^%76+6;>WMIO+LY&) 1IB@B9\JP*JQ(*L"!M.. M\K,HP?\ A$_^HSJW_@5_]:C_ (1/_J,ZM_X%?_6K>HH P?\ A$_^HSJW_@5_ M]:C_ (1/_J,ZM_X%?_6K&^%WQI\&_&BWUV;P;K/]L1:'J4FD:@WV6:#R;J/& M^/\ >HN[&1\RY4]C1\.?C3X-^+6H>*+'PIK']JW7AG47TK5H_LLT/V:Z4D-' MF1%#X*GYDW+QUH V?^$3_P"HSJW_ (%?_6H_X1/_ *C.K?\ @5_]:MZB@#!_ MX1/_ *C.K?\ @5_]:C_A$_\ J,ZM_P"!7_UJWJ* ,'_A$_\ J,ZM_P"!7_UJ M/^$3_P"HSJW_ (%?_6K>KB?C1\6M'^!7PPU_QWK]M?WFD:+"L]Q#I<(FN&4N MJ#8I91U89)8 #)) % &Q_P (G_U&=6_\"O\ ZU'_ B?_49U;_P*_P#K4O@/ MQA9?$/P1X?\ %.FQ7$&GZU80:C;Q7<829(Y8UD4.H) 8!AD GGN:W: ,'_A$ M_P#J,ZM_X%?_ %J/^$3_ .HSJW_@5_\ 6K>HH P?^$3_ .HSJW_@5_\ 6H_X M1/\ ZC.K?^!7_P!:MZB@#!_X1/\ ZC.K?^!7_P!:C_A$_P#J,ZM_X%?_ %JW MJ* ,'_A$_P#J,ZM_X%?_ %J/^$3_ .HSJW_@5_\ 6K>HH P?^$3_ .HSJW_@ M5_\ 6H_X1/\ ZC.K?^!7_P!:MZB@#!_X1/\ ZC.K?^!7_P!:C_A$_P#J,ZM_ MX%?_ %JWJ* ,'_A$_P#J,ZM_X%?_ %J/^$3_ .HSJW_@5_\ 6K>HH P?^$3_ M .HSJW_@5_\ 6H_X1/\ ZC.K?^!7_P!:MZB@#!_X1/\ ZC.K?^!7_P!:C_A$ M_P#J,ZM_X%?_ %JWJ* ,'_A$_P#J,ZM_X%?_ %J/^$3_ .HSJW_@5_\ 6K>H MH P?^$3_ .HSJW_@5_\ 6H_X1/\ ZC.K?^!7_P!:MZB@#!_X1/\ ZC.K?^!7 M_P!:C_A$_P#J,ZM_X%?_ %JWJ* ,'_A$_P#J,ZM_X%?_ %JUK"S^PVJ0>?-< M;<_O+A]SG)SR:L44 %%%% !1110 4444 %%%% !1110 445\C_M]?%SXB_#S M4O@QX>^'?BP>#+WQEXHCT2ZU/^S+>_,<(=)TJ&QO;?RE1W@EAB81*V M&("LF_#/_@H/\-OBAH.L>([32?%VC^#='TE]4O_ !7K&C&'2X70 MH'L_.5VWW(,B_NT#!N=I;C(!]-T5\N_#W_@H=\._'7C/PUX?N_#OC;P6GBA_ M+\/:QXKT3[%I^L$XV?9IA(VX-N3:2 #O4=2!6)^T-^WMX*\*M\3/ ND67C#4 M-8T'2KB'4?$_A_2WFT[0[J2&00B>X1M\3!PHW*I ;C=E6V@'U[17QA^S3^U= M9^!OV<_V<[7QU<>(O$WB7XAS2Z7;:HSK=N9QYEFE#[<.HR-YP.G KW:R M_:7\)W?QU\5_"IX-1L];\-:.NN7^HW4<2V MF"'Y9/,+Y D!.4 X/- 'K-%? M,?@'_@H%X%^)GB".Q\/^$/B!>:/=FYCTSQ-_PCKKI6J30Q/(T%O*7W&5A&X5 M65)_#OB#X<^(=*-KK-Y:V6KVFAR0Z?8V\2[D@U M"9YW\N\Z@HHQD@<4 ?8U%%% !1110 4444 %%%% !1110 445^6.B_M$?M&: MY\%?BM\9HOC=I>FZ=X+\27>F0^$M4\,V'D7T<;1,L8NE59 Q67:J@%F*CYOF MR #]3J*^1A_P44\*^%?"_P ,1XN\,>)9/%_C;PQ;Z]::3X;TS[9]HED(7[-" MOF!R[L&9 PV[<9?/7IO'7[>'@WP3J>B:%%X-\?>)_&6HZ3#K5SX1\/: ;K5= M)MY$##[9%YBB)AN 9=Q*DC/!!(!])T5\4_'O_@HUIVA_LNV_Q3^$NE7'B::Z MU :9'?A)4:%BK@)AB&9EZ@UZ5%/#OP=TOQSXM\+>, M_"EWJE^-)TWPMJFB-%K.J76U2!;6P=MR-N^5F8 ],Y(! /HRBOFS0_VN/"OQ MI\ _$[3;*W\9?#GQ7X=T.YO+W2M>TD66LV4)AH^-?$GC7QK#XLDOK>V\2:IIZR7SM'.__ !\QK4D 9QV /MZBO$?@)^UQX2_: \4^)O"^GZ-XF\)^*?#RQRWNA^+=,^P7GDO MC;*(][?*%?V)?#?Q;^,^H:EXAN;[79M(FOM M,T^W61Z?(-+M/'VEZ?+!I7V])HRT$5[$^Y)"N_!*J& ."0RD]AX?\=W=U^TQ^ MS5IMY\0O&4-YJ?@);Z?PY%&)=*U1S:2%I[J4W"MYN06YADR47YERQH ^UZ*^ M9[3]O[X>ZM\1IO"^C:#XTU_3;;5DT.\\8:7H33:%9WCR",12W.[(^O:Q:7WA3Q]JVBZ)>'3]6\4Z3X=>32+"X#A&CDN'9.0 MQ ^4-DGC.10!].45\6_'K]O_ %/X7_'CX:^&/#7@37/&/A#Q%8/J,]WI6B2W M5WJD3PB2'^R\3(LA4$&4.OR@BM;X>_%2UU#]MSQT]]XV\9:?86W@BUU:X\&^ M(+5+?2=(C9+>1IMWVEBLRACO4PKM+2?O" !0!]>45\D6'_!3;X4WFH:?--HG MC?3/!>HWW]G6?C[4-!:'0+B;)7"W!?=C*MG*#&UB< $UTWQ+_;R\"?#+XL:U M\-Y_#OC/Q%XPTZTAO8].\-Z-]O>^21!(1 $DSE$.YC($ .": /I&BO._@)\ M>/"O[1_PVL?&WA"6Y;2[F1X'M[Z(17%M,AP\4J@D!AD'@D$$$$YKT2@ HHHH M **** "BBB@ K!T?Q3_:WBKQ#HWV7RO[)^S_ +[S,^;YJ%_NX^7&,=3GVK>K M!T?4-)N?%7B&UM+7RM4MOL_VZ;RP/-W1DQ_-G+87(YZ5K!)QE=7T^[5:_I\R M)7NM?ZLS>HKR;]K#QQK?PT_9N^(GBGPW>_V;KVDZ/-=65WY22^5(HX;8ZLK? M1@17R;)XV_:D^&/[.GAWX]-\5-+^*&C/I-GKNK^#M2\,6VG-%9RQH\GE7-O\ MSM&'SDA1A2V#C8.],TOP1XM\*S:Y-X1N]. MD>_O\Q,Z2).("D?EY7<#,A^1AM;(QW/P_P#VQ/@U\5/B/<> _"GCW3];\4PB M0_8[>.;9+L&7\J8H(I<#)_=NW )[&@#V6BO%=-_;/^"FL_%8?#:Q^(&FW?C) MK@VBV,4!M>^)EU\/K#Q!#<>+K? M38]8:P$,H62S?;LFCE*^7*IW+]QFQGFN1N/VS/@Q9_#>^\>W/CJTM?"EGJ4F MCO?7%K<1M)>1X+PQ1-&))F .?W:L, G. < 'M-%>,^'_ -L;X.>*OA7KOQ'T MGQO:WWA#0BHU.\BM;CS;3/DYY(R 363HO[=_P "/$7B"TT; M3/B#:WUY=ZE#I$$D%C=M;/=R@F*(7'E>5EL'!WXX(SD4 >^45QVG_%_PCJGQ M2U3X,/%O_") MMH2_9/M7]J:I#IO^LV>5Y@8[^ASC;TXZ]:Z&N=\8:EH^FMH0U>U^U&XU2&"R M_=A_*N6#;'Y/& &Y'/-=%6TDN2+2[Z]R(WYGJ%%?GUJ7Q$^//Q(^/'[1&G>& M_CC9_#WPU\-I+>>VLM1\-V%U;21R0/(5DN'4/$@,1RY+G#]L5Z;\ ?V^/#&K M?LY_#_QQ\8=8L/!>K^))+ZUBD^SS+:W3VKL'D4A6$>54<,P!8E5R<"L2SZXH MKPSQ!^V_\#_"OPY\/>.M5\?6EEX:\0^9_9<[VER9[L1N4=EMA$9MJL,%B@ R M.>1GHK/]J#X57WPC?XH0^.-+/@2,[7U=G9523C]TT9 D$O(_=E=_(^7F@#U& MBOA/]K3]KCPW\4/V98O$_P &/B%=N]KXLTNQN[S1Y;G3[F)9)&S&ZL(Y K@' M@C# 'K7LFG_%36]/_:X^(.BZM\0-)E\$:'X4AU8^$X],F^VV+90O=/.+<*Z% M=_R+*[?,/D7&2 ?1%%?/6A_\% OV?/$GB;0?#^G?$W3;G5=<\K[%$+:Y5&:3 MA$DD,02)R>-DC*P) (!(J3P_\1O$,G[8WCCPS??$#1I?!^E^&+?4$\)_8)([ MNQD9DW74ERT"QF,C?P)G/S#Y%P20#Z!HKQ#P'^VQ\#_B9XIU3P[X;^(FF:CJ MNFP37-PA2:*+RHE+22)-(BQR*JJ6)1F STYJM\,_P!NGX%?&#QM!X1\)?$& MTU/Q#<%E@LWL[JV\\J"2L;RQ*CG )PK$G'% 'O%%?+'[)/C+7_$GQ_\ VF]. MU?7-2U33](\3VUOIUI>W@#G?A[XN_X3SP7I M.O\ V3[#]OB\W[/YGF;.2,;L#/3T%=%7._#W4M'UCP7I-[X?M?L.C31;K:W\ ML1[%R>-H) YS7SE^WM\4_B%\/S\']&^'?BW_ (0S4/%_BZWT&YU+^S;>_P!D MG;R(IMN";=SZOHKX+\,?'+XM>!_C9\ M3O@EXT\>6'Q*>P\#WGB&V\4Z9IL>F7NGS"/Y8I8X&V1GY@P_B^:,[OFQ5G]B M#]N;X;_\*7^&/@WQW\4?M_Q-U-)(Y5U:6YNIGE>ZE$2373*R*Y4* LD@."OJ M,XEGW717B/Q>_;5^"OP'\6+X8\<>.K;1=>,:2M9+9W-TT:O]TN88G"9'.&(X M(/0UJ?$/]J_X2?"KP-H7C#Q/XXTZP\.Z]&)=+NXA)H0IW11Q*SN &7)"_ M+N&<4 >M45Y5X@_:G^%'A7X3Z;\2]4\;Z=:^"=2 ^PZG\[&Z8DC9'$JF1W&U MLH%++M;(&#C3^#'[0'P^_:%T"XUGX>^)[7Q)8VTODW'E1R0RP,:C>M,7\ MP2&9#%#& HQL5G)YW+TKZK\=>,M-^'?@O7?%&LS"WTK1K&:_NI/2.-"[8'.'"#B3IR0T;#<>P!]IU@1>*O,\>7/AO[+CR=-BU#[5YG7?+)'L MVX[>7G.>_3BM^L"+4-);QY:*3 .UUC8J<'@X('6OS"TO] MIK]HSP5^R?X7_:+U7XRZ3XELK[4#:/X%U;PS96HN +J2 K'NOVK/A-9?!VV^*DWC:P7P%<.(HM6V2G?(6*^6(@ MGF^9D'*;-PPO7VD1F:\A$,UN4C#;3( MIE1 Z X^=,KR.>10!Z[17A/@S]N;X$_$+XB)X'\/?$?3=2\222F"&W6*=(;B M0'&V*X:,0RDG[H1SN[9KJ?VB-0\1Z7\-KBY\.^._#OPR9;B-;WQ7XEB26#3[ M=B5+HDC+&TI(9:^QJ "BBB@ JAK^J?V'H.I: MEY7G_8[:2X\K=MW[%+8S@XSCKBK]4/$%Q:6>@ZE/?Q>?8Q6TCW$6T-OC"DL, M'KD9XJX:R5U<4MF,\,ZS_P )%X;TK5O)^S_;K2*Z\G=NV;T#;I>-M'_;)^$U[\.;>.Y\:P>$=;?38Y,D[Q;7.YD !W2!=Q12,,X4'@FO MT2\,W5E?>&]*N=-A^SZ=-:126T.T+LB* HN!TPI Q7G_ (N_9U\-^-/CQX)^ M+-[>ZK%XC\(VMQ:6-K;RQ"TD29)$(A"K:I?:B!-=)K4TT4-Q-< Y#,AD#(&!!41Y!#' M/G7P9^(WQ@T/XE?"G5O#MK^T;XI36+ZVM_&"?$'1G;0'MI]HDN+/:7%NJ%BZ MDD *HRV,@_:_A_\ 8F^''A_4_B@8UU2[\/?$;<^M^%;FY0Z8)68L9H$5!)%) MN+'(DX)& -J[<;X;?L%^#_AOX@T.^7QQ\1O$>E:#/'&5\8K] /@!X7USP7\%/!>C>)]6OM=\1VNEP_VEJ& MIW+W%Q+6VMFFV[&<2)RN!>&_$VL>$O@#^W+KWA[5K[1M2M_&TQM=3TRY>":-OM8 M!*2H00<-@X/0^]?8/C[]@/P+XP\?:[XQT+Q5XZ^&6M:^2VLGP+KIT^+4G/5I MD*."222=N 2S$@DDGE_VAOV8M%^$W[!/Q"^'/PI\+W]V]Q;I,MG9QR7M]?W! MGAWR,%!:1RJ#H, * ,4 >%>(O$'Q.^ \G[,WQ-?XQ>+?&%[X^O["PUOPYJ MLRMILEOZ?X\_;,^-_P ;KR7XQ^,OAYI_ M@77CH?A_2/"EZMO;HT9<>==Q8Q<*S1!BC$9RZ[@,"N[_ &:QH.DVUU8^%-?U-Y=-T6^DAC:9H;9TWQ/YH+%"V W\/RKCLO'W[ O M@#QQ\1=>\86GB+QMX,NO$6W^W].\*:ZUC9:R1D$W,84EL@D$*R@Y8XRQ) /) MM6_X3;]J;]L;XB_#*Z^*/B[X>>$OA_I=D88?!=Z--N]1NIHT9KB24*Q*?,PV M8V_ M!OB=XSM/%UAK_C#X=>*8=/72I=7\$:TUA<7=H@ 2 M*8LK[@ H&0 3@!B=HPFJ?L(_#"\^ =C\(;"/5-"\+VVI1:LT^GW*&\N+I&W> M9+++&X8L< _+T V@ 4 ?-?BCP#\4_ O[7W@?X66G[0?CVZT?X@Z%->:S?WD M\4MQ!)#YCR_85*>79AP@52BDH&/+8%#OBK=7NJ M1^(?"UC<:?96T,L8M)(YE97,BF,N6 Z6>_A@N)=C[I9#^\D5!E >KGY5Y"5]D:7^R3X M0TGXE_#;QQ#J6MMJW@+0!X=TR%YX3!-;B)H]\X$6YI,.>591G'RUX3^V+^R+ M/8_!/XUW_P .M)U;QAXF^(>JV&I:KILTD"1(P4U^GM?G!^S/IOQ>E_:&\&3^%)?CW!\/88)E\7+\;YE$39C/E+9Q MMR3O Y4;AQDA,+W3TU":WWA"D,%O)^[8XDCSNZ[FY79\P!]BT5\4^ _CG\ M7/@7^U)IWP9^+GB"S^)FG>)=)GU/0/$NGZ5%IUVTD2.[0201D1\B*0 DY,9 MW?,0.WNO^"AWPQL_V;;?XURV7B!?#W_M(7(9@4,?G[/NJ7_P!9 MG;SCM0!]/T5X_K_[4G@_0_'7PL\*10:IJ^H_$:"2[T>3388WACMTB64S3LTB ME5*-D;0Q^5N!7BQ_X*H_"=M%N]7A\,^/[K3--OC8ZO>VV@"2WT@F3RT>YF67 MRU5S]T*S,)_&+]KKP+\';?PJDD.M>,M;\50_:=$\/^$=/:_U M"_@VAS,D65&P*0(K:#P=*L&N^'+W3U MM]8L96=56-X)) N3N!SOQPPSD$4 ?1%%?+4?_!17X;M\/]3\:/X>\<0>'(KF MULM(O)] :,>([B?S-L6G;G'G,IB<-NV ''/(KR3]MS]JB^\2_LEP>+_!\GC; MX8ZI8^,+/3=2M-3@GT;5+8>4TK1R*C9*,CQMPQ!!'<8H _0"BOGGX0_MN>!? MC!\3/^$ M-)\5^'-=GT[^U--?Q-H[6,6K6O/[^UW,792 6!=5R <9P<>)?L] M_M9^&/@O^S?K_CGQ?XS\>?$/1Y/'<^C?VCKUG"MY9LZ)A OVN0?9TVELJP/S M'$8Z4 ?>=%?/'PJ_;F^'_P 5_BI#\/X-+\4^&=)]':PBUFW 9O- MM=S;F4JK,"ZID*<9P:^AZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MKXI_X*._!_4?C-X@^ 6CQ^%=5\4>'O\ A,(TUU-.MIY$@LG:)96FDB&8DV[O MGRN,$Y&*^UJ* /GR3]EGX>? OX&_$K2?A=X(ATF\U;0KZ)EM/.N[R[5QD_*F<9/ R:\%T_]F_QC\0/^"4&E_#6QT2ZT3QK]@^TKHM_";*>2:._ M:#;;X-^,OAW'X)UFRU? MQ#KOB?3_ +#9VXMD"F.S&;/3W_M:.%KHME;9@')P@XQ_&I.%R1TO MAWP!\1/CS^TI\<_$=S\/O$7P]TSQU\-)=,T:;Q#:F,AF$<,:SLN4BF;86:'< M753S7Z.44 ?%'[$?Q0\=^!_ O@'X+:Y\#?&VC:SH?FV&JZ_>6B0:)#"K2N)X MKG<1.S?*-J#!+$AB.L7[$J^*_@_\9OC#\._$WP[\66JZ]XQU+Q#8^*H].+:( M]LX#(#=$@;V 7"J&.6P=I!K[)_B_P#"R\;Q1!XSO6T[_A(8[RU26SQ$\;?9V98YHR[2?,R, M&Y&2!BOT?HH ^1?B#\.M7N?^"CGP?\0VGAB^E\+:3X2OK9]5AT]S8V,OV5?VT_B9\1I?AAXP^)/@[Q]IMH+6\\%Z>-1NK* MX@1$,,D08%$.TG<2!]W&XA@/NZB@#\O;[]EGXI7?[ OQG^T^%+BU\8^-?%7_ M EL'@^ ^;-K#PO\>)M3N? FHZ)%J?Q?NX6O+N1U!2VAM5C\Y_NY5B^W.0%)(( MY;PG\'O'MO\ "W]B"TE\$>(XKKP]XHN;C68'TFX#Z9$;U6#W*E,PJ5YR^!CF MOU(HH ^3/!G@KQ#:_P#!2KX@>)YM!U.'PU=>";6T@UF2SD6SEF$L),23%=C. M #E0<\&OK.BB@ HHHH **** "BBB@ HHHH *S?$D3S^'=5BB1I)'M955%&2Q M*$ =S6E10!^2I^"?Q$_X=@^"?"O_"!>)_\ A*+?QN+N;1/['N/MLM?#.JVEYK5O9R-:VDDD4 MRHLDP78C$L,!B" ?V*_B+^SB_P,\::MXF@O+B1=?T^T M#Z7[67PR\7O^UU^S+JI\,ZU#I.E?#@Z?J. MIG3YA!87!M)E\J:3;MCDW$#:Q!R0*^]J* /SW_8U\1?$;]E3P]=_!;6?@CXS MUW7/^$EEDMO$>EVJ#0Y[69XP;B6]+;4*J&;;@G 53M;('B_[3GASX\_$36/C M+H7BC1OC9J^IR7TP\,:=X.4)X0FTM6#)]IV@^ M/Q4\,^-?ASJW['?Q'A^'GBKQ9IW@S0FL=;TGP[IKW.IVLDMC"@#6_##!#YW8 M *8)!(S8USX.>,/B]^UA\>[F'PWKOAW2?&7POCTW3]4U2PD@@6ZE@M\0-+@I MYBG*NJL2-K>E?H-10!^5NN6'Q5^*W[(_A/\ 9?B^!OC+0?%]C<6EAJ'B+4[% M8M!MH+>?>;F.\#%9&("Y"CG<^TOP#]#_ C^&_B3PW_P4:^(.M7.B:L/#3>" M;'3[;7I[*5;2YFC%J&19BNQG^1B5!)X/I7V710!\F?\ !-_P5XA\#?"GQS:> M)-!U/P_=W'C;4[N+.2VDEA<1;)55U!*-@X8<'!KZSHHH **** "BBB@ H MHHH *P='M-'A\5>(9[*;?JTWV?[?'N)V8C(BX[97-;U8.C^%_P"R?%7B'6?M M7F_VM]G_ ''EX\KRD*?>S\VZT_JS/-OVS=! MU/Q1^RM\4-)T73KO5]5O-$GBMK&P@:>>=R!A41068GT S7R'X\/V/AS5->\8:5_9.EVD*11QSRI*[$R9"L NU6PV<$C M:?TCHK(L^)K7X&ZW\.?VL/V==/T_1M2UKPWX3\ WFBW6M):2&T\Y8615DEQL MC:0CA6/\5>3?L]^%?B'X>^.'AGPY\/? 'Q&\(?#V*6_GUW1OB-IT,FF:#-)$ MR>9H^H']Z_SNX^3!8')W!F(_3*B@#\^/V,)O%?P?\#Z/\"?%'P)\62^)++7I MIYO%QTR)M#0-,774!>L<-+&K#:%#,=B@,#POF/A/3/B!\+?V5_'/[.>H?L\^ M,/$/CO6[J]@B\1V.FI-HMZ]Q)B.]FOLX5HUP03T\M 2G./U5HH _-OX__ WX MF_L]^&?@#X_\"Z%J?C+QIX5\-/X-UNST*SDNYI(WLW$3[(U8F.*0R?,1C/E^ MM<]\8/V/_&OP_P#@;^S2^B:9XRO[;P:MQ=>*+3P'ZNQ'+)/:Y4EI$? MS$X!. HX!)'ZBT4 ?ER?@+=7W[-/[16M>%_!GQJN==\46&G6RGXG;+C6=5EB MN,MY=K#'YOR+M^=RVX'@*%.?HCXZ?L]OXZ_X)^Z/XH:^OJYGXE>!;?XG> -?\ "5YJ6H:19ZU9 MR6,]YI,J1W4<;C:_ELZL%)4D9*GJ: /E#_@FDNL?%#0O'WQZ\4P"/Q!X_P!2 MB@BPV5M< Q.)C$\; MHDXRD8/W@..F>>Z_:X^"[:G\4OV6M*\-^!GOO!WA_P 2M]LM--THRV&GVH$. MTRJB%(H_E/+8'!K[,HK$L_//]NKX/^-)/VHO"7Q+MK+XHZAX*C\/MI$]Q\(K MD)K=A<>;(WRI@DQ.'7=T!P%[S_ (2C1"4UC0_)U74$B>3S'>WBWR"*$$ .YQASC '/8ZYX M!\3S?MC?'S6D\.:L^C:E\-%L+'45L93;W5SM'[F*3;M>3_84D^U?:%% 'Y=^ M(/@7XL7_ ()=?#7P[9_#W65\:6OB&"^N=)@T67^T86^V3[IGB">8I\LKEB/N MD[95'DK<$!"W4$ M Y SFONRB@#X)^!/CCQY%\ ](^&.C?L^^)M!^(?A'PQ?6D&N^)-)@MM*BOEM MI$1[6:3(G:>3 8 !3YA+,RY)^>?AG\/OBEXH^,7P UG6_#/QRO\ 4-#\0V[> M([GQQ W]BZ?(2,MI\"IF.#$9W2DA1A ?O"OU\HH ^6/V2?!NO^&_C_\ M-ZC MJ^AZEI>GZOXGMKC3KN]M)(8KV,12 O"[ "102.5)'-?4]%% '._#VST73_!> MDV_AV?[3HD<6+67>7W)D\Y/7G-?+'_!1CX17_P 9;CX&:)'X7U/Q/H)\;VHU MR+3K>>18;%_DF>5XN8DVD@OE<>HKZG^'OA+_ (0/P7I.@?:_MWV"+ROM'E^7 MOY)SMR<=?4UT5;5FG4DXNZN]>_F13NH)-6/"=)_9=^'7P'^$?C[3/ACX*@T: MYU72+N.3[,9KJ[NF,#A(_,D9Y&&3PF<9)P,FOC'Q!\"_%B_\$NOAKX=L_A[K M*^-+7Q#!?7.DP:++_:,+?;)]TSQ!/,4^65RQ'W2.<5^HE%8EGYH?M<:'\8/$ MGQY\?:3>:-\7[CPIJ.D6]MX4C^%QCM]/O)3!MD75KC:<1[V=2),G;T^7::JO M\-]3\._LG_L[OK7PZ^+5KXP\-VM^]GK7P]L2^L:%=-.2(KBQEVEH94Y);& F MWI(<_IS10!^5OQ1^#OQW\:_!OX!>,_%WAKQ5#J7AG4=2FUW3_AVL.GZ_%#<2 M*T-[%!$I5;D@,755SEN0I9BOT7^P3\*['PWXE^(?C.UT'XNZ9-KJV<,VH?&" MYA_M*_>/S=Q$*('4("@WR,VX, IS]CT4 ?!/\ P4R\7>(?&GA_3?ASX:^% M/Q&\37VGZUI^MR:SHWAV2[TR2) Y:-)HR29!N V[0,]ZT/VQ/C!=_'+X)_#? MX=Z-X?\ $?@[6?BYK\>DR:7XDLOL.IV-A!< W,LL.YMHPB'KRCY[XK[FKC]5 M^$OA/7/B7HGQ OM*^T^+=%M)K'3K][B7%M%+GS L6_R\MG!8KNQQG% 'E'[6 M'CSQC^SS^SS#:_!WP-J?B?Q !#HNE6FD:?+?#38A$0+AXD5BRHJ #(QN9U]I/@FUN/"2?"[XM:1XMUE9-8\1^./'GAIK&'4[P'+ S-,Y'+ML3O M\Q)+%B?MNB@ K BM-''CRYNDFSK[:;%')#N/%L)9"C8]W,@S[5OU@1>%O+\> M7/B3[5GSM-BT[[+Y?39+))OW9[^9C&.W7FM:;24KNVGW^1$KZ60[QY;RWG@? MQ%!!$\\\NG7"1Q1J69V,3 !O&_COX7RVGQ1A MEN9;C_A(DNDEB=+J40NUG,WEJPC6,J?+!Z,.>:^^:*R+/D3PO\-]6D_X*8>. M?%E_X6O&\/-X*MK:RURYT]S:&??$'CCG*[-^W<"JG.,YXS7S7X;\"_&OX?\ M['/B#3?"?A+Q5HUU_P +0N+J^M-+TMH]8CT._ WA+P_\0-%^&;^!;_1])G^+&DP6.IZ M5>S*1':V=R/WDEL<(#_"H'0%5)_3>B@#\D/@+^SUJ.I:A\,/"/C/P9^T=_PD M/AC6+2Y>VU&_@3P=IS13 M/;RO&P"!'/A[OU'X M67_Q>\.W%RD6K:#IEG!?SK 765;27BXQ*L8V#D9W?PUZI10!\&_L6_#'7O^ M&I?B%\2?#WPWUKX+_"74]+CL[?PMK=H+"6\O R9G%D"1"%VR=/E_>?+G((;.XT'4HM0?R[![:1;A\XVQE2'.>W&:OU0U_2_[^5Q6G6;X9T?\ X1WPWI6D^=]H^PVD5KYVW;OV(%W8R<9QG&37YK_\ M%./AO>_&#]JKX5^%-/FFCU&;PKJ]WI_DN5874$,\\.".A+PH,BB=N9V=Q1V5 MS].JQ?%GC3P]X#TL:GXFU[3/#NFF581>:M>1VL)D8X5-\C ;B>@SDU^?7Q%_ M:"N/VGOV4?@/\/\ 2]3D_P"$K^*-]!H^N^0Y$L=O9$#4G;'W02JM@_>1SU&: M\%\"ZSIOAW_@F/9MJGA?2?&%FGQ,-M%8:X]T(8LH/G4V\T3AA\W\6T[FR#FH M*/U]M?'7AN^\5W?A>V\0:5<>);2!;JYT:*]B:\AA;&V1X0V]4.Y<,1@[AZUN M5\#Z+XPT[X>_\%)/CKXGU4M'I6B_#F#4+GRERPBB2V=@HSR<*<#UKC;/_@I_ MXULM(T;XAZTGPH_X0#4;](9?!^F>(GG\76-L\A0321AMC%0-Y4(#@@$)R0 ? MI517Q-\5/VTOB):_M/ZI\+? =AX!LHM(L[6Z5/'.HSV5SXB:9%<1:=(N(P^& MVC?N!()SP0.1\5>-_P!HUO\ @HY?^%_#&N>%5LO^$86^M=#UB]U$Z4-/^T!3 M+)#&V/MV!LVXYH _0>BOBC5/VKOCA\5?&?Q.C^!_A/P7<^$OAY=RZ??7? MBR>Y^U:M=1*3+':+"RJA&Q@/,.#N0[ADJ,+Q'_P44\6ZS\-O@'XH^'_@O2]2 MU#XAZI:%JMRR-'=1.L6R*X#!44R-NW.C?*1P#0!]Z45\A?"W]KKQUX?^ M)?Q6\#?'#1O#FGZEX*\/_P#"4KJ'@UYY+:>Q"!G7;.VXR#< "=F2"-O0GQ*S M_P""G_C6RTC1OB'K2?"C_A -1OTAE\'Z9XB>?Q=8VSR%!-)&&V,5 WE0@." M0G) !^E5%,AF2XACEB8/'(H967H01D> %%%% !1110 4444 %%%% !1110 M 5\*_$7P_P".OV8?VWO$'QGTKX?>(/B1X"\::-%I^IP>$[;[7J.GW$:QJI6W MR"ZGR$.!],FM-(M M/%$(MM4U&YE20,SP DQJ/-)Y./D7!.Y@OA,'[)WC?Q3^T]XF^"^K>$M6C^"7 M_"2ZIXOAUJ:TG-@TEQ8E8(TFP(R4>11M!+!E;T-?JU10!^;7_!/7X1_%'4OC M1%XA^*GAG5M!3X:^%E\'Z%)J5G-;QWF9Y?WT)D4!PL0*;DR"&0]ZI_"OX2^. M=/\ ^"<'QY\,W7@SQ#;>)-2US4);'1YM*G2\ND9K;:T4)3>X.UL%00<'TK], M:* /RZ^-_P"S_P"/M-U[X"_$2/1_B<="T_P#8^'M:C^&%P;;Q)IDZ1EL")E+ M%6,FUDP.4;<5X!F'P!U%OV5_VC-7\.>"_C!-K7B^VTZ.%?B/-'>:YJSPSY9A M:01^:A4-C,A\4?"SQ;XRL;.RTR*>Q M\%P[-;T.9+/:MS! <%GC?"%#P-Y+ A2*^8_'7@/X[>.OV)Y]+\0Z#XY\2&+X MA6TWANSU[3Y+CQ"FD(KX>\2,,XP3U<9!W<[2E?J[10!\D?%;P3XBU'_@H1\# M_$=IH&J77A[3O#NIP7NK0V7?M$?L M\^'/VF/ UKX5\3WNJ6&G6^HPZFDND2QQRF6+=M!,D;C;\QR,9]Q0!\K:9#X^ M_:?_ &VOA7XPN?A?XK^&WAWX=:;5W$ MA&_^@U9 M_P#?T4?\+ \-_P#0:L_^_HH Z"BN?_X6!X;_ .@U9_\ ?T4?\+ \-_\ 0:L_ M^_HH Z"BN?\ ^%@>&_\ H-6?_?T4?\+ \-_]!JS_ ._HH Z"BN?_ .%@>&_^ M@U9_]_11_P + \-_]!JS_P"_HH Z"BN?_P"%@>&_^@U9_P#?T4?\+ \-_P#0 M:L_^_HH Z"BN?_X6!X;_ .@U9_\ ?T4?\+ \-_\ 0:L_^_HH Z"BN?\ ^%@> M&_\ H-6?_?T4?\+ \-_]!JS_ ._HH Z"BN?_ .%@>&_^@U9_]_11_P + \-_ M]!JS_P"_HH Z"BN?_P"%@>&_^@U9_P#?T4?\+ \-_P#0:L_^_HH Z"BN?_X6 M!X;_ .@U9_\ ?T4?\+ \-_\ 0:L_^_HH Z"BN?\ ^%@>&_\ H-6?_?T4?\+ M\-_]!JS_ ._HH Z"BN?_ .%@>&_^@U9_]_11_P + \-_]!JS_P"_HH Z"BN? M_P"%@>&_^@U9_P#?T4?\+ \-_P#0:L_^_HH Z"BN?_X6!X;_ .@U9_\ ?T4? M\+ \-_\ 0:L_^_HH Z"BN?\ ^%@>&_\ H-6?_?T4?\+ \-_]!JS_ ._HH Z" MBN?_ .%@>&_^@U9_]_11_P + \-_]!JS_P"_HH Z"BN?_P"%@>&_^@U9_P#? MT4?\+ \-_P#0:L_^_HH Z"BN?_X6!X;_ .@U9_\ ?T4?\+ \-_\ 0:L_^_HH M Z"BN?\ ^%@>&_\ H-6?_?T4?\+ \-_]!JS_ ._HH Z"BN?_ .%@>&_^@U9_ M]_11_P + \-_]!JS_P"_HH Z"BN?_P"%@>&_^@U9_P#?T4?\+ \-_P#0:L_^ M_HH Z"BN?_X6!X;_ .@U9_\ ?T4?\+ \-_\ 0:L_^_HH Z"BN?\ ^%@>&_\ MH-6?_?T4?\+ \-_]!JS_ ._HH Z"BN?_ .%@>&_^@U9_]_11_P + \-_]!JS M_P"_HH Z"BN?_P"%@>&_^@U9_P#?T4?\+ \-_P#0:L_^_HH Z"BN?_X6!X;_ M .@U9_\ ?T4?\+ \-_\ 0:L_^_HH Z"BN?\ ^%@>&_\ H-6?_?T4?\+ \-_] M!JS_ ._HH Z"BN?_ .%@>&_^@U9_]_11_P + \-_]!JS_P"_HH Z"N7\/^&[ MO3/&WBO5IC&;74_LGD!6);]W$5;<,<:W#_93_9?L'F3@IQ&?-V#/'S8S6]-OEG9]/U6QG*UX^OZ,]'HKG_\ MA8'AO_H-6?\ W]%'_"P/#?\ T&K/_OZ*P-#H**Y__A8'AO\ Z#5G_P!_11_P ML#PW_P!!JS_[^B@#H**Y_P#X6!X;_P"@U9_]_11_PL#PW_T&K/\ [^B@#H** MY_\ X6!X;_Z#5G_W]%'_ L#PW_T&K/_ +^B@#H**Y__ (6!X;_Z#5G_ -_1 M1_PL#PW_ -!JS_[^B@#H**Y__A8'AO\ Z#5G_P!_11_PL#PW_P!!JS_[^B@" MGX_\,7GB:3PP;,Q@:=K5OJ$WF,1^[17#8XY/S#BNLKS3Q]XZM9G\,_V-K<0" MZU;M?>1&_\ H-6?_?T5O-OV<$WW,XVYI'04 M5S__ L#PW_T&K/_ +^BC_A8'AO_ *#5G_W]%8&AT%%<_P#\+ \-_P#0:L_^ M_HH_X6!X;_Z#5G_W]% '045S_P#PL#PW_P!!JS_[^BC_ (6!X;_Z#5G_ -_1 M0!T%%<__ ,+ \-_]!JS_ ._HH_X6!X;_ .@U9_\ ?T4 =!17/_\ "P/#?_0: ML_\ OZ*/^%@>&_\ H-6?_?T4 =!17/\ _"P/#?\ T&K/_OZ*/^%@>&_^@U9_ M]_10!3^%/A>\\%_#O0]$U Q->64'ERF%BR9W$\$@>OI765YI\*_'5K;_ ]T M./Q%K<1UI8,71N;@-)OW'[QR&_\ H-6?_?T4 =!17/\ _"P/#?\ T&K/_OZ*/^%@ M>&_^@U9_]_10!T%%<_\ \+ \-_\ 0:L_^_HH_P"%@>&_^@U9_P#?T4 =!17/ M_P#"P/#?_0:L_P#OZ*/^%@>&_P#H-6?_ ']% '05R\/AN[C^)UYKY,?V&;1X M+%1N._S$GF<\8Z8D7G/K5C_A8'AO_H-6?_?T5S$/CJS_ .%F7DCZW#_8!TB! M8P9QY7VGSI2^!G[VSR\GTQ6]-NTK/I^J,YVTOW/1Z*Y__A8'AO\ Z#5G_P!_ M11_PL#PW_P!!JS_[^BL#0Z"BN?\ ^%@>&_\ H-6?_?T4?\+ \-_]!JS_ ._H MH Z"BN?_ .%@>&_^@U9_]_11_P + \-_]!JS_P"_HH Z"BN?_P"%@>&_^@U9 M_P#?T4?\+ \-_P#0:L_^_HH Z"BN?_X6!X;_ .@U9_\ ?T4?\+ \-_\ 0:L_ M^_HH Z"BN?\ ^%@>&_\ H-6?_?T4?\+ \-_]!JS_ ._HH Z"LOQ3ILNL>&=7 ML+?:)[JSF@CWG"[F0J,GTR:I_P#"P/#?_0:L_P#OZ*S/%'CW1Y/#.KKI^M6P MOVLYA;^7, WF;#MP>QSBKIWYU8F7PLV_!NDSZ#X0T/3+DJ;FSL8+:7RSE=R1 MJIP?3(KPWXG?LZ^)/&G[8_PE^+-E>Z5%X<\):??6E]:W$LHNY'FBF1#$HC*$ M R+G./B->:GIU_X5G^UMX6TN&25 MI=/:ZD5IF9&0)&0H,8*,VY6YQTKA+?\ X)W_ !'B_8WA^$IUKPO_ ,)&GC8> M)#="[N?LGV;;C9N^S[_,]MF/]JON_P#X6!X;_P"@U9_]_11_PL#PW_T&K/\ M[^BLRCYWNOV0]6\1?M/?%?QMKE]IS>"?&W@T>%_LUK-)]OC9HXD=RK1; ,(Q M!#DYV\5XOX!_X)\_$OP7I]EX.ETWX"ZIX8M)2J^,M2\$B[\2/#OW#='(GD,^ M/ER[,<%?BU\+->\,2O;^&X_#&K6GC3[4[/;I+N,T;0C+R$<_,R_,O) M(8X^D_\ A8'AO_H-6?\ W]%'_"P/#?\ T&K/_OZ* /D;4/V4?CG\*_&_Q/;X M*>+O!5IX.^(EY)J-[!XIM[K[9I%S*&$LEH8E9)#\Q8>9QPHV\%BC?\$_M4\) MZ'^S;H7A36M-N;'X:Z\^LZU=ZFTD,M\TDL'?N&Z.1/(9\?+EV8XY))%?>'_"P/#?_ $&K/_OZ*/\ MA8'AO_H-6?\ W]% &^JA5"J !@ =J6N?_X6!X;_ .@U9_\ ?T4?\+ \-_\ M0:L_^_HH Z"BN?\ ^%@>&_\ H-6?_?T4?\+ \-_]!JS_ ._HH Z"BN?_ .%@ M>&_^@U9_]_11_P + \-_]!JS_P"_HH Z"BN?_P"%@>&_^@U9_P#?T4?\+ \- M_P#0:L_^_HH Z"BN?_X6!X;_ .@U9_\ ?T4?\+ \-_\ 0:L_^_HH Z"BN?\ M^%@>&_\ H-6?_?T4?\+ \-_]!JS_ ._HH Z"BN?_ .%@>&_^@U9_]_11_P + M \-_]!JS_P"_HH Z"BN?_P"%@>&_^@U9_P#?T4?\+ \-_P#0:L_^_HH Z"BN M?_X6!X;_ .@U9_\ ?T4?\+ \-_\ 0:L_^_HH Z"BN?\ ^%@>&_\ H-6?_?T4 M?\+ \-_]!JS_ ._HH Z"BN?_ .%@>&_^@U9_]_11_P + \-_]!JS_P"_HH Z M"BN?_P"%@>&_^@U9_P#?T4?\+ \-_P#0:L_^_HH Z"BN?_X6!X;_ .@U9_\ M?T4?\+ \-_\ 0:L_^_HH Z"BN?\ ^%@>&_\ H-6?_?T4?\+ \-_]!JS_ ._H MH Z"BN?_ .%@>&_^@U9_]_16OI^HVVJVJ7-G/'0!;S_ (_)_P#KHW\ZAJ:\_P"/R?\ ZZ-_.H: "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ KFM"UVZU#QEXGTV8J;73_LOD +@CS(RS9/?D5T MM8FE>)/[3\2:[I/V?R_[+\C]]OSYGF(6Z8XQC'4YK:G\,]+Z?=JM?T^9G+>. MO7]&;=%%%8F@4444 %%%% !1110 4444 %%%% '+^.O$%YH#^&Q:,BB^UB"R MFW+G,;JY('H?E'-=16%XJ\4?\(RVBC[-]I_M+4HM/_UFSR]X8[^ASC;TXZ]: MW:WFOW<7RVWU[FH4445@:!1110 4444 %%%% !1110 4444 >*O .BZM?E&O+J'?(8UVKG<1P.W2NHK"\"^*/\ A-/"6F:W]F^Q_;8O,\CS M-^SDC&[ ST]*W:WKZ59KEMJ].VNWR,Z?P1UOIN%%%%8&@4444 %%%% !1110 M 4444 %-+C0/L^ M/)T^*^^T;^N^21-FW';R\YSWZ5M3VEI?3[MM3.736VIMT445B:!1110 4444 M %%%% !1110 4444 %9OB:^ETOPWJM[ 0)[>TEFC+#(W*A(R/J*TJI:YJ7]C M:+?ZAY?G?9;>2?R]VW=M4MC.#C.*N'Q+2Y,MF5O".I3:QX4T6_N2IN+JRAGD M*C W-&K' ['],U/RO(^VVL5SY6[=LWH&VYP,XSUQ6A3J?&] M+:A'X4%%%%9E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !72:1_R#XOQ_ MF:YNNDTC_D'Q?C_,T 7**** "BBB@ HHHH **** "O*O#G_)TWQ#_P"Q,\,_ M^EVO5ZK7E7AS_DZ;XA_]B9X9_P#2[7J .KO/^/R?_KHW\ZAJ:\_X_)_^NC?S MJ&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **Y/POX\'B77]3T M_P"PFV@@!>SNC+N%Y&LCQ2,%P-NUTQU.0RGO6Q9^*-&U'59],M-7L;K4K<$S M6<-RCS1X(!W(#D8) Y'>@#4HKF[OXC>&+6WU.0:]IL[Z;&\MU##>1-)&%."& M7=P=V%YQR0*R%^*^CW4NA7L&IZ>FA7UO-+<7<]P@$#*(MJ,X?:K9DP0<\X% MSNZ*R[SQ5HNGZ3#JEUK%A;:9-M\J]FN42%]PRNUR=IR.F#65JWQ-\-:)J.C6 MEUJUFG]K(TEM/]IB$6P+E7+%A\K=%(SD\4".IHK!L?%D/V+5KS5&L])M=/NY M+9IY+V-X]J[<.[ XC)W?<;D<>M:ECJEGJMA'>V-U#?6QVY".P7<6<_*N2<$]2,=:!G345DWWBS0 M],OH[.\UG3[2\DD$26\]U&DC.0"%"DY)(9>/]H>M:U @HHHH **** "BBB@ MK$TJ^TRX\2:[;6MOY>HV_D?;)M@'F;D)CY[X7(YZ5MUB:5:Z5%XDUV:TEWZG M+Y'VZ/<3LPA$?';*YK6%N65[[?JM_+];$2O=?UT9MT445D6%%%% !1110 44 M44 %%%% !1110!@^*M0TK3VT4:I;?:3/J44-I^[#>7<$-L?D\8 ;GWK>K!\5 M6ND73:+_ &M-Y)BU**2S^8KON0&V+[Y!;BMZMI6Y(VOU]/D1&_,PHHHK$L** M** "BBB@ HHHH **** "BBB@#"\"ZAI6J^$M,N]#MOL>DRQ;K>#RPFQK45SGA?X@:+XL55L[H)^W]7\B)7T M-NBBBLBPHHHH **** "BBB@ HHHH **** "J.N7%M:Z+J$U['YUG';R//'MW M;HPI+#'?(S5ZJ.N16LVBZA'?/Y=B]O(L[YQMC*G<<_3-7#XE<4MF-\.W-G>> M'],N-/B\BPEM8GMXMH79&4!5<#I@8XK0K/\ #L-E;^'],BTU_-TZ.UB6V?.= MT00!#GO\N*HW/BJ*S\5MH\\:0PIIS:B]Y)*%5%60(001P,'.[/:B=N9V%'9& M]16&WC'2[NTU5M*U#3]6N]/B9Y;6"]CRC $A7.3Y>2",MTY]*S++XGZ)-KFG MZ)64=V+?[7$Z[GQB)6#?.QSD8&".14%G7T5SFG^-K)?"]MK.MW%A MH44S,A,VH1/"K!F4*)00K$[*!'4T5EMXHT9-:71FU>Q75V&5T\W*?:",;N(\[NG/3I6 M;XK\4:AHNJZ+INF:=;:A=ZF\RK]KO&MHT$:;R25BD)R/:@#IJ*\^M/BK%)/I MCZ@+71+1FO8-0:\G&V":W=(R%E)"E2S'!(!.1P#Q76WGBK1=/TF'5+K6+"VT MR;;Y5[-1=7%U&D4N M1D;7)PV1SP>E-U+QAH.CVMK=7^MZ;8VUV-UO-M C8H MJ&ZF>&TEFBA:Z=4+)#&5#2$#(4%B!D].2![USNA^*M1N/$D^AZQI5OIUXMH+ MV%[.\-S%)'OV,"6CC*L#CC!!SUH ZBBLK6O%FB>')((]6UC3]+DGSY2WMTD) MDQC.T,1GJ.GK69:_$KPY=^(]4T0:K:QWVG*&F62XC (VEFV_-GY IW9 VT = M115;^T[/[1%!]K@\^6(SQQ^8NYXQ@%P,\J-R\].1ZUQDWQ.MKSQ&MIH=WIFM MV2Z7=WDCVUVA_?1-"%C,@8J@(D.=PXX/2@#O**P9/&FD:9I&FWVM:GIVB_;8 MED1;J^C"%BH)5') ?&>HX/7O5C6/%FA^'9($U76=/TQ[C)A6\NDB,F,9V[B, M]1T]: -:BLK7M:ET?^SC%;Q7 NKR.UJUY5X<_Y.F^(?_8F M>&?_ $NUZ@#J[S_C\G_ZZ-_.O./C'\0=1^'NEZ17RVT@ND9@%*DY M&UASQ7H]Y_Q^3_\ 71OYUXA^U -WAWPX,D?\3:/D=OD:O;R6C3Q&84J557BW MJODSDQ$_"]O:7C6_[S5KJZ5F2WCR,JNUA\^#[\ MD#L<8\GQ"\,?C=X]MSK.K:.(PC%]*N?) M,F0HP_!R/:OIX8/"4)U(N"Y(4E*,FF^:\HWE;YM)=#SG5J346F[N336UK)Z? MJ>@_#WXG:EX\\%ZCJ%OHR?VW8S&V:S\_9%)( #D.>@YZ<].O-8FJ?$SQGX'\ M4Z!8^*-.T6:PUB;R8VTEI3)&=RCG?UQO' '/K6=\!-432K'Q=XU.G@<+_ &E6P;IJTK\J][6\+JTK^[;1ZK2]F$JU3ZO& MKS.ZWV[VVZGI/BCXA:Y<>.O^$1\)65A/J4%O]IN[K5&<00J<87"!?BM>:[IWB.'5M(==>\/L4N;/309?/QNQY2DYR2I&,GL<\\<]X3?^S?V ME/%4=WB*2^L4>VWGEU CR!_WRW_?)IWP=_XF'Q6^(VIV[>98M[3ISYM;MR:NK]G=JW2QI&K4E43YMY25O)&A\/_BMX MA\4?$K4?#VKZ+!HL$%G]J2W)9KAS:"BBBO!.T**** " MBBB@ HHHH **** ([B9;:"29PY2-2Q$:,[8 SPJ@DGV R:YG3_B7HFJ:H=.M MUU9KQ617CDT6]C\K=]TN6A 0'U8@<5U5><_V7/K7BKXC6-K>3:?=3VMDD-U; MR%'B?RGVL".>#B@9Z-17ATWC75/%7AG6?$,5[?Z5%I\=IIC1VV\.EV)T-TP3 M!#EL:-#;63->-?R7?DRM*PN-DY\QEQ" M%9@,[/O!1W L>Y5BW_C'1]+_ +4^TW?E?V6L37?[ISY8D^YT'.?;..]?\ -4?^ MN&F_UI!8]9M=8L[S4KW3X9M]W9",SQ[6&S>"5Y(P<@'I5VN,\,_\E*\;?[EA M_P"BWK"N-6LG\?:O;Z_K]YI5]#=6RZ/8P7KPB:$JIW)"IQ.6D\Q6W*^ N.*8 M'J%O7VKSE]>FFN)'&MWJ^/4UWR%T1 M;R0+]F%QMQ]DSL,1MOWGFE>IW;\XQ/)_RV_['V/_ -DI#L>S45X5JGC:1_'% MJUG>2172:]'92V]QKVL,FNKK M&J/>)XJ6Q2)KV3[.MNUV(FC\K.QAMY%JBI;2+MD92L:,2K"-_F9B=IZFLSP1X&U?29/#]CJT7B"9=&>1 MHY8WTW[ S;'4D$!;@JX8\,,Y;YLXW5Z7!XNT.ZUE](AUK3Y=60D-8QW4;3J0 M,G,8.X8'M6M0.YY?X?T#7X;6_P!&M;+4M.\.MITT$%IKDEH[02-Q$D+V[NQ0 M L&\TL>$P>M6O#OA_4KN?P-/J.AR63:+936\PNG@D,FWFGVMS-Y<]_*T-LNUCO<(SD9 P/E1CSCI0%SR:/P%XCTN'0; MR"._A?3[K5 UMI3V9N%CGN&>)T^T Q8V C(8!^.XK5L_"^I:%_PB-[9Z5JU M\EE>7LMU:WDUFMW'YX?YOD=8=NXYVJV0&''8>EV-_;:G:I01^%):7]M?\ G?9KB&X\F1H9?)<-L<=4;'1AGD'FD%SS2X\(:U:R MR:@NFM??9?%$FJK8++&&N8&B\M64LP4,I;> Q7[G8XKO]$DGDTV2=](72+B5 MY)/LDDB%B23AI&CRH9NIP6Z]36I13 \AN/!NIZAJ&KW>E^&YO"ZW>EW4-]:_ M:H?(U"YD7$;(D;E<@[LRN$8AAD6(3 MRR;EW0S$D9* ?(RC;L 7@CGV.B@+GFGBSP/?ZGIOQ'-MITGUXK\1?A;K^O>,+_ %.QAAGM MKGR]H\X*R[8U4Y!QW!Z9KVLIC0GB>7$R2@T[WTOV5^FMG\CCQ3FH7IJ[N+_P MT)/\ X$_\P]IC?/[O^ =+_P -"7'_ $!8O_ @_P#Q-'_#0EQ_T!8O_ @_ M_$US7_"F?%7_ #XQ_P#@0G^-'_"F?%7_ #XQ_P#@0G^-'U7(>\?_ )_YA[3 M&^?W?\ Z7_AH2X_Z L7_ ($'_P")H_X:$N/^@+%_X$'_ .)KFO\ A3/BK_GQ MC_\ A/\:/\ A3/BK_GQC_\ A/\:/JN0]X_^!/_ ##VF-\_N_X!TO\ PT)< M?] 6+_P(/_Q-'_#0EQ_T!8O_ (/_P 37-?\*9\5?\^,?_@0G^-'_"F?%7_/ MC'_X$)_C1]5R'O'_ ,"?^8>TQOG]W_ .E_X:$N/^@+%_X$'_ .)H_P"&A+C_ M * L7_@0?_B:YK_A3/BK_GQC_P# A/\ &C_A3/BK_GQC_P# A/\ &CZKD/>/ M_@3_ ,P]IC?/[O\ @%GQ1\7)_$S:,6TV.W_L[48M0&)2WF% PV=!C.[K[5N? M\-"7'_0%B_\ @__ !-<=J/P/\771M=EC#^[G61LW"=!GW]ZN?\ "F?%7_/C M'_X$)_C6DL/D;BDY1T_O?\$A3QB;=G]W_ .E_P"&A+C_ * L7_@0?_B:/^&A M+C_H"Q?^!!_^)KFO^%,^*O\ GQC_ / A/\:/^%,^*O\ GQC_ / A/\:S^JY# MWC_X$_\ ,OVF-\_N_P" =+_PT)TQOG]W M_ .E_P"&A+C_ * L7_@0?_B:/^&A+C_H"Q?^!!_^)KFO^%,^*O\ GQC_ / A M/\:/^%,^*O\ GQC_ / A/\:/JN0]X_\ @3_S#VF-\_N_X!TO_#0EQ_T!8O\ MP(/_ ,31_P -"7'_ $!8O_ @_P#Q-/\ X$_\ MP]IC?/[O^ =+_P -"7'_ $!8O_ @_P#Q-'_#0EQ_T!8O_ @__$US7_"F?%7_ M #XQ_P#@0G^-'_"F?%7_ #XQ_P#@0G^-'U7(>\?_ )_YA[3&^?W?\ L^"/B MY/X,\*:;HBZ;'=K9Q^6)C*4+\DYQ@XZ^M;G_ T)>>,/$K>+=>FU-X!;-*JKY:MN VJ!UQ[5O?\*9\5?\^,?_@0G^-R&^/]K6@X_?-B51[/W_'/U%>?5O>&? ^L>+) +"T M8PYPUQ)\L2_\"[_09-=^-I86K2?UM+E7?I\S&C*I&7[K<^A?"_Q T7Q8JK9W M02YQS:S?)(/H._X9KHZ\Y\)_!72]$:.YU%SJ=XI#!2-L2'V'?\>/:O1J_(L= M'"0JM823JS"L2/PWY?C2XU_[1GSM/BL?L^SILDD??NSW M\S&,=NM;=9MW;=RE'=4L8-HFN;66%-QP-S(0,^V35P^):V) MELQWAW2?[!\/Z9IGF^?]BM8K;S=NW?L0+NQDXSCIFN2\8>&=3U3Q!JUS:VWF MP3^'+BPC;S%&Z=GRJ8)XR._3WKJ/">F3:+X6T;3[C:;BTLH;>38=_IYMS="':W^K#!=V<8ZG&,YHJ:S>M]0C\*T.#U#P3?)?6'V M'3XXK:'PQ=:8RQ,B*LS&'RX\9''ROST'/(S4NAZ'K&A>(O"]R^ERW-NN@QZ7 M#RFX\=*]$HJ"[GD=KX=\5:)X?\ #5O;V-U&UL;S[4^E M_8GOHB\I9 C7),8C8'YL?-D+[TOA[PKXB\.Z9X(GN-*FO[G2[J^^UV\%Q 9% M68R;'!9D1ARI(&#SPO8>M,P522< @;:3CH>OI0%SS&V\!ZS;ZI=6-Z/$%Q83:T=32;37TT6O,PE1W,H%P"O ;&> M%PI(.*Z_QMX1E\3^)O"\A2Y%A9R7+7,UI>/;2)NBPF&C=7Y/'RGZ\5O:1XJT M7Q URNEZO8:DUMCSQ9W*2F+.<;MI.WH>OH:-&\4:-XBCGDTG5['5$@($K6=R MDPC)Z;BI..AZ^E & ? ]MIWB/PI_9VFQ)I6E176"2&,4CA,-ECN+-\^6Y))) M)YYY2V\-^*=#TK28;:PN8DAO-2>1]*^Q->Q))<.\(0W),8C9""P'S<(.,$5Z M7HOB;1_$JS-I&K6.JK"0LC65RDP0GH&VDXZ'KZ5-;ZS9W6JWFFQ3;[RS2-YX MPC80/NV?-C&3M/ .1QGJ* /*],\):WHOA/0%?3-;7Q%9&\"WFCSV#&)))F;8 MXG98V5AL;Y4XV\;.E3ZMX9\6-KEIK-R+^:XN='BLKR/P[]A)2569G!%X"/+; M?_"77^OZ!?V>N7R W%[-);-;Q*I^2WB$<[OM7<>2HW' &WGAW6)_$'B^W:P9K;7M.BABU".2 M/R89%AD1E=2PDZL,%588/.*Z]?%&C2:TVCKJ]BVKJ,MIXN4-P!C=S'G=TYZ= M*&\4:,FM+HS:O8KJ[#*Z>;E/M!&-W$>=W3GITH \UU+POXF\7, VD2:#M\-7 M>E"2ZNH6;[1)Y..(V;Y#L.&Z\'*KQNF_X1W6M:UQ;[_A%SHD,7ANZTE5EG@, MC2,8BB 1NP$8PVTEO[V0O&[T1?%&C2:TVCKJ]BVKJ,MIXN4-P!C=S'G=TYZ= M*%\5:*VM'1AK%@=7'73Q2ZN+L%2C;NJ-U7D$8(LWGAG5M!MM+_ .$8T[Q!#JL&F0V: MW4TU@\$BH28XKL,^<(2V6@4'#':QXQZO10%SEO&NCW^L6_A\6\*S2VNK6MU< M;6"A40DNPW$9 ].M!M0_L6X2#3HUO9?%,>ILRM&&:$72L9"V>OE \9SC MC':O3J* "BBB@052_MBS&LC2O._T\VYNA#M;_5A@N[.,=3C&+4=3TWPW-#MM668PW7FDI&P&7*LH>/$UJZC;1M; MDNX8_"=]-*]I.Q1;A?(VEB#CS5R>/O+NYQN&0+'L]%>/74FL^&;P1:/J&I:E M?WWABZOO+O;A[G?=QF+8Z(Q*H296&U %/''%2?"G5I[[Q!"+?7=-N[=K$M=V M2^)IM4N6D!3;)Y4L:F#&6#*N!E@,?** L>NT444""BBB@ HHHH **** "BBB M@ KI-(_Y!\7X_P S7-UTFD?\@^+\?YF@"Y1110 4444 %%%% !1110 5Y5X< M_P"3IOB'_P!B9X9_]+M>KU6O*O#G_)TWQ#_[$SPS_P"EVO4 =7>?\?D__71O MYUS_ (H\&Z/XSM[:#6+/[9%;3">)?-=-K@$ _*1GJ>O%=!>?\?D__71OYU#6 ME.I.C)3IR::ZK1DRBI*TE=&!XD\!Z%XNNK&ZU6Q^TW-B^^WF65XGC.0>"C ] M0#S6-KOP3\%^)=6N=3U+1?M%]<-NEE^U3)N. ,X5P!P!T%=Q1752QV+H65*K M*-M%:35D]6E9]7J9RHTY_%%/Y&':^!] L?#\FAPZ1:)I,G^LM/+!1SQRV>IX M')YX'I61X?\ @YX-\+ZHFHZ;H<,-XARDDDDDNP^JAV(4^XKLZ*F.-Q45**JR M2EOJ]?7O\Q^RIMIN*TVTV.:\7?#GPWXZ:!M&&&RP.XDCOG/O6]14_6\1R1I>TERQU2 MN[)]TN@_9PNYC*H50!P!P*6BGB,9B<5; MZQ4E.VUVW;[Q0I4Z?P12]$%%%%8LOFO)YWG%B=N.7Z\=*Z2BB@ HHHH **** "BBB@ MKB[?X6V=N\,/]JZE)I$-[_:$>DL8! LWF&4'<(A*0)#NP9#R #D<5VE% !11 M10 4444 %%%% !6)XW-^O@W73I98:D+&;[-Y?WO,V';M]\XQ[UMT4 W$]ZY7P]XKUJ:'P3K+ZY_:* M>))"D^D^3"(K=6B>0F(JHDS$4"-O9\Y.=IQCT"W\(:#9ZP^K0:)IT&JN69KZ M.TC6=BWWB7 W'/?FGV/A?1M+U*YU&STBQM-0N<^?=P6R)++DY.YP,MD\\GK0 M,\Y\.^)/$< \&:C>ZS)JB:X\T,UB;:&.--L$DB,A50^[]U@Y8@[C@+P!F:7J M5_K6K_"[5M0U_P"WRZK1T/L,>C:?$M MFJ6-LBV9+6RK"H$!(*DIQ\IPQ''8GUJK9^$M#T^^DO;71=/MKR27SWN(;6-) M&DPPWE@,EL.XSU^9O4T@/(]&M[K6+GX:S+JLVE%Y=201V%O;1H-IDY53$0"0 M,'CISP>:V(O$E]!=7&FVUS#I(U+Q7<:>U_#;Q*T2B'S!@%=K2.5VAG#'YNAP M*]%NO"NB7UC!97.CZ?<6<$GFQ6\MJC1QODG'=*OK*ZL[C3 M+.XM+N3S;BWEMT:.9\@[G4C#'(')]!0%SSAO$?B+[1-HD.N-(\&OQZ:NL-:Q M-))"]N965E"B/S$)VY"@?*N5/(-B'4O%MYIVMV%C?W.HW&DZT+66ZA2VCOI; M4PQR?)O40>8#(!\R@%5/1L5Z#::!I=A9VMI;:;:6]K:OYEO!# JI"W/S(H&% M/S-R/4^M5M2\'Z#K,7CH\D,LFH1QI.LB.5='$2JF58%@04444 %%%% !1110 4444 %,O$^FS%3:Z?]E\@!<$>9&6;)[\ MBMZ=^6=ET_5;?UL9RM>-^_Z,Z6BBBL#0**** "BBB@ HHHH **** "BBB@#F M/'$>K._AW^RO/ 75X#>>0V/]'P^_=ZKG;G\*Z>N7\=>(+S0'\-BT9%%]K$%E M-N7.8W5R0/0_*.:ZBNB=_9PNM-3.-N:04445SF@4444 %%%% !1110 4444 M%%%% ',?#1-6C\":,NN^>=7$/^D_:6S)NW'[Q]<8KIZY?X8>(+SQ5X!T75K\ MHUY=0[Y#&NU<[B.!VZ5U%;XBZK34E9W>VVYE2M[.-MK(****P-0HHHH *\/^ M('@?6/%GQ$O186C&'9$&N)/EB7Y!_%W^@R:]PHKTL!CIY?4=6FKMJVOR_P C M"M15>*C+8\X\*_!/2M'V3ZFW]JW0YV,,0J?]W^+\>/:O1(XDAC6.-%CC4855 M& !Z 4^BL<3BZ^,ESUY-_P!=$53I0I*T%8****XS4*YR%=4_X6)=LWG?V+_9 M4(CR?W7VCSI=^!_>V[/PQ71US4.O7;_$B[T8E?L,>DPWBKM^;S&FE0\^F$7B MMZ5[2LNGZHSG:ZOW.EHHHK T"BBB@ HHHH **** "BBB@ HHHH *S?$BW3>' M=4%CO^VFUE$'EG#>9L.W'OG%:59OB:^ETOPWJM[ 0)[>TEFC+#(W*A(R/J*T MIWYU;N3+X6,\)K>+X6T9=1\S^T!90BY\TY?S-@W[O?./?\ "2:W MJ$FNZ)>7NL0Q7/AZ;4$?4DT\3(0P ,8@W (P8C$@+?+P9YWV+[%'Y/F?W]FW;N M]\9K(TN5O#$FH7GA!E\5VBPR@31W"WWDGS8 6"O*(V:,%DP6 .W)/0<5P'BK M[7XDT#QGXOTN-K:T?0I+#3W5"DEW&"SM/ZA>T?J,MT85ZI;^'M*L]'.DV^F6 M<&E,K(;&.W18"K9+#8!MP.U;3?["NUN5VKY'V(B'8&[;,],\8W58T"&V M\6:]JGBN:"&+P]-IW]G6_P!IC %Y &+O,X;_ )9G.%SU76MEH6FV=M>+MN8;>SC1)Q@C#@###!/7U-067P\\*Z;YQL_#.CVIGB:"7R;" M)/,C;[R-A>5/<'@T!M^)-1\:A!9Z*+ 6=I*Z%6NHE8R-<'/1.R>HR MW1A7-R:UK&C^$]*U.VANHM3\6ZL)9V@6$W$$;HQB1//(C#B..)/GXR3P3@5V MMS\*_"LEA>6MIH=AI/VN(P33:;:102M$2"R;E7.U@,'V_.NBOM*LM4T][&]L MX+RRD4*]M<1+)&P'0%2,$<"@#SEO$GB/3-"-KJO]K6=[=:BMKILAAL9-0NXS M'O(^5_LR."'^9N"J_=W&LK3_ !KXBU33K*R34KBRNO\ A)WT>6ZN8;62Y\D0 M/(0XCS#YBG@%1@%1D'Y@?28_ OAN+29-+3P]I2:9+)YKV2V40A=QCYBFW:3P M.<=A5FT\,Z/80PQ6NE6-M%#()HDAMD58Y FP.H X8+\N1SCCI0!YM>3:MH.L M>.+O3KV:YN]-CTVYF>6*-I+J&-&,JD!0H9D#?= YQBNP\"^(YO%TVL:K#=+< M:"\X@TWRPI5U1<22!@,G,A9>3_!QUK>N]*CDAOVM4AM;V\B\M[KR0Q)"D*7Z M%@N>A-5_"GAVV\(^&]-T:T \BR@6%6"[=Q Y8CU)R3]: .5U2&V\6>*M.TG2 M((5M=#U$:CJ%['& D<^&80H1P97+EG]%)SRPKDU4/\,KHN%;7#XI;[O,ANAJ M V>^?+"^^SVKTP_#SPJVH_V@?#.CF_\ -\_[5]@B\WS,YW[MN=V><]PD*NSLRA$) ;+<$-UI^'GA5M1_M ^&='-_YOG_:OL$7F^9G._=M MSNSSGKFK4'A+0[767U>'1=/BU9R2U]':QK.Q(P] &M1110(**** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NDTC_D'Q?C_, MUS==)I'_ "#XOQ_F: +E%%% !1110 4444 %%%% !7E7AS_DZ;XA_P#8F>&? M_2[7J]5KRKPY_P G3?$/_L3/#/\ Z7:]0!U=Y_Q^3_\ 71OYU#4UY_Q^3_\ M71OYU#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %8FE>)/[3\2:[I/V?R_[+\C M]]OSYGF(6Z8XQC'4YK;K$TJ^TRX\2:[;6MOY>HV_D?;)M@'F;D)CY[X7(YZ5 MK!)QE=7T^[5:_I\R)7NM?ZLS;HHHK(L**** "BBB@ HHHH **** "BBB@#"\ M5>*/^$9;11]F^T_VEJ46G_ZS9Y>\,=_0YQMZ<=>M;M8/BK4-*T]M%&J6WVDS MZE%#:?NPWEW!#;'Y/& &Y]ZWJVDER1:7?7N1&_,]0HHHK$L**** "BBB@ HH MHH **** "BBB@#"\"^*/^$T\):9K?V;[']MB\SR/,W[.2,;L#/3TK=K"\"ZA MI6J^$M,N]#MOL>DRQ;K>#RPFQ-+C0/L^/)T^*^^T;^N^21-FW';R\ MYSWZ5MUB1WVF-XTN+);?&LKI\4TEQL',!DD"INZ\,'./>M::34KJ^GW>9$KZ M:FW1116184444 %%%% !1110 4444 %%%% !5+7-2_L;1;_4/+\[[+;R3^7N MV[MJEL9P<9Q5VJ.N7%M:Z+J$U['YUG';R//'MW;HPI+#'?(S5PUDKJXI;,;X M=U;^WO#^F:GY7D?;;6*Y\K=NV;T#;>'],N-/B\BPEM8 MGMXMH79&4!5<#I@8XK0HGI)I*PH[(****@H**** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH *Z32/^0?%^/\ ,US==)I'_(/B_'^9H N4444 %%%% !1110 4 M444 %>5>'/\ DZ;XA_\ 8F>&?_2[7J]5KRKPY_R=-\0_^Q,\,_\ I=KU ':W M6EW4ES*ZQ95G)!W#U^M1_P!D7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D M7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ M #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^- M=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D M7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ M #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^- M=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D M7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ M #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^- M=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D M7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ M #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^- M=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D M7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ M #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^- M=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D M7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ M #R_\>'^-']D7?\ SR_\>'^-=)10!S?]D7?_ #R_\>'^-8>DZ#:1^)M>DLSO MU63[/]NC\P'9A#Y?';*YKT"L'1_"_P#9/BKQ#K/VKS?[6^S_ +CR\>5Y2%/O M9^;.<]!CWK6#2C*[MI]^J_X?Y$2O=:?U9D/]D7?_ #R_\>'^-']D7?\ SR_\ M>'^-=)1619S?]D7?_/+_ ,>'^-']D7?_ #R_\>'^-=)10!S?]D7?_/+_ ,>' M^-']D7?_ #R_\>'^-=)10!S?]D7?_/+_ ,>'^-']D7?_ #R_\>'^-=)10!S? M]D7?_/+_ ,>'^-']D7?_ #R_\>'^-=)10!S?]D7?_/+_ ,>'^-']D7?_ #R_ M\>'^-=)10!YYXLT&QN&T3^V&\@QZE"]E^]"[[D!MB^^1NX]JW_[(N_\ GE_X M\/\ &G^,/"7_ EC:$WVO[+_ &7JD.I?ZO?YOEAALZC&=W7GITKH:VDUR12? M?Y$1OS/0YO\ LB[_ .>7_CP_QH_LB[_YY?\ CP_QKI**Q+.;_LB[_P">7_CP M_P :/[(N_P#GE_X\/\:Z2B@#F_[(N_\ GE_X\/\ &C^R+O\ YY?^/#_&NDHH M YO^R+O_ )Y?^/#_ !H_LB[_ .>7_CP_QKI** .;_LB[_P">7_CP_P :/[(N M_P#GE_X\/\:Z2B@#F_[(N_\ GE_X\/\ &C^R+O\ YY?^/#_&NDHH \\\!Z#8 MVO@_2XO#[?:=&6+%K-YH;'^-.^'OA+_A _!>D MZ!]K^W?8(O*^T>7Y>_DG.W)QU]3715M6:=23B[J[U[^9%.Z@DU8YO^R+O_GE M_P"/#_&C^R+O_GE_X\/\:Z2BL2SF_P"R+O\ YY?^/#_&C^R+O_GE_P"/#_&N MDHH YO\ LB[_ .>7_CP_QH_LB[_YY?\ CP_QKI** .;_ +(N_P#GE_X\/\:/ M[(N_^>7_ (\/\:Z2B@#F_P"R+O\ YY?^/#_&C^R+O_GE_P"/#_&NDHH YO\ MLB[_ .>7_CP_QK#CT&T'C>YF4YUTZ=$DD/F#BW$LA1L>[EQGVKT"L"+PMY?C MRY\2?:L^=IL6G?9?+Z;)9)-^[/?S,8QVZ\UK3:2E=VT^_P B)7TLB+^R+O\ MYY?^/#_&C^R+O_GE_P"/#_&NDHK(LYO^R+O_ )Y?^/#_ !H_LB[_ .>7_CP_ MQKI** .;_LB[_P">7_CP_P :/[(N_P#GE_X\/\:Z2B@#F_[(N_\ GE_X\/\ M&C^R+O\ YY?^/#_&NDHH YO^R+O_ )Y?^/#_ !H_LB[_ .>7_CP_QKI** .; M_LB[_P">7_CP_P :/[(N_P#GE_X\/\:Z2B@#F_[(N_\ GE_X\/\ &J.NZ+YN MAZ@E^OEV#6\@N'W@;8]IW'.?3-=E5#7]+_MS0=2TWS?(^V6TEOYNW=LWJ5SC M(SC/3-7"W,KNPI;,YGPYHBP^'M+CTQ?-TU;6);63>#NB"#87_CP_QK2\,Z/_PCOAO2M)\[[1]AM(K7SMNW?L0+NQDXSC.,FM*B=N9V=Q1V M5SF_[(N_^>7_ (\/\:/[(N_^>7_CP_QKI**@HYO^R+O_ )Y?^/#_ !H_LB[_ M .>7_CP_QKI** .;_LB[_P">7_CP_P :/[(N_P#GE_X\/\:Z2B@#F_[(N_\ MGE_X\/\ &C^R+O\ YY?^/#_&NDHH YO^R+O_ )Y?^/#_ !H_LB[_ .>7_CP_ MQKI** .;_LB[_P">7_CP_P :/[(N_P#GE_X\/\:Z2B@#F_[(N_\ GE_X\/\ M&C^R+O\ YY?^/#_&NDHH YO^R+O_ )Y?^/#_ !H_LB[_ .>7_CP_QKI** .; M_LB[_P">7_CP_P :/[(N_P#GE_X\/\:Z2B@#F_[(N_\ GE_X\/\ &C^R+O\ MYY?^/#_&NDHH YO^R+O_ )Y?^/#_ !H_LB[_ .>7_CP_QKI** .;_LB[_P"> M7_CP_P :/[(N_P#GE_X\/\:Z2B@#F_[(N_\ GE_X\/\ &C^R+O\ YY?^/#_& MNDHH YO^R+O_ )Y?^/#_ !H_LB[_ .>7_CP_QKI** .;_LB[_P">7_CP_P : M/[(N_P#GE_X\/\:Z2B@#F_[(N_\ GE_X\/\ &C^R+O\ YY?^/#_&NDHH YO^ MR+O_ )Y?^/#_ !H_LB[_ .>7_CP_QKI** .;_LB[_P">7_CP_P :/[(N_P#G ME_X\/\:Z2B@#F_[(N_\ GE_X\/\ &C^R+O\ YY?^/#_&NDHH YO^R+O_ )Y? M^/#_ !K;TV%[>SCCD&UQG(S[FK-% !1110 4444 %%%% !1110 5Y5X<_P"3 MIOB'_P!B9X9_]+M>KU6O*O#G_)TWQ#_[$SPS_P"EVO4 >JT444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !7+^'_#=WIGC;Q7JTQC-KJ?V3R K$M^[B*MN&..3 MQ745R_A^/5U\;^*VO#/_ &4WV3[!YC9C_P!4?,V#M\V,^];TV^6=GT_5;&AIXA-P=:$'^E?:FW M2[MQ^\?7&*ZRM\0VZTW)W=WMMN94K>SC9=$%%%%8&H4444 %%%% !1110 44 M44 %:^3']AFT>"Q4;CO\ ,2>9SQCIB1><^M=17+PIJ_\ PLZ\ M=_/_ +!_L> 1Y/[K[3Y\V_ _O;-F?;%;TV[2L^GZHSG:ZOW.HHHHK T"BBB@ M HHHH **** "BBB@ HHHH *R_%.FRZQX9U>PM]HGNK.:"/><+N9"HR?3)K4K M+\4K=MX8U<:?YGV\V<JT45Y)^T7XZUSP'H?A^XT*^^PS76J);3-Y4.'IM)R[[?J95:BHP*C]F+>MN MFOWL^@**\>^#/Q$\5_$SX;ZK<'^SUUZTN6LX+Z1&^S3$!3O*KUQN/3 /'2N= M\2>,?'OPO^(?A/3+[Q5:^+X-:N!%-IZZ=%;20J75-/%'B[XLW'@7PI MJL/AV/3;075]JCVB7,A8A2$5'.W'SK[]?3!;\,/B!XO\21^,?"][-I\OBW0) MQ##J$T16"=2Q&]T3'(VD_+@'4UHT?;.4=HR:N[J,G92>EK;;-M7U1 M7UF#GR6?5?-;H]FHKYV\:^./B#\(?''AB#5/$EKXITS69O+>U_LV.V,?SJK! M2N3T<8)8^X]?HFN?%X">$A3JN2E&:;35^CL]TGOY%TJRJN4;--;W"BBBO,.@ M**** "BBB@ HHHH **** "BHKEIEMY6MT26<*3&DCE%9L< L 2!GO@X]#7GU MC\1O$/\ PD&JV&JZ+H&E6>D?9VO[Z37Y"B)*"0R;K502 .C%1G S0!Z-15*[ MUO3K"X6"ZO[6VF9!(LFYE7/JP'>JNE^+M"US3[F_T[6M.O[& MU+">ZM;N.2*+ R=[*2%P.3GM0!KT5FZ#XFTCQ3:O=:+JMCJ]LC^6TUA<).BL M #M+*2 <$''N*J:3XH_M3Q5K^C?9O*_LI;=O/\S/F^:C-]W'RXV^ISGM0!NT M5EWWBK1=+U6UTN]UBPM-2N\?9[.>Y1)ILG V(3EN>.!36\7:%'KRZ&VM:>NM ML,KIINHQO+H;:UIZZVPRNFFZC%R1MW9$>=WW03TZ70VUK3UUMAE=- M-U&+DC;NR(\[ON@GITYH$:U%8P\:>'SK$6DC7=-.JREECL?MD?GN5)# )G<2 M"K \<;3Z5LT %%%% !1110 445D>+K/4]0\,:I::+/#:ZK/;O%;W$Y(2)V&- MYP#TSG&.2!0!RW@CXA7WB/Q->6M[#:P:9=Q/=:+)&&$DT,4K12E\D@G/ENNW M'RRCCC-;.E?$GP]K6J)8VE[(\DGF"&:2TFCM[@I]\13L@CE(P3A&/"D] :YI MO@S:Z'<>&[KP[/>)/I,JPF/4=5NIXC:,ACE1$=G5#@JP"J!E%&0*S/ _PCO_ M K=:-;7=E#J5KI#,;;4)/$VH$Y".J.+%D,*$JVT@-@!F(_NTAZ'63?%;1GT M35-2L8M2OX;&V>Y$B:5=K#.J\#RY?*VR G'S(6&,MT!-8'_"X8+BZ\&Z@WVZ MQTW5;6X>:Q;3IVFDF"0LJQIY7F2 ;V^:-<, 3T'!H/PZURWFU.$QVGAS1KJP MGMCI=CJUQJ,!ED^ZZ)+%&MNJ9?Y(@ V_D#:*TO"O@_7K63P=+JJ:= ^AV,UC M*MGRW-OJ186D=I:33W$ MI7.\"!$,GRX.[*_+T.*RM2^,6D6>J^&;:VM[W4;76Q,RW5K97,OE;%/!1(F. M[<"K(<,F"6 Q7+R_!K5X;;1[F*:&YOK"ZU-FMH=6NM.22&ZN6F4BX@7>&7"9 M4J5.3Z UK6_P]U;25\*7NDZ?I]O=Z7=W<]U87.L7-PDGVA6#N+J2)I&?)#$, MF"21GN06ANV/C^WLK'6;K6KZT\NUU:33H%T^"=Y&/R[(O+VEI)N>1&"#VZ&N MAT;7K/Q!IHOK!I)8LLA26%X9%9205:-PK(P(Z, :X&?X;:S;22ZC92V,VI6_ MB276[2WN)72&6*2+R6CD<(2C;6<@A6P0.N3CO=(.KR:66U1;*WU)BQ\NS9Y8 M8AD[1N8*7P,9.$SZ"F!YMX=^(^N>)? .OZ^NHZ,'M["YD-A9PNMWI5P@8K%/ MO=@[#!SE(^5X4AN-W6/B1%:^%[U['4;,ZUI]I;3W;WD$SVT)D*\2&)3AB"2$ M'S$%OO>^*OAYJ.N:/\ $2T@FM4D\10K':&1V 0BW6/]YA3CY@>F>/RKT")3'$BG MJH H$/HHHH$%%%% !1110 5ROA[Q#>:EXZ\6Z7,R&TTW[)]G"K@CS(BS9/?D M5U5>*_%#XW:KX7\57&C:99VZ?9-OF33YD\W>B.,*,;<9(ZG/M7H8'"U,94=& MDKMKKTU6OZ?,YZU2-)*7W_P# #Z_1\SZ9HKYF_P"&B?%7_//3_P#O MPW_Q5'_#1/BK_GGI_P#WX;_XJC_5O'>7W_\ #Z_1\SZ9HKYF_X:)\5?\\]/ M_P"_#?\ Q5'_ T3XJ_YYZ?_ -^&_P#BJ/\ 5O'>7W_\ /K]'S/IFO#/BG\2 MM<\#_$0KI]R'M#;1L]I.-T3'G)QU!]P17,_\-$^*O^>>G_\ ?AO_ (JN*\7> M+;[QIJW]HZ@(A<>6L?[E2JX&<<$GUKU\KR*M0KN6*BG%IKNMQMG;,3'V?M_P "Q^->DJP=0RD,K#((Y!KX8KJ_"'Q. MU_P6RI979EM >;.XR\7X#JOX$5>.X9C*\\)*WD]OD_\ ,5',&M*J^9]'_$+Q M+>^&Y/"XLF11J&MV]A/O7=F)U>"])U_[)]A^WQ>;]G\SS-G)&-V!GIZ" MNBK>OI5FN6VKT[:[?(SI_!'6^FX4445@:!1110 4444 %%%% !1110 5RL'B M*\D^*5[H19/[/BT:"]5=OS>8\\R,<^F$7BNJK B\5>9X\N?#?V7'DZ;%J'VK MS.N^62/9MQV\O.<]^G%;4]I:7T^[;4SETUMJ;]%%%8F@4444 %%%% !1110 M4444 %%%% !65XKU";2/"^L7UN0+BULYIXRPR-RH6&1]16K5#7]4_L/0=2U+ MRO/^QVTEQY6[;OV*6QG!QG'7%7#XEI6$%Q*5& M!O>-6; [#)-;-9OAG6?^$B\-Z5JWD_9_MUI%=>3NW;-Z!MN<#.,XS@5I4ZGQ MO2VH1^%!1116904444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%8+>*-OCE?#OV;[VFG4/M/F>DHCV;<>^HK$TSQMX=UJ. M^DT[7]+OX[$;KMK6\CD%N.>9"K':/E;KCH?2KL^NZ;:LJS:A:Q,UNUT!),JD MPKC=)R?N#CZUI^K/;$"=;&ZCF,1.5>'/^3IOB'_ -B9 MX9_]+M>KU6O*O#G_ "=-\0_^Q,\,_P#I=KU 'JM>"_M>*&\,>%E/0ZU&.#C^ M!Z]ZJAJ_A_2_$$<4>J:;::E'"XEC2\@64(XZ, P.#SU%>GEN+6!Q=/$R5U'_ M ".?$4W6I.FNIX'\/[I_@%\5KSP1J,G_ !36OR_:]*O)/X)#\H1CZG 0^X4\ M;JYM/#_@;Q!\?OB#%XXFLH;6,HULU[?FT&\A0<$.NXX[E4-2^'GA76+Z6\O\ PSH]]>2G,EQ79M*S.*6#E905G%.Z3[=O\ M(\1^ 7B2V\/Z#X[BU#49)/A[I]\+;3KZXWE CR,A56 SM(:,G' W9XR37*?$ M'3_"'@7Q'X4O?A)J$;^(YKKRFL],O6O$DC/9\L^,G P3T)..,U]90Z?:VMD+ M.&VABM%78+=(PL87^[M QCVK-TGP7X>T"[:ZTO0=,TVZ88::TLXXG(/4%E4& MBGGE*.)J8GDE[V\;KEE[MO?5M7>[?=OIN.6#DZ<:=UIUMJM;Z?D>*:;JMI\/ M?VGO$T_B"[@TNSUK3DDMKJZ<1Q,0(\C>Q '*./P]ZK_"?Q)I^G^+/BM\0[B8 MIX:^T".*Z )$VUC]P=R]ZUX9TCQ+%''J^E6.JQQGH!Z=:YY9M0J4N6<'S2C"$M5; MEBUMINTEOHBUA9QE=/1-M>K[GS9X US1?BAX_/Q \;>(]'TR"RD*:-H=SJ$2 M/$%.5D=2P/!YY&6;GA0H/U&K!U#*0RL,@CD&N6_X53X)_P"A.T#_ ,%D'_Q- M=2JA%"J JJ, 8 KBS7&T<;.,J"<8Q5E%VLET2M^+>[-<-1E134]6^O=BT44 M5X9V!1110 4444 %%%% !1110 5PL?@I]4\3>/%U2T#:-K=M:VR,64^:JQ.D MG&21C<.H^E=U10!\WPV.J:]\,/$6M:Y;V][?":TT"W623,-U!;7:(TA.TX$L MA!/$7CH>)]0ATB3PX]Q::?;06,\]N9;DVT[3.3L,D0!#!$WY M'!W*%Z^O+H>G)IJ:>NGVJV"$%;40KY2X;<,)C PPSTZ\U>H';3=LBH7*[!9<9&\Y+\X( SCC3\/:'?6/Q \7:E/!LLK M]+(6TN]3O\N-P_ .1@D=0/:NLHH \XBTG5=%\9>)0WAD^(++7;NVN8[XS0+% M J1I&8YE=M^$*%UV(^=_8YKGSX)\02Z7/X6DT([G\1?VL/$GGPF'R_M0N ^W M?YWG!!Y.-F./O[:]GHH"YY._@?6SYN++[WC5-6'[U/\ CU&W,GWO8_+][VK' MU7PKXVU3Q';(]C>0V=OXCBU I:MI\6FM;K,#YB\?:6F*GIP M>!?#5KKAUJ'P]I46LEVD.HQV42W!9@0S>8%W9()!.>!O$-AIS;;^ZT^>& @X_>-&P7GMR>M %73OB9X=U:_@M;2[GF%Q(8H M+S[%.+.9QGY8[DIY+DX(&USD@@9-=37 ^%?B5X9GT/3-+TV_MHM86W6W30<8 MN[>15V^7);CYXPI&"6 SG'-<)X)\1-J%]X+FL/$.H:CXLNI7'B;2IKZ25; M9/*9:L=MMYWS9.0=CWFLC6?$UKH>J:)83QS--JUP]M T:@JK+ M$\I+9(P-L;=,\D?6O(O"(++3[NQU"&6'4/,%IOS&\VPD/M1L,<;3 MGCH,]*GT?Q!8>(/MIL)_/^Q73V<_R,NR9,;EY SC(Y''O7@UNUE?1_"_6?$N ML7UO$USJ5O+?S:M/;(&S+Y2EUD4!CC:.)+R*.^74]7O+'PZWC M">SU'4%N7B-K:B$&-/.!S#&9?+4L"N-^,KG- ['N-%>$VMY=ZI'%8:=X@U6; MPO/XGCM=/U.*_=Y9[8VK--&MP27DC$N]0Y)(Q\K952"^OI;#1_$>F3^+4TRR MTKQ*((!KFNRVC74!MHI3;&]W&92&D9@P+'"!3E2<,5CW:BN5^&.L0ZYX+L;J MW@N8([]KL"Z3R$M+&Q&4<]5(X'2NJH$%%%% !1110 4444 %%%% M !7CGQ&\"P?$SQ5=VNC_ &>QU32MG]HS7"%?/\V-3%AE!+;50CG&,U['6#H] MIH\/BKQ#/93;]6F^S_;X]Q.S$9$7';*YKOP>(GA)NM3^)+3\%KY6_&QA6IJH ME"6S/$_^&:M<_P"@II__ )$_^)H_X9JUS_H*:?\ ^1/_ (FOHJBO6_UBQ_\ M,ON1S?4:'8^=?^&:M<_Z"FG_ /D3_P")H_X9JUS_ *"FG_\ D3_XFOHJBC_6 M+'_S+[D'U&AV/G7_ (9JUS_H*:?_ .1/_B:/^&:M<_Z"FG_^1/\ XFOHJBC_ M %BQ_P#,ON0?4:'8^=?^&:M<_P"@II__ )$_^)H_X9JUS_H*:?\ ^1/_ (FO MHJBC_6+'_P R^Y!]1H=CYU_X9JUS_H*:?_Y$_P#B:X#QMX.N? VM?V9=SQ7$ MOEK+OASMP<\<@>E?9->+?$KX5:SX\^(!GMA':Z>MO&CWJKU M;^7O7NG@WX,^'_".R9H?[3OUY^TW0!"GU5.@_4^]=Y5X[B;>&#C\W^B_S^X5 M'+^M5_(\GM?AOX.^&K:)+J5I)J]_>:C#:6UQ,@8).P8JP3.% VGGDBO6*YWQ MA9Z+>-H7]LS^08=4AEL?G*[[H!MB^^06X]JZ*OC<3B*F)Y:E63 M7-BMMC75TV*>2Y\L_O6_6!%::./'ES=)-G7VTV*.2'<>+ M82R%&Q[N9!GVK6G:TKWV_J_D1*^AOT445D6%%%% !1110 4444 %%%% !111 M0 50\07%I9Z#J4]_%Y]C%;2/<1;0V^,*2PP>N1GBK]4/$$-G<:#J46H/Y=@] MM(MP^<;8RI#G/;C-7#XE<4MF1^&;JROO#>E7.FP_9].FM(I+:':%V1% 47 Z M84@8K3K,\,PV-KX;TJ'2Y/-TR.TB2UDSG=$$ 0Y[Y7%:=$[621B)%$3NRH !]X*WS?=X->HT4 >+:' MX!UC58)X=1A\26E['H5QI4$FJ/I7V%!(J+L7[(!*0"JE=R@ *> 3@NO/#OBG MQ-<)/+X:FTI(/"E]I 2YO+=WDNI/(V@!'8;#L.&)!X.Y5XW>ST4#N>2>(?AG MJ6HR6=IIEM#IEO\ \(C>:,9HV5$AF

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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover - shares
6 Months Ended
Jun. 30, 2022
Jul. 29, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2022  
Document Transition Report false  
Entity File Number 001-38210  
Entity Registrant Name Krystal Biotech, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 82-1080209  
Entity Address, Address Line One 2100 Wharton Street  
Entity Address, Address Line Two Suite 701  
Entity Address, City or Town Pittsburgh  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 15203  
City Area Code 412  
Local Phone Number 586-5830  
Title of 12(b) Security Common Stock  
Trading Symbol KRYS  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   25,664,287
Amendment Flag false  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q2  
Entity Central Index Key 0001711279  
Current Fiscal Year End Date --12-31  
Security Exchange Name NASDAQ  

XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets    
Cash and cash equivalents $ 218,720 $ 341,246
Short-term investments 206,845 96,850
Prepaid expenses and other current assets 3,205 4,171
Total current assets 428,770 442,267
Property and equipment, net 151,214 112,355
Long-term investments 12,902 64,371
Right-of-use assets 8,279 7,228
Other non-current assets 159 74
Total assets 601,324 626,295
Current liabilities    
Accounts payable 9,229 8,398
Current portion of lease liability 1,417 1,041
Accrued expenses and other current liabilities 23,781 16,297
Total current liabilities 34,427 25,736
Lease liability 7,716 6,983
Total liabilities 42,143 32,719
Commitments and contingencies (Note 6)
Stockholders' equity    
Preferred stock; $0.00001 par value; 20,000,000 shares authorized at    June 30, 2022 (unaudited) and December 31, 2021; 2,061,773    shares issued, and no shares outstanding at June 30, 2022    (unaudited) and December 31, 2021 0 0
Common stock; $0.00001 par value; 80,000,000 shares authorized at    June 30, 2022 (unaudited) and December 31, 2021; 25,664,287    shares issued and outstanding at June 30, 2022    (unaudited); and 25,207,985 shares issued and outstanding at December 31, 2021 0 0
Additional paid-in capital 779,583 734,523
Accumulated other comprehensive loss (1,545) (163)
Accumulated deficit (218,857) (140,784)
Total stockholders' equity 559,181 593,576
Total liabilities and stockholders' equity $ 601,324 $ 626,295
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.00001 $ 0.00001
Preferred stock, shares authorized 20,000,000 20,000,000
Preferred stock, shares issued 2,061,773 2,061,773
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.00001 $ 0.00001
Common stock, shares authorized 80,000,000 80,000,000
Common stock, shares issued 25,664,287 25,207,985
Common stock, shares outstanding 25,664,287 25,207,985
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Expenses        
Research and development $ 10,890 $ 6,594 $ 20,204 $ 12,795
General and administrative 17,863 9,799 33,771 17,951
Litigation settlement 0 0 25,000 0
Total operating expenses 28,753 16,393 78,975 30,746
Loss from operations (28,753) (16,393) (78,975) (30,746)
Other Income (Expense)        
Interest and other income, net 645 30 902 64
Interest expense 0 0 0 (1,492)
Net loss (28,108) (16,363) (78,073) (32,174)
Unrealized loss on available-for-sale securities and currency translation adjustment (348) (24) (1,382) (27)
Comprehensive loss $ (28,456) $ (16,387) $ (79,455) $ (32,201)
Net loss per common share: basic (in dollars per share) $ (1.10) $ (0.74) $ (3.08) $ (1.48)
Net loss per common share: diluted (in dollars per share) $ (1.10) $ (0.74) $ (3.08) $ (1.48)
Weighted-average common shares outstanding: basic 25,545,167 22,204,659 25,331,000 21,731,711
Weighted-average common shares outstanding: diluted 25,545,167 22,204,659 25,331,000 21,731,711
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020   19,714,220      
Beginning balance at Dec. 31, 2020 $ 292,084 $ 0 $ 363,292 $ 6 $ (71,214)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock, net, (in shares)   2,489,837      
Issuance of common stock, net 152,033   152,033    
Stock-based compensation expense 2,350   2,350    
Unrealized loss on investments and other (3)     (3)  
Net loss (15,812)       (15,812)
Ending balance (in shares) at Mar. 31, 2021   22,204,057      
Ending balance at Mar. 31, 2021 430,652 $ 0 517,675 3 (87,026)
Beginning balance (in shares) at Dec. 31, 2020   19,714,220      
Beginning balance at Dec. 31, 2020 292,084 $ 0 363,292 6 (71,214)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Unrealized loss on investments and other (27)        
Net loss (32,174)        
Ending balance (in shares) at Jun. 30, 2021   22,205,032      
Ending balance at Jun. 30, 2021 418,540 $ 0 521,950 (21) (103,389)
Beginning balance (in shares) at Mar. 31, 2021   22,204,057      
Beginning balance at Mar. 31, 2021 430,652 $ 0 517,675 3 (87,026)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock, net, (in shares)   975      
Issuance of common stock, net 14   14    
Stock-based compensation expense 4,261   4,261    
Unrealized loss on investments and other (24)     (24)  
Net loss (16,363)       (16,363)
Ending balance (in shares) at Jun. 30, 2021   22,205,032      
Ending balance at Jun. 30, 2021 418,540 $ 0 521,950 (21) (103,389)
Beginning balance (in shares) at Dec. 31, 2021   25,207,985      
Beginning balance at Dec. 31, 2021 593,576 $ 0 734,523 (163) (140,784)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock, net, (in shares)   1,475      
Issuance of common stock, net 55   55    
Shares surrendered for taxes and forfeitures (in shares)   (10,379)      
Shares surrendered for taxes and forfeitures (649)   (649)    
Stock-based compensation expense 6,571   6,571    
Unrealized loss on investments and other (1,034)     (1,034)  
Net loss (49,965)       (49,965)
Ending balance (in shares) at Mar. 31, 2022   25,199,081      
Ending balance at Mar. 31, 2022 548,554 $ 0 740,500 (1,197) (190,749)
Beginning balance (in shares) at Dec. 31, 2021   25,207,985      
Beginning balance at Dec. 31, 2021 593,576 $ 0 734,523 (163) (140,784)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Unrealized loss on investments and other (1,382)        
Net loss (78,073)        
Ending balance (in shares) at Jun. 30, 2022   25,664,287      
Ending balance at Jun. 30, 2022 559,181 $ 0 779,583 (1,545) (218,857)
Beginning balance (in shares) at Mar. 31, 2022   25,199,081      
Beginning balance at Mar. 31, 2022 548,554 $ 0 740,500 (1,197) (190,749)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock, net, (in shares)   472,706      
Issuance of common stock, net $ 30,748   30,748    
Shares surrendered for taxes and forfeitures (in shares) (7,500)        
Stock-based compensation expense $ 8,335   8,335    
Unrealized loss on investments and other (348)     (348)  
Net loss (28,108)       (28,108)
Ending balance (in shares) at Jun. 30, 2022   25,664,287      
Ending balance at Jun. 30, 2022 $ 559,181 $ 0 $ 779,583 $ (1,545) $ (218,857)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Operating Activities    
Net loss $ (78,073) $ (32,174)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization 1,991 1,202
Stock-based compensation expense 14,619 6,508
Non-cash interest expense 0 1,492
Other, net (166) (117)
Changes in operating assets and liabilities    
Prepaid expenses and other current assets 848 1,366
Other non-current assets 15 0
Lease liability (286) (175)
Accounts payable 24 (680)
Accrued expenses and other current liabilities 2,476 2,795
Net cash used in operating activities (58,552) (19,783)
Investing Activities    
Purchases of property and equipment (33,706) (6,462)
Purchases of investments (147,255) (59,561)
Proceeds from maturities of investments 86,829 2,959
Net cash used in investing activities (94,132) (63,064)
Financing Activities    
Issuance of common stock, net 30,807 152,065
Taxes paid related to settlement of restricted stock awards (649) 0
Repayment of ASTRA build to suit liability 0 (7,960)
Net cash provided by financing activities 30,158 144,105
Net increase (decrease) in cash and cash equivalents (122,526) 61,258
Cash and cash equivalents at beginning of period 341,246 268,269
Cash and cash equivalents at end of period 218,720 329,527
Supplemental Disclosures of Non-Cash Investing and Financing Activities    
Unpaid purchases of property and equipment included in accounts payable and accrued expenses 22,234 10,143
Initial recognition of right-of-use assets $ 1,394 $ 4,060
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2
Organization
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Organization Organization
Krystal Biotech, Inc. (the “Company,” or “we” or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 24, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. On January 7, 2022, the Company incorporated Krystal Biotech Switzerland GmbH, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's pipeline.
We are a clinical stage biotechnology company leading the field of redosable gene delivery. Using our patented platform that is based on engineered herpes simplex virus type 1 ("HSV-1"), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a doctor’s office or potentially in the patient’s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions. Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities.
Liquidity
As of June 30, 2022, the Company had an accumulated deficit of $218.9 million. With the net proceeds raised from its public and private securities offerings, the Company believes that its cash, cash equivalents and short-term investments of approximately $425.6 million as of June 30, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.
The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to commercialize product candidates.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), as found in the Accounting Standards Codification (“ASC”), the Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”), and the rules and regulations of the US Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company’s previously reported financial position or results of operation.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on February 28, 2022.
Risks and Uncertainties
The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.
Segment and Geographical Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products.  
Concentrations of Credit Risk and Off-Balance Sheet Risk
Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company’s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.
Cash, Cash Equivalents and Investments
Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90 days or less at the date of purchase.
Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.
As our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders’ equity in the condensed consolidated balance sheets.
Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:
Level 1— Valuations based on quoted prices in active markets for identical assets or liabilities.
Level 2— Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.
Level 3— Valuations based on inputs that are both significant to the fair value measurement and unobservable.
To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.
The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company’s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the holding period is longer than one year. The Company classifies all of its investments as available-for-sale.
Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.
Property and Equipment, net
Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:

Computer equipment and software
3 - 7 years
Lab equipment
3 - 7 years
Furniture and fixtures
3 - 7 years
Leasehold improvementlesser of remaining useful life or remaining lease term
Construction in progress ("CIP") is not depreciated until the asset is placed in service.
Impairment of Long-Lived Assets
The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and six months ended June 30, 2022 and 2021.
Leases
The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, Leases. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease. Right-of-use lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company’s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.  Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.
For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria. If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.
Research and Development Expenses
Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.
The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company’s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.
In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company’s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.
Stock-Based Compensation Expense
The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, Compensation—Stock Compensation ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant.
ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.
The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i) the expected stock price volatility; (ii) the expected term of the award; (iii) the risk-free interest rate; and (iv) expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.
The Company estimates the expected term of its stock options using the “simplified” method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates
are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.
Comprehensive Loss
Comprehensive loss is defined as the change in equity during a period from transactions from non-owner sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss Per Share Attributable to Common Stockholders
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Net Loss Per Share Attributable to Common Stockholders Net Loss Per Share Attributable to Common Stockholders
Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 3,686,862 and 1,688,965 common share equivalents outstanding as of June 30, 2022 and 2021, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.

Three Months Ended
June 30,
Six Months Ended
June 30,
2022202120222021
(In thousands, except share and per share data)(Unaudited)(Unaudited)
Numerator: 
Net loss per common share$(28,108)$(16,363)$(78,073)$(32,174)
Denominator:
Weighted-average basic and
   diluted common shares
25,545,167 22,204,659 25,331,000 21,731,711 
Basic and diluted net loss per
   common share
$(1.10)$(0.74)$(3.08)$(1.48)
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Instruments
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Instruments Fair Value Instruments
The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of June 30, 2022 and December 31, 2021, respectively (in thousands):

 June 30, 2022
(unaudited)
 Amortized CostGross
Unrealized
Gains
Gross
Unrealized
Losses
Aggregate Fair
Value
Cash and Cash
Equivalents
Short-term
Marketable
Securities (1)
Long-term
Marketable
Securities (2)
Level 1:       
Cash and cash equivalents$218,720 $— $— $218,720 $218,720 $— $— 
Subtotal218,720 — — 218,720 218,720 — — 
Level 2:
Commercial paper46,157 (53)46,105 — 46,105 — 
Corporate bonds97,808 — (890)96,918 — 88,853 8,065 
U.S. government agency securities77,317 — (593)76,724 — 71,887 4,837 
Subtotal221,282 (1,536)219,747 — 206,845 12,902 
Total$440,002 $$(1,536)$438,467 $218,720 $206,845 $12,902 
 December 31, 2021
 Amortized CostGross
Unrealized
Gains
Gross
Unrealized
Losses
Aggregate Fair
Value
Cash and Cash
Equivalents
Short-term
Marketable
Securities (1)
Long-term
Marketable
Securities (2)
Level 1:       
Cash and cash equivalents$341,246 $— $— $341,246 $341,246 $— $— 
Subtotal341,246 — — 341,246 341,246 — — 
Level 2:
Commercial paper40,469 (4)40,466 — 40,466 — 
Corporate bonds83,300 10 (114)83,196 — 35,768 47,428 
U.S. government agency securities37,621 — (62)37,559 — 20,616 16,943 
Subtotal161,390 11 (180)161,221 — 96,850 64,371 
Total$502,636 $11 $(180)$502,467 $341,246 $96,850 $64,371 
(1)The Company’s short-term marketable securities mature in one year or less.
(2)The Company's long-term marketable securities mature between one year and two years.
See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company’s fair value measurements.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Balance Sheet Components
6 Months Ended
Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Components Balance Sheet Components
Property and Equipment, Net
Property and equipment, net consist of the following (in thousands):
 June 30,
2022
December 31,
2021
 (Unaudited) 
Construction in progress$142,893 $104,340 
Leasehold improvements5,736 5,723 
Furniture and fixtures900 891 
Computer equipment and software96 85 
Laboratory and manufacturing equipment6,740 5,530 
Total property and equipment156,365 116,569 
Accumulated depreciation and amortization(5,151)(4,214)
Property and equipment, net$151,214 $112,355 
Depreciation expense was $494 thousand and $956 thousand for the three and six months ended June 30, 2022 and $475 thousand and $914 thousand for the three and six months ended June 30, 2021, respectively.
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
 June 30,
2022
December 31,
2021
 (Unaudited) 
Accrued construction in progress$14,631 $9,606 
Accrued professional fees3,812 2,011 
Accrued payroll and benefits2,896 2,882 
Accrued preclinical and clinical expenses2,094 1,602 
Accrued financing costs29 26 
Accrued taxes22 83 
Other current liabilities297 87 
Total$23,781 $16,297 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Significant Contracts and Agreements
Lease Agreements
On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and was scheduled to expire on October 31, 2017 (the “2016 Lease”). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately 47,000 square feet and includes the commercial scale cGMP-compliant manufacturing facility, ANCORIS. As a result of the lease amendments, the 2016 Lease expiration date was extended to October 31, 2031.
On December 26, 2019, the Company entered into a lease agreement for a second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord", "Northfield", or "Lessor") with an initial lease term that expired on October 31, 2035. The ASTRA lease contained an option ("Purchase
Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the "Ground Lease"). A cash contribution in the amount of $2.4 million was paid to escrow on January 21, 2020. The contribution was intended to reduce the amount of the building construction costs and had the effect of reducing the base rental rate of the lease and as such, was recorded as prepaid rent in the consolidated balance sheet at the time of payment.
On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $9.4 million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020. The Company recorded a $10.0 million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contribution of $2.4 million.
On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $9.4 million. The Company held approximately $1.5 million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement. As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale. As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of June 30, 2022. The interior of the building is currently under construction and is expected to be completed and validated in 2022. From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.
As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $82 thousand, and are subject to a cumulative 10% escalation clause every 5 years through 2071.
On December 15, 2021, the Company entered into a 3 year lease agreement for the Boston, Massachusetts office that commenced in January 2022 and expires in January 2025.
As of June 30, 2022, future minimum commitments under the Company’s operating leases were as follows (in thousands):
 Operating
Leases
2022 (remaining six months)$743 
20231,510 
20241,539 
20251,277 
20261,277 
Thereafter12,063 
Future minimum operating lease payments$18,409 
Less: Interest9,276 
Present value of lease liability$9,133 
On May 16, 2022, the Company entered into a 16 month lease agreement for the Zug, Switzerland office ("Switzerland Lease") that commences on September 1, 2022 and expires December 31, 2023. As of June 30, 2022, the Company has not recorded a right-of-use asset or corresponding lease liability, as the Company has not yet gained control over the Switzerland Lease. Future minimum operating lease payments under the Switzerland Lease are $22 thousand and $89 thousand for the years ending 2022 and 2023, respectively.
Supplemental condensed consolidated balance sheet information related to leases is as follows:
(unaudited)
 June 30, 2022December 31, 2021
Operating leases:  
Right-of-use assets$8,279 $7,228 
Current portion of lease liability1,417 1,041 
Lease liability7,716 6,983 
Total lease liability$9,133 $8,024 
Weighted average remaining lease term, in years12.914.4
Weighted average discount rate9.4 %9.5 %

The Company recorded operating lease costs of $391 thousand and $800 thousand for the three and six months ended June 30, 2022 and $278 thousand and $497 thousand for the three and six months ended June 30, 2021, respectively. The Company recorded variable lease costs of $71 thousand and $120 thousand for the three and six months ended June 30, 2022 and $81 thousand and $118 thousand for the three and six months ended June 30, 2021, respectively.
Agreements with Contract Manufacturing Organizations and Contract Research Organizations
The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of June 30, 2022 under these agreements is approximately $2.1 million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $1.2 million and $3.0 million for each of the three and six months ended June 30, 2022 and $718 thousand and $2.5 million for the three and six months ended June 30, 2021.
Commercial Preparedness Activities
The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate. These contracts typically call for the payment of fees for services upon the achievement of certain milestones. The estimated remaining commitment as of June 30, 2022 is $5.1 million. The Company has incurred expenses under these activities of $3.1 million and $6.2 million for the three and six months ended June 30, 2022 and $974 thousand and $2.3 million for the three and six months ended June 30, 2021.
ASTRA Contractual Obligations
The Company has contracted with various third parties to construct our second cGMP facility, ASTRA. Additionally, the Company has entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of June 30, 2022 is $17.9 million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of June 30, 2022.
On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the “Agreement”) with The Whiting-Turner Contracting Company (“Whiting-Turner”), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to 1.75% of the cost of work.
Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be
paid by the Company is $83.0 million, subject to certain additions and deductions by change orders as provided by the Agreement. Whiting-Turner’s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner’s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement constitutes only a portion of the total estimated cost of building and equipping ASTRA.
Legal Proceedings
On May 1, 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. The Company answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that the Company did not misappropriate PeriphaGen’s trade secrets or confidential information, and to further declare that the Company is the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages.
On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022. During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions. On March 12, 2022, the Company entered into a binding term sheet to settle the dispute. On April 27, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $25.0 million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications. Upon approval of Krystal’s first product by the U.S. Food and Drug Administration, Krystal will pay PeriphaGen an additional $12.5 million, followed by three additional $12.5 million contingent milestone payments upon reaching $100.0 million in total cumulative sales, $200.0 million in total cumulative sales and $300.0 million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of Krystal products by Krystal and its affiliates and licensees, as reported by Krystal in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $75.0 million.
The Company recorded the $25.0 million under litigation settlement expense on the condensed consolidated statements of operations for the six months ended June 30, 2022. The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of June 30, 2022, and therefore no additional accrual has been recorded.
The Company has received $768 thousand of insurance proceeds during the three and six months ended June 30, 2022 and Company recorded an additional $369 thousand as a receivable within prepaid expenses and other current assets on the condensed consolidated balance sheet as management determined that the amount was probable of collection relating to legal defense costs and expenses associated with the PeriphaGen litigation. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Capitalization
6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
Capitalization Capitalization
Sale of Common Stock
The Company sells shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program") finalized on December 31, 2020, under which Cowen acts as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $150.0 million ("Placement Shares"). The issuance and sale of the Placement Shares by the Company under the Sales Agreement are made pursuant to the Company's effective "shelf" registration statement on Form S-3. During 2021, the Company issued and sold 262,500 shares of common stock at a weighted average price of $66.50 per share for net proceeds of $16.9 million after deducting selling commissions of approximately $524 thousand. During the six months ended June 30, 2022, the Company issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share for net proceeds of $29.1 million after deducting selling commissions of approximately $900 thousand, resulting in a remaining $102.5 million available for issuance under the ATM Program.
On December 3, 2021, the Company completed an underwritten public offering of 2,866,667 shares of its common stock, including 200,000 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $75.00 per share. Net proceeds to the Company from the offering were $201.9 million after deducting underwriting discounts and commissions of approximately $12.9 million, and other offering expenses payable by the Company of $227 thousand.
On February 1, 2021, the Company completed an underwritten public offering of 2,211,538 shares of its common stock, including 288,461 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $65.00 per share. Net proceeds to the Company from the offering were $134.9 million after deducting underwriting discounts and commissions of approximately $8.6 million, and other offering expenses payable by the Company of $198 thousand.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation
6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
Stock Options
Options granted to employees and non-employees vest ratably over four-year periods and stock options granted to directors of the company vest ratably over one-year to four-year periods. Stock options have a life of ten years.
The Company granted 544,500 and 1,724,000 stock options to employees and directors of the Company during the three and six months ended June 30, 2022, respectively, and 297,500 and 799,950 stock options to employees and directors of the Company during the three and six months ended June 30, 2021, respectively.
The Company granted 45,000 stock options to non-employees during the three and six months ended June 30, 2022, respectively, and zero stock options to non-employees during the three and six months ended June 30, 2021, respectively.
The following table summarizes the Company’s stock option activity:
 Stock
Options
Outstanding
Weighted-
average
Exercise
Price
Weighted-
average
Remaining
Contractual
Life (Years)
Aggregate
Intrinsic
Value
(In thousands) (1)
Outstanding at December 31, 20212,043,179 $57.00 9.0$31,331 
Granted1,769,000 $62.19 
Exercised(39,399)$44.13 
Cancelled or forfeited(151,642)$55.24 
Expired(876)$74.92 
Outstanding at June 30, 20223,620,262 $59.75 9.1$28,341 
Exercisable at June 30, 2022536,979 $47.48 7.5$11,184 
(1)Aggregate intrinsic value represents the difference between the closing stock price of our common stock on June 30, 2022 and the exercise price of outstanding in-the-money options.
The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three and six months ended June 30, 2022 was $704 thousand and $739 thousand, respectively, and during the three and six months ended June 30, 2021 was $64 thousand and $872 thousand, respectively.
The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the three and six months ended June 30, 2022 was $42.90 and $43.03, respectively, and during the three and six months ended June 30, 2021 was $42.53 and $47.25, respectively.
There was $115.7 million of unrecognized stock-based compensation expense related to employees', non-employees', and directors’ option awards that is expected to be recognized over a weighted-average period of 3.3 years as of June 30, 2022.
The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and six months ended June 30, 2022 and 2021 as follows (in thousands):
 Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
(unaudited)(unaudited)
Research and development$1,995 $1,084 $3,363 $1,600 
General and administrative5,776 2,625 10,357 4,240 
Total stock-based compensation$7,771 $3,709 $13,720 $5,840 
We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $146 thousand and $287 thousand of stock-based compensation that was capitalized in the three and six months ended June 30, 2022, respectively, and $66 thousand and $103 thousand of stock-based compensation that was capitalized in the three and six months ended June 30, 2021, respectively.
The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and six months ended June 30, 2022 and 2021:

 Three Months Ended June 30,Six Months Ended March 31,
 2022202120222021
Expected stock price volatility78 %72 %78 %72 %
Expected term of the award (years)6.176.106.216.18
Risk-free interest rate2.92 %1.05 %2.17 %1.02 %
Weighted average exercise price$61.51$66.58$62.19$73.42
Forfeiture rate— %— %— %— %
Restricted Stock Awards
Restricted stock awards ("RSAs") granted to employees vest ratably over a four-year period. The Company granted zero RSAs to employees of the Company during the three and six months ended June 30, 2022, respectively, and zero and 98,800 RSAs to employees of the Company during the three and six months ended June 30, 2021, respectively.
Number of SharesWeighted Average
Grant Date
Fair Value
Non-vested RSAs as of December 31, 202198,800 $78.89 
Granted— $— 
Vested(14,321)$78.89 
Surrendered or forfeited(17,879)$78.89 
Non-vested RSAs as of June 30, 202266,600 $78.89 
There was $4.7 million of unrecognized stock-based compensation expense related to employees’ awards that is expected to be recognized over a weighted-average period of 2.7 years as of June 30, 2022.
The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and six months ended June 30, 2022 and 2021 as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
(unaudited)(unaudited)
General and administrative$418 $486 $899 $668 
Total stock-based compensation$418 $486 $899 $668 
Shares remaining available for grant under the Company’s stock incentive plan were 530,991, with a sublimit for incentive stock options of 1,296, at June 30, 2022.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Subsequent Events
6 Months Ended
Jun. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventsThe Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), as found in the Accounting Standards Codification (“ASC”), the Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”), and the rules and regulations of the US Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company’s previously reported financial position or results of operation.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on February 28, 2022.
Risks and Uncertainties
Risks and Uncertainties
The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.
Segment and Geographical Information Segment and Geographical InformationOperating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products.
Concentrations of Credit Risk and Off-Balance Sheet Risk
Concentrations of Credit Risk and Off-Balance Sheet Risk
Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company’s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.
Cash, Cash Equivalents and Investments
Cash, Cash Equivalents and Investments
Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90 days or less at the date of purchase.
Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.
As our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders’ equity in the condensed consolidated balance sheets.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:
Level 1— Valuations based on quoted prices in active markets for identical assets or liabilities.
Level 2— Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.
Level 3— Valuations based on inputs that are both significant to the fair value measurement and unobservable.
To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.
The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company’s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the holding period is longer than one year. The Company classifies all of its investments as available-for-sale.
Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.
Property and Equipment, net
Property and Equipment, net
Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:

Computer equipment and software
3 - 7 years
Lab equipment
3 - 7 years
Furniture and fixtures
3 - 7 years
Leasehold improvementlesser of remaining useful life or remaining lease term
Construction in progress ("CIP") is not depreciated until the asset is placed in service.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets
The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and six months ended June 30, 2022 and 2021.
Leases
Leases
The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, Leases. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease. Right-of-use lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company’s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.  Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.
For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria. If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.
Research and Development Expenses
Research and Development Expenses
Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.
The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company’s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.
In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company’s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.
Stock-Based Compensation Expense
Stock-Based Compensation Expense
The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, Compensation—Stock Compensation ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant.
ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.
The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i) the expected stock price volatility; (ii) the expected term of the award; (iii) the risk-free interest rate; and (iv) expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.
The Company estimates the expected term of its stock options using the “simplified” method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates
are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.
Comprehensive Loss
Comprehensive Loss
Comprehensive loss is defined as the change in equity during a period from transactions from non-owner sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Summary of Estimated Useful Lives of Assets Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:
Computer equipment and software
3 - 7 years
Lab equipment
3 - 7 years
Furniture and fixtures
3 - 7 years
Leasehold improvementlesser of remaining useful life or remaining lease term
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss Per Share Attributable to Common Stockholders (Tables)
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Net Loss Per Share Attributable to Common Stockholders
Three Months Ended
June 30,
Six Months Ended
June 30,
2022202120222021
(In thousands, except share and per share data)(Unaudited)(Unaudited)
Numerator: 
Net loss per common share$(28,108)$(16,363)$(78,073)$(32,174)
Denominator:
Weighted-average basic and
   diluted common shares
25,545,167 22,204,659 25,331,000 21,731,711 
Basic and diluted net loss per
   common share
$(1.10)$(0.74)$(3.08)$(1.48)
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Instruments (Tables)
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Summary of Cash, Cash Equivalents and Available-for-Sale Securities
The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of June 30, 2022 and December 31, 2021, respectively (in thousands):

 June 30, 2022
(unaudited)
 Amortized CostGross
Unrealized
Gains
Gross
Unrealized
Losses
Aggregate Fair
Value
Cash and Cash
Equivalents
Short-term
Marketable
Securities (1)
Long-term
Marketable
Securities (2)
Level 1:       
Cash and cash equivalents$218,720 $— $— $218,720 $218,720 $— $— 
Subtotal218,720 — — 218,720 218,720 — — 
Level 2:
Commercial paper46,157 (53)46,105 — 46,105 — 
Corporate bonds97,808 — (890)96,918 — 88,853 8,065 
U.S. government agency securities77,317 — (593)76,724 — 71,887 4,837 
Subtotal221,282 (1,536)219,747 — 206,845 12,902 
Total$440,002 $$(1,536)$438,467 $218,720 $206,845 $12,902 
 December 31, 2021
 Amortized CostGross
Unrealized
Gains
Gross
Unrealized
Losses
Aggregate Fair
Value
Cash and Cash
Equivalents
Short-term
Marketable
Securities (1)
Long-term
Marketable
Securities (2)
Level 1:       
Cash and cash equivalents$341,246 $— $— $341,246 $341,246 $— $— 
Subtotal341,246 — — 341,246 341,246 — — 
Level 2:
Commercial paper40,469 (4)40,466 — 40,466 — 
Corporate bonds83,300 10 (114)83,196 — 35,768 47,428 
U.S. government agency securities37,621 — (62)37,559 — 20,616 16,943 
Subtotal161,390 11 (180)161,221 — 96,850 64,371 
Total$502,636 $11 $(180)$502,467 $341,246 $96,850 $64,371 
(1)The Company’s short-term marketable securities mature in one year or less.
(2)The Company's long-term marketable securities mature between one year and two years.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Balance Sheet Components (Tables)
6 Months Ended
Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]  
Schedule of Property and Equipment, Net
Property and equipment, net consist of the following (in thousands):
 June 30,
2022
December 31,
2021
 (Unaudited) 
Construction in progress$142,893 $104,340 
Leasehold improvements5,736 5,723 
Furniture and fixtures900 891 
Computer equipment and software96 85 
Laboratory and manufacturing equipment6,740 5,530 
Total property and equipment156,365 116,569 
Accumulated depreciation and amortization(5,151)(4,214)
Property and equipment, net$151,214 $112,355 
Schedule of Accrued Expenses And Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following (in thousands):
 June 30,
2022
December 31,
2021
 (Unaudited) 
Accrued construction in progress$14,631 $9,606 
Accrued professional fees3,812 2,011 
Accrued payroll and benefits2,896 2,882 
Accrued preclinical and clinical expenses2,094 1,602 
Accrued financing costs29 26 
Accrued taxes22 83 
Other current liabilities297 87 
Total$23,781 $16,297 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies (Tables)
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Operating Lease Payments
As of June 30, 2022, future minimum commitments under the Company’s operating leases were as follows (in thousands):
 Operating
Leases
2022 (remaining six months)$743 
20231,510 
20241,539 
20251,277 
20261,277 
Thereafter12,063 
Future minimum operating lease payments$18,409 
Less: Interest9,276 
Present value of lease liability$9,133 
Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases
Supplemental condensed consolidated balance sheet information related to leases is as follows:
(unaudited)
 June 30, 2022December 31, 2021
Operating leases:  
Right-of-use assets$8,279 $7,228 
Current portion of lease liability1,417 1,041 
Lease liability7,716 6,983 
Total lease liability$9,133 $8,024 
Weighted average remaining lease term, in years12.914.4
Weighted average discount rate9.4 %9.5 %
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Company's Stock Option Activity
The following table summarizes the Company’s stock option activity:
 Stock
Options
Outstanding
Weighted-
average
Exercise
Price
Weighted-
average
Remaining
Contractual
Life (Years)
Aggregate
Intrinsic
Value
(In thousands) (1)
Outstanding at December 31, 20212,043,179 $57.00 9.0$31,331 
Granted1,769,000 $62.19 
Exercised(39,399)$44.13 
Cancelled or forfeited(151,642)$55.24 
Expired(876)$74.92 
Outstanding at June 30, 20223,620,262 $59.75 9.1$28,341 
Exercisable at June 30, 2022536,979 $47.48 7.5$11,184 
(1)Aggregate intrinsic value represents the difference between the closing stock price of our common stock on June 30, 2022 and the exercise price of outstanding in-the-money options.
Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and six months ended June 30, 2022 and 2021 as follows (in thousands):
 Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
(unaudited)(unaudited)
Research and development$1,995 $1,084 $3,363 $1,600 
General and administrative5,776 2,625 10,357 4,240 
Total stock-based compensation$7,771 $3,709 $13,720 $5,840 
The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and six months ended June 30, 2022 and 2021 as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
(unaudited)(unaudited)
General and administrative$418 $486 $899 $668 
Total stock-based compensation$418 $486 $899 $668 
Fair Value of Stock Options, Valuation Assumptions
The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and six months ended June 30, 2022 and 2021:

 Three Months Ended June 30,Six Months Ended March 31,
 2022202120222021
Expected stock price volatility78 %72 %78 %72 %
Expected term of the award (years)6.176.106.216.18
Risk-free interest rate2.92 %1.05 %2.17 %1.02 %
Weighted average exercise price$61.51$66.58$62.19$73.42
Forfeiture rate— %— %— %— %
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity
Number of SharesWeighted Average
Grant Date
Fair Value
Non-vested RSAs as of December 31, 202198,800 $78.89 
Granted— $— 
Vested(14,321)$78.89 
Surrendered or forfeited(17,879)$78.89 
Non-vested RSAs as of June 30, 202266,600 $78.89 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Organization - Additional Information (Detail) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Accumulated deficit $ 218,857 $ 140,784
Cash, cash equivalents and short-term investments $ 425,600  
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Additional Information (Detail)
3 Months Ended 6 Months Ended
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
segment
Jun. 30, 2021
USD ($)
Significant Accounting Policies [Line Items]        
Number of operating segment | segment     1  
Equipment        
Significant Accounting Policies [Line Items]        
Recognized impairment losses for long lived assets | $ $ 0 $ 0 $ 0 $ 0
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)
6 Months Ended
Jun. 30, 2022
Computer equipment and software | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives of assets 3 years
Computer equipment and software | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives of assets 7 years
Laboratory and manufacturing equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives of assets 3 years
Laboratory and manufacturing equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives of assets 7 years
Furniture and fixtures | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives of assets 3 years
Furniture and fixtures | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful lives of assets 7 years
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) - shares
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Earnings Per Share [Abstract]    
Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share 3,686,862 1,688,965
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Numerator:            
Net loss per common share $ (28,108) $ (49,965) $ (16,363) $ (15,812) $ (78,073) $ (32,174)
Denominator:            
Weighted-average common shares outstanding: basic 25,545,167   22,204,659   25,331,000 21,731,711
Weighted-average common shares outstanding: diluted 25,545,167   22,204,659   25,331,000 21,731,711
Net loss per common share: basic (in dollars per share) $ (1.10)   $ (0.74)   $ (3.08) $ (1.48)
Net loss per common share: diluted (in dollars per share) $ (1.10)   $ (0.74)   $ (3.08) $ (1.48)
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents $ 218,720 $ 341,246
Gross Unrealized Gains 1 11
Gross Unrealized Losses (1,536) (180)
Amortized Cost 440,002 502,636
Aggregate fair value, total 438,467 502,467
Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 46,157 40,469
Gross Unrealized Gains 1 1
Gross Unrealized Losses (53) (4)
Aggregate Fair Value 46,105 40,466
Corporate bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 97,808 83,300
Gross Unrealized Gains 0 10
Gross Unrealized Losses (890) (114)
Aggregate Fair Value 96,918 83,196
U.S. government agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 77,317 37,621
Gross Unrealized Gains 0 0
Gross Unrealized Losses (593) (62)
Aggregate Fair Value 76,724 37,559
Cash and Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Aggregate fair value, total 218,720 341,246
Short-term Marketable Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Aggregate fair value, total 206,845 96,850
Short-term Marketable Securities | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Aggregate Fair Value 46,105 40,466
Short-term Marketable Securities | Corporate bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Aggregate Fair Value 88,853 35,768
Short-term Marketable Securities | U.S. government agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Aggregate Fair Value 71,887 20,616
Long-term Marketable Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Aggregate fair value, total 12,902 64,371
Long-term Marketable Securities | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Aggregate Fair Value 0 0
Long-term Marketable Securities | Corporate bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Aggregate Fair Value 8,065 47,428
Long-term Marketable Securities | U.S. government agency securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Aggregate Fair Value 4,837 16,943
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 218,720 341,246
Aggregate Fair Value 218,720 341,246
Level 1 | Cash and Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 218,720 341,246
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 221,282 161,390
Gross Unrealized Gains 1 11
Gross Unrealized Losses (1,536) (180)
Aggregate Fair Value 219,747 161,221
Level 2 | Short-term Marketable Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Aggregate Fair Value $ 206,845 96,850
Debt securities, available-for-sale, term 1 year  
Level 2 | Long-term Marketable Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Aggregate Fair Value $ 12,902 64,371
Level 2 | Long-term Marketable Securities | Minimum    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale, term 1 year  
Level 2 | Long-term Marketable Securities | Maximum    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities, available-for-sale, term 2 years  
Cash and cash equivalents | Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents $ 218,720 341,246
Aggregate Fair Value 218,720 341,246
Cash and cash equivalents | Level 1 | Cash and Cash Equivalents    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents $ 218,720 $ 341,246
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 156,365 $ 116,569
Accumulated depreciation and amortization (5,151) (4,214)
Property and equipment, net 151,214 112,355
Construction in progress    
Property, Plant and Equipment [Line Items]    
Total property and equipment 142,893 104,340
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment 5,736 5,723
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Total property and equipment 900 891
Computer equipment and software    
Property, Plant and Equipment [Line Items]    
Total property and equipment 96 85
Laboratory and manufacturing equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 6,740 $ 5,530
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Balance Sheet Components - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Balance Sheet Related Disclosures [Abstract]        
Depreciation expense $ 494 $ 475 $ 956 $ 914
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]    
Accrued construction in progress $ 14,631 $ 9,606
Accrued professional fees 3,812 2,011
Accrued payroll and benefits 2,896 2,882
Accrued preclinical and clinical expenses 2,094 1,602
Accrued financing costs 29 26
Accrued taxes 22 83
Other current liabilities 297 87
Total $ 23,781 $ 16,297
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies - Additional Information (Detail)
ft² in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Apr. 28, 2022
USD ($)
Mar. 12, 2022
USD ($)
Oct. 15, 2020
USD ($)
Jun. 30, 2022
USD ($)
ft²
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
ft²
milestone
Jun. 30, 2021
USD ($)
May 16, 2022
Dec. 15, 2021
Sep. 13, 2021
USD ($)
Oct. 05, 2020
USD ($)
Jan. 21, 2020
USD ($)
Operating Leased Assets [Line Items]                        
Cash contribution                     $ 2,400 $ 2,400
Purchase price of potential purchase     $ 9,400                  
Construction in progress, gross                     10,000  
Finance lease, liability                     $ 10,000  
Escrow deposit     $ 1,500                  
Lessor, operating lease, liability, annual lease payments           $ 82            
Cumulative escalation clause           0.10            
Cumulative escalation clause, term           5 years            
Operating lease costs       $ 391 $ 278 $ 800 $ 497          
Variable lease costs       71 81 120 118          
Loss contingency, guaranteed maximum price to be paid                   $ 83,000    
Litigation settlement       0 0 25,000 0          
Proceeds from insurance settlement, operating activities       768   768            
Gain related to litigation settlement           369            
PeriphaGen                        
Operating Leased Assets [Line Items]                        
Litigation settlement $ 25,000         25,000            
Litigation settlement, amount awarded to other party           $ 12,500            
Number of milestones | milestone           3            
Litigation settlement, total consideration   $ 75,000                    
PeriphaGen | Milestone Two                        
Operating Leased Assets [Line Items]                        
Litigation settlement, amount awarded to other party           $ 12,500            
Litigation settlement, milestone payments, sales threshold   200,000                    
PeriphaGen | Milestone Three                        
Operating Leased Assets [Line Items]                        
Litigation settlement, amount awarded to other party           12,500            
Litigation settlement, milestone payments, sales threshold   300,000                    
PeriphaGen | Milestone One                        
Operating Leased Assets [Line Items]                        
Litigation settlement, amount awarded to other party           12,500            
Litigation settlement, milestone payments, sales threshold   $ 100,000                    
Clinical Supply Agreements                        
Operating Leased Assets [Line Items]                        
Estimated remaining commitment       2,100   2,100            
Project management service fee       1,200 718 3,000 2,500          
Other Contractual Obligations                        
Operating Leased Assets [Line Items]                        
Estimated remaining commitment       5,100   5,100            
Project management service fee       3,100 $ 974 6,200 $ 2,300          
ASTRA Facility                        
Operating Leased Assets [Line Items]                        
Contractual obligation       $ 17,900   $ 17,900            
Cost of work, percentage       0.0175   0.0175            
2016 Lease Agreement                        
Operating Leased Assets [Line Items]                        
Additional area of real estate property leased | ft²       47   47            
Boston, Massachusetts Lease                        
Operating Leased Assets [Line Items]                        
Operating lease, term of contract                 3 years      
Switzerland Lease                        
Operating Leased Assets [Line Items]                        
Operating lease, term of contract               16 months        
Lessee, operating lease, lease not yet commenced, liability, to be paid, remainder of fiscal year       $ 22   $ 22            
Lessee, operating lease, lease not yet commenced, liability, to be paid, year one       $ 89   $ 89            
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]    
2022 (remaining six months) $ 743  
2023 1,510  
2024 1,539  
2025 1,277  
2026 1,277  
Thereafter 12,063  
Future minimum operating lease payments 18,409  
Less: Interest 9,276  
Present value of lease liability $ 9,133 $ 8,024
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Lessee, Operating Lease, Liability, Payment, Due [Abstract]    
Right-of-use assets $ 8,279 $ 7,228
Current portion of lease liability 1,417 1,041
Lease liability 7,716 6,983
Total lease liability $ 9,133 $ 8,024
Weighted average remaining lease term, in years 12 years 10 months 24 days 14 years 4 months 24 days
Weighted average discount rate 9.40% 9.50%
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Capitalization - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended
Apr. 05, 2022
Dec. 03, 2021
Feb. 01, 2021
Jun. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Schedule of Capitalization, Equity [Line Items]            
Offering expenses   $ 227 $ 198      
Placement Shares            
Schedule of Capitalization, Equity [Line Items]            
Sale of stock, aggregate offering price           $ 150,000
Public Offering            
Schedule of Capitalization, Equity [Line Items]            
Sale of stock, number of shares issued in transaction 434,782 2,866,667 2,211,538   262,500  
Sale of stock, price per share (in dollars per share)   $ 75.00 $ 65.00 $ 69.00 $ 66.50  
Proceeds from initial offering of shares $ 29,100 $ 201,900 $ 134,900      
Underwriting discounts and commissions   $ 12,900 $ 8,600      
ATM Program            
Schedule of Capitalization, Equity [Line Items]            
Proceeds from initial offering of shares         $ 16,900  
Underwriting discounts and commissions       $ 900 $ 524  
Sale of stock, remaining available issuance amount       $ 102,500    
Over-Allotment Option            
Schedule of Capitalization, Equity [Line Items]            
Sale of stock, number of shares issued in transaction   200,000 288,461      
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock option expiration period     10 years    
Stock options granted (in shares)     1,769,000    
Intrinsic value of options exercised $ 704 $ 64 $ 739 $ 872  
Share-based payment arrangement, amount capitalized $ 146 $ 66 $ 287 $ 103  
Director          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock options granted (in shares) 544,500 297,500 1,724,000 799,950  
Stock Incentive Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares remaining available for grant 530,991   530,991    
Share-based Payment Arrangement, Option          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock option vesting period     4 years    
Weighted-average grant-date fair value per share of options granted (in dollars per share) $ 42.90 $ 42.53 $ 43.03 $ 47.25  
Stock-based compensation expense $ 7,771 $ 3,709 $ 13,720 $ 5,840  
Share-based Payment Arrangement, Option | Director          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Unrecognized stock-based compensation expense $ 115,700   $ 115,700    
Estimated weighted average period     3 years 3 months 18 days    
Non-Employee Stock Option          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock options granted (in shares) 45,000 0 45,000 0  
Non-Employee Stock Option | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock option vesting period     1 year    
Non-Employee Stock Option | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock option vesting period     4 years    
Restricted Stock          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Restricted stock award granted (in shares) 0 0 0 98,800  
Restricted stock award outstanding (in shares) 66,600   66,600   98,800
Unrecognized stock-based compensation expense $ 4,700   $ 4,700    
Estimated weighted average period     2 years 8 months 12 days    
Stock-based compensation expense $ 418 $ 486 $ 899 $ 668  
Restricted Stock | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock option vesting period     4 years    
Incentive Stock Options          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares remaining available for grant 1,296   1,296    
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Stock Options Outstanding    
Beginning balance (in shares) | shares 2,043,179  
Granted (in shares) | shares 1,769,000  
Exercised (in shares) | shares (39,399)  
Cancelled or forfeited (in shares) | shares (151,642)  
Expired (in shares) | shares (876)  
Ending balance (in shares) | shares 3,620,262 2,043,179
Exercisable end of period (in shares) | shares 536,979  
Weighted- average Exercise Price    
Beginning balance (in dollars per share) | $ / shares $ 57.00  
Granted (in dollars per share) | $ / shares 62.19  
Exercised (in dollars per share) | $ / shares 44.13  
Cancelled or forfeited (in dollars per share) | $ / shares 55.24  
Exercised (in dollars per share) | $ / shares 74.92  
Ending balance (in dollars per share) | $ / shares 59.75 $ 57.00
Exercisable end of period (in dollars per share) | $ / shares $ 47.48  
Weighted- average Remaining Contractual Life (Years)    
Weighted-average remaining contractual life (Years) 9 years 1 month 6 days 9 years
Weighted-average remaining contractual life (Years), exercisable 7 years 6 months  
Aggregate Intrinsic Value    
Aggregate intrinsic value, outstanding | $ $ 28,341 $ 31,331
Exercisable at June 30, 2022 | $ $ 11,184  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Share-based Payment Arrangement, Option        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total stock-based compensation $ 7,771 $ 3,709 $ 13,720 $ 5,840
Restricted Stock        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total stock-based compensation 418 486 899 668
Research and development | Share-based Payment Arrangement, Option        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total stock-based compensation 1,995 1,084 3,363 1,600
General and administrative | Share-based Payment Arrangement, Option        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total stock-based compensation 5,776 2,625 10,357 4,240
General and administrative | Restricted Stock        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total stock-based compensation $ 418 $ 486 $ 899 $ 668
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail) - Share-based Payment Arrangement, Option - $ / shares
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected stock price volatility 78.00% 72.00% 78.00% 72.00%
Expected term of the award (years) 6 years 2 months 1 day 6 years 1 month 6 days 6 years 2 months 15 days 6 years 2 months 4 days
Risk-free interest rate 2.92% 1.05% 2.17% 1.02%
Weighted average exercise price (in dollars per share) $ 61.51 $ 66.58 $ 62.19 $ 73.42
Forfeiture rate 0.00% 0.00% 0.00% 0.00%
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details) - Restricted Stock - $ / shares
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Number of Shares        
Beginning balance (in shares)     98,800  
Granted (in shares) 0 0 0 98,800
Vested (in shares)     (14,321)  
Surrendered or forfeited (in shares)     (17,879)  
Ending balance (in shares) 66,600   66,600  
Weighted Average Grant Date Fair Value        
Beginning balance (in dollars per share)     $ 78.89  
Granted (in dollars per share)     0  
Vested (in dollars per share)     78.89  
Surrendered or forfeited (in dollars per share)     78.89  
Ending balance (in dollars per share) $ 78.89   $ 78.89  
XML 51 krys-20220630_htm.xml IDEA: XBRL DOCUMENT 0001711279 2022-01-01 2022-06-30 0001711279 2022-07-29 0001711279 2022-06-30 0001711279 2021-12-31 0001711279 2022-04-01 2022-06-30 0001711279 2021-04-01 2021-06-30 0001711279 2021-01-01 2021-06-30 0001711279 us-gaap:CommonStockMember 2021-12-31 0001711279 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001711279 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001711279 us-gaap:RetainedEarningsMember 2021-12-31 0001711279 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001711279 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001711279 2022-01-01 2022-03-31 0001711279 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001711279 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001711279 us-gaap:CommonStockMember 2022-03-31 0001711279 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001711279 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001711279 us-gaap:RetainedEarningsMember 2022-03-31 0001711279 2022-03-31 0001711279 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001711279 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001711279 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001711279 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001711279 us-gaap:CommonStockMember 2022-06-30 0001711279 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001711279 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001711279 us-gaap:RetainedEarningsMember 2022-06-30 0001711279 us-gaap:CommonStockMember 2020-12-31 0001711279 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001711279 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001711279 us-gaap:RetainedEarningsMember 2020-12-31 0001711279 2020-12-31 0001711279 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001711279 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001711279 2021-01-01 2021-03-31 0001711279 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001711279 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001711279 us-gaap:CommonStockMember 2021-03-31 0001711279 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001711279 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001711279 us-gaap:RetainedEarningsMember 2021-03-31 0001711279 2021-03-31 0001711279 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001711279 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001711279 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001711279 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001711279 us-gaap:CommonStockMember 2021-06-30 0001711279 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001711279 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001711279 us-gaap:RetainedEarningsMember 2021-06-30 0001711279 2021-06-30 0001711279 srt:MinimumMember us-gaap:ComputerEquipmentMember 2022-01-01 2022-06-30 0001711279 srt:MaximumMember us-gaap:ComputerEquipmentMember 2022-01-01 2022-06-30 0001711279 srt:MinimumMember krys:LabEquipmentMember 2022-01-01 2022-06-30 0001711279 srt:MaximumMember krys:LabEquipmentMember 2022-01-01 2022-06-30 0001711279 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-06-30 0001711279 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-06-30 0001711279 us-gaap:EquipmentMember 2021-01-01 2021-06-30 0001711279 us-gaap:EquipmentMember 2022-01-01 2022-06-30 0001711279 us-gaap:EquipmentMember 2022-04-01 2022-06-30 0001711279 us-gaap:EquipmentMember 2021-04-01 2021-06-30 0001711279 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2022-06-30 0001711279 us-gaap:CashAndCashEquivalentsMember us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2022-06-30 0001711279 us-gaap:FairValueInputsLevel1Member 2022-06-30 0001711279 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2022-06-30 0001711279 us-gaap:CommercialPaperMember 2022-06-30 0001711279 us-gaap:ShortTermInvestmentsMember us-gaap:CommercialPaperMember 2022-06-30 0001711279 krys:LongTermMarketableSecuritiesMember us-gaap:CommercialPaperMember 2022-06-30 0001711279 us-gaap:CorporateBondSecuritiesMember 2022-06-30 0001711279 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateBondSecuritiesMember 2022-06-30 0001711279 krys:LongTermMarketableSecuritiesMember us-gaap:CorporateBondSecuritiesMember 2022-06-30 0001711279 us-gaap:USTreasurySecuritiesMember 2022-06-30 0001711279 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2022-06-30 0001711279 krys:LongTermMarketableSecuritiesMember us-gaap:USTreasurySecuritiesMember 2022-06-30 0001711279 us-gaap:FairValueInputsLevel2Member 2022-06-30 0001711279 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0001711279 krys:LongTermMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0001711279 us-gaap:CashAndCashEquivalentsMember 2022-06-30 0001711279 us-gaap:ShortTermInvestmentsMember 2022-06-30 0001711279 krys:LongTermMarketableSecuritiesMember 2022-06-30 0001711279 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001711279 us-gaap:CashAndCashEquivalentsMember us-gaap:CashMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001711279 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001711279 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001711279 us-gaap:CommercialPaperMember 2021-12-31 0001711279 us-gaap:ShortTermInvestmentsMember us-gaap:CommercialPaperMember 2021-12-31 0001711279 krys:LongTermMarketableSecuritiesMember us-gaap:CommercialPaperMember 2021-12-31 0001711279 us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001711279 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001711279 krys:LongTermMarketableSecuritiesMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001711279 us-gaap:USTreasurySecuritiesMember 2021-12-31 0001711279 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001711279 krys:LongTermMarketableSecuritiesMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001711279 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001711279 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001711279 krys:LongTermMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001711279 us-gaap:CashAndCashEquivalentsMember 2021-12-31 0001711279 us-gaap:ShortTermInvestmentsMember 2021-12-31 0001711279 krys:LongTermMarketableSecuritiesMember 2021-12-31 0001711279 srt:MinimumMember krys:LongTermMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0001711279 srt:MaximumMember krys:LongTermMarketableSecuritiesMember us-gaap:FairValueInputsLevel2Member 2022-06-30 0001711279 us-gaap:ConstructionInProgressMember 2022-06-30 0001711279 us-gaap:ConstructionInProgressMember 2021-12-31 0001711279 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001711279 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001711279 us-gaap:FurnitureAndFixturesMember 2022-06-30 0001711279 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001711279 us-gaap:ComputerEquipmentMember 2022-06-30 0001711279 us-gaap:ComputerEquipmentMember 2021-12-31 0001711279 krys:LabEquipmentMember 2022-06-30 0001711279 krys:LabEquipmentMember 2021-12-31 0001711279 krys:TwoThousandSixteenLeaseAgreementMember 2022-06-30 0001711279 2020-01-21 0001711279 2020-10-15 2020-10-15 0001711279 2020-10-05 0001711279 2020-10-15 0001711279 krys:BostonMassachusettsLeaseMember 2021-12-15 0001711279 krys:SwitzerlandLeaseMember 2022-05-16 0001711279 krys:SwitzerlandLeaseMember 2022-06-30 0001711279 krys:ClinicalSupplyAgreementMember 2022-06-30 0001711279 krys:ClinicalSupplyAgreementMember 2022-04-01 2022-06-30 0001711279 krys:ClinicalSupplyAgreementMember 2022-01-01 2022-06-30 0001711279 krys:ClinicalSupplyAgreementMember 2021-04-01 2021-06-30 0001711279 krys:ClinicalSupplyAgreementMember 2021-01-01 2021-06-30 0001711279 krys:OtherContractualObligationsMember 2022-06-30 0001711279 krys:OtherContractualObligationsMember 2022-04-01 2022-06-30 0001711279 krys:OtherContractualObligationsMember 2022-01-01 2022-06-30 0001711279 krys:OtherContractualObligationsMember 2021-04-01 2021-06-30 0001711279 krys:OtherContractualObligationsMember 2021-01-01 2021-06-30 0001711279 krys:ASTRAFacilityMember 2022-06-30 0001711279 2021-09-13 0001711279 krys:PeriphaGenMember 2022-04-28 2022-04-28 0001711279 krys:PeriphaGenMember 2022-01-01 2022-06-30 0001711279 krys:PeriphaGenMember krys:MilestoneTwoMember 2022-01-01 2022-06-30 0001711279 krys:PeriphaGenMember krys:MilestoneThreeMember 2022-01-01 2022-06-30 0001711279 krys:PeriphaGenMember krys:MilestoneOneMember 2022-01-01 2022-06-30 0001711279 krys:PeriphaGenMember krys:MilestoneOneMember 2022-03-12 2022-03-12 0001711279 krys:PeriphaGenMember krys:MilestoneTwoMember 2022-03-12 2022-03-12 0001711279 krys:PeriphaGenMember krys:MilestoneThreeMember 2022-03-12 2022-03-12 0001711279 krys:PeriphaGenMember 2022-03-12 2022-03-12 0001711279 krys:PlacementSharesMember 2020-12-31 0001711279 krys:PublicOfferingMember 2021-01-01 2021-12-31 0001711279 krys:PublicOfferingMember 2021-12-31 0001711279 krys:ATMProgramMember 2021-01-01 2021-12-31 0001711279 krys:PublicOfferingMember 2022-04-05 2022-04-05 0001711279 krys:PublicOfferingMember 2022-06-30 0001711279 krys:ATMProgramMember 2022-01-01 2022-06-30 0001711279 krys:PublicOfferingMember 2021-12-03 2021-12-03 0001711279 us-gaap:OverAllotmentOptionMember 2021-12-03 2021-12-03 0001711279 krys:PublicOfferingMember 2021-12-03 0001711279 2021-12-03 2021-12-03 0001711279 krys:PublicOfferingMember 2021-02-01 2021-02-01 0001711279 us-gaap:OverAllotmentOptionMember 2021-02-01 2021-02-01 0001711279 krys:PublicOfferingMember 2021-02-01 0001711279 2021-02-01 2021-02-01 0001711279 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001711279 srt:MinimumMember krys:NonEmployeeStockOptionMember 2022-01-01 2022-06-30 0001711279 srt:MaximumMember krys:NonEmployeeStockOptionMember 2022-01-01 2022-06-30 0001711279 srt:DirectorMember 2022-04-01 2022-06-30 0001711279 srt:DirectorMember 2022-01-01 2022-06-30 0001711279 srt:DirectorMember 2021-04-01 2021-06-30 0001711279 srt:DirectorMember 2021-01-01 2021-06-30 0001711279 krys:NonEmployeeStockOptionMember 2022-01-01 2022-06-30 0001711279 krys:NonEmployeeStockOptionMember 2022-04-01 2022-06-30 0001711279 krys:NonEmployeeStockOptionMember 2021-04-01 2021-06-30 0001711279 krys:NonEmployeeStockOptionMember 2021-01-01 2021-06-30 0001711279 2021-01-01 2021-12-31 0001711279 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001711279 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001711279 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001711279 srt:DirectorMember us-gaap:EmployeeStockOptionMember 2022-06-30 0001711279 srt:DirectorMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001711279 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001711279 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001711279 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001711279 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001711279 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001711279 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001711279 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001711279 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001711279 srt:MaximumMember us-gaap:RestrictedStockMember 2022-01-01 2022-06-30 0001711279 us-gaap:RestrictedStockMember 2022-04-01 2022-06-30 0001711279 us-gaap:RestrictedStockMember 2022-01-01 2022-06-30 0001711279 us-gaap:RestrictedStockMember 2021-04-01 2021-06-30 0001711279 us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001711279 us-gaap:RestrictedStockMember 2021-12-31 0001711279 us-gaap:RestrictedStockMember 2022-06-30 0001711279 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001711279 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001711279 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001711279 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001711279 krys:StockIncentivePlanMember 2022-06-30 0001711279 krys:IncentiveStockOptionsMember 2022-06-30 shares iso4217:USD iso4217:USD shares krys:segment utr:sqft pure krys:milestone false 2022 Q2 0001711279 --12-31 P1Y 10-Q true 2022-06-30 false 001-38210 Krystal Biotech, Inc. DE 82-1080209 2100 Wharton Street Suite 701 Pittsburgh PA 15203 412 586-5830 Common Stock KRYS NASDAQ Yes Yes Large Accelerated Filer false false false 25664287 218720000 341246000 206845000 96850000 3205000 4171000 428770000 442267000 151214000 112355000 12902000 64371000 8279000 7228000 159000 74000 601324000 626295000 9229000 8398000 1417000 1041000 23781000 16297000 34427000 25736000 7716000 6983000 42143000 32719000 0.00001 0.00001 20000000 20000000 2061773 2061773 0 0 0 0 0.00001 0.00001 80000000 80000000 25664287 25664287 25207985 25207985 0 0 779583000 734523000 -1545000 -163000 -218857000 -140784000 559181000 593576000 601324000 626295000 10890000 6594000 20204000 12795000 17863000 9799000 33771000 17951000 0 0 25000000 0 28753000 16393000 78975000 30746000 -28753000 -16393000 -78975000 -30746000 645000 30000 902000 64000 0 0 0 1492000 -28108000 -16363000 -78073000 -32174000 -348000 -24000 -1382000 -27000 -28456000 -16387000 -79455000 -32201000 -1.10 -1.10 -0.74 -0.74 -3.08 -3.08 -1.48 -1.48 25545167 25545167 22204659 22204659 25331000 25331000 21731711 21731711 25207985 0 734523000 -163000 -140784000 593576000 1475 55000 55000 10379 649000 649000 6571000 6571000 -1034000 -1034000 -49965000 -49965000 25199081 0 740500000 -1197000 -190749000 548554000 472706 30748000 30748000 7500 8335000 8335000 -348000 -348000 -28108000 -28108000 25664287 0 779583000 -1545000 -218857000 559181000 19714220 0 363292000 6000 -71214000 292084000 2489837 152033000 152033000 2350000 2350000 -3000 -3000 -15812000 -15812000 22204057 0 517675000 3000 -87026000 430652000 975 14000 14000 4261000 4261000 -24000 -24000 -16363000 -16363000 22205032 0 521950000 -21000 -103389000 418540000 -78073000 -32174000 1991000 1202000 14619000 6508000 0 1492000 -166000 -117000 -848000 -1366000 -15000 0 -286000 -175000 24000 -680000 2476000 2795000 -58552000 -19783000 -19783000 33706000 6462000 147255000 59561000 86829000 2959000 -94132000 -63064000 30807000 152065000 649000 0 0 7960000 30158000 144105000 -122526000 61258000 341246000 268269000 218720000 329527000 22234000 10143000 1394000 4060000 Organization<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc. (the “Company,” or “we” or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 24, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. On January 7, 2022, the Company incorporated Krystal Biotech Switzerland GmbH, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's pipeline.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company leading the field of redosable gene delivery. Using our patented platform that is based on engineered herpes simplex virus type 1 ("HSV-1"), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a doctor’s office or potentially in the patient’s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions. Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company had an accumulated deficit of $218.9 million. With the net proceeds raised from its public and private securities offerings, the Company believes that its cash, cash equivalents and short-term investments of approximately $425.6 million as of June 30, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to c</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercialize product candidates.</span></div> -218900000 425600000 Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), as found in the Accounting Standards Codification (“ASC”), the Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”), and the rules and regulations of the US Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company’s previously reported financial position or results of operation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on February 28, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographical Information</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company’s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90 days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders’ equity in the condensed consolidated balance sheets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company’s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the holding period is longer than one year. The Company classifies all of its investments as available-for-sale.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress ("CIP") is not depreciated until the asset is placed in service.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and six months ended June 30, 2022 and 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease. Right-of-use lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company’s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.  Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria. If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company’s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company’s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation—Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i) the expected stock price volatility; (ii) the expected term of the award; (iii) the risk-free interest rate; and (iv) expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options using the “simplified” method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from non-owner sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), as found in the Accounting Standards Codification (“ASC”), the Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”), and the rules and regulations of the US Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company’s previously reported financial position or results of operation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on February 28, 2022.</span></div> <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.</span></div> <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div> Segment and Geographical InformationOperating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company’s chief operating decision maker view the Company’s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products. 1 <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company’s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</span></div> <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90 days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.</span></div>As our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders’ equity in the condensed consolidated balance sheets. <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company’s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the holding period is longer than one year. The Company classifies all of its investments as available-for-sale.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div> <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress ("CIP") is not depreciated until the asset is placed in service.</span></div> Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table> P3Y P7Y P3Y P7Y P3Y P7Y <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and six months ended June 30, 2022 and 2021.</span></div> 0 0 0 0 <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease. Right-of-use lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company’s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.  Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria. If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div> <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company’s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company’s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div> <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation—Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i) the expected stock price volatility; (ii) the expected term of the award; (iii) the risk-free interest rate; and (iv) expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options using the “simplified” method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates </span></div>are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from non-owner sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.</span></div> <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.</span></div> Net Loss Per Share Attributable to Common Stockholders<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 3,686,862 and 1,688,965 common share equivalents outstanding as of June 30, 2022 and 2021, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"/><td style="width:47.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,108)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,363)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,073)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,174)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   diluted common shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,545,167 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204,659 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,331,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,731,711 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>   common share</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.10)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.74)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.08)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.48)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3686862 1688965 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"/><td style="width:47.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,108)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,363)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,073)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,174)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   diluted common shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,545,167 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204,659 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,331,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,731,711 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>   common share</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.10)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.74)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.08)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.48)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -28108000 -16363000 -78073000 -32174000 25545167 25545167 22204659 22204659 25331000 25331000 21731711 21731711 -1.10 -1.10 -0.74 -0.74 -3.08 -3.08 -1.48 -1.48 Fair Value Instruments<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of June 30, 2022 and December 31, 2021, respectively (in thousands):</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,808 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(890)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,918 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,853 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,065 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,837 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221,282 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,536)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,747 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206,845 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,902 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,002 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,536)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438,467 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206,845 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,902 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:22.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,300 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,196 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,768 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,428 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,943 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,390 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,221 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,636 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,467 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company’s short-term marketable securities mature in one year or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company's long-term marketable securities mature between one year and two years.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company’s fair value measurements.</span></div> <div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of June 30, 2022 and December 31, 2021, respectively (in thousands):</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,808 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(890)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,918 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,853 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,065 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,887 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,837 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221,282 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,536)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,747 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206,845 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,902 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,002 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,536)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438,467 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206,845 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,902 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:22.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,300 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,196 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,768 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,428 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,943 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,390 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,221 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,636 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,467 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company’s short-term marketable securities mature in one year or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company's long-term marketable securities mature between one year and two years.</span></div> 218720000 218720000 218720000 218720000 218720000 218720000 46157000 1000 53000 46105000 46105000 0 97808000 0 890000 96918000 88853000 8065000 77317000 0 593000 76724000 71887000 4837000 221282000 1000 1536000 219747000 206845000 12902000 440002000 1000 1536000 438467000 218720000 206845000 12902000 341246000 341246000 341246000 341246000 341246000 341246000 40469000 1000 4000 40466000 40466000 0 83300000 10000 114000 83196000 35768000 47428000 37621000 0 62000 37559000 20616000 16943000 161390000 11000 180000 161221000 96850000 64371000 502636000 11000 180000 502467000 341246000 96850000 64371000 P1Y P1Y P2Y Balance Sheet Components<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,893 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,340 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,736 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,740 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,365 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,569 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,151)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,214)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,214 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,355 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $494 thousand and $956 thousand for the three and six months ended June 30, 2022 and $475 thousand and $914 thousand for the three and six months ended June 30, 2021, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,631 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,011 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,896 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,781 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,297 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div> <div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,893 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,340 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,736 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,740 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,365 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,569 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,151)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,214)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,214 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,355 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div> 142893000 104340000 5736000 5723000 900000 891000 96000 85000 6740000 5530000 156365000 116569000 5151000 4214000 151214000 112355000 494000 956000 475000 914000 <div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,631 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,011 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,896 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,781 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,297 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div> 14631000 9606000 3812000 2011000 2896000 2882000 2094000 1602000 29000 26000 22000 83000 297000 87000 23781000 16297000 Commitments and Contingencies<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Contracts and Agreements</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and was scheduled to expire on October 31, 2017 (the “2016 Lease”). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately 47,000 square feet and includes the commercial scale cGMP-compliant manufacturing facility, ANCORIS. As a result of the lease amendments, the 2016 Lease expiration date was extended to October 31, 2031. </span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2019, the Company entered into a lease agreement for a second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord", "Northfield", or "Lessor") with an initial lease term that expired on October 31, 2035. The ASTRA lease contained an option ("Purchase </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the "Ground Lease"). A cash contribution in the amount of $2.4 million was paid to escrow on January 21, 2020. The contribution was intended to reduce the amount of the building construction costs and had the effect of reducing the base rental rate of the lease and as such, was recorded as prepaid rent in the consolidated balance sheet at the time of payment.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $9.4 million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020. The Company recorded a $10.0 million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contribution of $2.4 million. </span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $9.4 million. The Company held approximately $1.5 million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement. As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale. As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of June 30, 2022. The interior of the building is currently under construction and is expected to be completed and validated in 2022. From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $82 thousand, and are subject to a cumulative 10% escalation clause every 5 years through 2071. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2021, the Company entered into a 3 year lease agreement for the Boston, Massachusetts office that commenced in January 2022 and expires in January 2025.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, future minimum commitments under the Company’s operating leases were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"/><td style="width:83.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.756%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,063 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,409 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,276 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2022, the Company entered into a 16 month lease agreement for the Zug, Switzerland office ("Switzerland Lease") that commences on September 1, 2022 and expires December 31, 2023. As of June 30, 2022, the Company has not recorded a right-of-use asset or corresponding lease liability, as the Company has not yet gained control over the Switzerland Lease. Future minimum operating lease payments under the Switzerland Lease are $22 thousand and $89 thousand for the years ending 2022 and 2023, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental condensed consolidated balance sheet information related to leases is as follows:</span></div><div style="margin-top:2pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,279 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,228 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,716 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,983 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,133 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,024 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded operating lease costs of $391 thousand and $800 thousand for the three and six months ended June 30, 2022 and $278 thousand and $497 thousand for the three and six months ended June 30, 2021, respectively. The Company recorded variable lease costs of $71 thousand and $120 thousand for the three and six months ended June 30, 2022 and $81 thousand and $118 thousand for the three and six months ended June 30, 2021, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreements with Contract Manufacturing Organizations and Contract Research Organizations</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of June 30, 2022 under these agreements is approximately $2.1 million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $1.2 million and $3.0 million for each of the three and six months ended June 30, 2022 and $718 thousand and $2.5 million for the three and six months ended June 30, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Preparedness Activities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate. These contracts typically call for the payment of fees for services upon the achievement of certain milestones. The estimated remaining commitment as of June 30, 2022 is $5.1 million. The Company has incurred expenses under these activities of $3.1 million and $6.2 million for the three and six months ended June 30, 2022 and $974 thousand and $2.3 million for the three and six months ended June 30, 2021.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASTRA Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to construct our second cGMP facility, ASTRA. Additionally, the Company has entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of June 30, 2022 is $17.9 million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the “Agreement”) with The Whiting-Turner Contracting Company (“Whiting-Turner”), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to 1.75% of the cost of work. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">paid by the Company is $83.0 million, subject to certain additions and deductions by change orders as provided by the Agreement. Whiting-Turner’s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner’s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement constitutes only a portion of the total estimated cost of building and equipping ASTRA. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. The Company answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that the Company did not misappropriate PeriphaGen’s trade secrets or confidential information, and to further declare that the Company is the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022. During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions. On March 12, 2022, the Company entered into a binding term sheet to settle the dispute. On April 27, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $25.0 million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications. Upon approval of Krystal’s first product by the U.S. Food and Drug Administration, Krystal will pay PeriphaGen an additional $12.5 million, followed by three additional $12.5 million contingent milestone payments upon reaching $100.0 million in total cumulative sales, $200.0 million in total cumulative sales and $300.0 million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of Krystal products by Krystal and its affiliates and licensees, as reported by Krystal in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $75.0 million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the $25.0 million under litigation settlement expense on the condensed consolidated statements of operations for the six months ended June 30, 2022. The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of June 30, 2022, and therefore no additional accrual has been recorded.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received $768 thousand of insurance proceeds during the three and six months ended June 30, 2022 and Company recorded an additional $369 thousand as a receivable within prepaid expenses and other current assets on the condensed consolidated balance sheet as management determined that the amount was probable of collection relating to legal defense costs and expenses associated with the PeriphaGen litigation. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.</span></div> 47000 2400000 9400000 10000000 10000000 2400000 9400000 1500000 82000 0.10 P5Y P3Y <div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, future minimum commitments under the Company’s operating leases were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"/><td style="width:83.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.756%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,063 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,409 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,276 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div> 743000 1510000 1539000 1277000 1277000 12063000 18409000 9276000 9133000 P16M 22000 89000 <div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental condensed consolidated balance sheet information related to leases is as follows:</span></div><div style="margin-top:2pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,279 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,228 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,716 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,983 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,133 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,024 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div> 8279000 7228000 1417000 1041000 7716000 6983000 9133000 8024000 P12Y10M24D P14Y4M24D 0.094 0.095 391000 800000 278000 497000 71000 120000 81000 118000 2100000 1200000 3000000 718000 2500000 5100000 3100000 6200000 974000 2300000 17900000 0.0175 83000000 25000000 12500000 3 12500000 12500000 12500000 100000000 200000000 300000000 75000000 25000000 768000 768000 369000 Capitalization<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program") finalized on December 31, 2020, under which Cowen acts as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $150.0 million ("Placement Shares"). The issuance and sale of the Placement Shares by the Company under the Sales Agreement are made pursuant to the Company's effective "shelf" registration statement on Form S-3. During 2021, the Company issued and sold 262,500 shares of common stock at a weighted average price of $66.50 per share for net proceeds of $16.9 million after deducting selling commissions of approximately $524 thousand. During the six months ended June 30, 2022, the Company issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share for net proceeds of $29.1 million after deducting selling commissions of approximately $900 thousand, resulting in a remaining $102.5 million available for issuance under the ATM Program.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, the Company completed an underwritten public offering of 2,866,667 shares of its common stock, including 200,000 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $75.00 per share. Net proceeds to the Company from the offering were $201.9 million after deducting underwriting discounts and commissions of approximately $12.9 million, and other offering expenses payable by the Company of $227 thousand.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, the Company completed an underwritten public offering of 2,211,538 shares of its common stock, including 288,461 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $65.00 per share. Net proceeds to the Company from the offering were $134.9 million after deducting underwriting discounts and commissions of approximately $8.6 million, and other offering expenses payable by the Company of $198 thousand.</span></div> 150000000 262500 66.50 16900000 524000 434782 69.00 29100000 900000 102500000 2866667 200000 75.00 201900000 12900000 227000 2211538 288461 65.00 134900000 8600000 198000 Stock-Based Compensation<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees and non-employees vest ratably over four-year periods and stock options granted to directors of the company vest ratably over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMTgy_bb1fc8be-f9a4-4a8f-bc53-08d908577b13">one</span>-year to four-year periods. Stock options have a life of ten years. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 544,500 and 1,724,000 stock options to employees and directors of the Company during the three and six months ended June 30, 2022, respectively, and 297,500 and 799,950 stock options to employees and directors of the Company during the three and six months ended June 30, 2021, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 45,000 stock options to non-employees during the three and six months ended June 30, 2022, respectively, and zero stock options to non-employees during the three and six months ended June 30, 2021, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:38.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043,179 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,331 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151,642)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,620,262 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.75 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,341 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,979 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.48 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,184 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on June 30, 2022 and the exercise price of outstanding in-the-money options.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three and six months ended June 30, 2022 was $704 thousand and $739 thousand, respectively, and during the three and six months ended June 30, 2021 was $64 thousand and $872 thousand, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the three and six months ended June 30, 2022 was $42.90 and $43.03, respectively, and during the three and six months ended June 30, 2021 was $42.53 and $47.25, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $115.7 million of unrecognized stock-based compensation expense related to employees', non-employees', and directors’ option awards that is expected to be recognized over a weighted-average period of 3.3 years as of June 30, 2022.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and six months ended June 30, 2022 and 2021 as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:36.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.977%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,776 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,357 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,240 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,771 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,709 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,720 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $146 thousand and $287 thousand of stock-based compensation that was capitalized in the three and six months ended June 30, 2022, respectively, and $66 thousand and $103 thousand of stock-based compensation that was capitalized in the three and six months ended June 30, 2021, respectively.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and six months ended June 30, 2022 and 2021:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"/><td style="width:37.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.713%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.51</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.58</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.19</span></td><td colspan="3" style="padding:0 7pt 0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.42</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards ("RSAs") granted to employees vest ratably over a four-year period. The Company granted zero RSAs to employees of the Company during the three and six months ended June 30, 2022, respectively, and zero and 98,800 RSAs to employees of the Company during the three and six months ended June 30, 2021, respectively.</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"/><td style="width:50.452%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,879)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,600 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $4.7 million of unrecognized stock-based compensation expense related to employees’ awards that is expected to be recognized over a weighted-average period of 2.7 years as of June 30, 2022.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and six months ended June 30, 2022 and 2021 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"/><td style="width:36.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Shares remaining available for grant under the Company’s stock incentive plan were 530,991, with a sublimit for incentive stock options of 1,296, at June 30, 2022. P4Y P4Y P10Y 544500 1724000 297500 799950 45000 45000 0 0 <div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:38.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043,179 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,331 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151,642)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,620,262 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.75 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,341 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,979 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.48 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,184 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on June 30, 2022 and the exercise price of outstanding in-the-money options.</span></div> 2043179 57.00 P9Y 31331000 1769000 62.19 39399 44.13 151642 55.24 876 74.92 3620262 59.75 P9Y1M6D 28341000 536979 47.48 P7Y6M 11184000 704000 739000 64000 872000 42.90 43.03 42.53 47.25 115700000 P3Y3M18D The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and six months ended June 30, 2022 and 2021 as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:36.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.977%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,776 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,357 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,240 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,771 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,709 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,720 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and six months ended June 30, 2022 and 2021 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"/><td style="width:36.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1995000 1084000 3363000 1600000 5776000 2625000 10357000 4240000 7771000 3709000 13720000 5840000 146000 287000 66000 103000 <div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and six months ended June 30, 2022 and 2021:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"/><td style="width:37.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.713%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.51</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.58</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.19</span></td><td colspan="3" style="padding:0 7pt 0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.42</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 0.78 0.72 0.78 0.72 P6Y2M1D P6Y1M6D P6Y2M15D P6Y2M4D 0.0292 0.0105 0.0217 0.0102 61.51 66.58 62.19 73.42 0 0 0 0 P4Y 0 0 0 98800 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"/><td style="width:50.452%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,879)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,600 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table> 98800 78.89 0 0 14321 78.89 17879 78.89 66600 78.89 4700000 P2Y8M12D 418000 486000 899000 668000 418000 486000 899000 668000 530991 1296 Subsequent EventsThe Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements. EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

$;TMI*LY41_3 M'$=RB1/P-YVJLOY+5!+.6FF-HNKH!OM.WO8_^BLIA\S$FTDY/D MC9R\,4L(7K0I@"#5NQ; !S%^:=]+.,B1";T25\BH7;J@GP-2O3NM>3!/&6SR MX!=Y:,_ *107JA070L:WY&HVXV2&)0&?50YH)F@$ON-DV8[[3HII0WX*_84J M_87,^JLBIR7Y2I.? U;M)>G%L#45;F.E1@/7@[4UL&68"UT7MJ_IJ-)5Z"!= ME:_I6((ORXQ4NWFOA>PU8H$0#NJRPCSSL66Q=W9V4\)G^8:W4&_<,I/%)F]Y MM=Q4O\JWDNUJ>+$C_Q5S]74@0$*FRM11W=,"O-CD+DXD6^3[Q(],2I;FAW." M8\+U '5_RIC&PO=V]R:W-H965T(_)(UTCQ,!3GA5T8JP9VUR;)HW7*(?T"F]0P:\L,!AW2U9F+ MG(XW<(7FB'W=W!-^9M8L29JC@J:X 0M)\:-?1W9@0B0B#]3M*='QT"DLL#X M49S<)1/#$G>$,A0S00'YSP[-4)8))GX?WRI2HYY3!!X?O[#_+)/GR2P@13.< M_94F;#TQA@9(T!)N,_: ][^B*J&!X(MQ1N5?L*^PE@'B+64XKX+Y'>1I4?[" MIVHAC@(XCSK J0*<=H!W(L"M MQS9_"J ._<&095@$S=+'.7"Q="!J=C@O> M"#1G$P=R]64T7Z^T$(4R9X1?37D*S?YV'X..'3^ #2 OP98VWE ?2LKIU%4G6:B3+-)$UM!U4.LZ MZ'WJOF &,T"E]9>JQ4-.UD57ZK[IVSWNMZ9WSM96JDRS4219I(FL( M9UN'IL=Z?QY4W9,F:;6RA5K9(EUL376/6EI;LQ-5A,?V8(]&@Y87J5#6T&NY MD0+ENK[;\B,5EV^=>,.QG4/J3F_JOZ "$9Z\L"28Y&F1\G<>*+[%?)\K]4_[ MZMK5R19J98MTL34%//3#MOL.G4EK+ZV5+=3*%NEB:ZI[Z*?MWK;N+<[D=7QB M$ 1^VYFZ*,=W!FUGZJ)LRQT$;6OJPCSG5/-E'WI.N[_I[+6F7XP/C M3V*+*.$Y2W,Q\;92%K>^+^(M9D1T6(&YVEDSGA&IIGSCBX(C20PH2_TH" 9^ M1FCN3<=F[9Y/QVPG4YKC/0>QRS+"CS-,V6'BA=[+P@/=;*5>\*?C@FSP$>4? MQ3U7,[]B26B&N: L!X[KB7<7WBY'VMX8?*5X$"=CT)&L&'O2D\_)Q NT0YAB M+#4#47][G&.::B+EQM\EIU<=J8&GXQ?VCR9V%!#OA&19"58>9#2W_^2YS,,)(.HV *(2$%T* MZ): ;AW0;P#T2D"O#N@U /HEP(3NV]A-XA9$DNF8LP-P;:W8],!DWZ!5OFBN M=?(HN=JE"B>GCY+%3SH$YBQ3\A/$5/ &/A+*X2M)=PAL#<80?B_TIK@V MZ];P3BB-V66X6J D-'VOT(];PO%F98COR5%)2\(=YR3?H!Y?EU3*\AWX(+2U M&/M2A:0=\^/2_9EU/VIPOPM?6"ZW I9Y@HD#OVC'#UKPODIEE<_H)9^SJ)7P MUUW>@6YP#5$010Y_YI?#0UO>G//X6#X!=7 M:=Z2;/&69,LW(CLK8J\J8J^-?;I\+M2EKBHCS U0715Q1*& M5F;Z3;6?!IWA:.SO3]/MMHK.K187<2U?XSJ+O%]%WK\L@W"(0H\NK M(Q(NWKN";^<<@$%"!)F]>$)(B"N)\\MX0LL# TWCND 7/^I/OXEI^8-,/0?1 M61T&51T&K

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 195 242 1 false 43 0 false 7 false false R1.htm 0001001 - Document - Cover Sheet http://www.krystalbio.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited) Sheet http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited Condensed Consolidated Balance Sheets (unaudited) Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Sheet http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Sheet http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) Sheet http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited Condensed Consolidated Statements of Stockholders' Equity (unaudited) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 6 false false R7.htm 2101101 - Disclosure - Organization Sheet http://www.krystalbio.com/role/Organization Organization Notes 7 false false R8.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 2108103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders Sheet http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders Net Loss Per Share Attributable to Common Stockholders Notes 9 false false R10.htm 2112104 - Disclosure - Fair Value Instruments Sheet http://www.krystalbio.com/role/FairValueInstruments Fair Value Instruments Notes 10 false false R11.htm 2115105 - Disclosure - Balance Sheet Components Sheet http://www.krystalbio.com/role/BalanceSheetComponents Balance Sheet Components Notes 11 false false R12.htm 2120106 - Disclosure - Commitments and Contingencies Sheet http://www.krystalbio.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 12 false false R13.htm 2125107 - Disclosure - Capitalization Sheet http://www.krystalbio.com/role/Capitalization Capitalization Notes 13 false false R14.htm 2127108 - Disclosure - Stock-Based Compensation Sheet http://www.krystalbio.com/role/StockBasedCompensation Stock-Based Compensation Notes 14 false false R15.htm 2134109 - Disclosure - Subsequent Events Sheet http://www.krystalbio.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies 16 false false R17.htm 2305301 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies 17 false false R18.htm 2309302 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) Sheet http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables Net Loss Per Share Attributable to Common Stockholders (Tables) Tables http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders 18 false false R19.htm 2313303 - Disclosure - Fair Value Instruments (Tables) Sheet http://www.krystalbio.com/role/FairValueInstrumentsTables Fair Value Instruments (Tables) Tables http://www.krystalbio.com/role/FairValueInstruments 19 false false R20.htm 2316304 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.krystalbio.com/role/BalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.krystalbio.com/role/BalanceSheetComponents 20 false false R21.htm 2321305 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.krystalbio.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://www.krystalbio.com/role/CommitmentsandContingencies 21 false false R22.htm 2328306 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.krystalbio.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.krystalbio.com/role/StockBasedCompensation 22 false false R23.htm 2402401 - Disclosure - Organization - Additional Information (Detail) Sheet http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail Organization - Additional Information (Detail) Details 23 false false R24.htm 2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 24 false false R25.htm 2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail) Sheet http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail) Details 25 false false R26.htm 2410404 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) Sheet http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) Details 26 false false R27.htm 2411405 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail) Sheet http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail) Details 27 false false R28.htm 2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail) Sheet http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail) Details 28 false false R29.htm 2417407 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) Sheet http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) Details 29 false false R30.htm 2418408 - Disclosure - Balance Sheet Components - Additional Information (Detail) Sheet http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail Balance Sheet Components - Additional Information (Detail) Details 30 false false R31.htm 2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail) Sheet http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail) Details 31 false false R32.htm 2422410 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 32 false false R33.htm 2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail) Sheet http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail) Details 33 false false R34.htm 2424412 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail) Sheet http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail) Details 34 false false R35.htm 2426413 - Disclosure - Capitalization - Additional Information (Detail) Sheet http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail Capitalization - Additional Information (Detail) Details 35 false false R36.htm 2429414 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 36 false false R37.htm 2430415 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail) Sheet http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail) Details 37 false false R38.htm 2431416 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail) Sheet http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail) Details 38 false false R39.htm 2432417 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail) Sheet http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail) Details 39 false false R40.htm 2433418 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details) Sheet http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details) Details 40 false false All Reports Book All Reports krys-20220630.htm krys-20220630.xsd krys-20220630_cal.xml krys-20220630_def.xml krys-20220630_lab.xml krys-20220630_pre.xml krys-20220630ex311.htm krys-20220630ex312.htm krys-20220630ex321.htm krys-20220630_g1.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 58 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "krys-20220630.htm": { "axisCustom": 1, "axisStandard": 14, "contextCount": 195, "dts": { "calculationLink": { "local": [ "krys-20220630_cal.xml" ] }, "definitionLink": { "local": [ "krys-20220630_def.xml" ] }, "inline": { "local": [ "krys-20220630.htm" ] }, "labelLink": { "local": [ "krys-20220630_lab.xml" ] }, "presentationLink": { "local": [ "krys-20220630_pre.xml" ] }, "schema": { "local": [ "krys-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 367, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 1, "http://xbrl.sec.gov/dei/2022": 5, "total": 6 }, "keyCustom": 32, "keyStandard": 210, "memberCustom": 18, "memberStandard": 25, "nsprefix": "krys", "nsuri": "http://www.krystalbio.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.krystalbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112104 - Disclosure - Fair Value Instruments", "role": "http://www.krystalbio.com/role/FairValueInstruments", "shortName": "Fair Value Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115105 - Disclosure - Balance Sheet Components", "role": "http://www.krystalbio.com/role/BalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120106 - Disclosure - Commitments and Contingencies", "role": "http://www.krystalbio.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125107 - Disclosure - Capitalization", "role": "http://www.krystalbio.com/role/Capitalization", "shortName": "Capitalization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127108 - Disclosure - Stock-Based Compensation", "role": "http://www.krystalbio.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134109 - Disclosure - Subsequent Events", "role": "http://www.krystalbio.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "krys:EstimatedUsefulLivesOfAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "krys:EstimatedUsefulLivesOfAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)", "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables", "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - Fair Value Instruments (Tables)", "role": "http://www.krystalbio.com/role/FairValueInstrumentsTables", "shortName": "Fair Value Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)", "role": "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited", "shortName": "Condensed Consolidated Balance Sheets (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316304 - Disclosure - Balance Sheet Components (Tables)", "role": "http://www.krystalbio.com/role/BalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321305 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328306 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.krystalbio.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Organization - Additional Information (Detail)", "role": "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail", "shortName": "Organization - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "iab27a23368df44c0b545b31a362ffad0_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)", "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail", "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "iab27a23368df44c0b545b31a362ffad0_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)", "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)", "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)", "role": "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail", "shortName": "Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417407 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)", "role": "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail", "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)", "role": "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418408 - Disclosure - Balance Sheet Components - Additional Information (Detail)", "role": "http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail", "shortName": "Balance Sheet Components - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "krys:AccruedConstructionInProgressCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)", "role": "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail", "shortName": "Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "krys:AccruedConstructionInProgressCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "i9992e6e26f6f4543965ca3f6dcd6c353_I20201005", "decimals": "-5", "first": true, "lang": "en-US", "name": "krys:PaymentToEscrowForReducingLeaseRentals", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "i9992e6e26f6f4543965ca3f6dcd6c353_I20201005", "decimals": "-5", "first": true, "lang": "en-US", "name": "krys:PaymentToEscrowForReducingLeaseRentals", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)", "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail", "shortName": "Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424412 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)", "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail", "shortName": "Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "i4230c7dd2e1041b68fd5534af97a61fc_D20211203-20211203", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426413 - Disclosure - Capitalization - Additional Information (Detail)", "role": "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail", "shortName": "Capitalization - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "i4230c7dd2e1041b68fd5534af97a61fc_D20211203-20211203", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429414 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "role": "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "id9e4439435f24487b699ba4fbdccaff9_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430415 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)", "role": "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail", "shortName": "Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431416 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)", "role": "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail", "shortName": "Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "i7c64f9e68a3641cda1e0a998c7be368a_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432417 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)", "role": "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail", "shortName": "Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)", "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "i5c44a0f0edbf4e42a4210967f72907b4_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433418 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)", "role": "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails", "shortName": "Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "i953b502a78c24cafa839047b77dd0496_D20220101-20220630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "i5122f0ff5eea45fbb8d3ef9bec229dfd_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)", "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "i025425ccecb5443b909699e65613a02c_D20210101-20210331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)", "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization", "role": "http://www.krystalbio.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders", "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders", "shortName": "Net Loss Per Share Attributable to Common Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "krys-20220630.htm", "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 43, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.krystalbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "krys_ASTRAFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ASTRA facility.", "label": "A S T R A Facility [Member]", "terseLabel": "ASTRA Facility" } } }, "localname": "ASTRAFacilityMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_ATMProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ATM Program", "label": "ATM Program [Member]", "terseLabel": "ATM Program" } } }, "localname": "ATMProgramMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_AccruedConstructionInProgressCurrent": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 5.0, "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued construction in progress current.", "label": "Accrued Construction In Progress Current", "terseLabel": "Accrued construction in progress" } } }, "localname": "AccruedConstructionInProgressCurrent", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "krys_AccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other current Liabilities.", "label": "Accrued Expenses And Other Current Liabilities", "totalLabel": "Total" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "krys_AccruedFinancingFeesCurrent": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 6.0, "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Financing Fees, Current", "label": "Accrued Financing Fees, Current", "terseLabel": "Accrued financing costs" } } }, "localname": "AccruedFinancingFeesCurrent", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "krys_AccruedPayrollAndBenefits": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 3.0, "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued payroll and benefits.", "label": "Accrued Payroll And Benefits", "terseLabel": "Accrued payroll and benefits" } } }, "localname": "AccruedPayrollAndBenefits", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "krys_AccruedPreclinicalAndClinicalExpenses": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 1.0, "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued preclinical and clinical expenses.", "label": "Accrued Preclinical And Clinical Expenses", "terseLabel": "Accrued preclinical and clinical expenses" } } }, "localname": "AccruedPreclinicalAndClinicalExpenses", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "krys_AdditionalAreaOfRealEstatePropertyLeased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional area of real estate property leased.", "label": "Additional Area Of Real Estate Property Leased", "terseLabel": "Additional area of real estate property leased" } } }, "localname": "AdditionalAreaOfRealEstatePropertyLeased", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "areaItemType" }, "krys_BostonMassachusettsLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boston, Massachusetts Lease", "label": "Boston, Massachusetts Lease [Member]", "terseLabel": "Boston, Massachusetts Lease" } } }, "localname": "BostonMassachusettsLeaseMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": { "order": 2.0, "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash cash equivalents and debt securities available for sale.", "label": "Cash Cash Equivalents And Debt Securities Available For Sale", "totalLabel": "Aggregate fair value, total" } } }, "localname": "CashCashEquivalentsAndDebtSecuritiesAvailableForSale", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash cash equivalents and debt securities available for sale amortized cost.", "label": "Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "krys_ClinicalSupplyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical supply agreement.", "label": "Clinical Supply Agreement [Member]", "terseLabel": "Clinical Supply Agreements" } } }, "localname": "ClinicalSupplyAgreementMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_CostOfWorkPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost Of Work, Percentage", "label": "Cost Of Work, Percentage", "terseLabel": "Cost of work, percentage" } } }, "localname": "CostOfWorkPercentage", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "krys_CumulativeEscalationClausePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative Escalation Clause, Percent", "label": "Cumulative Escalation Clause, Percent", "terseLabel": "Cumulative escalation clause" } } }, "localname": "CumulativeEscalationClausePercent", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "krys_CumulativeEscalationClauseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative Escalation Clause, Term", "label": "Cumulative Escalation Clause, Term", "terseLabel": "Cumulative escalation clause, term" } } }, "localname": "CumulativeEscalationClauseTerm", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "krys_EstimatedUsefulLivesOfAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the estimated useful lives of assets.", "label": "Estimated Useful Lives Of Assets [Table Text Block]", "terseLabel": "Summary of Estimated Useful Lives of Assets" } } }, "localname": "EstimatedUsefulLivesOfAssetsTableTextBlock", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "krys_IncentiveStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive stock options.", "label": "Incentive Stock Options [Member]", "terseLabel": "Incentive Stock Options" } } }, "localname": "IncentiveStockOptionsMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_IncreaseDecreaseInLeaseLiability": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in lease liability.", "label": "Increase Decrease In Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "IncreaseDecreaseInLeaseLiability", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "krys_InterestIncomeExpenseAndOtherNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest income (expense) and other nonoperating, net.", "label": "Interest Income Expense And Other Nonoperating Net", "terseLabel": "Interest and other income, net" } } }, "localname": "InterestIncomeExpenseAndOtherNonoperatingNet", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "krys_LabEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lab equipment.", "label": "Lab Equipment [Member]", "terseLabel": "Laboratory and manufacturing equipment" } } }, "localname": "LabEquipmentMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail", "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Remainder of Fiscal Year", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Remainder of Fiscal Year", "terseLabel": "Lessee, operating lease, lease not yet commenced, liability, to be paid, remainder of fiscal year" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Year One", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Year One", "terseLabel": "Lessee, operating lease, lease not yet commenced, liability, to be paid, year one" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "krys_LessorOperatingLeaseLiabilityAnnualLeasePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessor, Operating Lease, Liability, Annual Lease Payments", "label": "Lessor, Operating Lease, Liability, Annual Lease Payments", "terseLabel": "Lessor, operating lease, liability, annual lease payments" } } }, "localname": "LessorOperatingLeaseLiabilityAnnualLeasePayments", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "krys_LitigationSettlementMilestonePaymentsSalesThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Litigation Settlement, Milestone Payments, Sales Threshold", "label": "Litigation Settlement, Milestone Payments, Sales Threshold", "terseLabel": "Litigation settlement, milestone payments, sales threshold" } } }, "localname": "LitigationSettlementMilestonePaymentsSalesThreshold", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "krys_LitigationSettlementTotalConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Litigation Settlement, Total Consideration", "label": "Litigation Settlement, Total Consideration", "terseLabel": "Litigation settlement, total consideration" } } }, "localname": "LitigationSettlementTotalConsideration", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "krys_LongTermMarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term marketable securities.", "label": "Long Term Marketable Securities [Member]", "terseLabel": "Long-term Marketable Securities" } } }, "localname": "LongTermMarketableSecuritiesMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "krys_LossContingencyGuaranteedMaximumPriceToBePaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Guaranteed Maximum Price to be Paid", "label": "Loss Contingency, Guaranteed Maximum Price to be Paid", "terseLabel": "Loss contingency, guaranteed maximum price to be paid" } } }, "localname": "LossContingencyGuaranteedMaximumPriceToBePaid", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "krys_MilestoneOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone One", "label": "Milestone One [Member]", "terseLabel": "Milestone One" } } }, "localname": "MilestoneOneMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_MilestoneThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Three", "label": "Milestone Three [Member]", "terseLabel": "Milestone Three" } } }, "localname": "MilestoneThreeMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_MilestoneTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Two", "label": "Milestone Two [Member]", "terseLabel": "Milestone Two" } } }, "localname": "MilestoneTwoMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_MilestonesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestones", "label": "Milestones [Axis]", "terseLabel": "Milestones [Axis]" } } }, "localname": "MilestonesAxis", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "krys_MilestonesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestones [Domain]", "label": "Milestones [Domain]", "terseLabel": "Milestones [Domain]" } } }, "localname": "MilestonesDomain", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_NonEmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non employee stock option.", "label": "Non Employee Stock Option [Member]", "terseLabel": "Non-Employee Stock Option" } } }, "localname": "NonEmployeeStockOptionMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_NumberOfMilestones": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Milestones", "label": "Number of Milestones", "terseLabel": "Number of milestones" } } }, "localname": "NumberOfMilestones", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "krys_OtherContractualObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other contractual obligations.", "label": "Other Contractual Obligations [Member]", "terseLabel": "Other Contractual Obligations" } } }, "localname": "OtherContractualObligationsMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_PaymentToEscrowForReducingLeaseRentals": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment to escrow for reducing lease rentals.", "label": "Payment To Escrow For Reducing Lease Rentals", "terseLabel": "Cash contribution" } } }, "localname": "PaymentToEscrowForReducingLeaseRentals", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "krys_PaymentsForSuitLiability": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Suit Liability", "label": "Payments For Suit Liability", "negatedTerseLabel": "Repayment of ASTRA build to suit liability" } } }, "localname": "PaymentsForSuitLiability", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "krys_PeriphaGenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PeriphaGen", "label": "PeriphaGen [Member]", "terseLabel": "PeriphaGen" } } }, "localname": "PeriphaGenMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_PlacementSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Placement Shares", "label": "Placement Shares [Member]", "terseLabel": "Placement Shares" } } }, "localname": "PlacementSharesMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Offering", "label": "Public Offering [Member]", "terseLabel": "Public Offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_PurchasePriceOfPotentialBuildingPurchase": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase Price Of Potential Building Purchase", "label": "Purchase Price Of Potential Building Purchase", "terseLabel": "Purchase price of potential purchase" } } }, "localname": "PurchasePriceOfPotentialBuildingPurchase", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "krys_RemainingCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Remaining commitment amount.", "label": "Remaining Commitment Amount", "terseLabel": "Estimated remaining commitment" } } }, "localname": "RemainingCommitmentAmount", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "krys_RisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risks and uncertainties.", "label": "Risks And Uncertainties [Policy Text Block]", "terseLabel": "Risks and Uncertainties" } } }, "localname": "RisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "krys_SaleOfStockAggregateOfferingPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Aggregate Offering Price", "label": "Sale Of Stock, Aggregate Offering Price", "terseLabel": "Sale of stock, aggregate offering price" } } }, "localname": "SaleOfStockAggregateOfferingPrice", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "krys_SaleOfStockRemainingAvailableIssuanceAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Remaining Available Issuance Amount", "label": "Sale Of Stock, Remaining Available Issuance Amount", "terseLabel": "Sale of stock, remaining available issuance amount" } } }, "localname": "SaleOfStockRemainingAvailableIssuanceAmount", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental condensed consolidated balance sheet information related to leases.", "label": "Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases [Table Text Block]", "terseLabel": "Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases" } } }, "localname": "ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate", "verboseLabel": "Forfeiture rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" ], "xbrltype": "perShareItemType" }, "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]", "verboseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "krys_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "krys_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "krys_StockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock incentive plan.", "label": "Stock Incentive Plan [Member]", "terseLabel": "Stock Incentive Plan" } } }, "localname": "StockIncentivePlanMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_SwitzerlandLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Switzerland Lease", "label": "Switzerland Lease [Member]", "terseLabel": "Switzerland Lease" } } }, "localname": "SwitzerlandLeaseMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "krys_TwoThousandSixteenLeaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand sixteen lease agreement.", "label": "Two Thousand Sixteen Lease Agreement [Member]", "terseLabel": "2016 Lease Agreement" } } }, "localname": "TwoThousandSixteenLeaseAgreementMember", "nsuri": "http://www.krystalbio.com/20220630", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r170", "r171", "r172", "r173", "r187", "r194", "r219", "r220", "r332", "r333", "r334", "r335", "r336", "r337", "r356", "r386", "r387", "r404", "r405" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail", "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r170", "r171", "r172", "r173", "r187", "r194", "r219", "r220", "r332", "r333", "r334", "r335", "r336", "r337", "r356", "r386", "r387", "r404", "r405" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail", "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r164", "r170", "r171", "r172", "r173", "r187", "r194", "r210", "r219", "r220", "r253", "r254", "r255", "r332", "r333", "r334", "r335", "r336", "r337", "r356", "r386", "r387", "r404", "r405" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail", "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r164", "r170", "r171", "r172", "r173", "r187", "r194", "r210", "r219", "r220", "r253", "r254", "r255", "r332", "r333", "r334", "r335", "r336", "r337", "r356", "r386", "r387", "r404", "r405" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail", "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r127", "r320" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r24", "r323" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxes": { "auth_ref": [ "r12", "r13", "r274", "r361", "r376" ], "calculation": { "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 4.0, "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.", "label": "Accrued Income Taxes", "terseLabel": "Accrued taxes" } } }, "localname": "AccruedIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 2.0, "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r9", "r159" ], "calculation": { "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r33", "r34", "r35", "r378", "r392", "r393" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r32", "r35", "r41", "r42", "r43", "r74", "r75", "r76", "r279", "r319", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r17", "r323" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r74", "r75", "r76", "r265", "r266", "r267", "r286" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares surrendered for taxes and forfeitures" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r222", "r270", "r271" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r207", "r208" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Offering expenses" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r11", "r71", "r112", "r120", "r124", "r141", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r277", "r280", "r298", "r321", "r323", "r360", "r375" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r23", "r71", "r141", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r277", "r280", "r298", "r321", "r323" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r134" ], "calculation": { "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 }, "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": { "order": 3.0, "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r135" ], "calculation": { "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 }, "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": { "order": 1.0, "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r132", "r148" ], "calculation": { "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": { "order": 2.0, "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r129", "r133", "r148", "r364" ], "calculation": { "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Aggregate Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r131", "r148" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Short-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r225", "r226", "r227", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r248", "r249", "r252", "r253", "r254", "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail", "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails", "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r73", "r109" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Organization" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r65", "r66", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Unpaid purchases of property and equipment included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r6", "r63" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": { "order": 1.0, "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": { "order": 1.0, "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Aggregate Fair Value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r64", "r359" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Investments" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r23" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-Term Investments", "terseLabel": "Cash, cash equivalents and short-term investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r58", "r63", "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r58", "r299" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r28", "r366", "r382" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r166", "r167", "r168", "r174", "r400" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r74", "r75", "r286" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common\u00a0Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r207" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16", "r323" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock; $0.00001 par value; 80,000,000 shares authorized at \u00a0\u00a0 June\u00a030, 2022 (unaudited) and December\u00a031, 2021; 25,664,287 \u00a0\u00a0 shares issued and outstanding at June\u00a030, 2022 \u00a0\u00a0 (unaudited); and 25,207,985 shares issued and outstanding at December\u00a031, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r37", "r39", "r40", "r46", "r368", "r384" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment and software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail", "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r103", "r374" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r158" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Construction in progress, gross" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "Contractual Obligation", "terseLabel": "Contractual obligation" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTerm": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Debt Securities, Available-for-Sale, Term", "terseLabel": "Debt securities, available-for-sale, term" } } }, "localname": "DebtSecuritiesAvailableForSaleTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r61", "r157" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r61", "r157" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r224", "r225", "r260", "r261", "r263", "r272" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r47", "r79", "r80", "r81", "r82", "r83", "r87", "r89", "r91", "r92", "r93", "r97", "r98", "r287", "r288", "r369", "r385" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per common share: basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r47", "r79", "r80", "r81", "r82", "r83", "r89", "r91", "r92", "r93", "r97", "r98", "r287", "r288", "r369", "r385" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share: diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r94", "r95", "r96", "r99" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r259" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Amount Capitalized", "terseLabel": "Share-based payment arrangement, amount capitalized" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Estimated weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Share-based Payment Arrangement, Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail", "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r41", "r42", "r43", "r74", "r75", "r76", "r78", "r84", "r86", "r100", "r142", "r207", "r208", "r265", "r266", "r267", "r275", "r276", "r286", "r300", "r301", "r302", "r303", "r304", "r305", "r319", "r388", "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r365", "r401" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow Deposit", "terseLabel": "Escrow deposit" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees": { "auth_ref": [ "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expense related to distribution, servicing and underwriting fees.", "label": "Expense Related to Distribution or Servicing and Underwriting Fees", "terseLabel": "Underwriting discounts and commissions" } } }, "localname": "ExpenseRelatedToDistributionOrServicingAndUnderwritingFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r289", "r290", "r295" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r289", "r290", "r291", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Summary of Cash, Cash Equivalents and Available-for-Sale Securities" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r188", "r190", "r191", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r290", "r329", "r330", "r331" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r188", "r211", "r212", "r217", "r218", "r290", "r329" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r188", "r190", "r191", "r211", "r212", "r217", "r218", "r290", "r330" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r188", "r190", "r191", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r329", "r330", "r331" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r296", "r297" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r309", "r317" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Finance lease, liability" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r136", "r137", "r138", "r139", "r140", "r143", "r144", "r145", "r146", "r147", "r149", "r150", "r151", "r152", "r189", "r205", "r284", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r412", "r413", "r414", "r415", "r416", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail", "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r169" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "terseLabel": "Gain related to litigation settlement" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r49" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r61", "r156", "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Recognized impairment losses for long lived assets" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r155", "r163" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r162", "r165" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r60" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r60" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r60" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r60" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r44", "r111", "r306", "r307", "r371" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Company, Capital Share Transactions [Abstract]", "terseLabel": "Investment Company, Capital Share Transactions [Abstract]" } } }, "localname": "InvestmentCompanyCapitalShareTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Operating Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r317" ], "calculation": { "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Future minimum operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r317" ], "calculation": { "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r317" ], "calculation": { "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r317" ], "calculation": { "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r317" ], "calculation": { "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r317" ], "calculation": { "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022 (remaining six months)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r317" ], "calculation": { "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease, term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25", "r71", "r121", "r141", "r176", "r177", "r178", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r278", "r280", "r281", "r298", "r321", "r322" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r71", "r141", "r298", "r323", "r363", "r380" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r27", "r71", "r141", "r176", "r177", "r178", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r278", "r280", "r281", "r298", "r321", "r322", "r323" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Litigation settlement, amount awarded to other party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Litigation settlement" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r7" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-Term Investments", "terseLabel": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r58" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r58" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r58", "r59", "r62" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r36", "r38", "r43", "r45", "r62", "r71", "r77", "r79", "r80", "r81", "r82", "r85", "r86", "r90", "r112", "r119", "r122", "r123", "r125", "r141", "r176", "r177", "r178", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r288", "r298", "r367", "r383" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss per common share" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental Disclosures of Non-Cash Investing and Financing Activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other Income (Expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r112", "r119", "r122", "r123", "r125" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r312", "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r309" ], "calculation": { "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liability", "totalLabel": "Total lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail", "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r309" ], "calculation": { "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail", "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r309" ], "calculation": { "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail", "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r308" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail", "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r316", "r318" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r315", "r318" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term, in years" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r10" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r31", "r33" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized loss on available-for-sale securities and currency translation adjustment", "verboseLabel": "Unrealized loss on investments and other" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r26", "r323" ], "calculation": { "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 7.0, "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r62" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Other Noncash Expense", "terseLabel": "Non-cash interest expense" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other, net" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r55" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedTerseLabel": "Taxes paid related to settlement of restricted stock awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r50", "r52", "r130" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r53" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r225", "r226", "r227", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r248", "r249", "r252", "r253", "r254", "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r225", "r226", "r227", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r248", "r249", "r252", "r253", "r254", "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r15", "r192" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r15", "r192" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r15", "r323" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock; $0.00001 par value; 20,000,000 shares authorized at \u00a0\u00a0 June\u00a030, 2022 (unaudited) and December\u00a031, 2021; 2,061,773 \u00a0\u00a0 shares issued, and no shares outstanding at June\u00a030, 2022 \u00a0\u00a0 (unaudited) and December\u00a031, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": { "auth_ref": [ "r56", "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.", "label": "Proceeds from Insurance Settlement, Operating Activities", "terseLabel": "Proceeds from insurance settlement, operating activities" } } }, "localname": "ProceedsFromInsuranceSettlementOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from initial offering of shares" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r54" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Issuance of common stock, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": { "auth_ref": [ "r51" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments", "terseLabel": "Proceeds from maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r394", "r395" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional Fees", "terseLabel": "Project management service fee" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail", "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r8", "r158" ], "calculation": { "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail", "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r160", "r323", "r373", "r381" ], "calculation": { "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail", "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r160", "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail", "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives of assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r273", "r357", "r406" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r153", "r154", "r406" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails", "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r208", "r323", "r379", "r391", "r393" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r74", "r75", "r76", "r78", "r84", "r86", "r142", "r265", "r266", "r267", "r275", "r276", "r286", "r388", "r390" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r314", "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Initial recognition of right-of-use assets" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of stock, number of shares issued in transaction" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, price per share (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses And Other Current Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCapitalizationEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Capitalization, Equity [Line Items]", "terseLabel": "Schedule of Capitalization, Equity [Line Items]" } } }, "localname": "ScheduleOfCapitalizationEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCapitalizationEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.", "label": "Schedule of Capitalization, Equity [Table]", "terseLabel": "Schedule of Capitalization, Equity [Table]" } } }, "localname": "ScheduleOfCapitalizationEquityTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r257", "r269" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail", "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r221", "r223", "r225", "r226", "r227", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r248", "r249", "r252", "r253", "r254", "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail", "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r229", "r244", "r247" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Company's Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Fair Value of Stock Options, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r113", "r114", "r115", "r116", "r117", "r118", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment and Geographical Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r60" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Stock option vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Surrendered or forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Surrendered or forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted stock award granted (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r238", "r239" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Restricted stock award outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r238", "r239" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail", "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares remaining available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted- average Remaining Contractual Life (Years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable end of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Cancelled or forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled or forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)", "verboseLabel": "Stock options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value per share of options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r264" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Stock Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r225", "r226", "r227", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r246", "r248", "r249", "r252", "r253", "r254", "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail", "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails", "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r228", "r250", "r251", "r252", "r253", "r256", "r268", "r272" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation Expense" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Stock option expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term of the award (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r264" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable at June 30, 2022" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual life (Years), exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual life (Years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Shares surrendered for taxes and forfeitures (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r396", "r397", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-Term Investments [Member]", "terseLabel": "Short-term Marketable Securities" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r69", "r73" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r29", "r41", "r42", "r43", "r74", "r75", "r76", "r78", "r84", "r86", "r100", "r142", "r207", "r208", "r265", "r266", "r267", "r275", "r276", "r286", "r300", "r301", "r302", "r303", "r304", "r305", "r319", "r388", "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r74", "r75", "r76", "r100", "r358" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r15", "r16", "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net, (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail", "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r16", "r207", "r208", "r235" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r15", "r16", "r207", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r20", "r21", "r71", "r128", "r141", "r298", "r323" ], "calculation": { "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r70", "r193", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r206", "r208", "r209", "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Capitalization" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/Capitalization" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r324", "r325" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/BalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplyCommitmentArrangementMember": { "auth_ref": [ "r14", "r362", "r377" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.", "label": "Supply Commitment Arrangement [Domain]", "terseLabel": "Supply Commitment Arrangement" } } }, "localname": "SupplyCommitmentArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SupplyCommitmentAxis": { "auth_ref": [ "r14", "r362", "r377" ], "lang": { "en-us": { "role": { "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.", "label": "Supply Commitment [Axis]", "terseLabel": "Supply Commitment" } } }, "localname": "SupplyCommitmentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r136", "r137", "r138", "r139", "r140", "r189", "r205", "r284", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r412", "r413", "r414", "r415", "r416", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r72", "r211", "r218", "r372" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. government agency securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r101", "r102", "r104", "r105", "r106", "r107", "r108" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r313", "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r88", "r93" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding: diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r87", "r93" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding: basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited", "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r174": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r272": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r325": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.14)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(d)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r407": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r408": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r409": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r410": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r411": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r412": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r413": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r414": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r415": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r416": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r417": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r418": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r419": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "21B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080549-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" } }, "version": "2.1" } ZIP 59 0001711279-22-000047-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001711279-22-000047-xbrl.zip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�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`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ᡩ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

$!J8!-IM MO&I!M3U3 S9 D0D+3'PWUSHQTO.TRCJO\MG&5QVW^-N&W?:+-UMP'QY"4PONZ'3^ RXZSD8\-EW-ZM=T&YFVL&PFYH+_#FR/MN"6J1@989-$+7S ,V M8OM'U"'[P3^R(V5$- BOED#6""N-<-$@7'>%*&KQ?_64*N$&5F?ZA.6CQDNI M<--M+\W"\=8K0K38Y3@ =B8.X(.V6U=T(;143>CK;1WXNHU[;86]FJ4FFE6U M<:BV-PFF1%N>C$,:AOJ?L4@$DX+%RLGR? 8=IK:>;,..FZCCW6$!;T4=SZ^+ M.A[Y/;&SEB<^^P.OB#X#QUI(W( &"W#;&<=N\/ <7?8\<^DS_FQD#<:/4'N> M*3H9P_9,HCQ/0'1+XDWH;)3(,(U,?G<2*XB(BB%.400#&F:!WE_1)$:S.N+W M\XH6*X<5U:><+HQY*.UPY/E"WN>+BM(8U;_@\OF"HH]GEHJ82(0)#*-8FN.] M &(3'1&%62*C,$ECFFQF]O5"_##SVL@ZY'&7F.B4.A@TSS5)/ZJY,K4X][.3 M,)$X]V/Y?J@X][/P^HYS/S]0#__H[>>[3[=O**]B1C9GC#&)%4-) E5BBL5Q MPB FG)MNHRI@<9"E@545@W,#3&VG6HD(&AD=G'2GP+/P<5X)R L^@SOP M">P0Z=./Z!0T#L[**R$:R3-9OSAJ(Z8OWV.'[IV.QE/WC>=5[)!ZSX78=5W/ MCB>T?##U#?0?K__W.O]*YR;NK>JSPR(2)A1C&"C)-).E!-)8&ZQA1H,LR@(1 M8J=Z+.>'FAJG5:6L([M3LYC:V7X?#5Y^3\ M0.-V.;FH\%&/D\MW]"R1:6RH.WUO]?HBFD51PF.8!G$$4<0HQ*E(H*8+AAB3 M3! GC__>TZ?&!I5PP$CG6.)R#S*[+[XW$$/;-5L,O'_5)U7V57]R[]GC%ID\ MI=91)+;6S(+5_E7^N:JEFDJ-Z&((C" M4.F5/120BB2$.$Q)()"*"<,N7=+MAW;ZMD=HFF[Z?7.S;JV-9R)?M%)SZ59H MQ^Q<^WFPXX1AT!V8, RPE4'0B&V\0#__4:/\2RNZ[/8RS.YIO2^>ED6U_ZP"[5\NUXM5\?WE4L@9"644RRB$) XD M1*:0 ,-(:-,CBM- ,!5AJ_(!EN--S1C9Y'[LR=S* -E(#HSHKFDSW;AW<]4 M: Y,4#Z [)%.8P7/%5DUW<\?.;G&2MGC'!N[VWKX:TVQ[@_J\VK)_[&M8/]! M*5EH OM8Y%S.9!+1-$8A9$0&$"%&M&44QS#*8A5@)0,BK%HPV@TW-7(Q IL0 M[]*(? /HMLK_#)B.W@R+R-NX?+UBN/0!V(&P@\*?*XAW#5*: 0&'[U# MZ. :]@KE2([B:R%U^ZHM62Z>!B7%5U+>M9 M@I#>?288IIG*()(X@2R@"C)!"1$H"?2/G1LM[8\Q->VZP=%IYG^V5#D88O[G2:15/ME8Z M86F%:",>,3BC$&)E8!(20*QB 4D,@V#+(MCHF*G[[USN*E]^DW[ MT*J5Y7)A#*\Z':-IN6AYFFX)MB4=>(-P:&;H*.;BOP^C%2J^**-[L''9PTKQ M(R*QNZL?I[R@95Y^4+>/=/2]U$:.?L=X'&,8 M$*$@BD,"B0D-Y-JXD42;.#2Q*NMD,]C4Z*>1M8H/D8V@-V A'6LQ="*,8XR!L1^Z^]^!G'LI4@M(?!4F[1IJW#*E%DH?%2VUN:=GDA9_D&)MO%FO'Y_F MR^]2?I;%UYS+,['D\VI:]=\^J$^2+^\7^3^E^%@EN[QQB]V\:#X_8!!0^ MY9I!C6(WX/;1+.#@2Z6793#UL&^ '2D^^[P.?>!Q*K/'ZY2ZY_H,";FO?)]! M9!PWYV=(F(_R?@8=[+G:(3WE]2%W^791RS:+F,J"-.4P%HE>5F1,-%UR G&J M),6!3$4@9HOJ-$;15#YK.Z3C6;5<*IYIDGZ\ M5-&6IB9HL]9U.LFB'1,QD7314Q+^4 FC'1#[;XUT?JAK=R2G2UY\DN6JR+EF MS/K\?2$.?O+'(E^5FY#+[]52MG/$!HA%8:(B2'"H5Y X5A"K+(0!0R2EF4"2 M./57&E+8'VY_LE.M#D>IC-JC'QJ-;YK(9L=3O$'?#=+1T>X!HKG:." M+=_"]J1_ZZOZSR48NG,VSMT\8JK&!?GW,S0N7=S/P-^>KYC'URZPYGU,LYC) MD,*,)12B.)*0R8Q#(F0H*4D33KF+97YVI,GQX"6W4"V\F[U\'F<[0]<+>L_M M8JGE'J!AU45T/)F$Y\<9U9:[J.ZA$7;YAG[LH?FH,$'?KV3]I[;4FJR2.OK[ MMBSEJIQ%E! D(P5QQK4]16,&*3;1>TAF"4OB@. ^YYR6PT_T[++.=EJ8E+!- M;@BMQ'4C%MLIL*,9GXB.0SJ-Q.#G1N9?C(=CETJVP?:V&UMGRG%$RA,!V8XZ M*ATY0G%(3JZWNU%56:QF=_G*>%??+H3>/(HUG?\M7SU\DO/ZF.\A?[I;UK4( MZB;J,YXD+([C#"8)9IJN%(54B "2)$L93Q7/DL#&].DQ]M2,H4I\DQ&Q4\". MG_K@WLU1 Z,Y,$^= !)\J:7T8 A=@4T7,^G'MEA)_VO'2'U&'(65KH"B8:9K M'C%R<-FV":DFR?7C-H1!FK.A_UP::4TNWB=MT\R2-))"!3&,TPQ#)'@$,0WU M/YG(XDBA6$2A<^.F866>&ALV4M8U4^KZ*.#K5N210L\V M/9ANO])\;D(2WNJ134N7.@]@1B(5A1Q1&$L9080B#&F,4I@F"0HI18'3$8O] MP%-;4@ZJ<.TZ_]%&?I!O% "TTJ!?-:F+$V)S3#,,S$/S_7Y%J5TGO*WHH)%] MDZ0R$,+]*G?Y1/IY:GA=@WCO%Z2A=B_T,23<]7HN!=T #S?(/ MLQ.J]0EU^?I!R]6Z3R%IU$9$2BT2%(60T$A#1,(&8T0 RDD@B"(IHZEC5ZO1 4]L3 M;>0$E:"@D=2UD-494.T6!!]0#IU'RWK'E$A+>BE&=&6;D\E/=RAX7G+IP M?4^[>6>A5]5W-80A81#&JH (J9,\[8LEDPZ^?#/##0U M1CCPDM2.]R=M9E3V9V6)BN5\3HMR]U-7H_0^P"%+Z,IW/#C&OI7%#VR"RY='W/SH[+QT?3/D$_MGI<>;M>/2P+4P=C MQK.8QJDFC9"'&40B01!+TYH\"%,>8*$H=JI)US'6U'BC%K6AC7JS"NA67,<. MCQT8VY&$)^0&YHD-:!N:J 4%MY=!!D.7ST>.T8:M\GC996/NCQ:W-*/ M-)I:O:8[&94(:RZ(-3^H"** 4TB3+(%!EI(@Y32E4>Q25K'U;"=2&*&*XIT9 M8UMWVSGUL8V:W6??$XN!/_-W%@ X?](G5/7T";>?/.HG>T*EPT_TU"4^:NC_ M3>;W#RLI;K_JG][+K;>^^N6=+![#&8I,JPR20&WY4XA(3" ))(9$)OK_$R)X MZE29T%6 J:WXC<2 UB*W3E3K>OM:B,<;XX;\+O5VX9JB^Q:S8\;?XK\1OW7Z5UT!C 9#U>JWAVZ0ZOT6PS]C/7][<+HK_#L\9^13PW?Y0E;9 MQ3,>1RP)XQ#J?8\TT242$H$EI"IB*::DW;U$_K[&9LO..W(Y"?^U1M)]"/<5AV!*"W,[#C M)U]ISF[J I>S!),L4HC#D,;8E.\/(8FR"'*>A*&V86/"AXV=Q5W M-AW?^EJ>6R =3YW M^BU_7#\V]0'" "DL$IA&6:(WGE$ J33A5VG,!8JX_KRMD^3VGCPU2VDCG'W: MVSY.W=_I5=H/_'UNY/*8KW]6VRN2T/:?-UJ*V4DUV@EDIR_HMXR^EZM399'> M+K[*\DS]M#A!H51<04)XJM?9B$/*(@I10I,X(GH?%#O%CKB+,+7O>"MJJ\Z9 MVR+<8QKL5NEAP1V8)DR]N8[R5\_;B>FY#G*AK/;&<*^: MFORKW%6/TW)]4'?TVTQA%2$:8,C22+-?H@)( M0I5"13*9(B8)B]W*BKJ-/S7J:XD/EE5X+F\K4!4*=:S_Z3@A=CPX(,P#DV ; MX3H >D_V_8*<5=LQ$XFC=?!87K,?>+ZJ93J./F[QRW[0'-6R[/F8GF[PJN); M6:ZE>+4N3#/+*MBX2N-\+_^L?E/.D! DE0'7)AX*(=+[,+,#DS .XUA%*D,R MM=J&.8TZ-7[;9I/I;XKOA?PX=T:T0]W2_>P;RZ$]S'6-RTI@4$N\2=:XJ;/= M#7']65_@T5?C!),O'['5F..Z@5U@./+T.MWLJ]J;)L1"C]@*?[A=U-2X.S)L M1DKZ@7>Y@%W/Y_H(&1-UM;SM =Y,1C+)$.:0HR#3I$LHQ'$0PT1AQ%E(<) X M;86[AYL:I1[$)XE-'<@K@A[^EDJVRID MOVN^6A=5!%*Y_>'_S#6;%?RAJ0;+",IP9#)<68I,KBN&E"(&0Y0%/$L#1*23 M9\MI]*G9,:V*@UM)JVW'^]O_=+-?W";!SIP9#-J!^:<+58_5>:^"R9.UXS;V MJ,9/+U@.;:%^#^F9;$O+![VA,W^88B%?Z=P,MFO*>/KW'Y?SG'^?\8QR*CF& MC 48(E.BBB)*((V0C%B&5!@CIVS<*X29&LL9(6_J8(*6K-4769\M5[/JF+5[ MS639T=]84S P&U:X&ZP/)V"O.6['5;5&X,OFST&ZXOK VE=2\36BC)MU[ &T MH[1D'\_TR;^WJY>T*+YK,[6B_%FJJ$I3K& 6)2E$R&0TIS2"3(:<1RAF4>84 M 6W#Q(]1/P:MKP"Q^>C16HBWVJI:S-R:)X[@]*@A'8X MY@28ZPP,=A1U[N:>D6F5T^UE?3PW2Q%/I" FS%8(B-(P@(1$!#(5)"R0/(EY MX)+=LO=T)VX9+;/EFN95^^#9T4=O2 :FB5HN;;W6DGF,ZSJEL*^HK;UGCQN3 M=4JMHXBKDQ?U^U(_%B8):_7=],Y<:5HPE/!D-A3&3JW,U%F0\A %*H12(::_ MX22&3' !<=/O,+9"W M^_;]XCDP(33"WE2]@E?[*((O=U4=]$'V2/8P>:(1BP%'Y19[ X)Q^'.GO9" M4VC]S;(PM> ^2[V 5F$ KR1;[?[5+(HR9#3#,8,*Q1E$*DH@09)#G,09Y0'! M,7>J[^(X_N3XZ6%9K*"IX0+ROAXAURFPM$N& W9@HC+R@9V -[LV#5 M"VB4 M&<*LZ8>7+\/'\DDKJ!XG6T6$=D#JC04)3Q&(8T.XB*JW1^I M3ZR&]F9N8-J*"8R/7'ARTQBH%2EY4"3S]3=9\+R45K6/-],/G>]S?X*_!CU.:^>(&_U/*^7I&\2 MT>='.I^_6)?Y0I;E+-,&"#8!$6D4Q7JY"Q/().(0!RE&21P$06*]X3_Q_*FM M19O\EDI&T CIFA"TC^!E-\"5N Q,W6Z0]$CP.:GX%1D]^\\;.87GI#+'.3NG M+_,<)O%'*=5Z_BY7K_+$J][2N9 3S_*LL3=A$GT H&]!MG?Q>H1S_@M$/JO!R\0^&+ 1MTIK#MOFI:GWO+W4_X'V.[?=7$C-<^OE.**Y;, MO4(1. TEID%@@@4SB#*,((D3#*.8\ 2EDN$@FCU5->(^KVBQ_S1=5RC&UZI)L&T77HC6M7Z"-DTS!(LDC$4& DZVZ96% "A=[S,)+2 MD!.Q0?;U0HR&:S/6D#MW,1"D#NOP1 N9U++=^"U:EG-]1UFS]OOE2K[*2SY?FA("N^P$I 1'&12TS!Q\G=8CSPU\_XE?U36M8+;D@^& '%HGFC)_"^-=6S$ M!CNYP9=!DD*4;Q=UC> 9"51,E;9H A9I6S&,%23F>"8A<13$),L8CV<+>6^\G>-$(5R4 MV>J3)O4GW99\2&;4K]U\;AHL%$#5\NM_7&HYA&68*%BW%]>PEX996 MM^KJF]X7>[LUP"^B Y.X53:CWR;T]OAX8D^+ 4>E/WL #OG+X<[)GB8>A%+] M53]Z]4J;G-OJ@S,49D@%00:3--46=AQP2% 2FA[((J-)0E@L>GICGUFU'\D! M+);S.2U*H.6H;?*Q3'*?KU*:/0*(F P KOBQ1/81@XPY\^]T_2I MTH^Q&1U@$I_A6-U>MIX!LK54Y=WREFNA"ME=9V.6Q8Q&:29@AC($48HPQ&%, MH2)Q'/(@"Y5^N)-[U5&"Z3E+/^H'/="RCI?M7C^FY=\[O%[G*N8GTY7RY7IA> M0U4%9_W\W7&M3*E,$HEA%G &D2(9Q%&&(4W"-(ZE*7?O%D%K->S4G'B?UX^/ MM/A>12[N% [#4"C@N..P6X2+&UZ[] .;75W0SG46;D33+X,5;M!QS4EG8 X M,O;<[NY1X<2<43P]T+_*Q>_2Q W/PI1F@F2:@5"4:"X*$XAE*J'$*!.1""*> M)-9E30Z?/C7*VOH,C9BWKG/#_(^=SL;^GB^RQ)]/8O83'D M+"80H2" +(DR&"XV(8".C<\)S&[YN=KH>E('I MR0F//MG.)]2^)MFY_;BQ&J0J7VTM8Q@)Z3C#N44CI;[D2O1 M&7KW<0@,^&(D]+G3Z # U[[BU!#C[B(ZE#S:,W1=^^QEO=K9HY@2'*LL@4$0 M8HAD)"!3+(&)R A/*54QY<]4NFO""<)5V'1SUN7>)WG@.1WX9-3;3$W_K/-4 M?:WIY?):3([6992?GB2)DIVZ ]R1J(,DS ,8<0"O?]3)G>,Z06#RU@& M$A,6<:MEHN?X4^/_NP=92&HD='#3](#=PJLU+)@#4W0MO.'9C?B@DO\&;#6X M,>> 3 *CQ0VH( =&$6 T&19\!R_:L),PDI]MJ,EP<\[UA[+3?=?CL>,Y^/KK MO.<"O.(Q?5:1?)7?5Z_D9[E:S:NEK&JF^%(O6KF0=0K&#,DT1%',8!JHJH9# M JE*&50L(W' *8FQ53 M-79X?F[A67?R?#DLGBZ+@G=;M'C7QVA*GQ MBAG4133 M+(Y#F* LT@8J2R". @S#*",HP40&S*EY15]!IL:*^NV*W=S9O:? SF$]!K 3 M\W=4F^L/"X_1S=>"Z,F-W%N,41W%UX)UZ J^^GG/?G3X=K'2C%WF?)/'*1*< MAHF *DLQ1 1E$..(PD"FB8Q5@BF/GNGT<%_2J9'K[?U]426I@+R1$WPU@MZ MY01.$P^F>?0#Q?Z3]V.>*=Z K<:328:TG97I'2P>R/FCGBV>AGO X\4S WKN MP&'Z@;Y:/M)\,N"NQV?>T9S:--ZN;B'[_*OFG#O],]S-I?@UC0Q 5]J63U&:C@@,W3S MC=:(TVB^<0R!=?.-$[?VXYY-5TTZWV5:5^&< 26)#!(,,QD%$"5<:KY1 :0X MC@B-HH2[]:D\,\[4.&8K9JMHPZ484"=<[?C$ UH#0-HY_9+TW^O$,BRQ%ZW=_YM9@,_'&[PN&4QW).[UY9 M+$1(LP@C;B" 0]CE:&$A@5OX&^]A=M.6%!+>P,V\GH%T.%HTRN0(YUS7@>HV^FG-3Z=1Z&7GS+> MN:BU1GN'I/9WN1M&KS:OS<>F"*&I+36+$=4@1@I&(@PA2BF!5,H,1@IEG!*& MB%V'D+,C3(U?&R$WE?F"/GM8M/LILI8>UN6:RG, M?TTIT)?+['PJ8Z$],-NTU*CJOFT5J>(@3*N)C2XWH$Z]K-6Y 8U"H-+( MGY/&!ZZ>/#E7B3*JN\<':(<^(2_/[!496Q=W_%CD7'Y0'Y M&M'!T^9W3L&CEN!;;%N'@'1@-MRB6L&UX5H7\N'C1D![*;?052PX\W]S.4S\7>S* D5XQ&"2ADF5UA +*,4 MAEB%.$QDA EUL83/C#,Y[M8/,QN]*OS,4/?.E0Y4X,@:K=!\(#3P*O=^5AH M?^;\!10\6>KG1AG5"+^@ZJ%]?>GRGAX)$WA3&G^B%)RDD*6F)V>D-*.R2$*< M")($3 B,J/N M@_<4.=K1[O^V3^;]LBQ?+JLZQ'+!O_]U34UW""G%[_1;_KA^K.RG)M]_AE2< M2E.K128DA"C0*R\.M8&34,)I& 52"2NSQGWHJ5DZ1GB3;]](?P/NM_*#QUJ! MS0ZV3L)YTDJXI) [S8O%WG4PM =FA@KHEVV@=Z*#C>R;7=8* ML]BT<*1Z/Q9@O3/3KQ=,>:)D$@01CE73S^?.UGMY9C"K#V6_=<_=",O!)_FT MR?;@$SG@;S:91:?M<-6S?@-J[*:_ ;N3N/EA$8(2UV:PX@N3@> M/8 UEJ.Q!VB.;L4+8'2[$<_=/*+;\(+\^V["2Q?W"42DY8/YG\E%^$KGYO&W M"]'=UW=&6$(%0@S&<TMP=1VPKNL5F7:.FX2 M6JN178+M^LR%!;T.C?# U&M$!]5_6@J 6Q.7L]\>;=<=K2:!;&"H@T$\'-?V1K-DSVGC"S4>YF@VYG0^G9*/65O_H*E+P"RN[8R3X/'C&< M\@J]]R,LKWF0SUH,=2ZN'OOMP@1VYE^E28XKJRY3WV=IAI!2"NF9DB9I!6%( M>"0A,06Y0IG)+$/75UGHE&%JKIPJY.-4'O[K.E++1^6$[DFQ<]H.#/7 2\[) M*@:M0@=?:HG!,.WK^D,W:$F";@DF4&S "B*[,@)VC^K'A*]IL<@7]^5'652# MW[)R55"^FC$12,H8@US2!"))%<0J"F :<)5E642)7:WQ2P--C=,:.4W(=5U M!'QI9'5,U#V+K1UK^4!L8&KJ!Y8S"5U"PA/3G!UF5#JYI.PA9UR\OA\Q:*Y9 M/LK/VH*O5IEW9I(,"YE,40R%86AY$X9_!UC M38T>:E'!5E;0".MWHVK&#)\P&)HBS<'E/Z+? PQ--=(TT*E-8J'Q(%C:W M]'#9Y:/&Z0O>+Q=% M\T^]0GZ&$$2',T35.E#8)$PRIZ4\<*B45C2D+D\RIJ)-W$:>V M$GQ>/S[2XKLY]C;>SYOC4P7S%6X=GU M"VAZ4?YGW:T2=">+QQD.!4(B%1 ' 88H35)(I%201P%6DLDX2:U\ A9C38W)N^H#W0 M MP:.7(C<5S#8G[-[ &_HLO;.R"R@&(4Q9,9U@B*A MC/_$9/-%1$C.6,*=+&W;@:?&NBVY*PNK+?F_@%IVQ\XIME-@9_8. >S C'R( M:2WH(&)Z?\^P&?X@Q7HN/ZA;SI=KOGE&&)SS03:L=Y8TS(P$Q[,2*4( MV&A2.V8VT]2FS"'W]3YP]161 #M*$;'QS/[\>\?G^^*:MO_?><# MW!Q/D,R$)XH4!K@*UY$AQ"&*8132E*"8!B)RZ@%U?JBI<>,S9]JZC(8G4NH8:%3* MN:SP(:%8W#%0Q[GR0E>BOYI\R/+MHBZ3^3>9WS^LI+C5GYK^R%Y_DP7/-W6" M9JEFF"Q3!,8H3"'BJ8(D3C!$ 0W2*.1)&GN(CAY$]JD16B6YMBQ^SA= +.=S M6I3@25M_I5'W%\_=Z#R^ I;VX30G=FASTJ)C76G;LJY&P-3CK#&X 0T*8 ,# M:'"HT\Q'[&/G?_;&ZFSG4?()A)\/.B7.W>\&$*%G2:2#/**#+*/'9;'*_VG4 M*%?5\=E,Z'4KH"2" 6$<(LQ32*(L@#*, Q3Q)*N*L3L43W(4P&EQ&B.YM)&P MJO7K6&C)%7R[%65(2 =>%@YR1F].A'OHG]E![E[IJ2=NOFI"N0X_;O6HGN < MU9GJ^YQGCNR:I=J:%T1;\'K>I#;HI80LH!02GF:<9 IC'C]+0-?4S/5= )!% MS(]KJS]OTVE'I<\R20-SK*?Y>;Y K*G&7_V@85>#1UL-[;6Y8$OKA4;)?*6E M-3J\_O:4%]43[#;Q/$EEC"B#C$D"D4D 93*D,$A3I1*:"L659NI+14O M35.$^5Q;9X M+)?1H+I,RXDTQK0YNY5&$>J9SEX:8>P(6+(P)CR+(4JHZ1\6(<@0CR"CB*:* MAED6^%VVO8H_M76Z$6XB9S!NK\)(QS"#3? $%E_KDY@M"--<:P>9PZF3*!.$$)U,N@",,4!QES:I?I-/K45JN=\*#<2G\#:"4_H+4" MIISRL@HB?3(ZN ;&NTR.W0(T&.0#KQ\MM#^WT*Y%![<[M.N0W8^=:/>(FN^! MFK?0>9>Q1XZ?[P'+<1!]GX?TH[OWOQ6 +_Q*_)M MYDE(LS @H80)E53;^8F".(PP5!G"DH1Q@K!3F&=/.:9&@>_7CZ:!TK+XBQNQ M]9T&.XH; =R!R4YK #8EG'XV2OS2JFJL*:Y69"_SZ@94N@R2,G0EGIYHL*\4 MHQ+BE5 =4N.UC^M-DJ8FQL=B^377]/OB^Q_:3GV[>),OZ(*;$QB^RK]6QS.S M@*1A(((,JH@1B+@@D)%80JZR.$I%@' J7<)T[(>>6H".^62KBMA/&]G-7E8U M<@.Z%=R9*6WGPIHG^?*[E!55UMOK35()C8),QBF!"0L#B CF MD,0QT3M;%"9)EHK,KM_MQ9$F9[,M%[ 1MC8A-GXUAZ(/GK==6+F4";#%W8C%G:4Q.A\P7F$,&SWV MRF)8W= S7+O.L#1=QTVQ+K[*_A-(6OKTK\-G:,^]@<:(!]Y:0./NFC^O MO"\'_(D1QG6SGU?QR)G><6F_#_P_:9$;KU-5#]?D2\P$(0J'6, LEC%$88P@ MEBF'/&0L02'F49OW!,%/[L+<5AIYJ,7L9\8=0.AGP5P TCO&^K;YTTY3! M\FZWG\' K\U^.,ASV.MG%#UCJY^[NF=@[/FRBHG^]&4893 S"==(AC&D041@ MD 4ICX3D5#@=;O\XM2SW:U?*'K4KKZY6^4/4ISQ5XQ/+D05C%,GZS5+7BC3+$DEA4F@ M0H@R$6D&22CD-,F2.(MY2)RJ$%F,.34JV8@,9%,^TF0%U9%_?%,^DE;RN_&+ M#?IV1.,9TX$9IX%S(VZ%9AW95TL\@#7B ) GMK$9<53:<8#@D']<;O73,G57 M(551)M*442A,[@U*A( D(0@F:2"(DD1%;EDX9T>:&NF8N @3&M3J WJX*I^( M%;NNFZIK85HO8 [,-J?ZJ0Y23?8B& .U5'VF.K 7U;W45-57!=>/Q9)+*I$ M*NXB3(UM&@V F6B0-SKL93\L&S5Z1[SUF"I; VC("1C<'FICOQ5_+Q=BJ\$@ M87#]X?-F+3D+,++QU!>@8UNJ]Y.N;3!P.C&M%5]2FEHM=49;6:X?ZY\=5*P/ M,<)I2K45QDVKE$!BR"*$H8AY%#(J RR*Z/L]P8S(A\]GKQ2I??7^3SV7QDJ[D_;+X M/HM5%D4QX9!$%$&4A1RR()$0,4D5BQ.52:M0IC//GQH?U2*"2D;0"&E'1N<0 M[.8;#[@,[?IS@L2:-"XH?H(72LE_O5]^_4W?65."_LN."H@I'&3-8,XH1B'(90!$Q I_1\B,P'C.,LRSN,D")T"$<\/-;4/ MN9*TCC?^G1;_D+6[OV^'^@Z(+^DR&MYJ.9T=:.2Z M2Y<4/JZ1=/$.#XY^O1TRQL0'UQB=-_9CFH.B;._7AKTV[IKRPWI5KNA"; J4\UD< M)3P@$D,J6&B2);6I@DS;-IF&0UV"EO";(D+^N*L7:IYXS&WL43FM M%RR'_-;O(6-75:[^9Y J MS8L)$2A-PH1BZI0E.H204V/.2E)@1!VK%G+'!-KN#9]W6@8FV-V,@"^U<%YW MDL-A]^SUA#M$_$&J!E\&V5]M8(NQ>H;5-C5$9/$U-Y[W4Q*^7U;[=%F+4=Z9 M@FKMWYO$Q/?+U=_EZI/DR_N%Z:U6URY^LRPV/S+7A;,@D*$,E(0B2%/C<4^T M(8Q3R-.$RT0*%+LE&HXK_M36@]?E*G^DQK[[LS'T&IOZJ9+?,=9WW'?!;@&9 M[@P/[K \$5ZRHXH;L%6ZB3HQ6NJ?KL!WN0([16\V-?)-[R/04M9C7/.SS)&O M8.EQA1\W OM9)N8HK/MYI+ABL\,NM[]AW>7[S8G,P1[MDS3KM=Z3O5PNJM2\ M-9T;)W@X$U%,XPP3F,0Q@BB)$HA33F FW/MQ82)[K-;-$ M+3B PR"JH=D<^GRGM6JYM6< M2'%ZR[#)-I^A1#$L0@Q%@F.(J"2:'_3?0H'T>X-2D=!TIJF++:WK5UD-[/+Z MMX(?%4FLQMT MW$IE3D <52YSN[MG>QJM"2T?ZLA!DP6[$-O&$6]7\G%72IO%21K(((09%MQQ>]:XPG'4LL;Y ;VWP(]Y'1"M MAS#[:SV 7)B*[3-.(XFCB&H["VDS5^$4DC2D4*19QD(<)4HYA2YWC#4U!FN) M6GU"O"TL^/G]]\24P_.V/SXXT]A[Y MDLHG]LD7;_G_NGO7'KEQ+$WX^_X* ;O8J0*2"XJD)'('6,!5MFMS7[?3:V=/ MHU$? KS:,1V.\(8B7<[^]2^I2]Q#02HHI:IGT':Z4A+/>2@^XN6Z4XGGW@:#F.7>[L)SEV7MO)YUV_(3SYZX,@)RN?=.4$9%< F9+ D%S9#[KA@#NM98T$EES* FHTJ^/^ M/FWX>N.W"AC)^I!1=>S#< /L%_L>+*M3>]'(B?PT7R9JM5CP=>EB*.NDI,"5 MQ5@O!,29R%!6 ,B)_4CD$ &6%LR^&AER2T*3TK1Y(=XLU9_\=6@]&))MU9_U M3?!;KTZP;T<\2K@U_N<@4^XD_J=%(*D@&#$')&Z?C946$LGJ:66*Q.V*X.21 MR,W?4&C&)5QK]=JNDI:?ZQC=.B_QO?ZC^E4YDR[I&2(*-#00$)01(#"'P.02 MR<((S30++CISM=FIK7HZM1CNJB]0G10=^MGQZP3/KT9T:("7]05(NORFNE,B=O8JOD]72QNTJM9)/54R#F]U,I\L.S/I7Z#KO[V!4J.O/ MHWMD][(O^9OO[B1S)S^,\K4;>E>*-'J]UK4X?5718H8P3PLJ-3!4 M$$ $LLM\D:<@%8I!GMM?YUXQ"!UM3(T)MB;62_E_3_X;_!_0_E]J9[7KY+LS M^=\3!._L?W+_:U7/^-/FRVKMDIH3ODG^^W]-<_CO]9_)_WE:ZOI'#.\2]QXF M/STM^9.:;[3ZN8KI>:UEE6_17)96EZ6VG3N8IW=%@0^?V+0YKQ99=]43EJLS M^FO.E#.M'SS+SY3@LI-?L542M97D)A7BU M*T]:&+M6Y247S]2FO'AI/ZK[J,O->BXWS2-;/>I"48GMO,<.]@P0S0Q@F.5 M:,0)U2BG*$B/^FPK4Z.[G9%7E$\#@/0;ZC?#,_!@/T9F@'S$3@@BC?3S;8PZ MUCO=/![MW1?WV"W:J!3A&T UYRP%(B 3,%Y922 M+,N0]S;@Q6:F-N)WHE/[DAJMS0$[0)>!]=B%BP+7X RPTX1HC4QJ*Z/ %+ # M%@6ND;:V/IYYK1)>6?L_(NU2786C<_OI\MWC[2M=]>!@P^CZU;WU]K_I]>;9 M21)N7BW5-OW[W7RIJ[R8&4D%4L+R(X=2 )(J!3AB!9"9%$CD'+*,!@KN7VER M:H396GR75#97JZ0]E0)G=YT)=GEFT!=\WT533$@'7T/=C&8?$7Y/@.*I\%]K M<&P9?D\ SNCP^][9CX)^TTN]Y@O[Z%?JJ^4X%]:[F7_73;9QLZ0PFM!ER]=JW,Q9.; M+S^L:_G+.GGXKTO[U#] 2L4 0DK)' I% M=9@P_L3^XHBK+^M+%OK M7U9+M:MRV,PS($-0I9FK,YTI0) T@!>2@"Q'N, \YRP-6F!VMC8U>FOEG5 MKY2R+U'YJ_WQ8?VX^F,YPY8EA+ 3*Z:+%) TM;Q!E02"I!F7F*F\\"H[U-'& MU#BBR2)N[+Q+G*7NV^UL#DS1\ZY MONC4:=KUY4M[!B+*+UH]+?2#.8R%5*_*4F_*1Z==/&.9A))E.2@@,X H(@&7 M>6;_F0E7-#HS)FA^X-/HU"B@M=DE&AU%#*NDMCOYO;(\< _:JP?\9A*Q<1V8 M,V) &A[;&(!1K#!'GR;'C7@, .$D^#'DWA[! I_FGY=S,Y=NLUM6.Q4N@6FU MF#N%IWHT4)I!E@H#4 ZEVXJ&@ M,[#\9%YG("(*Y=]3 ]?8F1T4[BY.=R4EK MS4 #(#DT^;P$B 'A!G'!'"GN8!]4O@/U6V-VK-@#?VPZ@Q \'C-> M-(*_3P=A"0&W]=PYXN47I[-G_W('C]_YPD6\MV>"BA84*0($Y P0#!'@*33 MS@LQUE1K6:B@C:..QJ;&PI7D;Z4&Z7[8,S=P!ZD+7\\-I$BH#;U_= FP(?:/ M/"")M7W4U=2XNT<>3I]L'OG'>\,P^(&1)P)!^\!GO>VU^WOXI-'V?,\ZL+_3 M>_Z"?A_A.L^]VJ IJV7!\RXQFA*F-27:3MQS.Q0IY(!+C$&N"2S2HL@8"IJ] M=[0UM<%9&QGV&>Z"TN]#' F@@8=MJXM1VYG\7EN:#))I[H%(I"]R5TNC?I,] M7#[^*OO7NMO:RWGM0[>4KWZNEIOYO^LMZ<*+85V+SY8FZYIY,B\JQA,IDP!@% 2&H )1 3+"#604BLQO81#)GJE14EV7\E2' M-Y"-;NPD3\8:#_JA3XFZ"RD.I+\3";]8='>C->-28ASH3F@STF/#J+5<;V9_ MF2_G7Y^^;@4R#,5VN09T6@C@=E'=R;=VQ;P)QY@S++V6;"=/GAK=-<;YL=LI M3MT\=9/W S-.8U?$,Y&+WG;Q@[UICQOLOW:\]L?HFC*VQY-CJR[ M[0_"J>IVP+U]P_'??-7KS_/EY]_6JS\V7]Q4A"^?9X7&0A(C@%U#(?\"QZMEM1_P@:\?UA7OJ$J4[X->5ZN0 MF4;22$Z(72=D!2 I2BTA: &05H+E&F*,@@JW>[0Y-7+X]: :R%8Y-$I1*I\N M\)N81 9V\!/="M-&>O.#*RZP3FJ3:R%.5R6DKA 2MRRR)T01RR-?:W'T,LF> M$)PKE^Q[:U\M\V_?%L][LEB[_;%F-NJ?[I[KHOC?VG?DLJU74$U\\B,7\D MI,/_:-.0O=?W&C_/R'V_76M\O M[1#5Y>:CG0K-5*%EEL$"9$H;5XG, *81!AQ"E7,$[?3$2\Y@-(NG1D7.1F"L MDF_$P^V>I7V=U\W*;\_ON\1YGCC7D];WY&/7 M.S%>4=_0?GKI]OXY"OF&PA^MA&]PP_TWY^K);^G2JE95/J9>NFS,70S! M?B(48H3:J:O1&!!C!&"YF[H:B&FA(8%94+V+H-:G]AW9,[Y.$]PW/]G9W_L\ M,:QO_/?O!D%\A)V\6&#WVM$+!BWBWIY_VZ/O\@7#/WZ*!MK ?+2'UYZE \57>H$2B6^ZVQJ57[SJB/ M_,??YILO7U8+5SOO[6I]?KHW[7?G%]<>AT/A%3AN1#%678Z^9HQ; MK>-&L$YJ>-SZO)[9OTWU:COYLY/!ZA#8M6BYQXE];)YG6&.<<[OVI&FF@:5. M!*@N&%!%FC/BJ@NQ=+99;?C"CT&O-1@T3=LV.R!%NC:2Q<[J:C%4[MG];XFN M+ _,%;X&O!_SQ81S8(9[=X3AFV[4PC.%/:&(E2Y\K;EQOXJ5HL9409;NI# ,&0G9"AE@$*8@X)*2R58TDQZ5:D^>?+4UG6- M<4EMG7^(Z2%_@>%C9[UM5>@Z.&31@L-/>O ?C#H^0OZQH"_ MG2_T^Z\];.1([5,W3L.SSUS30['XE93K M)ZVVDEE+];#YHM>_/JW7596^[3=XIB5$&1<$T,(@0)C3RRR8 4ARI:@T7%/F M,]T.:W:2D^X 85U_?+M']7"H#3S>&YMWTGC6ZJ0R.VGL3O8,'P39 .7B01 > M2<"X15JW2+NES*I"6IXB'4O/.!BQ3EEC_Z>-IVX<[.&!R''XW?VV2S[J4MN; MG"#J:_U=+U95F=6FV5F!B" T-T#E* -$6P87C$A J=0I9$JE&0DYS^IL;6J3 MK];8:D"HG;EAVR+= /OMB42#;6#2/D!LS]*6Q>-MC7@A$FE?I+NM43=%O-P^ MWA'QNZG')/ O=BI9;E9+2T\_YN4,2TH,1@7(C7)D(>U,3T ,!*:*:T6Y*;R" MTL\\>VK4L+,N^=W9%U(SX0@UC_E;?RP&'N\180B8;/6'8Z09U<[ 2).E\QYW MSHB.;AEOVG/>UH.YS85+>E9/;DO#-ZE@*BVH)*0 4F>.A1@"--4/FZYW_.N MG=3PO7!9GU)7,8.9W1S&Q7&\7:V-GF^>UKI*>]"%*)C" M!,Y8 4. 4\(PQ@ M(_)<"97!K)A]UVNQ\JN6-;S)(2-IW_#A!M3.OH#,EM%ZV&/2-+%>&YC_*E>2 M*WDMOS1Y+$ M'R8^E7O7?6M>D"H^+C'N!:GU1/C>"Z+;%\0<,D:TPF?C=5=WY;01[!BQ]-IX MJ![6;ANQW9[KB:_?%JMGK3_I]?>YU!<,7E1OK?WIP7S4OYZM: M&/7=?*GO-_IK.4,R19AF$#">(T",793868@!B,&,92R'@@=MH4:V;VKKF3HV M5'@F:(IS"9H'MSEOD]^=NTGE;V#^5.RWP7.=]7)]/,8\Y7+H[UV[4ZR:JGG? MYAN^<'[=.47]IZ5G7X:O\89!/-8:,;)UXZXQAX'V9(TZ4#/A\M6/\XTK%7V_ M5//O<_7$%]4&IR$LI46!@5U^*D"43@$KL 8*:RPHIZDLO/0J+[8P-2:OC'3Y M%CLS_:6MSV/8S9Y1D!F8_\Z W)4H0[0T.M.'T*89IJ!(2FKBP[R0&3J0 L+9A62CLYIEX)GZ=M36U\ M5[8EJ&=^YQDL_>9&D1 :>)SO=E/NDMI05URL FR '6H/3&*G=IYIZ642.R^[ M?#&ML^.6D16;ZI2$O6SI*LCG\0M?/M1+W-_L(S;E_;*>HLQ25FBHJ (I*9BE M&RDM\:0(:&@H3HG@0K!1A)L"#9\:=WT\FP*:?'9&V__F]'*KC; R4"1WM!=! M042JO!.5Y1H04D# M,3 4*)HS@PL4N1WQ#'E5V&%G&)/CKBM MT%/6JW9^7[FB"3?>6/^3AU;EJX8@L:]*#<($Y+UZ=MM+JWR%FOWG$/OJV1G1 M-+_ZMM^CQGD=BOQV7DJ^^+OFZS=+]=J=Q0E,">04@3S+(""<8B XS@ KD(99 M2GG*O1,C+S4RM0E%FY-0&YHX2Y,W+@C6^ZBT$])NXH\%U, DW0NCL#KI5T#H M5S+]TD/'JYY^Q:V#0NK7KNT1L_-NM?S\J-=?_\+7_] ;+A;ZDY9/ZRK]H%F[ M(YI)C&'J%&41()I30$U& )(TRW*$"LZ]%&4]VYO:\'<6 ]O0UV1G<[(S.B!8 MP@-KC^"7N @.S O.V.3Q(GC7]TMZH1@0,1(7S9$"/G:OY-<=JN76[ECA&?[8 M=$97>#QFO. (?Y\.8AL";NLI;:/+4NN';WK-G<+A.VTG?VTFV/-?E\IROCLB M=5ECTEY:'YC.,,0BQUD!-$D%($YK561*@C1-12H5-YD(TB3L9<7D"-M:]C^W M0LV!0C>]NL%O[3XXN$-S>67_7;+U(*E%^1.F<6W", MI:?3RX9Q179N@>E$>>>FA_68E[H3^P?SM]7Z'W8Q*]TG];.>907!F' ,.%$% M( @6@&<"@YPA*;$E0@F]\C\NMC U*JLBG%8F^<-:>>?*NS5V!DR7S@+I,3_*U"YD,T9 *FCKRR^V#J MUWEASSA4OEY:%BW;BG6OYXLGRYTS33-2<)T"A8QT6;89$&F! $6IL5,Z8[30 M0?&DY]N9&LN]UYMDL2KK^I6RJ7/I[/V?B:HMCE+E\A+J?K.W"%@.3(FMA;NB ME7=)8V7$8,IN&&(%15YH9=S@QFY73X(4KUS>,_R NYBG2NKPO>W[!_.XYLN2 M2_?-J L%SK""+$5%!AC%EC5@3@"W$R1@%X(4"X99JL+*45YMOX>I[,1D5MZ#/5?<"&J#CI#4:LD\KK#8Y[QN@-P,GIH/^=_1CEKZ5] MZ)MR,__*-[J<.790&>:@,)P"0K"= MWA>NZEF=BY=.^]VQZVQ%0K'27VMX >,'$9=_?$?NG3;SG5<4SK+)"(< MDPQDTNT#$\Z *#*7@:M5+I71F?:2B1["N*D17CW%7U4!8LGWVE2WA=(5WSA\ M#WJNJ5ZH7X9>?=T>T5KK>C0>3B=$I6W7!5#,J,&89XP 2*&=DV*EG0"M 04DE$@NA21! M"2]76YP:-;?F.3$69U\8'U\'V(]DH\(V,'.VMB8_M=;^[,+UMT!^N )D,!-Z M@Q.)WJZW-RIG>;M_3$3^-_9CEU?J/Y_*NBSLX^J54G/'KU1Q=_G-#R&:U MKO5X]GR*1\-C 1^)Q0%5X"(M7"\U,RXB\ KSIXLZ*Y=?W,AU2:I: :+ MU! A,L"4T(#HW*[&M*:@H#HW@DA"4=_2J4T305.4T8JEMG5P%J$5ASJP]&. MVQ :>.SO&7?75F4:I/KID>OQZYVV#;Q4A=,C!SMJFAY?.4 F25NX^?63=@F$ MCW^L9A+FC!'(@#"( V((!BQ5.>!I::3&%7I$A@0@!A4@,& M ??!ZU1?[3'O);!]IM%8M\Y4/R.!+R(3G2P_; 6$G3\7LB,)VZ/XS= M^=4]GCMBPG5_KP\SL&]XSBWU[QZ6NE$5@"K'A6$:Z-1@^RG!*6 :YT!#0@J3 M0H6YEQ[HA>=/[9NQ&QC6Q#[%WW;(>;#\;7@,3.('4/31K#B#29^B>+VP&;LP M7N?KTK,VWHGC?O7Q=K>]0(V\$YO/U\D[O2Q.3N$OO)S+F918IUQ0X+0@ $%V M(DQS5 !&E;JR"<4SMY!L@EKO/W6]C>C.##?G$]O0EI>6KTT=I>!;BO*IW0>>7& M7;+4GGHRX?![S)&& G5@-MGB6=O=EH%)K.6-#.N^[\J%[M6+IA?;#KG- %/7"\J5X?/P\F@;T><$/^Q4F@ MQ&EDL#@1G?WQ;;ZN+F[ER5.)&(,%,-Q 0+1!@#.M@$8F150QE4(3G'P1P[*I M?4<.,B_TUMC^R1=1NL]OAOHBG3+P=RB&D/BN%P?)N8B)>,R$BRAVC9]M$1/. MLZD641OH2>SRBU9/3C-@6U&O>G@M%OYN6YV0YTHKRB1 U,[Q"14I8$0(((3B M'!N)"N6EW!W8[N1(N3';9;X?&KXM$]"_HJ1O7WAR<'R$AV;82."&DV<85+&H MT;/5<8DO#(H36@N\?808)=M;>D840P)G%!CH#E\PS !72 $NH4JY,83X';[T MMF!J1&;?QFS .*4*=#^>&A3*H8_G>\4J.2=>*%II'[^7B%>JVI]NQ-(^/#?% M+!T\J,?6Z\=Y^8_2+N7_:GU<;_A\Z0(\:UT=)ZM3J>K,6.&(2RF0ZTJ^6U+ MG9";_8\:$HVP9\DW[Q:G1F*5S=66U('5 ?M_7CA[[*W&1F]@WJJ!>W4,7)!T M4T\P S918X,ZTN;I[JU\VC<\UO9H""J=VZ)>#QIO.S3$KX-MT* ;>RIEK:JJ M696*WOWRPWKUV;XPY6_K55G.$*:IY=\_&\<8"OL+WSCBDP]/SK)E-T4')$BY7G&@3 % B25 M!E"'UB-_8 M)>'F^952;FK7_.7.(M","PPQMBR8:COO(C)'@/*< "&%8A+E,*5>YP*=K4R- M[&I#D\;$N_:'I#I;Z\JD#0"VF[NBP34P._5&*J@V\54D>A4GOOS4T:H37W5L MOSSQ]8O[S9#LDDYJKK]T,K?5 M)WY6,)F23" @[90($"4DH )2P#'.4BBXPF%1#S?8,C42:5U)7)7WCEC\,Z$[0:V_]QJ2C+FO9&*,K?J$A;O/[<:21/'[>JN\,CN1.T<" MLU8'ZF^_N=L$>G%@3KPJF%M;G/SJT8'A.;7#PALK*W<@*\?-ZQT6ZI/,X(&; MZYEZX!*:,8%SG\7'Z:.GMEYHK?,;T6>@ZA[)MP$P\ AN M#;NNQ^4]3B_[VS4^[5U[8]/^:S.X@_?[297?C.O7G*-@[2$=&*_4[C'4]4J1?2;E^LK;9 M18B]9"[YP@4Z-#\V0?;EK*!$H )SD$N, !$9!#17")@4,5PHE'/C+TOIU>34 M/JF-T,G409X=9%.'W=EO2;?E_]?S4BY6I?M6 M;+/UM!$LPTR#+$\M8Q=VM44-(B 3IBB@5+K(@I(BNQJ;&E?O)I3)GK4^"7WA M./LM0V*A-S O]P(+N@TBD:7-G4Z-.9GVMW3CT!:Y=N&CV:<:DT( MRH#&6 !"E$OC21G@B HJ!*692&=+_=G./=6C/W4<->/UOK/Z?3]I;+AW?RO6 MW*LV^C&4?K30!YF1Y<+?7$$C>.!?\#G26#]^^JC#^X)KQR/ZTF5]H\:KYUDV MF'_7=EG(V_JW B$L"$P!*S"U:S:H@1W#&9 9@1"J-->95]61:PU-[>O?1$3O M&>NVF?C5^KEAZ'8/\)B8#3S2^\+5(WZ\&XL;0L@O/'CD*/)N]TX#R:])//*!2H:ZN USM^N^UE_L-,J2:"T,\]?E6M?AU?][M7 !E[_Q^?+=JBP? MEI^T;-)K7ZWGI?W5:_O/Y>?*Y) M=5$?17+UGT]U2F5@G,Y0KP0I\H+G% *=4@X(R@O N5^M(L530K.,6 (HX ML9,(P"A&(--:()Q#1C/4K^Y+=\-3FR.TUMXEE;T5^V\M;H3)>I=[N=('G@NJ M 9 =F*EO _6&,B]^"$6O\W*EV1B M<4T^ZO9 DY-,9Q!+('*H 2&& I9C^[W/"#)2BYRRH.6/?]-3(ZM?O[@HKM+M M0NQD8GE9ZF;:NFB4]KQK)?3H#=]SI"$P'OR(J38V^:DU^V<']4["LC%]D./G M<,2B'5!Y-SSRV54H(*?'6L%/Z$=F'^WB<3V7&ZU^Y>47%U=C_W)T^=TN1Y8N MP_[69 M/86FJJCS[>2"I33CR.0 Z=1)6Z26"PEF0.=,T,QPD=&@9*S#QT^-W=K:ESVC M (^P\^.I_H@,?>KO#4:X -)9GV/I%AT^?%RYH;..G:@$G;^J1VJ&70G**HFD M/D)K/I"%1K)0!0:& *S4 ,,XQY';D(N6UE72YB:D-W*V1S>EP0%+ M>0B[QVX<8(;>\SG"Y'JFMB\X 1D2-X,T4D:$]PL4EO?0Z7YGGL/Y.\?+:^BT M_""/H?O*ONLW5UY.JS=\[92EVA,#L1H%]#T74?=BM' /-<:F+06#B!)T0U" MM#7/V49&7LUT.7JZ3NF\>D"IV_>K*D! JRI5MJS$_?9_[W04WZ\V?]>;G<)B M%7/4Y,[."H-HAC([*4J- :20'-",V86-EDH11@U#\85O;[5Z:LSDSE9;.^NH MR$835^[+!O3*EACG+?![Q#EI?[M)GO4FV?G9 MRNF.+*$;JTO&%-2]V>;IR>O&ZH9>8KO1&N^Q.G?[M-%2 M;U=K%RME!\IZXXQPALUR8I?L68H!4D(#(E,*.$T+._7-"XY9GBI)?61ZXY@3 M]/D90=)W:US%.P'+VML[QF-_8%2XQSB%.#F!<'H,1^%_N^@_)^Y3%M=+"6(:#!W M[I[RWXLUQD]UKXVLQ #KY+;)* >=;_?"FY2O?FOIN+7O"OV M5:E!^#-(])WOMLF+\!V9_2\BLW>^,\83TKO0?K\/7YM>\%%7._:/JW?V6_NY MLO63WFP6E:FS3"HC>&Z U.Z(E@H#N,HEX*@@F=._Y7E07(57JU/;/JQ2@-:U MQ:Z,PV)KLYV:MD:'?7?\T/?[:$3'=&#&W\NH2C[N4-U9G7RZCFHP1P>A%(E@ M_=H+@J1K,M1OZ)OZTJ=9N7L67STTH?C69VA-CV D:DB)E M.2J8*S!LU]UV)@,H5@AH)##5B"E$ _-_ BV8&I'L'$@:#^ZVJ2F5$_L:)?U5 M)L-[RF^B,RC^ S-2?.A[) KUA"]:OE!H^R.G#?6$YS1[J.^#^A&C;>6KG8"Y MP\ F8BJ5U%"8(@ ALZLVJ M M2@ ,904@A=4L*"@D9,6ID9LM8'__;^F.?SW MRLPPPCI%T(^0;L)EZ*.PRK9:EFJ 2+.+KD_ZRD;$?F4\ M#RVF\"*,>$IQ-M2L>0%4DP.Y+8R]K=!>BUB"Z\$5L.U]( M*6,@N"]+:PS58)]R.TK-71O<0JVY:XDOWI0;2W^M_L<[ESNO9I)#G682@HSP M'!"&W!D"D4 PI(U=BQO!O6:C0:U.[2.RLSNQ7<;=1\'I/26ZLCWYUAB?+"KK M0XK%^'9#-YD/!N[ Q+R'J[,Y>3")LSJIS4Y:NY-W@^$:4H=G 'S'*L43]/Y& MJ\<3"%AW21[?AXU8E2?0O\/"/*$WCQPA=2B;NQ_$5=5]FS&&J4@1 XQ( TBF M&*"9Y$! HZ3*,R.*,,GN@0R=VJ>D29-=:R>K40DY'01%?G8VCQ0%=:V+/1<0 M$^BX$=2)-GG[QT"-,U,_\<(4N>8$<+4?)MK^>7 MQGV[=BJ7&@N8PI0!I(L4$)%"('@N "+<_B.G#*8BZ/MP\/C)L7IK74_MT$/L M/(FW-R)#TZ4W&.'$=M;G6'1T^/!Q2>2L8R=#__Q5/4^>S@;O?_JR6F\>]?KK M[B"LG"F:<8$+!B!2&2"DH(!+*@%2-!49M[])O4HXA3<]M8'NK+X[G^U2.O.! M->+KOK!\X%F6?Y]X'G(-@O30IU\5R,>98'<5RI7IP-F>W'N@''XT%@Q8K#,S M_X;'/4P+!N3DE"W\"=-.![I:"'W&1 XSCA0HE?$4">[@L836.0/U?\OO2L0W:\_QS;"4-WY4JE1_@;V./>\MWVQ M=)4N]^4WFK Q*# 36!# E*& <*$ ASP#,B\R3A1'&=?>1YT=#4WM&[HU]2#2 M)43>L@M5CY/+2%@-_&VY %,?QH$:8P,)83 M 8$*VF4-RH#A!%,#&9&0^B9Q76AC:N38FIEL[4QJ0_WSMBZAVLR(PLF$Y#=W:G.FK2Q1HB]?;/;[&4!-N45;UG6UO:%4%7&SXCZ;RL_V7 MT?/-D[OJ-B6BT,X+V.8;HB\F$GO?=%#EEE[4O>-2O_?\3![$HE$JB+Q]UA/7 MF#M=H2:,ORG5$Z2S^T=]G]6/4]\^K9?5T'ZU5&_G/ZI!WGR\A4PYX:D&TA [ M\<$( B$U!9SK0EE.S0H8E&5YN:FI382VEM;TU]@:QG<=P/JQ6ARX!N:N0Z1: M,P>8-UU'(Q+C=#0T*J]<=_B8/3SNZ,<1KZI"JK]6\X/-5M, I@6F!43 LD0* M"-,:V/\I@/("%864NZ+^PWW;2W8*KWB75,Z^?F]-;]N9X8,0RB7 M$IC4:;U6!T(9AB!+B. ZOGZ<$!6U@?EA M5RJZ,O8NV9I;5;%H#(['%=[81.*-Z^V-RB'>[A_SB?^-8=Q2KC>SCVY%^^K' MO)QE!<5&P!1HS04@AC! )32@R"C+%55YD7L%RQX\=6H* R]KW$> #LWL'9&F!><];MK/-L;]L:R_==N'!\^:Y2Q M>M;\=CR>_V6_[_DY$EH M:VKC\]WM*K==R/I]PR/A-?!(/BM=N]4$B??5]D CTO>ZJZ51O]0>+A]_HWUN MB9;OZ_IO^^_%D]O ?/-#?G&$]I%O]!MCM%WZ MYK)@+$[U)YHWYR4^J M<>!G%W\KXQWLCOAZ^!\>3[/31SB@/I<"M*>Y55]R),1U>D>-0G*_?7E:('Z^ M2[98)"T8B4,CJ>$8-*EHA&X<+C%I2.-?.KEIA([Q2) :PXJ>$V[W>'=N=__U MVWKUO?I ;R.HI7&BS0@@S.S25U $.+)+7Z(SC07A&*&@/-&.MB8WX6Y-3>9[ MM@;.N#N@]9QQQP%LZ!GW%JM],PCON6 M#DS7K;%):VWRTSZ2C<&7(^:":=L?G4CL[='@J"3N#\ QEP?JS?=W:<]I9SC*-#,% 2IE61:0!8[ EF3R(J,9%'Z[KMXM M3I#0GAT31 V#JUO_T>="(VI\!?AWJ?H;5F-W&P=O%ZH^MBM0L2XE@!8,4"P9*&"1YCFB F.OC.?@EJ=& MV97A=\E2!TX(_:'VFQ<. N# 9%VK8^QB8'96-QNXSO!D:WG$,)A0L&*%PWBW M.VY83"@<)^$QP0_H7_)(K^6<+SYPVUJSP:4Y1;E=[0-5:&RYB.2 YQD"I%!" M84/LI+((+7MTTLK4>&=G9/+-61E>^>@42,^3I5OA&?H :(=,9>! 59 N0A"Q M$M)I&Z-70[KHYKF*2)/_T\\S)*C)7)XBS*0+QTDU MX!DS@$*!H=!$VYE'6#'8HQ:F-LYK(Y/&RJ0R,[%VAA9_/0:R>ZQ'@6?@<1Z, M3(\BKQ>\OZ&XZ_$31R[J>L&ATV*NERZ\4>*Y5G1RB7JKI3LLJ.(X$9,DH[D! M&G,WJ#D"G-L_,#$"2ZRHO:"7XO.YUB8WP&O5N)V1/06@SR+K]T6/AM?0(_X8 MJF@QLT%(Q!:-/MO6RVA(=[E]45*Z\Z:IZ;&^7U6BL?JZ6-S'U6+Q=K5V3YU) M#5.H#0(H,]HN,>Q/7# *W'8U))E=8:03467MY=_4./%&0Q]&]76D,?O7Y M\[H*/+FWJZ3YLIS+RKJ="(#(F"F@!)"F!I 4,D A-4 )1DQ*#32(SZR/8N5U MECVPN2&LOF_T@(>-K<')UN*0;_XH?>QQ>#ZA?AOE:RP\O\;BW-=X^[V]V/D^ MW]7QWX. H_\)O0\C10V,\EY$BC@8J71T#P(D1BKS? D_UUR MXJ^V[4?[@-J=<'9_E&.!-/#'-!B?(&V :P#<(!5P\=&C*0=<4K[,D1-H7B' @L)2 9+0#/4PJP82DB*4MEKGJH MLMY@DM>PF+8X:Z G-W1O3$2>M4TH'$V7-0*NL>32;K!D7%&UVR$[ MD5Z+\,B1#XV:V=^;'RY^I70%4H_VH9K?Z _KN=0SD[,L9\R # MD2;K@@"F8 M6:9F+%40(Z*#9-Y&LGMJL\ ]LQ/+X:["^;W@HV?S/3]_\HM63PO] M8*[:6UXRN*XB+Y2AN.!VV<&X 81(# 3'R$D8TSSC*4Y3%/2!BV79U#YAK6/N MV^6STUEV;G5>+7H_<+=[?LI>HC.'_EB=]&/WAZOL_')=[[G)#:<)Q^,Z WT...N#ME_72VKK>LGOM@MN5ME&&D,T5Q(P"2M@NDIH)(7 M($\AAYIC3/TJ6?@U-S7RKD-]]BS>VY0(R;2^CK/'27%4] 9FRT[@^A0UO8Y@ MP!EK5"1'.B6M$95[B*YV5L=*J/8&IO. \OI3QCMB]/;HX)#0_Z[>28K?UOJ+ MY?KY=Z>FMOJJ/ZP6<_E<__FH?VQ^L2[\8V:!S0B%.&I$?&!W\F[EJW,1#+C?!'<(& =FY$,$:YOODMK>Y/?F;V=X M4ED>-Q,R"*QXR9%^S8Z=+QD$QID4RK#[>VX4Z,_NFU87A)TO/Y\?+,P4B&DI M 36$ T(I HQ" [)"$%YPJ@H5M@G@T^K4J*DQNCI1_$VO/J_YMR^5A\V5+K8U M-0XZ,+5T6U2UK8DSMF*F!V/ +]S>)'7RZ8O6]:]")U&7P?>=-T6!=/"ITIZ5 M%4YW^WB.-6NZ"E6TB=+EED:>&UUU^70Z=/V6@2(%+N[*;4]TOLV; 7F_K'6T M.T^)A2J8D9@"B24!),LA$)"E0.8II"CGC*L@^AK;@:EQ8FO<2+$"L5^'2$$# M+]C)$X@>Z#Z$.0@?V,+@! MK(*842#!0/XX541#;_&F%%@S4.<$Q!D/9$:[, M]+K9%'\[+^U2^.^:K]_:_U+.D"!04FI JJ2;HYL"L((QH(P21AO[Y2N\:CAT MM#&U[U!K9E+;F3A#D\I2?WVF2W!V?R0B@30PC_? )TBEZ0H"O72:+CUS-*6F M*T[M:S5=N[3'L?%?Y@M=;E9+_?C'JCE]RXLTI41H (W* 3&".+VU N"<%$;8 M44^UU\"^\/RI#>JMA8DU,> 8\PQR'B>_M^$Q\/@]@*+/T>X93 +.RL]K+CG8>S9VX;[S3VLLT'QZ\=E_5;S+_7&Z]M)/]Q:NE>J6^SI?SL@IB M^*[?_' G.WHF.!9$&&IGYE@#DNL4")-1H#)D*$]YS@L6,LZOM#>U0=^86\4N M\0.#PP;^-9C]6" B> -3PCYNA[8FC;'QZ,$3E4A<<:VU48G#T_5C%O&]K>>Z MHRSU9K=UEE-E.$$I2+., +OLYX!!HH!FF#&80:U-D"#]X>.G1ABU=8&+B$/ M/!<-O6$8>I%0&3;(UN!YGV.M 0X?/NZ<_ZQC)W/\\U?UWAU8/2TWY0?^[-)W M+1=4V6;-.N+=G(OYHJZ,UZQE#4JYQFD!M,KLC!\S#@0Q#.@\@YAD5(G <1QH MP.1&>K,8UC5IUEINJSH]LK8X6>R<"-Y6".L<[XV&P2 ??NNA,CUI;*^CR2NT MVX[8LW^8_8A>V,7;H0AK?NP]BU[@G-G%Z/>?]41Q((17!1*)#G2 *B M( &",^(.='.3(00)\M(O&-WRJ;'N1VO;>BY=,&RY6 M_(E?BF,OAGLU?M&?Y\NE>P-$DV'T)W@3",("%2D'A77/T0$!5-@E$M:P$(1J M*C1OWH0W2_6G?P]:'X9["][4)/ G>@4\=X"GV*E#;RR_1.&L&H4)B#/V[;B7 MEF<,MGM:612QN^,%:E,=&= CM/I-N9E_=8K(?RVU>5J\F]L'/YAZ Z*2^]I3 M7R@DAUQ!8.*$K<& M/BWX.E'S4BY6Y=.Z$INT7)/H;5<\U5VQ:%]L7KD62_\K'+[.6/. QXT7@Q[N MXT%L>H_;;XS]>#"?W(+;*>-;.JT_1MLSB]08Q;AE?9QANZ E4 .60F0[0TN1 M26-@6#"95ZN3^P1LXR"<..N>V?_63D-#J\*%=4)@*$DL:$>++KD!U?XQ)SXH MQ0Y#Z6SS92)3?&"X&*SB=7-/>GH2Y5S-["YYJ1,"&+2RU-CH9X(P_M# SDF8MH>G)+#(R&YI-]>"QW M6.MB\L8U!&)QQ<5VQN6':^Z><,+5&_KQP+;L\B_/VQ__]URO[8.^/+_3WRT* M[C6&2F.C9 J09@H0[(+>,RQ SI'2FF6BX"J$%/R:G1I#[-5_WQI;':B^?_4? M883A";L?>\0'BK\^3>D87?N?SA=N&M&I'SZ^E157/QMO2K+OR[7FB_F_]3*2:K_HLUJK1_YCQE5"-., MYH 97@!"&+=T2#&P_Q%IF1F99;Q/C=D8QGD-Z/&KS58F)SN;*Y'ZX/##*+WG M1Z7C=<9(.E+6_F3GP%VR=1!88X%S\2[9-)"&34A_=C[ZT Q#M7%?FCD^9[,/:341TOS 2#@G&D 60X!21' M.:","E"0'.O4SE?M_X?,5#M;F]JDM#(/K QX*G5SZA7&K=W8^G%F-,0&YL*= M9DQEZ%VR1<\:6Q_?QB,W+U BD59W6Z.2D9?;QR3C=U,_\K"33*FU*M]:4^_+ M\LF%X=TO+7OQQ8;22E,7"BT1 I98%-!4%T9 C&06 M5)W:N^6ID4IK>.*ZUR["*I.356.MVZRN0QC#F,:_(_Q89Q!X!V:@0V1;JY/& M[*2V.VD-CT=&P5A%(B;_=D =F#B M>O7PZWWR:K-9S\73IHIOVZR2#[Q**[PJ;MHGN2T,H7A9;9[MCIW.%@;'F3RV MP ?$3&";22&TEH8!B6D&"(,IH#3/ )=8$$,HTS@L&NML,U,CHNHHN:E6+O>S M!?05Q8D0:/T8YW; !J:7LQD3NQ#T*B%"NC."Z&H=W= ,FKLPA42#BW$1W5?W MHX?[K]_X?%U%8*U?S\MOJY(O'LR[E5WW61Y2=;3H235%FB/*W/$C90(0(HW] M24N@4\-U44"1D2R$//H8,35JV?G@%F/.=E 9'Q30?U.O^/'.T%@/S$K[,*^3 MUH&SD(]3_>P6/"-162\31B6Z6T ZIL&;GM4CS\GRA@M'_>9:;-84!9%9RE$. M,"MR5QL& RI=P6N>ZXQ#JC2$WOE,I\^?&K79QZ_6;AC4D4M?^?+)N&KCU44 :F!>LL8E6^OZU)8X@TE -M%MV(R4->0PVKXNL1*!+GO> MF?!SYK;Q$GLNVWR0P--QVPV9FY&H)99H2E( M(=2 %*( E.4&:$JI1%DA#0D*6!O9_JGQ<&LPX$V-O\_.9*"LS8EQ<:;?JSC3 M;>%(-RM:U9[7EXY583+R:W3+@GH2+\>(*_6>&@A;E8,:A<[*DM4EB0,CV44W M3T ,X;9^?&E)A)[63V"_8O"NB2:/<*,9?18/VBY'].%9>O7'^]7F[WIC[;?& MR9UNV?/CZA?]@<_51_V5SY>VE0>S*XNL^IZ:N_/AL'0Z9V\=]"WS62B_6MT.OLYIN/8D;JOY*K'O) MWUWP^JY;W^VZ]7&5_**3#U6W?MSOUKV"GB_7K2'+O1?KWK&6BB_6S8&KST$Z MHGOE&K?)$5>]@V!UN&(>IHG^5:4?[6RBG+NQ\E%_6ZTW,XH1AEFN@)9%"@@7 MS)540D"D!+*<*I'F7BJ?78U,[5.\K9N\,S2I+0VO*WT":/?',!9, W_5>B#4 MJ[+T)0AN*BU]\M#1:TM?F+UX8/\G<6\\6'+ZNE;F0:J=0T4Q !AA4# M)"\,8 ))@ 1'!PW6DX>--D@ON;$_."]>TS.^O%[SEX^K5_+_/ M+=5V6WW&38YXFKM0AFI9#040$$N02IT5PNB@7>,S7HR?\=GDCHSM2B'ECM-M7:,Q.6KOODLKRNPKE M-U=1#@\S#P8L5IRY?\/C!IH' W(2:1[^A)[G=?*+5D^5!L[9+<\JG+'9U&SR MLY^/%"E%JE(B& *Y740"4FC+;P9"D,LBTQ(K"@L>= 1WLTE3F\BT'CG*9Y\C=HG(QYFG0T[K1VYVW9*B+AK^&%4-&AC MG2_=;M"X1T;1 #PY!8KWY!M3H.MH?9?$,BO2/$>&9D#:620@&+F(!UV G FH MD,DU,FRV66WXPH]NS[01Q)_;EH9<_I1-[EQSU&+Q[IGOO >D'_/=",_ 5+;; MO*[-2WYR!EX.MNB?SWSJ?NPLYKT67B9W^=3%BQG+9R[M-\(_ZE([T2\[I7OM M9+]6U:2NR7=H@O2,+HB=9'% C+03+)I!P)2=9:4R@Q!EE L8%./DT>;49E"M MR=421NV,#F,!'[#]6"$RA .SQ %Z>_:V>34#Y/(% !2)1WQ:')57 B XYIF0 M6_OQSIO2^O+':_UM5=3B?=>MXX)Z_ MJ*]\YQ]-)4H[X?BP7BWMC[):H3:Y)\?96<(0H]Q&3&9$!@C/%:#&,, X*@B3 MT.1A6N.A!DQMH'_4LEK:;WU(#IT(E?$,[ X_=A@2Y($)Q)I^&=QQ4N/ZHA=- MNS.P^9&5._N!HGUR'_H M3!0TIQK) BB$W:"G#%!H![T[-L=93C$V0542>MHQ-6;8/TQR(MK5YJCUI,Z] M.5'K<0&)J^5!R:*^9TQAW1=ZL#18IPQ]FK37'ZT/N_ZX2RH_ZIV7VI.13I-Z MX1G]""G,BA7#HGZ/Z[E_?*B:^2 V?+YT[/WFA_SB3C3?KM9'P D)0 B@QUY?)RF!=Y9E20QLH-MDR-9%MIQK66J\_+.EK6 MCN_UK;J[MW27Y\[T.)TP]([UB41OTGKB$D=;7Q*S6A\G<.S2-"+N9M\.:JQ= M[ALL&7?W^W;(3G;%(SRRIX354J[=\U[K^N_[Y8>U=KE[K[71Z[56S=:\)?E* M::]6B)FA#*<:"FJGK"D%!%,.!",0I&F1":F05@4-B_SL9XC7P!XW"K2VNA7% M*ZOYT:K2[91/ZTI?L@^]]NPG/V8=$/N1A*T:!Y*?6A=^KK+PF[YH#P-=5]02 MJE=TQ<*%K&Y",):453\CQA6SN@FH$SFKVY[6CS+K=6>U[*PFP>7#TZ;>F,O6LDU9/5 MSMXPQNN$V8_78H$W,'OM;V3GTD[NRO*U+N5Z7L586GYR2^GRP5C^*ML,\;T-0Y225" %LBQE@&BI M@,@$ 2*5AD.N&,N]-//ZFS UKGE8?^;+^3\K(\-XI0?\?FPS+*@#K(>7[BB$I^^:+WY MJ"OI]M?S4BY6Y=-ZKSXH1T;E+,4 8IH"DN4:L%0BP#*,D) %*HJ@\U"_9J?& M;HW5265VTMB=[!GN4S#TEF[P9+SHX [-U()AB49E?H^/25Q 0)Y05 M=O//3RT4Z/<'Y^J<72PQKS#_]/EU_^>GO&5?_ M^*DL%R<__7VQ_,?T6P#XM\T_>K'X^GTY_?QE_9-@0MS^Z?*? _N;C^D+G@28SE?K,$]U M@=7TGU>;;[Y9I+#>R/R'=/WTX&_4O\'%KT']%G !DO_UCU7^R[_]TT\_G8EC MN9CA!RP_U?_^]N'UC27_L?Q.Q,WB=/'7M#CYN?[*SR\6! @B=O./U]^_XK_^ M934]^3K#B^]]66+YU[_4?PI5J\Q(5I?\/\_^X<]7*W]=XHK LN'T#7WC_-_7 M5?:A O]8XSSC&6\7:\P6Z<8OS:ID%Y?_J.(%::_?EY\^YD^^.\^T>].I$DV:<- D^B);!; L6Q "QLQR&*"TP>1?7VU MFU1?U^BS9?IILU&8)LJ_M?!6.!#]X^ 0>78"B?>XG"[R M+_/\DH[@B-0%)-,QJF 22:4)(&XLNQ4<9/]PV%^6G8#A MTS+,5],J^'- !\X1?=+ F0N@K"*)A*0@)6:]+#&5>-BA]M#*6T%"]0^)@R0Z M,BI^F:^GZ^^OIC-\>WH2<3E)04M$5\!'28@VG"R;8PC:.B8Q8G)<'H2&VRMN MA0+=+PH.DF 7VO^ GZ=5"//UVW""$^-B":B12&=$?T'R>;PW%"3"6!W)07:%-D$T))_(&H=)"MEV Y%G.I(+5 M^7_>3.?()XI.Q(0Q //>@_*$^:")$XJV4W)>.L5% X#<,!ZM4>0N<2'H.$R&0_ I @9!(7=VC#7Q3>]??3MT=)SK;";: MGB#R?E'OB/[?Z=>-4RT<#8!>!2I)'1! MLT/ *)4$8!(LAJ^0#T^PP^__8ZMMAHON,9 /1=@&1UW/Z-!+']!N^#.MPSM8D M!^%9D PTMW2^L4P1L?8)F+2*I"1M;I)BN'_U[2#2?5ZR@6B[@$B]U5V^H'#X M\V+Y?1(TUTIJDD2JL4[9V+_"@:7,LA7&8SKL!+EGT>VJJ+I/1^XOR"YP\/$D MS&;/3U?3.07 -6UPT7WJ\7#!=H&/CU]P-KN@OI"'+*1@X%0BB3!KP//@P$:N9; 9HSDL MQ71WS>W0T'VF<6\Q=@$"(ORD5G4LTC\^?B&YK=Z=KNN#CAI.3:3SSK%Z![>Y MMI>)^.+)@\_(K6'91]?BGN(Q&K8#2UPT7$FLXU0^W M MB(UEF+V>9_SC_\;O$R^T??S+&%BWEKV>T0T7\> M\P!ACGV5?990N[)T%^^1%)?U'B80F".G/P*!.7H!##D7:+62KAQVK?W RMMA MHN/$91.1=G+?^> MUU?=[K5?QVG+@T79# K_\O,=&;ZA;QSR7)\LWGR%F;Y8+6;37/LR/ ^SVG* M(F]'!W8(.!T!9]#^#K95,Q5%^-=>36= MTZI3\C,69T\"KY H(F>B"$@FD;-!9PTX730D[ISVV1!X'GN$7\(J;I!RONC9 M9L39>G7QG:M=N0M=^]J;BS6>K58DWTLNLPJRU-8<'#'1%F&^]N\7"Z2?WY47O)1-!&6<>(B:3HF,TV00Q* M@5/",TL<1/W8";4_9FX1,BYT#M'LO2 Y1,P=8.5%6'UY-L_U/[_\U^GT6Y@1 M,ZMGZQ=AN?P^G7_^CS [Q4G &*SG&FP4#)3@Y*];[,P)4XJA.I2M#=5N)([3=&4XV VIH0X ^'Z)7\,T__+'U^J^TOYZ MM_Y"P,T>QG0,NTMW?VAL:# MY'= M67S%Y?K[>PJ1UP3V>J1_K6'+6UQ/N(W9%,Z!:4V>9[$%HI 63.@=V)8WB_GG3[@\>3W_AJMU96(U"3RB9%Z!U.0!*DP: M@G8"=(Q>BLB2?K0,:A_CBAFB"GG=A[P-"5 M'_9V,4_GYRU+@3SY$H@)3TR@Y> B.LUX+R'C-"\; C,'B[D# MK)S1/^$J6A:3ARS#IL^% .\4 I?*QQ)44>ZQ%QS[N[KC-#$;+(&XDR [\&K? M3$.BL:A,,I*!RYN*H,*!?"P-B5"NF;,$ M^=:QT+:TC>OM#GY],8B*.K \U_BZ'63F&(I%]"!5;9^AN(5 0@.5O+)1)&MT MZZ/J86K&34L/H_V'(7:(*CH U;.4:E? U?OPO:9 +U_18.AUFZ)QC[V!H-10"1U ZM;&N$R1I[0\)6+N MB'""/@F*+,E=]*KVC:KC5U)PX(,T E61\M&^X@WLU ]I'#=9=!P+UE91'0#Q M'@Y"4IX96Z"PVH:?HP.*6QU([XQ.V66%K2]F]P338/FC@FSD>M2U![6OCLE$0O1.U:7MRZK&F( U/PQT32\5)DFM"+!%'*S0BT##Z&")G69T%HC1P;H^D>,L:N]&^C MX;MU: >)NP/$7&O,<$:_8A8#I_BC<%US9UJ#0X.@C1&QT+[*K+4O=)N&L:]5 M!L'*08+N "C//ZT0/!IH78>T!/2J>KZ3>L Y9. M\,UBM7J+ZW?E4_AC4HRR*:(%&14CN9D 3D<#(3!,%"%@RJW+TW8D<5QO>RBT M#:BF#E#X ==A.L?\2UC.*7!876/W)99IFJXGVCJ*2#D#7FK'9.DSN$#.9!#D M0FI4W+K6Z:4?4S6N#SX0UAHKHP-XW174)-4^1J%$,#+2!N'<0/26 \O6.42R MU+[UW=U=*L:M=!H(/@<*NX/,TH]BVXEDQ1'-#$3A#I2SG@PK"8KGPI,UJ)P8 ML!CE7IK&A=*QIL'QO&V6O_B9L)$Y+UN^5FV;P)B=_C MCIP MRVYR==9^]-GI^LMB.?UOS)-0K"EU8F\MD8<:.D,H(H/5P7+R'T((C[5P/!QL MMRD:._UU5) =I(Y.P?5ZM3HE3JPA7KS*@*)F@FLKR^"D!XJ*:<M%=,7UNZ<\Q@".N8%E%P;N&IEP#-C"!GHI"M!2-,ZT?H(.6.G MR(Z'K8,4T2.F+H[YZ,DSE 48;1(RPW36QY@E2"D=2L>497EH/.W@:C5OP3T> MEO900(\XNC&10L;DM(X@E*\^8TAD8ED&8[A-P4NC<^N:F8.'@#1OX3T>HO95 MQ1-KXWLIV-6BG-=7TT]#+6R\=NU:+US;]_C=9^TAL[$'RZ)1=O;LDON2FDM\ M>^:Y+,6#\8GP38^O4@,>-F6EN@X,$7% ?)O8.3\P/I@@BH'49?XC>< M+39]LJ,\2M"X0&JD]#NE$ZTT MT &<_H9SDM&,>'F63Z;S:95/G45[P0YY$:Q8H<"DA!2?) X.-8,<$WF;10:& MK=.H/R!IW 3],)!JJ84.0/6&O-//&Y5\Q/5ZAM?WA\U6\^A)0KYV[\NFU$ES M'GB2SA26\?&I?ON553Q(SKB)^6' U$KZ'0#ICH F++!DT03P*4CB(GKP7#&0 MEKDH?9+*MG[T=8>(<5/NPX#F,$EW4,]URPD:N&TJJ-PK3%D-KT%+Y*% ME$7*/&K-W6"].Z[(&/? &M29WE/6'<#E[6*^N,G%13_K"P$)BTD&4S,I=>(V M"QI<4@CH4S2YD %MWHSJAT2->UP- :6V>ACQR*JY%I(0?1"NUC\JQP4).G1*@L^2ND'D-Y=8=S-WLTLZKCAN0-=;VXABB[\ - MNN#MPHMCUCJFR6US)I&01# 0!84#@KCA240>F[]\OT7"N&?:,#!J(>W=P>+/ MP#+'SS41^ZD99@CFUTYGI[7 7"R(B'0Z,ZWKZ6Q "RZE*MDXT3HO=(. <5WF M00ZNO>7;@??ST/.RW^9+#+-Z,?WOBUF] /I;F,XK@^_F5P-DGBVG*_K12_KK M_//9C.#+)VDZ:A_0>XBN/@+1M$TB5[56U02;+!>A-$]B#\3+N 4O@[CM/6B] M@^/T'A%P[ M,*(73RA]4T363!J$HDAU)&"ZH(!;&0WZ M8\I'9-*TMH#W$C)N'A)Q^:[<*=HYWQ?&*,69!5F[3BII M:N&]49 D"Z56WH?8.D;IH3[S()=0 M4/@<8Z88NO:&2UY)UKK >$<2M\N$L3\! ILHZ0E7]]U]13YL1=]CZQVKBF]K MGMN_JWZL,X"))GKRTW)0ACQ\#."#1= BL8)&.0RMR\2W(NSPWB/GBWRJ;<0G MV3$LDIQ01[87=P5EZ2?V9 M1&I(O)AONJK^,5U-LC9)UT',*G RRB6'VL39@I'*NQPM>MXZ@'R4H$ZPM(>F M'P+-P6+O $.W>'BY. G3^<0FAMXA!Z-DK#4^%@)F#L0!ET@[+N76=];W$M() M9@Y7].U(\F"I=P"=:P\^?L7J(4Z\CEGD0L&'SW5:MZNW%](!JJB8#R9KU;I. MY@X1XT*F@6(??E:SAY0[@,D#O2_/F7$ID$R*I%WD!*A$1WBT%+74%XM:!A9E M:#XC_3&"QKV0;@^?=M+O 4H_;FQYSAB+6F1+![HTPM'Y7J>H9I. ,Y%<2L$1 M=:UAM2UQXQ9?#0"Q0;32 =QN][:\X")%G4IMU5MK617+"$[JS1",Y+SEGF/K M4^Y^2L8MAF@/I ;R[@ UEU[C&^+E-7VYFC@>"_+$0-LJ%*=JH($,- MDP#?2% MI+/^,]?+ L_VR5O\??,C,ND)E>;D!QJL,U-Y+;;/K-YY)Q]S<2;&0=#U0\I& M?TUS7,2UU50/!^+]7&V:METQQ97(B%R"]G6D:^$:8E;DMRJF7'?=9Z4$S%5YVSRB-Q M+U6J&7U'D4)*!GQTQ5LG,39OCC#J.[\AWSL<;7=T@8:]=\4W7,;%((^C.,9=?Z,-TS_<[_'!35;_#YP6^M[ MECG6VY$FOWN&E#ZK # M7^Y6]QXA2BK*D!O!)2A>>P@H=!"8J/5O.=#/1P\ AFO*-K"V'V^1NX5=UQT=P60#C;,2Z25T_1,W?/\[&2Q7$__^^P&0A0?E=86 M9#0!%#G:X+TNA%!E(OGWQ4K5&.N/D#.N$>X+-XMAE-@!'A^X#!,<30,6XY7-?0.U1IO>#N'OE<)$LN$R@3SI3V MVBEPR9#[P^M3(*N(Q>(3"XE$Q5L?RUL3-V[17/\8;:[@#I![-S5\R>5Y%N12 M?B5X;Y6@LX#5Q[')U/1'K>'*G"ZK/LX9TR87G@,#J:.B@\<[<(7BN:*"\$9'*9MW MK-J2M-Z>!1T)CH>K:?R:S?.Y'+=9>U/_\V8:XG16KUY9#(HQ+8 703Y/*20R M)&>:R]I3GY4OQ+\2&4UL&4 MC 3%>L,RB1>%SZ[+:W:D<.R[IH!ZHE0X[ M,)KDM%R\&DK_=3I=(O%*>V_]_?TL4/0US[5.=#/GO6YSRU)MT& "G0D:)?DU MM-+&8SW)P^=?C)8KDF,WUR=6"1!V.EU%J2.-'6QH"> MMB7*>H>:C;( >1V>6TS&&Z/I-8.COSM)3O1Y%-GJP+ARI%$-9TC MGC@%5EQ.)>64;>NNM-M3UV6<-!0^!U):OW'2J^D\S-/]@@RL'A266-(E@B(? M!Z(3%K*RVN@0@C2MDY^[4SEVUKV#.*F5#CLPFM?/A]JWB?C"=^5:K_L)BT:6 MVA^],X=;H03 M.81H(54!*B,81$_'@(V>"2DL#ZW09=S2&E+M9#P^7G87 MW80,N24_MH#D&^JZ#$R&LFD#*:V#P*2R5?^_ M)E._A=F9X2:)31.AOO[@V3S?_,:UWSQK%'3W"C;-3JNI_^6/]"7,/^,'VD&_ ME(*D!%0R%\89R!0E[=D4P%O4X)*2''V11;9.#AV7P['+0XX9$'6,G:>^LR;: M!E68EJ"39_6Z.4 ,SH%S*.F4TU(WOR4]B."QBTV>#.YWTFPWS> /8[EH[9.3 M')#5_CLF.PC9DJ?F=&#&&QM*ZPX,PX-YP!:S3P?,NVBVDQ9=%V^[+I/*\WSI MQVT>?%V*56H665$>G(VT4Z.4X)2A/VPJTK)LI6_];'AKXL;N^GK4Q.L@&NL@ M]W4NMH+R+9Y/^7L\O MO.]7BVM%LSX/[DC9V"/@M)C M:;,9<)MW1WRW_!SF%PU?;E"[7=O#&_^^43_#AVEJU*CP_&5&[=N\F$W3]927 M)Z<,96+DDV'-1=6&FMEIX(8)"I^3H!\VWJ,/4W.HL7I^NB(XKU8O<966TZ_G MW6J>A]5T]:Z\OZ:A3R38Y[-Z%>9E9-IK 3HF2_P+ YYY0K7G13L3I/6M^=^= MRI$[$[5!SVU;-+"RGH8)NAI1\'I>%LN3S3=?UG&ZLT.MTV,?/8#AVIJ3X6T: MBJ!8;41OL)Y4BF4(%B5H9-QD850R \P0'\BFW9ZM?&UH]TLLM-1Z$H)+7NH M]3$21=B>@7?>@-6<65:$CJ5U^_H?4]6MS=H%'3\:='V@,KHHY+TGNT-V>%/@ M^>E6@2>37+-D'%"H+D!YMHG594WE9!^SHT.@=;9C>^I&;IPV#. &4DZ_A^/' MTY.3L/R^*!^GG^=3VE+U(<<=V>YS-F[YR8V.QGWX&/YDY-EDG:2"Z'UM]Y0U M.5 \@#>)60*I3HD_F9/Q4.8TA2H91D04.C+8?5QI",AFD9UA"5C:GYM-G MMZ*LVQ-R%Y3/?6 M_/_KS:+Q14Z\P% ZSO)E3M.NDS!M!*Z!!TB;%Y*G4[ MRKHU8KN@Y$YJHKU21DSE;THD/TQ7_ZBNXV_SA,L:Q*PO=O UAFKHPJ+8&'X& M*B4)#EV"R,A_S=IGYL./+-;6JW7KK^^#G&%DW,']SV\K?%=^6:VG)Q1PKB84 M581H@P'C0@"E&8=0B)E$48:*L1CI6Y=IW*1@Y![%P]B; X3< 40^XN<:@7[ MK[4K_$/&,J2BC7$(C%=CJ;(%,I$6R'2$XH7C*)LW6-^&L)$;"@\#J/8JZ0!G M+Q9D5^?KY=FX7K*U+XB&Z;I^-1')!86>0W*Z]AH3&0*OYS'+6DL7K'/-R\<> M)F?<2L>!,-5*_#T@Z:QF[4$U"LVXO3TY!I3MCC)-'/ MBA*T UT@:>8"+,IL-5[)UTVVU EV-$;\&P M8D")2,;>D>02CS[EJ!3>[M?;XH'W5K2-.\I](+0-HI@. /?ZY"OMH\K(N^7+ MZ>KK8A5F[\J;16V^^0WS66M?K M[$/GN!/=!P+BX KK )1OD+C 3>GC'598\%*SK$!KB^0X" ]>D1]AB)7H$+5A MK>M*'B%GY+GO V&LE?P[@!*YHT@$?'F)WW"VV%CL31>MDZ^GM,C'15G_3I*^ MS60TA>.F1D G!W6H!'@O$;PE[D,IEJ%H#+*]"!UY7/Q \!M>9QT \_[F&N\N M2C!?;^)\LNC5X;AP9DO(Q4C40#*MO=U8#9HB RMMD5DFYWAN#,L]R-P.E$_E M4N%8^NH DI6Q)7XAWHB/LP%J]^+>XN_7)+9NK%19]J2^$!2XO./_^HA47W\31\69'T M ;FK?9>Y%W6.M86 VD'6!H4HI3#7_ZN!31W"Q4UR_FV%Y716@_-:S;()SS>R MO6:T,QGK0C&4-S;1?DFRMF*UX%T./*J@H]AN]M;V:W9;,;0+ &[4?0PD[Z=N MFAJ_;3I\T:,:L8[>0RD7L(2H(67!0*&60-^AKX))Z)+)@O=?];W9:3\^-B9! M2<9-LI"$H5CR/Z6H2=;1!$ ]*Z4#.:3T",&N@&%K4@9HIN-9MM+<@:QQT#0*# M;2^T]M1)SS"K#+UM2ZI/:][QXBIE=G:4^UW\Z -M%!!V"Z5D%RNV[DWW&67RV6OZUP M4GPT1FX&IP8%*EL2E0AD<'FQF3%EA&_]P&\KPGJU6VU UEXW3SV!=?E;]R7X M%N<)OJ$36KL0<=0$U][2&3[AE84*WF0#VI54>[!X<-X&\.B+MQAK/5KW":_+ MV__T!?/I#&M3K(<\W8WCXDO4RO$ K*:5R0[P^JB0-K]#EFQPVK'6:;YM:>LV M4[8+4NZ490RAF X.Z:UBV@G)[Q=BV 9R5F%:0$K-U(E-$6G,4"46;G>,0H1>NRGS]'[FP7*.R1 M.]M%+QU [:*0\W9.IQ@*E)3U4(2F'ERONGUONG6_<>FZ_L%H@539&(9R,@-*%,VS1C:J#32PHAX6BW7DP^U_?KFS!;!6*^C)7JK>U@'LSJA&7"+ M5K*80XE;%9K2IUZ##?WM"C(W%AS7Q SJ->\OV![0< YB(YA6!CU$%S87$@P\ M5P:0=D6*T4F>F^%A3"?D &7=5O<>DAM9X;].Y].3TY,+NV6=4K)V%LNU Z/A MM0.C5, UHJF=7)5NH?(;BXZL]'U4MF@AO[$5'_ZX1C@:C2R2QU-JVEXI380[ MHZ#X9*43(?@VBK^^Z#CVOYGB]Y9?!P[D@T?>U96.$ 69L!00N;#I)ZXA<(K@ M0T+O>9!)J-93'G],U;@.Y;B)MOU4TS/8+NYM"DZ2ESQ*VG;2N@0*4X80.<7E MCKQH9T*QS8?O;D%6ITF1/9&P+=#V5$N_MZYOO%B+](\OBQEI=*]'3;LNT>C&]"#.&MV'7LRDN"3BXHZK&.7) M&\J H3[,] K!R^R!12Y"%H[;W/IATT.T'%S[>.MSK_6&D(+\!G+QE"D:E% * M'',,M.)1&YF#%:TO/Q\D9EQSU00'=XH@FPC^3V.:]G]UN=]"XYBI =]A/@A2 M$Z(05G,07.AZ$T @+=( 10;T/UWG7P^]C]L7;MQ>H?873W34OYS.3M>8;[T1 MI*#%"\4M:!29]FDR) )5)X2RC((\V6*;M]K8C]1.#=TN&'JXJ&,XI?UIS&#C M%YX-5Q_'8![[S>>#.T"@*[)@ A,QMQ>'TZ)L#J-P>1C= M^ASZ 7WYVWRZ/IHQWINT<2QU&TD.;<9EY@17SB'K.@C"N01!RP FNAA+EHG; MI^(,DUS/FD=5Z3[[1J+<^$_WJ.;,S[H0 :.-GI(MH'5]_"F8K;Z<)SEPYX4O M5NG6(MB3U$Y-]2X8NMMY:7BE=9 8O\'FQ!3O9-*UZ"C6Z2L4/03N$&Q.)3B; M%4^M*W=N$# NCHZB\L=@MI/\]P;/-US&1:L'V?<&BI>NDF+&"E,@)Y&('2O! MA\"!N^)ML2[K[:IY#K#ANYNIP:I]!C%3[130@3'Z.TX_?R%'Y!E!-'S&BZ>? M&\96[T[7Y/G,,W&[87+B#2^ZEDDBT[F^_ZQ-%[D!B9HSSGU UMI8[41@7X?B M 2+4*T?@N](8E]& M;W 8-M%4!T"\5W 3YQS7DAR,X&NW;8PD,"R:' 23H\W>9MYZ!,2]A(Q;!'.\ MDW0G@7>(FO/=,%&J\)A5@F*- N610T!CZFQK$]%EQLO0]^#GI(P[<_ HR-E' MZ/WFZ2X'/EV;\K1/4NW>SVF4 ?LQC8W259<+O9RNTFRQJN\MKEH/EF!D<(R. M+[5I],S!:<7 \A1$RM%C:+W)'J.GV?"U:Y]]=>FGK?:Y" %)R5JH7@C<-DG0 M16B"O63M+ZL?)6A<;[L9+AXKEG/;&1D+74[0Y9RU4GLWSFVF(T]GFGNQ7#'6Q_&[^H=Z= M+>G,I5]XNY@O+_ZZ&5Y_JSK!Q"!)&J*VB>*@5T#&LMRVN,.UY'>A&48>7F8(#@5!RUHEPC-FT;M;T)*SW)'O)I#$)A*A= MO)TP9%Z#KOUPH^.MTVK-B._85N^"M\%L]4[*[2"G;HH$ V/IOD5Q,/4=(*[X\)CJ^'H.^NJ ]3]:*#[_=\]?PKJ M@PR2"0>FUN&JK)$B3G+,T&1;4/B<0NN648?0.RYR6V'F[CC-XRBP [!6)LXI M9RX4[@/MV=HX6L7:QH:G^A19%XU91I%;G]Q7JX\+I.-I_!ZKMX?X.P#.Y:GQ M_/OEE_\^Q241]>7[FSJ(=K,/IL/AZ_O5TO=I(C)\;_.2*(*LN0=DH0 42GY,8 '7( M0C/O8O.;W4?(Z01G[4'P$-P.U$BGX!(7/0D+IDB+U@Y"O-XO&8@%.6"20KAH MHFH^'>P18B6<6N9^O#AFNBI4[R=[TCEL\V)>3"8ZSV5X104 MV?IN+U@A'1=2MWX&^3 UXYZ3;;2]!83V$'T'('HT3M=X$I[5>$>!R=*'8I%9U=J[>IB:<9VK@8#42/BCMUU?S#]7+GX-RW_@ MYEWOU=7U10O)8G30:,$FZ2GR0/(W0U0@D^4"H[$JW,J0/=2&_8=KC>LO-4;* M$/+MH7_RYCCG-ADZM"6(>H@K(Q1$HR-(;I"<08*_V,K -.VF/5AM][B>]/Z2 M[P$NYRCG*%/TB4,(,A/*ZR-642=$"1^,+]*)\B=LM[V3LAYHM[V+Y,;NNGRC M7;23-FHK.$3EZ@,7,I\1F0*7!5HT.4NS5<>MI]=N>R>5/=AN>Q?YC:WX&^VB MC4XJ!24 1>W;F@CP+G +3&KRI#%YGG4+Q??7;GMOQ>\MOP[BD%?3.?E-T]J> MZZ)>3LA4X])_3>VBII0[ M]FD9YJM2N\+-\T=K*CS$;C@86<:E_[# YE M 8^,*Z98<+)UXJXE_2-?B;4 U*(3[7: [-H+!I>5E??A*R[/SX+ >32)I*D1 MZ41!$R$85X EE@-GTMHRP R]NX2,B[7Q<'%WU-Z!2NH":>M M? 0B2SGQ"%;:4,NY$8*VFG#"G30EBZ*:5QX_1M"XZ<..D-=*:1T@\+>/GY8; MQ^?['4XLCYG'8L%$3\YOL.1"Q\A <(TE%"FP>4'>P]2,FY#L!GN-U-4!\%KX MXF\N!Y0P%R+YW@EB+.2/2PK.?1V31 *@_58\#SC82_46#&P%;_,GCXM&0T0' MV^&!!PKK%V&Y_$[<;00SR3KP8(V J.L<8:DY^("*O!V%PBJ,Q;0N0=V*L$Y* M H\/G.V>)AV@Q6ZA><\;Q FQ8QPC=YO<; [*>P'.2HHZO4>*07E(S2?Q;$U< M)X6%G4+T4&UV -/+E]^OSEY^O\2XOG*2GITLENOI?V-^L5BM-^*<8(Y*5,=+ M2:7HK,KD@AGEP3JK6!8. [8.KW:E\>F7+;8![:"ZW1^[BW68'0.[*9V>G,XH MXLQ_6RY6J]](QF%6&?X;Q1//:ZL#_!3^F#@*(!*7 6A[4NA9N(>8$GV%7&@1 MBV:Q=:U1$\*??DG!45 ^ KZ-]L/,EU[:5\Q+5F.)AI6Y^+2696*H' :(_UA MM69%^-3\$4,3PI_^?=BXT-\?!;M#WY]!?XZ?*R&?!ML!UUO67)?"I!3I(B.) MYL($*&LU"7@S(D8;9Z0+N?FLB&UI>_KYBV%PW$278Y>FWM-IJ;..)&>\Q0=.T?YNKP\T1!A7."_B]@X?I6?[8'*EW$X"6B^X,2!U[;%@2YU(K31D(6-6.O/,[&"(W0JD[O\'Z6%JZR#N>YR; M6JX^,=S;(!T'FU(&5>?11?2Q>O?99">MDJU3OC^F:BN ^C\O0 ?2W_]6O2HG MM_R;T;I5$B']]JN\+:7+CI4_[Z_,Z\]KZBS*Q1SW[/?^P"_M2,ZBRLD+#S9P XHI#TYR <5:8700J%WK8LU=Z.OGN6PC)-UY\3B4 MLOH]?^XW!?LWD'_T\P8U7P,VD=\2>A8-%^1X@+#"@3*9/)*@++CDF6()BVF> M*SV.$7N_7'S%Y?K[>UIL34Y?/6F_UFUR;3>XG*W,"%J02Z8DUMHKVH5,)1.U ME^ARZSN_'U/U) S6+JBY;; :*Z:#6XN+^YLXHZ^LSS% MZS')K?;UVG$==;2 7 A0NM[01%5 )I%9K,,^F@_X.H3>?KH&# 3/HRGSJ9VO M5U/$+W9PN+9YW^(!X]%)! U>=8E5^5+6E[$L?Y M+@AZV%XV5%('A_J#W#S_7JOZ-V_JDD(9 HFL."?IG$$/WFWZ:'EK3%%*F-9/ M:;<@:US(#8.';7W(/973,]XJ0^>/1:S/42K)P9GZ ITQ"M\SR4UX;P2C^)VG MUK._MB!K7+PUA\+6XND :B\6FXQTJBIZ/2<&/Y/.+EX.,1*145(!$ZQV M6Q,60BP1(@N:R:2]D:'Y.\.'Z>D47/LJ_\[KP4::Z !5;S"L\,MBEE^??%TN MON'UWFM$,K(<+'BK24:^%'(UO(>=SQZW)'PH/+009 ?FY$'QO+FL)XK12^D0@4LO0$E+1R\:0T$NLN*B5RQL MU6RO1<3V9J?WY8/Y/^,F"/933<]@VSR"F.3 *$"@$"$G32:4UUI'GB)D)1G& MX(Q)K<.VQRGJ-'#;4__;PFMW970 K6LO:EXB$9&F9TV6\>L,-PJ;Y_."[\WW M'V2>W$&7'7>13F\?*;RH[QADXA1MD#,8:Y=MWGJZ<2O:.XT)V\!U% 4?^J9J M6*OY%M<375 5U '0!3I@LI3@&$M I;!)IXR/UHZE>CI-(HB9MLK,0LP!?R&E7T#J(0 M!G@V2A&"Z=M##IL:[DK\NOF>J&R,C59"D)["I9(8^,@9L.*#\MF5F%O;K^OK M/XFK[5V0X_3+'U]QOL+ZGN;=^@LN7YPNEYO# MX++T:;ARGUU).%(!T$&2.:[]"\''$&KUF?&& A"IP'MDH+,I19N8G!UR]%E[ M^[?)&)TKX/Y+LW,U3(33(6C%(,F-"Q2[FTB.K:S]@KC@=12> <&=ER*H MK)J/=7ZLA._TJ3,Z'Y[C',MT39$3$R4;7T#+.C,D M2XJ@<]0@*?"Q0H5HM-_%*-U=HI\970-:H@,EVPL^R*FDGT]3J)R\./_RPJV8 M,.Z]TN19YMJC7SD>P"OG@?%4/=9.!X+-^TDW@F&SCM*SS]? MMY7)(%,E1+"JCGA 8\%%+,!U82@Y6E1I%^33[O7FI MXW^F9\.>P[SF*]9T=B.=X/OU WCLXQKE&K>FN%'>\-IZSVZM=X6\2^ QB:1W M$\D7EG7$I=K-2?G;O2GQ48VM_MR M2"-82$$#2RZ=U:U%P>CX*8Q<::L45WJK &-@0L>][1D>S]TI^TD>^XU+RO9< M:7@'X=C%93LZLMZ2@:U#&YURM1I2@E><'%DL4ACE31*M:RR.ZC5<;=.;YTX^ M:[1[\4;#<%<[%W)6WRB[6/OE\@"I>&$D"8+)UJ[3-G0]);]@%QP]W'RED8XZ MR#YOT]!!)Z],#!(*8PADT!D$&3T@9\8F8M$WKWQ\0HU76F%ACZ8KNRBF9ZQ= M>^#HO#:*20E<5R?"I@).&PZ"9UZ(39OM\;I$/J&F*SM!88^F*[OH9>SXYM/O MBT]?%J?5P_DX)6<%YYNM^>SS$O':^]<0'$O,&Y \59%A I<] R:TS5Y;E^-V M7K+)A0 M&XVK.@C06% Y)HB<"XA6"*<$&NNV*Q"Z__,[?<#6 AL-!-J!N[/)MWR_"D_. MFJ,YU%'+0J=SQ761D>*/5*?D1 RR)/II\^:9]]#12U."@9SG@T7?(WR6RT"! M[;7SU B?;"#+:+0G";' P"/S8!*+2'M$Z>87QS\D:N2H[&"]_PA(!REA[(/J MHA;WC*O;[AD%#0K)!:NU+S4U0E_5MA^@?$R),R^=WZXNZ-%E.@/(8?I<#"+< ML6%R5KZTF&\R9J=A]B[.II\W*KKH1&90BY2YK8VCZLB 6)\A&0,I6ANBXU*6 M[:KF?[C4R ?5<'!I*^2Q(?/LXZD9_%B:G6*MO73W @W$0"[E_ M6$+,(B-&W/)MX-T/']?Y'1 6APIR1""LENO)F^GZ',4O:@)@<_SFZ(2W&0P* M,G]1>XKD*"CP3 IK?0Z8MWKD1Q]_S4.AOUUY)_>O/#)&AO)Q&XBY*Y!<"QBS M$869C,!Y;7AC:B%OI\$!I["G?LX^0]+J=? MOX2_X?S"!$IAK"P*C%&9[*DO)(B(P+Q!'XU3G&_G<-S^Y%YTOJ^B%JVD-K;* M?YW.L&8$<;6!O^0H9!("$K.U.25Y0+%V=C.&!\E0!,'<5@J_^;GC/L <[$PX M5(+]*/]\#Q@?/=-: XNENCPN@?/:07;1L3I?P/+MFKS>_N1Q]OO!^KE?SWL( MJQM-?_I]<6ZE/%'(-)UT@BP?62FGR4H5"UKE$$MP1A>YFZXO/[L+;>^CI7OU MO9_(^M$X*>_R>H>%G'V*0*<3"4,H!YZK"%;RZ$K0/NCM[D;N^_1Q<@:#:7U/ ML76C]W?S"_*+(Z/'DH5(UNUL(()348!,R2-9P&3]=K>F=S][G&!O*)WO)[(. M+BWN]6O>7/6TE(C:_!&JIC M;'-R59[\;(GA7?F 8?;+BG2%%U?19SQ.3!2TV:(#G;*B\$G6\=[((-N,5KB0 MC-\N#&TO,<&T?OP?5.CL/AE13+^_=5B^8$V8+J0WH?-VXC5 M1(NBK:6-IC2C"-R2*7>93+GA"9DL,9N\W0.6[=8;]XYC* -(.O1X7.Z3%^( M]O?+::H3%19K8F(:9L]/2<+$V,7/)]':PESVU3'+H#(&"!@,>"V]+MH(B]N% M--NN.&ZN>S (#2'O#KRD^WL\GDTSL$QSJTRJ/?=RG:8M($3C(!AR[C5Y^_EV MU=A $P&WGRLQ6+YL %RU5D$':#KKGX4WGZE./(6*EEQ'X-9J4"IQB(7<1@HF M0A"U&"&T?C!U+R'C>M@#(NAPL7> G;.S^25^7:RFZXGV15FK-)C(+!W()A+P MR:IZQ4IB.HKD6K>V^6I;^$7RP?>PC^;ST_#;/.]MTO94"[0H/(?&UPOSN;D M3+\A;9 P.[L,G8538@>7"3%9IH_ M8+TC(CV^*Z^F=:?])X;EA#R_VCV]@'04.RBF O@4%3"O4O%:U,J?K;VF=G1M M!\47E/%K>5TW=SG$CKA5#6P>9.2HF8P.E"[@/3.C@*8"17PR+UG)+M ML/GDTN9'55 ')_5-3E\L5NL)2\HR"EJ FZS/WXDS-! 9"S*6DF5NWOGZ#A7; MP>LII=0;2;P#S/Q'6$[KW?@5 T4KE[++D$-]XR?)1_5::1"!!XR>I));#V2^ M0\1VB'F*R?+#Y#WVD7=V:)-@KCW8.5F<4NRK2JVU- &2KJ_*)1WA :6E@UL[ M'[5GEFV7JWIPB>TP\932WPU%VH$EN3T(:X*1.94+!;:L7D>C+M670_+JLE8R M^V1EZVN3VS1LAYFGF 8_2-H=H.7>YYKU>5YQW",PK&TN7D+[4$&.C80WB]7JJDGE][^=AF68KQ'S MK^&/Z9]&"O!..2^Y3DELUY-AIV6WP\Z3 M2W$/)_H.SJ:KYX0?<;T^Z_-\/I)FPI'1]I &K*X]FH6()#LCP4AD15FG$S9/ M=3],SG;ECD\RQ]U(!YW"Z_KA-"0%(:0')>W'W8, K '"=P.U@B^9.6BY.5C MH&_45W*K+XL9G=O6NB(U"2?[.O)(>/":>0A,9/32*R:W+$#:??'M4/24DL9' M44./,/NT.!N3L9KFC5 IX"PL:E^3GBCJ""U& :>+)8.(Q*I3*&/P._*7WRT6B2&+UBN3X>KXZ76XFJ5PR>"G,9VD]_78^#5)(XDTF MP,),G4Y+4:MUM$TL+\$XDB[JQD[3[E1N!\*GE, ^DL8ZP.3?PG1>8]ZK 3[W M;+V)4=YE52*@JP6C/EL(M3UF#4I<$H;SV^T7#H;A5H1MA[RGF 9OKY#<1JDC#RFUCJ5V)''<%_K](70?S3TU8-;.71.//J;H M(G#DM/.BX.3'VP!HG3#9)11'>6?R*)'C/O/O%)P[:^^)P?/5XG0Y*3P$B;6& M$S6G/WR!D$0$J54(7"3KO;'8+V0&AZ#O\TS2;%6 M:V#^Y8]$OWI>1A\X-R('!E@[1"LE0VT.;<&0%*TT/MK8>K377H2.VS6A$W0V MT6('YO(!]B:HI'(ADG?!2'K*U*M8603DHI")'(UI/F?N 5+&;;UP/+BUT,3_ M+G="DULM:L>X%2(:NKP7NBV;RYNAGP?6WF9"UN8>[;OR"N7\_+8GFR$=?YE>AZL6%FZ%N_ME0>$P$#RG>4V\/ 1(G*B?J, MAYRZ@ H"!1O 8V8A*"UD\R/FJ+>']QMT6NJ:9WLI#.FR]%$@G1P\4%S/#,12 M(OA0BI&BCO]K_9AY%_J>T@WA+KC:[A!NH+/N7+T/T\]?UN_*;RO$6N2Y#$3,2T27_J+)B+S6]3'B6HIP[K+7'P*. .44IW"+MT85^<+JO, M)Z4D-#D7(&9$?8E@(=CD ;/ XBVKS0J/$U.<4]13$_:C8>P@M?0+LK>+>3IG MR-L@,3H$H1%!:0J;(J\"DUEDYKP4N75F[X=$]=2L_?A0VU,Y_:)M$@T+U@4+ M,CD)2AD/KJ0(+$MC1=8EBM8WO(?D1X[T8N#XR-I)$1VDAF^R\7>L!S[F9]_H MNY_QLL7*9:=$/@G1T9;0#J*-GF16R#I+GL ZSIGRP9O;#0,: ^W'-/;4[OUH M"&RLNNY,W2W^7IYGNS_484#G;815G3Q8!\S*PEEM")4@JLWL>J90I9 S'S9D M^#&-/767'PN:AZJNXZ1R^#JE[TW_^^SMW#XIPYN?T"J=]PA=C5)MO_S7:6T& M?P$>IRS7(G&0ENR-*A[!R5P;0+K K5>$G=:YM)L4'&I\/JX7Z1_U$2EAYNR3 MWR[6>)7=^41R>T[_X!^T3X)*23#0$>NDEMK]AQ'30D96\4N35QXR8M M#L#$;8,RC#J>BB6YFH-W+8U^P+W$UA\^B/W9FIMA3!-+VGLE I12TPL4_H$3 M@1QTYHPV2:/)V+=INIS8>5.N9ZN<#^Q$5:P@!\\95E\N9X08%*<_>!%1VI19 MZWYP6Y#5E3G:!0=WS%%C%73@;7\\C:MIGH;E]]I$X5W96-S-D/BL$1T3"2BJ M)8MJ.0=?;(+$7-0ZIXBA=9KT06+&15!SM=^&51,=] "F*_+?AA/Z\M,RS%=A M,^GN?$"UT\4QHR0D9/4J@9AQV0;@#+.W'C.)KC6J?DC5R/!JH_[;H&JKB[&+ MN-_/0MH4'7S\0D)=G8\H%PJM1"V!8E;R+9DPX*(H$"TF7Y)726S7QO+>CQ\9 M%HT5N&@JS='Q=S!C+W/+A:D,L,@JJCR+SW 9*53+@22N+; MC>RZ[]/'O:4;% V'RG)L,#S[].MFC&HX.2<^6A_1FPPIE4 Q)['A>/!0)'E_ MJ*R46[9+NOW)X]Z?#0F"@V38@>_Q[ALNG\UFB_59!YTJDG-&E.)6F\! EOIF M7I!%\YF17)Q/WJ#PQC:_NGB(F'%OR0;"3UL5=("EQQW^-Y>=>#Q#E:4S(((E M&REHGX08$'+)KEA$^KKU[>N6I(U\6 T=, V@G['/L.N^_^?/2_P"](=+]1QN[ZG=Q6"B[L%>7;/K MYUU7SQS[UZO5*>;7\VMV?H):%";(P2]%FWH=+.N0+@%>14L!@*;]V#Q'N -] M/5NNP[ WN+;Z0N)F)[W'Y8:W2;%>6DN$FY+)FS1(EMY8#MZQ: /Z8E7K-MT/ MT3*R#W]SS'P%OP^BI P">3U"X[);Y]!@V51$^VJ^?7>5I2-6RMWE..YO88ZBEXO2U"??0O368WU+XZ$\]8$ M6:1H2_2024J@5)T"X;" %28D9YV5>,L5_'$<^Z-%QVUE\[!Y-']2G9*]JX8?^*1&U7O;T-FH M5.^JH).P=VVQ+6JS^_OOI5L6R0R910-%B5:0=G.@>\#QPDLU84Q)*:MW@Z MD.1Q,])'Q.=M@WE,53\UF[FY2%JULYSGGS>H_;R/YCZL:/2HZ$"WP&/MZRF- M *\U!^Z9$\I(KIJ_W1C7BE[Y.U<;Z#H5&P6>76.OSB?QG-U=7NTN5E+6S$70 MEM=1+$9!2#9 RM9E=%(D/]P%\+Y4/VE;N@M*'[XV/HK".PB>KCC^AE0^8%I_GT_\F'6RR$QO%7 DBHS8A: '9% /*,@4Q)0[6 MT?E&X4'@,0Z&_,;,C'OEV,6&&!,>7>V3.[[49I;M=B8."DY/SKYW MRTHHST.H5[7!^@B**P$AD+TH/NAB-=K$6T_=:D7>R(HP.AOVT0;QN M#U@O31+IX*QX9IYO?>>W^73]T-$9,%D1508G60%%HH&8@P..C)&I\,$W']0] M)#_CWNKVLT7& \E3"U<;/^?=?9%! ]MC/^\]< 12T>O[]_M/OK'+7*FF3]!XDT[P+TUT@&<]A?<%=OS_'X6YO4%SOFC MF\*\=EG61S'&@]*J3OJJ?5)*[1['4C:Y]22L(?@8%]P'P.JVK1Q;QQW@_#(A M=!7PGK_E8B1&+5( 6>IPB2CI% I" Y*\C2N!J&F=W'B0F)'-Z>@XN5WDV$1I M8]>2O5W,'V:$HQ+,$_FISKU7/-IZ\&0(6&6@\^^')<.DKG(4ALPRJ2'UDDBXNJ'G61$3S7 M3!KFA NM&Z(>/X:PN::^\,SRE*OI<=>^9#)FX\Z050364Q(:8N+S:+=Y5Y6P=7N&)]+0S7 MO Z<-IR!J^5%VG+%-%WHQ>R5A:'?>L=BT?^^6:M[']A+7^84D>OQG.\!+CN4 M.\M+YIR#5=:2Z@0'062$+(SPMD03]YO@O0]@IO3.3Q#60W$?P;F)!;Y;S+8[ M>,C28:JK2I.NLYP383UC H,&N7,ER?V&K;T@\GL?.K'0CQ'9N@7_IA9\^//. MP0GTC"DO@3-3)WG%7$OT/;E*7)I0(E.YQ>5P[T.GN2":"?YH_G40U]PX25N+ M%] *IHH!P5/U9AP#7^ 92&Q5Y#"9CZP>3GI+*QTOR"4@ MRU2-J>+1TR72&Z3^N=Q\W%9"U-3,Q^4?[]>O26,V7W?ZQW-AT2MBE"*G3F5& MI(5L(/GB)0NB]C0/ ;;GCS5=N-, ,_!J:$T)@;:J^4%)OKVSNH2@T(IW(&@ M:( BNRPAUD%(017+F=72YQ9!\?U/[0@F+06[;L+EJ1V<9Y^XM#32)%& 1<% M"9D@>*)&1ZV2\\9*OM\HX?X>',>"1ULF=Q CO7CG/W7E_WH[1"%JRUWT!8I7 M$92J+Z?( TCI;FY''/&%C%G) MR"R@5+F._57@NXR;GG^S@N.&F.O%?1/!4(O2O!=K\OWM,>' MM+_^\X_EQ?:'KRE?6$&4H940T-1-=77\9F()I%/"**LLT\V; UL=OO/"J!'@ M/SH$>L'^,7S?E5G\0C^XN7RSH_Z7B_7EY2)D[[R6#*0@%U()"E:CM0E,PIQT M#(:%YMV [!'7G>C&ZS_Q(BTO\98/[^N.]S>KS<5R M=;E,M<<8%]XD4U(A \$]!\4Y0M!H0'M%@9,,-C/>F;+L0U?G]6E]:T]SX,SY MHKD>4?AF=;FYN-K&?[]M/N+%^X]A]:BM611I3&*%08BJW(RGB)&D%VW6/LN$ MS9M2S_Q.6'C\2+G\A)#1]P^\U788,_ MA^7%]9T>L=:S:O*.I;/T5T@0.#G+5DJ)%A67HGG[_;@D3CRL>Z9Z-@*<.M"V MO0:5W5J4+6,NMY[QW>_700MOUYM_X>;;&+.[?2$+(9R,+BD*0^N:$D1BBJKL MT='1[>YL<:*QCHU"V,0#QJ?5K/Z@<\[Z=&U_?EY?[+Y4?XXOO/7>Q<2@%J. MRB(2=U #,N.=DCD4V3KM-RZ%>VF8_TO#Q@;37%3MQ1F;M[L9B('7"SU2-2N% M[$S=ZP&*YPP^.0:R#O=VA0N5Y10Z=3@I^[VNLA]9>P;&1P=JLJ,0\^,,V"WR M6CB'.I*2@_6V#GBI^X-5(N77V13ABT/9>O3V?B?;#\3G6B,P@/3F_5HOLM:J\ O50A)\^X&'T8U# 9M!&E<'_1[NUJ+/(HMB'Q0DER M&C@S$&0DI@OM(-:MS]YGEFW1.9N]BH+'8/H+M.QG?_YZE!X0(7.;3'M36;G> M3J4,JZ^7=T+:FTF]K2?5'O*A@TZN/9KZ/B;9RIB%DEZ"%Z*NI"AU/YJM;[PV M&>]MSJSUHMF))]F>F"'][6I#R%CEY>K#N_6G3Z3A]9N+2']$W:\9K:-HTN@" MWF0*+B/?HEEJ.4A=7G-*9CWC]A TMTZ=-P!&!_%30R[L/-*4N32B>,@YD[.. M@8&/10,/WA9N<\BQ=8*A.1$S+=QNB,SAE.4(F!RM)W]A(M-%]KR6!$C M@HDL0M$F @7.++EN*?#O3EV-K6_NK]>Y78TZ%2@]WRW.;R^\^ M@]U4)^:%X[RX.H;'!4[!G+,9@M(">'8N*&:CL,U+[0X^Y4SKN ?$^K""/AS* M_AK**_Q0O<@N3#_QN>!R8X**S):H&7 ?ZBM6"!#%]BE+)?(R0R[2 M=J9+QVI/?]79_6K/J5 Y55_>=QRWJY2CC^17>A(0**N(#TG3?PW)RW'$$GI3 MF>/B]OYJKOM5F--@U)VMD\R0R"\&D4\B"XS><1Y\EY8/LT3=UGD/!< M)<\<&513R_.\AR"# BM9EEQ8;NSH054[\L[FT:<+G9P(=G.X'5]BS7?C+9[E M3F":)R\X<):":A5X.![XYJ.:I[Q7/ M,HMB:A1!Y[JT7-3YL1&<# 7086WF8E&GWL+&DP@^F^>R+A2W&VC.08]?MG(' M\L?HFC+P8 ,KU0^)$'.D2"%9M-YFS=7H@R<:TW@VSW-=:.N4 )R#@C8*V4TB M!T05"U%9\C^B#G6W=P$6HB='1"%KOO"KIPS1'![_NE#'">!V?L^%S[*FCJ?B MC',(H@;I(@7PJDY?-$FCXY)YU>F@E$_?[T^QB"\DCW5VL($L> #ET=-='RT$ M'KU(Y$/G829XCDOFM,';U)=>QY":>MW>R?;RPX>+;?'U_6'WM[)+.2A7=UXZ M5\AB,J/ )4G_"KYHLICHPX,54T^M)1[VH-..N9U 0;J3_KPG2WU_23_8_J"3 MTM8;"]IQ15>Q(Z.0"P<=94Q9&?(LNMFU]A(QT[AX_2%VN*3?"> Y+S_N/B/X MHF2++F8#)=>[50L-47@%*6M65$[&Z4&6A0Q"S;03H,_#*SL%(+,;#7;U^7.X M^+HNCW][-\]Q)[_-NK:,AU7"W<_O9FAM!_V2E7F'),AEVNQ&9E]_O?E:':[V;C-#.#K M+<>^6%4X\CJ$OM:E10EU=B(X7BYGJUI/;'[V M0-,"L9G8]X/3$3+H %#DD2$=X.-/J_P*O^"G]1^5IIU7]_^X[4%V0)TJ%Q+@3!= 4BEX=!HB&R$,9$I+!=[FT3F_L=;!I6]&& UI[J70 MM6U(^9Y^>&OFN=8Q%\.A^&Q!,>DA9/JOM$42FTS.N775P;T#3-S%V)TG=KQT M.H#6\67FW\A>Y;]_"JNWX3/>*#!ZK3U'*(@:5.:>++F1((F1V3$=2AA],M\1 M=$Q[&9\ JV:M!(UDW '.;XW%MP3>[B[(T:!1+H'PEE>O&2$4+<%H9337(@C3 M.I'SY&$Z+[4:'"=/[>PZ26@=H.]!BGA'! 865+8:C!-(W@WYNO%:L67T2GAR M@ULC[]&#=#Z68&S4G2ZL#A#7QCGZ]79K4"H80LP"O&1T_Z14(&BF@"?/E?$L MTY>&LI)M2)BXR;\[MW5*A'2@('NNTDLR>UFX I$9L9G\+(H4R:[(J"P&DXW' MUFFBEHL0AX+SI. Y;BGB(9*<6QW![<+Y>R_4E_5+UY*XO+SZ?/VUU@4!AW_T MH"_[)W*BCR=ZSP(R3G8\1EFK_!."1RR0R-JC#Y8QWKI#JYL;D1=, M)7)!;IJUU?%+=?!N!I3>VJ2*L;)YDVBKP\_Z*?X0S#[]%#^F^'MP0N[E>*)F MV=)5!S+4_G3F!+B(VU6U(01#/EYI[FL.*+$(B M1:#"@1*Y+KZ6#GP2D@E31.YGO/MA";01WGVG= ]&EOVQQ0*Y+H;7Y&7 3,:D;G\70@.7'J7U3A;9.KD\ EF=V__& M2&VE* /!IA=-.J9'ZCF67#>HT_4KM,UUO2D+)*D8P#&=(9#,0B@LZS+(A.9! MJ.G\.7($O9D>)+VH2RL+\FYY^>^?+[ V%R(!:K.U'R&1PUJR!Y,D,20P0=XL M,R"*T5D6PS2V#A8&)VJFH\P[O'1.ALQL)X$\QHUGQ^NAE<0/H\':6HUCN($8 M4 "W7DD3LTSRQ=>E<8\\T\'AIZE)QZ@X*UVYN7:_#4S?V@ZIM8\E.1"&UP'+ MS(.+U@/]0QD;M39HQM>2QP\[TU'=O>E' R0TG*(SUE"#7:9FO7U&#*NOEP\[ MY--F^86"N.L'^,MVM0@'?_*P0P9.XD,?E0B6C+3-%"[4W62@M-/@14D@K/"& M_L4,;_V0+'5BC8TNM#:?QS?VS*L"X2!\[-78##]&*KV]FI[XT:43@CK($I',I3: M@M/$F)0,KXQ%P.W&EWC\VX6+3N3;^0K]B<[L2 M=!&*2D4C0K!8)5<8.&8T:.E1"2Z=[F>,_8&TS;20Z)QT\02PS7M]Q(N<^7TK MP5O.>!EY#0% RB0I"M4, A97'\MM8<()Q0:IX!N!MIF6))V3&IX ML/5T%^K MX6J[E:/6'G:OB[OG^3L<2@49Q^2@)$L<*ER2&)4%5,&2,Z%<#MV4!AY.WDRK MG\Y)(T^#W(^@E _=^)15CL)EP.QK18\4X#P7P(W"7(QBUG>3M1PD:NROW.J< M%/(4N,U]$?O^S'E0\+EU[U^11;DM?KLK:"Z"2S9[R$75M8G*@9#XX^1CWV1?8OB4G9<<(BZOE9%3O_BV0%%\26G3 SE M,TS5ODCWV6=QAU.<#HW 02C^X3+ +[,O"6%R=!&2-MN](A$\4^0*\23K&LO MXB K&GL@?J8W^ ]E"8;$\UD[ O?3@B\SSBLILF#D#19BE](\0DB>&!>SY243 M O)\#,&!Q)]]%OL,#,&0>#YK0_"M/^UA2^=CWI2WQD8KB5D 4=\A#JF M23,K&>)\GJH.H?SLT^9G8 (&0_)9Z_\!L905DG-,$9#5*2*RB+HEW(*(/'!# MUC.7&:;AV^C^G#/T9Z#[ Z&X:7:_?0_V5;S$_US1+WO]I3+EJ&[JA[^C55_T MLV=KU.'\\$-N^T Y!H%11'!*DXR9,.!S"A"L31P]*X&U[L)YZBPG6_X'O_<] M\>Y_Z0?^O> L6F7ISN*9(:BB$ )7F2XSDZ427"%O7JCPU&$FSIJVP,%WQJH) MXX=?)['[1OVK-D7_[7_^"U!+ P04 " !7/@A54^G=@]@' "K*0 %@ M &MR>7,M,C R,C V,S!E>#,Q,2YH=&WM6FU3&SD2_GZ_0FOJLJ3*+V,;!S"$ M*C!.Q74YR()SV?UTI9G1V"K&HUE)8^/[]?>T-,8&PX;;)(OADJJ8&4G=ZE8_ M\W1K-(<_G9[WAK]][+.QG:3LXZ>3#X,>J]0:C<_M7J-Q.CQE[X?__,!VZD&3 M#37/C+1293QM-/IG%5896YMW&XW9;%:?M>M*CQK#BP:IVFFD2AE1CVU<.3JD M%OP*'A_][?"G6HV=JJB8B,RR2 MN177LV:,BNN;8VG6\(E,Y]V?AW(B##L3,W:A)CS[N6H0AIH16B9^H)'_$; )YKG;66DR M]*0R$PL7FBTRNG\]EJ&TK-VL-V];O.HXUR/X;E4.*:A=L3W"8@O]W8W?O=?X M7O]B.'@WZ!T/!^=G[/P=Z[T?]-^Q_J_]WJ?AX%]]-*&W?_&@8YOBR,=/%Y>? MCL^&;'C.+OL]YTX[:)%+P_=]=GE\<7)\UK^LG?_ZH?\;.^X-J:<5!*W'ANR) MT#6HLG]H:<;LLNXO,IY5622TEP>/\6(?$^8\CD$+M50DMMM^ MLT"BS&($KUNCEB=RM%E?^/#7SWY[65I[]0XMPX"-^50P+:92S$"H=BP-^Z7@ M&BA/Y^Q"Y$I;IC+V3NG)JZWFF^"@&=1^\5N$&\0(T9C,V56F9JF(1Z+J@Z9]J&(%$S*%%(D9N,P8S^:LR*PN M!#Q TG3Y$Y'C;(([+1&\A$=HTDQ-0/%6^7%K S(1"6.XGM.0";\2F'=%IT%; M#&,P9>J2+^:@ 9'42+88ED$KMA974% M=69AS)JU+P1X.QL'O.&MV+S:VFLU=P],":BR5""J4$DB<;MM7KO #1C7PD$$ M(9=A*BB43 "788I"@R1HV 1,26Q)][$T4:I, 3GB4*U2CY5=I!)=[&'"2DS M__G"9[>U07CBFX.G_7JP2^MP*@P*>@30I:$O![U*&3+BA7F\"*6J4 IY4P^ M^:E"0P&(9"J-HR>, F^2'BIUE\2V2HY:I+@ .LOLMX1*M21.ZI0@.=AB5"IC MMS\V16AD++F6Y(#T.=H1=T::"D-YTSU#QB591V;8@,,@[(R=4(Y:4$9%RHF# MX98S8IE_(>&S^6H1@JM0T$#0).1%_.=I<:-@'&X.C$M:[$]Y6KA04TQ$DB 3 MRJG(4*FM9[0;UGP$=/WM_4G.01B"@)WQJ314A7W8@L<\7/QFM* Z(?ERC>Y$GZ?5)YLLS @*C MT*Y4;5Z7YQAPH8JB0E/H5XCG'JT392S:Z>4,=)D(BG[W>UBV_8!( @QC4W%G M=&DXRD+A]DBT?>ZO&W-RP-$B1.\R+V&4(MQ[IZ"7!C M'4<98)7V[$IC7 -43K"SMT+\04H(%=>.=V,)^YR2;< 9#&R(X?&7BI'%,RA^ M+R3,=\];D45N0_7Z1ZWZO3CW&/M=JB$EL$:[ ]I[1%( &66FOJD99X)?4>H5 M9L%EOOITKW<6>]__"6]E>>>W4?<0&X\A:,0-KSV(S5"FTCH1 $QI/!HN_QLD M?U-, ^LDG.FS"?WOB5X0;E]\XK)8V3P1(,SJ@BZ<$P'V+AW<26^JCX!RFRJ MTJF@+)CQ4?E*49?D*"9YJN8"O;.Q\G3(;Z$7:/LF)4+]4<<:.R[ M-\7B^X0 MZ!.ZAJ5.>6Y$=W%Q -K.4S[ORLPMF!,Z*)6%REHUZ=)QWI3H'V5#>2;D .6[ MRY.^_?WZ;K!+AWU6XW^\F+@\!ZR[<\"&C=?[.NUZ$'0>[ [JS0?[_DCM]]&Z M$]3?[#_UMI5Q8")1R[K?R:-6\?'1)"UU92?F2?R MZM76#MC&_:Z?/M[R]7M@]VD\)IB^N# ^TJF2]%U.R&$FO2-C"_N>D\<_P/KR MP?J [-SOCW]@]+F$\__%*0?"ABOQO[B+ MK#SXP=Z*R)UO_G+E/WKL^J.;J5C["G"9F=S.(EB*\!#IJ;#K(E_X<+#\]9\Q MN@\JC_X+4$L#!!0 ( %<^"%4G2\80QP< (8I 6 :W)YU:;6_;.!+^?K^"Z^"Z*> 7^:V)G32 X[A78WM)-W71 MVT\'6J0L(I*H)2F[OE]_#TDY=N)DF]NV&R?7 G4DD3.SB^'D MM_\_GKX;#TFEUFA\:@\;C;/)&7D[^><[TJD'33)1--/"")G1I-$8 MG5=()38F[S<:B\6BOFC7I9HU)I<-JZK32*34O,X,JYP"O:Z(SF&OQU@S.&@&K-,^;![2+NL=='M= M]BIH1]W@WTT8V4!W+Z/-,N&O*ZG(:C&WX_<[K?I!-S='"\%,W&\&P=\KKNO) M<20S@_$4Y/VE5[.ES/#/ID83,[*$V&GD1D?.5"LV6-'GV. MQ508TF[66S3\<4Y MN7A#AF_'HS=D,!Q>?#R?C,__@6=H'EW>Z]FN>/+^X^6'CX/S"9E'CW$BQX&S"ECX(5:PB/3;[]:05%D#,'KU^R31W*T M65_Y\->/?G-:6H?UKIV&,8GIG!/%YX(OP*@F%IK\6E %E"=+\5&(=2(5.D)9MAE\($\-!G?/0&6CUYC!- M,K@YAQ@CT^7F-#P3!+:?#@(YZBX[8;8Y$AFB;8&SCFX50(0@.JJ-=I%%X!5J MJT-8:MY<*1+0)6E@J4*&44"M_OZI0O*S)/J#!.+#FXS_Z',8TFW$R M #U=%@G79:9LTUJSN\]?^EL[\FV(0:]-P'^^OCEH[1!LZ.[ IE[@Z,2_8;S6E2N%#;F/ H0L(3/J "W<' M<->\Z8.Y#0J[GRC3G6NY$WG"OB7)?!5F@4!L:#>*,Z_+E/NB6_VK7SU%7X?SG2HKN[N#\Z\M M*]UK$[9:)-4U2UG2W 3JFK LU!X<]>IV"7!M'4498*3R[&K[N =0F6(#;SC_ M@Y0PE50YWF4"]CDE^X S&%A;AL=?6XRLUB#_O1 PWZVW(@O=ONGECUKU>W'N M -M:6T,*8,WN#NP6(Q0KE=>U>;$Y%(HP3 <"DPM)P^5\C^>LB!3PP2\Z9,I_<^3+@&>7V MW2LF!\C@D0)G5!%T[I@.L'&OW$I\57T"%-E<)G-NLV!&9^6;0U62(T_S1"XY M6A>Q]'1(;Z 7:/LF)4+]0:<7'1=@NZWGJ^8IT,=5#5.=T%SS_NKB"+2=)W39 M%YF;,"=T5"J;2F-DVK?'=G-+_R@;RJ,?!RC?7)[H]7KU@^# 'NH9A?]L-7!Y MWE=WYWT-P[;;NNUZ$'3O;0[JS7O;_DCM]]':">JO>O/""U"MV922O7NQUP#;N=_N0\8:OWP.[C^.Q MA>FS"^,#G2I)W^6$'&;:=V1D9=]3\O@'6)\_6)^24\-8\(@,PE 6F=LP7/@M M\0]8/I4(_K\XY4#8<%7]%S>.E7N_Q=L0N?4Y7R[]]XQ]?UHSYUL?^*V3D=M, M!&L1.D5&*LRVR!>^"2Q__1>*[EO)D_\"4$L#!!0 ( %<^"%7W>TW@0 4 M (,K 6 :W)YU:;7/:.!#^?K]B2^;Z M,H/?(>&MF2'@7+GV( 7GVGZZ$;:,-366*\LAW*\_2<97($V/N4G:).-\\!BO M=K7/[DK:W:CW;#@9>)\N7(CX,H:+R[-WHP'4-,/XX P,8^@-X8WWQSMHZ*8% M'D-)1CBA"8H-PQW7H!9QGG8,8[5:Z2M'IVQA>%-#BFH8,:49U@,>U$Y[\HMX M8A2<_M)[IFDPI'Z^Q D'GV'$<0!Y1I(%? AP]ADT;3-J0-,U(XN(@VW:-GR@ M[#.Y0@6=$Q[CTU).SRA^]PPU26].@_5I+R!70(+7-8+]1K-A.G/',LW&<:.) MFHWFB=4*3^S0;&,G_,L22AIB>,&3\76,7]>6)-$B+.?O-&S]I)GR[HH$/.H( M*;_6U-#37D@3+N9C@K]X+<3<$,;Q-==03!9)1T&J%:PEV:"(+01V3E/!)<1NZ>X+8V-V[\J??%/Y@3OU1N>C M0=\;3<8P.8?!FY%[#NY'=W#IC?YTQ2=!=:?0'P\WM/Y@,+D<>Z/Q;R7Q5M0/ M!>7%Y71VV1][X$T>O*Y6"R[UF3[08>8.E%_1GTAY,+SQW"8S)W M:>2V>2S#WWOCPJP_/>N/W9DV^?C._23BW9,4VS3M0Y?W3]J)1G5XRT@6P4PO M7A*4U&$0$1R">XW]G),K#),P)#YF=1 /3L)U'=*<93D2^G(*6^&'?7DP/3^R MCLVNBD% &:" IO)TV>;9&2D-24/@$8898G.4X$R;7,=X#7V?2XHT9%W0$7]^ MU&QU#[%I6\!/41"( TV+<<@[SG&YAY(D$.'3T:S63S.[I9<8?OSLNV:Q3+TI MS2"-_SY'3"RK> U3G%(F3)_ .67+C3]-[7WQ%E*FG,4CAC$LQ7Q1!EA8-8#? M\P07@QSA?)DPU.&E'/O\J&7;9O=":$P#XF]F4%^M[BL(\UA,Z]-E&A,!=$5X MI*9@^$M.&);9128C82_"7J)7()2QFB^#5_^&D(A:)A(D(<:]]B.4+' 91U;; M:8@(:G$K$W^?*[D!RH#%BZ48[*XR(Z:(J9FES]>LO6 M&1?#SPCEV(_J,$I\_:#]N*%OZXG>, ]3UE#F M+4PLG)BE*'E=RZY+V4.;U$A'K%U GV]$$C+%E7?]VF>5Z >":BGTZ.J M%F$%J@)U[Z!N:Z$1;74]5%V=-_ %!+ 0(4 Q0 ( %8^"%49/8#B M.HH! %<%$0 1 " 0 !K0 1 " 6F* 0!K M&UL4$L! A0#% @ 5CX(59:>5Q(! &MR>7,M,C R,C V,S!?9S$N:G!G4$L! A0#% M @ 5CX(5:Q+YKD7,M,C R M,C V,S!?;&%B+GAM;%!+ 0(4 Q0 ( %8^"%4+6>/\V6$ $F ! 5 M " =D=!0!K! !0 @RL !8 ( ![(\% &MR>7,M,C R D,C V,S!E>#,R,2YH=&U02P4& H "@"8 @ 8)4% end